(51) International Patent Classification:
C07D 41/14 (2006.01)  A61K 31/535 (2006.01)
C07D 41/12 (2006.01)  A61K 31/54 (2006.01)
C07D 41/17/12 (2006.01)  A61P 25/28 (2006.01)

(21) International Application Number:
PCT/JP2015/000234

(22) International Filing Date:
10 April 2015 (20.04.2015)

(25) Filing Language:
English

(26) Publication Language:
English

(30) Priority Data:


Published:
with international search report (Art. 21(3))

(54) Title: DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY

(57) Abstract: The present invention provides a compound which has an effect of inhibiting amyloid β production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or phylactic agent for diseases induced by production, secretion and/or deposition of amyloid β proteins. A compound of the formula (I) wherein X is -S- or -O-, R3b is alkyl, haloalkyl or the like, R2b is H, halogen, alkyl, haloalkyl or the like, R2a is H or the like, R3a is H or alkyl, ring A and ring B is each independently a substituted or unsubstituted aromatic carboxylic acid, a substituted or unsubstituted aromatic heterocycle or the like, and R1 is substituted or unsubstituted alkyl or the like, or a pharmaceutically acceptable salt thereof.

$$ R^1 \quad R^2 \quad R^3 $$

A

B

(1)
Description

Title of Invention: DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACEi INHIBITORY ACTIVITY

Technical Field

[0001] The present invention relates to a compound which has amyloid β production inhibitory activity, and is useful as an agent for treating or preventing disease induced by production, secretion and/or deposition of amyloid β proteins.

Background Art

[0002] In the brain of Alzheimer's patient, the peptide composed of about 40 amino acids residue as is called amyloid β protein, that accumulates to form insoluble specks (senile specks) outside nerve cells is widely observed. It is concerned that these senile specks kill nerve cells to cause Alzheimer's disease, so the therapeutic agents for Alzheimer's disease, such as decomposition agents of amyloid β protein and amyloid vaccine, are under investigation.

[0003] Secretase is an enzyme which cleaves a protein called amyloid β precursor protein (APP) in cell and produces amyloid β protein. The enzyme which controls the production of N terminus of amyloid β protein is called as β-secretase (beta-site APP-cleaving enzyme 1, BACE1). It is thought that inhibition of this enzyme leads to reduction of producing amyloid β protein and that the therapeutic or prophylactic agent for Alzheimer's disease will be created due to the inhibition.

[0004] Patent Literatures 1 to 39 and Non-Patent Literature 1 disclose compounds having a structure similar to those of the compounds of the present invention. Each of these documents discloses each compound is useful as therapeutic agent for Alzheimer's disease, Alzheimer's relating symptoms, diabetes or the like, but each of substantially disclosed compounds has a structure different from the compounds of the present invention.

Citation List

Patent Literature

PTL 2: WO2008/133273
PTL 3: WO2008/133274
PTL 4: WO2009/151098
PTL 5: WO2010/047372
PTL 6: WO2010/113848
PTL 7: WO2011/071057
PTL 8: WO2011/058763
PTL 9: WO2011/070781
PTL 10: WO2011/077726
PTL 11: WO2011/071135
PTL 12: WO2011/071109
PTL 13: WO2012/057247
PTL 14: WO2012/057248
PTL 15: WO2012/147762
PTL 16: WO2012/147763
PTL 17: JP2012/250933A
PTL 18: WO2014/010748
PTL 19: JP2014/101354A
PTL 20: WO2014/065434
PTL 21: JP2014/101353A
PTL 22: WO2013/110622
PTL 23: WO2014/001228
PTL 24: WO2013/041499
PTL 25: WO2012/107371
PTL 26: WO2011/069934
PTL 27: WO2011/070029
PTL 28: WO2012/139993
PTL 29: WO2012/168164
PTL 30: WO2012/168175
PTL 31: WO2012/156284
PTL 32: WO2014/166906
PTL 33: WO2014/114532
PTL 34: WO2013/027188
PTL 35: WO2014/134341
PTL 36: WO2008/103351
PTL 37: US2008/0200445
PTL 38: US2006/0287294
PTL 39: WO2014/098831

Non Patent Literature

[0006] NPL 1: Journal of Medicinal Chemistry, 2013, 56(10), pp3980-3995

Summary of Invention

Technical Problem
The present invention provides compounds which have reducing effects to produce amyloid β protein, especially BACE1 inhibitory activity, and are useful as an agent for treating disease induced by production, secretion and/or deposition of amyloid β protein.

**Solution to Problem**

The present invention, for example, provides the inventions described in the following items.

(1) A compound of formula (I):

![Chem.1]

wherein

- X is -S- or -O-,

(i) when X is -S-, then

- R³ is alkyl, haloalkyl, hydroxyalkyl or alkyloxyalkyl,
- R² is halogen, alkyl, alkoxy or haloalkyloxy and
- R³ may be alkyl when R³ is haloalkyl,
- R² is H,
- R² and R³ together with the carbon atom to which they are attached may form substituted cycloalkane,
- R³ may be H when R² and R³ together with the carbon atom to which they are attached may form substituted cycloalkane,

(ii) when X is -O-, then

- R³ is haloalkyl optionally substituted with one or more selected from alkyl, alkoxy and cycloalkyl, or cycloalkyl substituted with one or more selected from halogen,
- R² is H, halogen, alkyl, alkoxy or haloalkyloxy,
- R² is H,
- R² and R³ together with the carbon atom to which they are attached may form substituted cycloalkane,
- R³ may be H or alkyl when R² and R³ together with the carbon atom to which they
are attached may form substituted cycloalkane,
and \( R^{3b} \) is H or alkyl,

[Chem.2]

\[
\begin{align*}
\text{may be} & \\
R^{3b} & \\
R^{2a} & \\
R^{2b} & \\
\end{align*}
\]

ring A is a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted non-aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle,
ring B is a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted non-aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle,
\( R^1 \) is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted cycloalkyl,
\( R^5 \) is halogen or substituted or unsubstituted alkyl,
n is an integer of 0 to 2,

provided that the following compounds are excluded:
(1) a compound wherein \( X \) is -0-, \( R^{3a} \) is \( \text{CH}_2\text{F} \) or \( \text{CF}_3 \), \( R^{3b} \) is H, \( R^{2a} \) is H or F, and \( R^{2b} \) is H,
(2) a compound wherein \( X \) is -0-, \( R^{3a} \) is \( \text{CHF}_2 \), \( R^{3b} \) is H, \( R^{2a} \) is \( \text{OMe} \) and \( R^{2b} \) is H, and
(3) the following compound:

[Chem.3]

or a pharmaceutically acceptable salt thereof.

(1-1) A compound of formula (I):
wherein

X is -O- or -S-,  
(i) when X is -O-, then
R^3 is haloalkyl,
R^2 is H, halogen, alkyl, alkyloxy or haloalkyloxy,
(ii) when X is -S-, then
R^3 is alkyl or haloalkyl,
R^2 is halogen, alkyloxy or haloalkyloxy and
R^2 may be alkyl when R^3 is haloalkyl,
and R^3 is H or alkyl, and

ring A is a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted non-aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle,
ring B is a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted non-aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle,
R¹ is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted cycloalkyl,
R⁵ is halogen or substituted or unsubstituted alkyl,
n is an integer of 0 to 2,
provided that the following compounds are excluded:
(1) a compound wherein X is -O-, R³a is CH₂F or CF₃, R³b is H, and R²a is H or F, and
(2) the following compound:

![Chem.6]

or a pharmaceutically acceptable salt thereof.
(1-2) The compound according to the item (1)
provided that the following compounds are excluded:
(1) a compound wherein X is -O-, R³a is CH₂F or CF₃, R³b is H, and R²a is H, F or OMe,
and
(3) a compound wherein X is -O-, R³a is CHF₂, R³b is H, and R²a is OMe,
or a pharmaceutically acceptable salt thereof.

[0010] (2) The compound according to the item (1), (1-1) or (1-2) wherein X is -O-, or a
pharmaceutically acceptable salt thereof.
(3) The compound according to the item (2) wherein R³a is CH₂F, CHF₂, CF₃,
CH(F)CH₃ or CF₂CH₃, and R³b is H or CH₃, or a pharmaceutically acceptable salt thereof.
(4) The compound according to the item (2) or (3) wherein R²a is H, F, CH₃, OCH₃ or
OCH₂CF₃, or a pharmaceutically acceptable salt thereof.
(5) The compound according to the item (2) or (3) wherein R²a is H, halogen or alkyl,
R³b is H, and R³a is CHF₂, CH(F)CH₃ or CF₂CH₃, or a pharmaceutically acceptable salt thereof.
(5-1) The compound according to any one of the items (2) to (4) wherein R²a is H or
halogen, and R³a is CHF₂, CH(F)CH₃ or CF₂CH₃, or a pharmaceutically acceptable salt thereof.
(6) The compound according to item (2) wherein R²a is H or halogen, R³b is H, R³a is
For CF₃, Rᵢ is alkyl, or a pharmaceutically acceptable salt thereof.

(6-1) The compound according to any one of the items (2) to (4) wherein Rᵢ is H or halogen, Rᵢ is CH₃F or CF₃, and Rrob is alkyl, or a pharmaceutically acceptable salt thereof.

(7) The compound according to any one of the items (2) to (4) wherein Rᵢ is alkyl, alkyloxy or haloalkyloxy, or a pharmaceutically acceptable salt thereof.

(8) The compound according to item (2) wherein

\[ \text{Chem.7} \]

\[
\begin{array}{c}
\text{R}^5 \text{ is halogen and } n \text{ is 1 or 2, or a pharmaceutically acceptable salt thereof.}
\end{array}
\]

(9) The compound according to item (2) or (4) wherein Rᵢ is haloalkyl substituted with alkyloxy or cycloalkyl, or a pharmaceutically acceptable salt thereof.

(10) The compound according to any one of items (1), (1-1) and (1-2) wherein X is -S-, Rᵢ is halogen or alkyloxy, Rᵢ is H, Rᵢ is alkyl, haloalkyl, hydroxyalkyl or alkyloxyalkyl, and Rᵢ is H, or a pharmaceutically acceptable salt thereof.

(11) The compound according to the item (1) wherein X is -S-, Rᵢ is F, Rᵢ is H, Rᵢ is CH₃ or CH₂F, and Rᵢ is H, or a pharmaceutically acceptable salt thereof.

(12) The compound according to any one of items (1), (1-1) and (1-2) wherein Rᵢ and Rᵢ together with the carbon atom to which they are attached form cycloalkane substituted with halogen, Rᵢ is H or alkyl, or a pharmaceutically acceptable salt thereof.

(13) The compound according to any one of the items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), and (7) to (12) wherein Rᵢ is alkyl, or a pharmaceutically acceptable salt thereof.

(14) The compound according to any one of the items (1), (1-1), (1-2), (2) (5), (5-1), (6), (6-1), and (7) to (13) wherein ring A is
wherein R⁴ is H or halogen, and -Z= is -CH= or -N=, or a pharmaceutically acceptable salt thereof.

(15) The compound according to item (14) wherein R⁴ is halogen and -Z= is -CH=, or a pharmaceutically acceptable salt thereof.

(16) The compound according to any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), and (7) to (15) wherein ring B is substituted or unsubstituted pyridine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrimidine, substituted or unsubstituted pyridazine or substituted or unsubstituted oxazole, or a pharmaceutically acceptable salt thereof.

(16-1) The compound according to any one of the items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), and (7) to (15) wherein ring B is substituted or unsubstituted pyridine, substituted or unsubstituted pyrazine, or substituted or unsubstituted oxazole, or a pharmaceutically acceptable salt thereof.

(0011) (17) A pharmaceutical composition comprising the compound according to any one of the items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof.

(18) A pharmaceutical composition having BACE1 inhibitory activity comprising the compound according to any one of the items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof.

(19) A method for inhibiting BACE1 activity comprising administering the compound according to any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof.

(20) The compound according to any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof for use in a method for inhibiting BACE1 activity.

(21) The pharmaceutical composition according to item (17) or (18) for treating or preventing Alzheimer dementia, mild cognitive impairment or prodromal Alzheimer's disease, for preventing the progression of Alzheimer dementia, mild cognitive impairment, or prodromal Alzheimer's disease, or for preventing the progression in a
patient asymptomatic at risk for Alzheimer dementia.

(22) A method for treating or preventing Alzheimer dementia, mild cognitive impairment or prodromal Alzheimer’s disease, for preventing the progression of Alzheimer dementia, mild cognitive impairment, or prodromal Alzheimer’s disease, or for preventing the progression in a patient asymptomatic at risk for Alzheimer dementia comprising administering the compound according to any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof.

(23) A compound according to any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof for use in treating or preventing Alzheimer dementia, mild cognitive impairment or prodromal Alzheimer’s disease, for use in preventing the progression of Alzheimer dementia, mild cognitive impairment or prodromal Alzheimer’s disease, or for use in preventing the progression in a patient asymptomatic at risk for Alzheimer dementia.

[0012] (24) Use of the compound according to any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof for manufacturing a medicament for inhibiting BACE1 activity.

(25) The pharmaceutical composition according to the item (17) or (18) for treating or preventing a disease induced by production, secretion or deposition of amyloid β proteins.

(26) A method for treating or preventing diseases induced by production, secretion or deposition of amyloid β proteins comprising administering the compound according to any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1) or a pharmaceutically acceptable salt thereof.

(27) A compound according to any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof for use in treating or preventing diseases induced by production, secretion or deposition of amyloid β proteins.

(28) Use of the compound according to any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof for manufacturing a medicament for treating or preventing diseases induced by production, secretion or deposition of amyloid β proteins.

[0013] (29) The pharmaceutical composition according to the item (17) or (18) for treating or preventing Alzheimer dementia.

(30) A method for treating or preventing Alzheimer dementia comprising administering the compound according to any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof.

(31) A compound according to any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6),
(6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof for use in treating or preventing Alzheimer dementia.

(32) Use of the compound according to any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof for manufacturing a medicament for treating or preventing Alzheimer dementia.

Advantageous Effects of Invention

[0014] The compound of the present invention has BACE1 inhibitory activity and is useful as an agent for treating and/or preventing disease induced by production, secretion or deposition of amyloid β proteins such as Alzheimer dementia.

(33) A pharmaceutical composition comprising the compound of any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof, for oral administration.

(34) The pharmaceutical composition of (33), which is a tablet, powder, granule, capsule, pill, film, suspension, emulsion, elixir, syrup, lemonade, spirit, aromatic water, extract, decoction or tincture.

(35) The pharmaceutical composition of (34), which is a sugar-coated tablet, film-coated tablet, enteric-coated tablet, sustained-release tablet, troche tablet, sublingual tablet, buccal tablet, chewable tablet, orally disintegrated tablet, dry syrup, soft capsule, micro capsule or sustained-release capsule.

(36) A pharmaceutical composition comprising the compound of any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof, for parenteral administration.

(37) The pharmaceutical composition of (36), for dermal, subcutaneous, intravenous, intraarterial, intramuscular, intraperitoneal, transmucosal, inhalation, transnasal, ophthalmic, inner ear or vaginal administration.

(38) The pharmaceutical composition of (36) or (37), which is injection, infusion, eye drop, nose drop, ear drop, aerosol, inhalation, lotion, impregnation, liniment, mouthwash, enema, ointment, plaster, jelly, cream, patch, cataplasm, external powder or suppository.

(39) A pharmaceutical composition comprising the compound of any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof, for a pediatric or geriatric patient.

(40) A pharmaceutical composition consisting of a combination of the compound of any one of items (1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1) or a pharmaceutically acceptable salt thereof and acetylcholinesterase inhibitor, NMDA antagonist, or other medicament for Alzheimer dementia.

(41) A pharmaceutical composition comprising the compound of any one of items
(1), (1-1), (1-2), (2) to (5), (5-1), (6), (6-1), (7) to (16) and (16-1), or a pharmaceutically acceptable salt thereof, for a combination therapy with acetylcholinesterase inhibitor, NMDA antagonist, or other medicament for Alzheimer dementia.

Description of Embodiments

[0015] Each meaning of terms used herein is described below. Both when used alone and in combination unless otherwise noted, each term is used in the same meaning.

In the specification, the term "consisting of" means having only components.

In the specification, the term "comprising" means not restricting with components and not excluding undescribed factors.

In the specification, the "halogen" includes fluorine, chlorine, bromine, and iodine. Fluorine and chlorine are preferable.

In the specification, the "alkyl" includes linear or branched alkyl of a carbon number of 1 to 15, for example, a carbon number of 1 to 10, for example, a carbon number of 1 to 6, and for example, a carbon number of 1 to 4. Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl, n-heptyl, isooctyl, n-octyl, isooctyl, n-nonyl and n-decyl. Examples are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and n-pentyl.

In one embodiment, "alkyl" is methyl, ethyl, n-propyl, isopropyl or tert-butyl.

The term "alkenyl" includes linear or branched alkenyl of a carbon number of 2 to 15, for example, a carbon number of 2 to 10, for example, a carbon number of 2 to 6, and for example, a carbon number of 2 to 4, having one or more double bonds at any available positions. Examples include vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl and pentadecenyl. Examples are vinyl, allyl, propenyl, isopropenyln and butenyl.

[0016] The term "alkynyl" includes a linear or branched alkynyl of a carbon number of 2 to 15, for example, a carbon number of 2 to 10, for example, a carbon number of 2 to 8, for example, a carbon number of 2 to 6, and for example, a carbon number of 2 to 4 having one or more double bonds at optionally positions. Specific examples are ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl and decynyl. These may have further a double bond at any available position. Examples are ethynyl, propynyl, butynyl and pentynyl.

[0017] The term "alkylene" include a linear or branched divalent carbon chain of a carbon number of 1 to 15, for example, a carbon number of 1 to 10, for example, a carbon number of 1 to 6, and for example a carbon number of 1 to 4. Examples are methylene,
dimethylene, trimethylene, tetramethylene, pentamethylene and hexamethylene. 
Alkylene portion in "alkylenedioxy" is the same as the above "alkylene". Examples are 
methylenedioxy and dimethylenedioxy.

[0018] The term of "aromatic carbocycl" includes an aromatic hydrocarbon group which is 
monocyclic or which consists of two or more rings. Examples are an aromatic hydrocarbon group of a carbon number of 6 to 14, and specific examples are phenyl, naphthyl, anthr
yl and phenanthryl.

In one embodiment, "aromatic carbocycl" is phenyl.

[0019] The term of "non-aromatic carbocycl" includes saturated carbocycl or un
saturated non-aromatic carbocycl which is monocyclic or which consists of two or 
more rings. A "non-aromatic carbocycl" of two or more rings includes a fused cyclic 
group wherein a non-aromatic monocyclic carbocycle or a non-aromatic carbocycle of 
two or more rings is fused with a ring of the above "aromatic carbocycl".

In addition, the "non-aromatic carbocycl" also includes a cyclic group having a 
bridge or a cyclic group to form a spiro ring as follows:

[Chem.9]

\[ \text{Diagram of spiro rings} \]

The term "non-aromatic monocyclic carbocycle" includes a group having 3 to 16 
carbon atoms, for example, 3 to 12 carbon atoms, for example, 3 to 8 carbon atoms, 
and for example, 3 to 5 carbon atoms. Examples are cyclopropane, cyclobutane, cy
clpentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cy
clopropene, cyclobutene, cyclopentene, cyclohexene cycloheptene and cyclohexadiene.

Examples of non-aromatic carbocycl consisting of two or more rings include a 
group having 6 to 14 carbon atoms, and examples are indanyl, indenyl, acenaphthyl, 
tetrahydronaphthyl and fluorenyl.

[0020] The term "cycloalkyl" includes a carbocyclic group of a carbon number of 3 to 10, 
for example, a carbon number of 3 to 8, and for example, a carbon number 4 to 8. 
Examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cy
clcoctyl, cyclononyl and cyclodecyl.

The term "cycloalkane" includes a carbocycle of a carbon number of 3 to 10, for 
ex ample, a carbon number of 3 to 8, for example, a carbon number 3 to 5. Examples 
are cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, 
cyclononane and cyclodecane.

Cycloalkyl portion in "cycloalkylalkyl", "cycloalkylamino" and "cycloalkylalkyloxy" 
are the same as the above "cycloalkane".
The term of "aromatic heterocyclyl" includes an aromatic group which is monocyclic, or which consists of two or more rings, containing one or more of heteroatoms selected independently from oxygen, sulfur and nitrogen atoms. An "aromatic heterocyclyl" of two or more rings includes a fused cyclic group wherein aromatic monocyclic heterocyclyl or non-aromatic heterocyclyl consisting of two or more rings is fused with a ring of the above "aromatic carbocyclyl".

The term "aromatic monocyclic heterocyclyl" includes a 5- to 8-membered group, and for example, 5- to 6-membered group. Examples are pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazolyl, furyl, thiienyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl and thiadiazolyl.

Examples of aromatic bicyclic heterocyclyl includes a 9- to 10-membered group, and examples are indoliny1, isoindoliny1, indazoliny1, indoliziny1, quinoliny1, isoquinoliny1, cinnoliny1, phthalaziny1, quinazoliny1, naphthyridiny1, quinoxaliny1, puriny1, pteridiny1, benzimidazoliny1, benzisoxazoliny1, benzoxazoliny1, benzodiazaquizoliny1, benzothiazoliny1, benzothiadiazoliny1, benzofuryl, isobenzofuryl, benzothiency1, benzotriazoliny1, imidazopyridiny1, triazolopyridiny1, imidazothiazoliny1, pyrazinopyridaziny1, oxadiazopyridiny1 and thiazolopyridiny1.

Examples of aromatic heterocyclyl of three or more rings includes a 13 to 14-membered group, and examples are carbazoliny1, acridiny1, xanthenyl, phenothiaziny1, phenoxathiiny1, phenoxaziny1 and dibenzofuryl.

The term of "non-aromatic heterocyclyl" includes a non-aromatic group which is monocyclic, or which consists of two or more rings, containing one or more of heteroatoms selected independently from oxygen, sulfur and nitrogen atoms.

A "non-aromatic heterocyclyl" of two or more rings includes a fused cyclic group wherein non-aromatic monocyclic heterocyclyl or non-aromatic heterocyclyl of two or more rings is fused with a ring of the above "aromatic carbocyclyl", "non-aromatic carbocyclyl" and/or "aromatic heterocyclyl".

In addition, the "non-aromatic heterocyclyl" also includes a cyclic group having a bridge or a cyclic group to form a spiro ring as follows:

The term "non-aromatic monocyclic heterocyclyl" includes a 3- to 8-membered ring, and for example, 4-, 5- or 6-membered ring. Examples are dioxanyl, thiirany1, oxirany1, oxetany1, oxathioliay1, azetidiny1, thiany1, thiazolidiny1, pyrrolidiny1.
pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, morpholinyl, thiophenol, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, morpholinyl, thiophenol, thiomorpholinyl, thiomorpholino, dihydropyridyl, tetrahydropyridyl, tetrahydrofuryl, tetrahydroxypyranyl, dihydrothiazolyl, tetrahydrothiazolyl, tetrahydroisothiazolyl, dihydrooxazinyl, hexahydropyrimidinyl, dioxolanyl, dioxazinyl, aziridinyl, dioxolinyl, oxepanyl, thiolanyl, thiinyl and thiazinyl.

Examples of non-aromatic heterocyclyl of two or more rings includes a 9 to 14-membered group, and examples are indolinyl, isoindolinyl, chromanyl and isochromanyl.

[0023] The term of "alkyloxy" includes a group wherein an oxygen atom is substituted with the above "alkyl". Examples are methyloxy, ethyloxy, n-propyloxy, isopropyloxy, n-butyloxy, tert-butyloxy, isobutyloxy, sec-butyloxy, pentyloxy, isopentyloxy and hexyloxy.

In one embodiment, "alkyloxy" is methyloxy, ethyloxy, n-propyloxy, isopropyloxy or tert-butyloxy.

[0024] The term of "alkenyloxy" includes a group wherein an oxygen atom is substituted with the above "alkenyl". Examples are vinyloxy, allyloxy, 1-propenyloxy, 2-butenyloxy, 2-pentenyloxy, 2-hexenyloxy, 2-heptenyloxy and 2-octenyloxy.

[0025] The term of "alkynyoxy" includes a group wherein an oxygen atom is substituted with the above "alkynyl". Examples are ethynyloxy, 1-propynyloxy, 2-propynyloxy, 2-butyloxy, 2-pentynyloxy, 2-hexynyloxy, 2-heptynyloxy and 2-octynyloxy.

[0026] The term of "haloalkyl" includes a group wherein one or more hydrogen atoms attached to one or more carbon atoms of the above "alkyl" are replaced with one or more above "halogen". Examples are monofluoromethyl, monofluoroethyl, monofluoropropyl, difluoromethyl, difluoroethyl, difluoropropyl, trifluoromethyl, trifluoroethyl, trifluoropropyl, pentafluoropropyl, monochloromethyl, monochloroethyl, monochloropropyl, dichloromethyl, dichloroethyl, dichloropropyl, trichloromethyl, trichloroethyl, trichloropropyl, pentachloropropyl, 1-fluoroethyl, 2-fluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 1-chloroethyl, 2-chloroethyl, 1,1-dichloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 1,2-dibromoethyl, 1,1,1-trifluoropropan-2-yl and 2,2,3,3,3-pentafluoropropyl.

Examples are monofluoromethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 1,1,1-trifluoropropan-2-yl and 2,2,3,3,3-pentafluoropropyl. Examples are monofluoromethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, 1,1-difluoroethyl, and 2,2-difluoroethyl. Examples are monofluoromethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, 1,1-difluoroethyl and 2,2-difluoroethyl.

The term of "haloalkenyl" includes a group wherein one or more hydrogen atoms...
attached to one or more carbon atoms of the above "alkenyl" are replaced with one or more above "halogen". Examples are monofluorovinyl, monofluoroallyl, monofluoropropenyl, difluorovinyl, difluoroallyl and difluoropropenyl.

The term of "haloalkynyl" includes a group wherein one or more hydrogen atoms attached to one or more carbon atoms of the above "alkynyl" are replaced with one or more above "halogen". Examples are fluoroethynyl, monofluoropropynyl, difluoropropynyl, monofluorobutynyl, chloroethynyl, monochloropropynyl, monochlorobutynyl and dichloropropynyl.

[0027] The term of "haloalkyloxy" includes a group wherein an oxygen atom is substituted with the above "haloalkyl". Examples are monofluoromethyloxy, monofluoroethyloxy, difluoromethyloxy, 1,1-difluoroethyloxy, 2,2-difluoroethyloxy, trifluoromethyloxy, 2,2,2-trifluoroethyloxy and trifluoroethyloxy.

In one embodiment, "haloalkyloxy" is difluoromethyloxy, 2,2,2-difluoroethyloxy, trifluoromethyloxy, 2,2,2-trifluoroethyloxy, or trifluoroethyloxy.

The term of "cyanoalkyloxy" includes a group wherein the above "alkyloxy" is substituted with a cyano group. Examples are cyanomethyloxy and cyanoethyloxy.

[0028] The term of "alkyloxyalkyl" includes a group wherein the above "alkyl" is substituted with the above "alkyloxy". Examples are methoxymethyl, methoxyethyl and ethoxymethyl.

[0029] The term of "alkyloxyalkyloxy" includes a group wherein the above "alkyloxy" is substituted with the above "alkyloxy". Examples are methyloxymethyloxy, methyloxyethyloxy, ethyloxymethyloxy and ethyloxyethyloxy.

The term of "cycloalkylalkyloxy" includes a group wherein the above "alkyloxy" is substituted with the above "cycloalkyl". Examples are cyclopropylmethyloxy, cyclopropylethyloxy, cyclobutylmethyloxy and cyclobutylethyloxy.

[0030] The term of "alkylcarbonyl" includes a group wherein a carbonyl group is substituted with the above "alkyl". Examples are methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, tert-butylcarbonyl, isobutylcarbonyl, sec-butylcarbonyl, pentylcarbonyl, isopentylcarbonyl and hexylcarbonyl. Examples are methylcarbonyl, ethylcarbonyl and n-propylcarbonyl.

[0031] The term of "alkenylcarbonyl" includes a group wherein a carbonyl group is substituted with the above "alkenyI". Examples are ethylenylcarbonyl, propenylcarbonyl and butenylcarbonyl.

[0032] The term of "alkynylcarbonyl" includes a group wherein a carbonyl group is substituted with the above "alkynyl". Examples are ethynylcarbonyl, propynylcarbonyl and butynylcarbonyl.

[0033] The term of "monoalkylamino" includes a group wherein a hydrogen atom attached to a nitrogen atom of an amino group is replaced with the above "alkyl". Examples are
methylamino, ethylamino and isopropylamino.
In one embodiment, "monoalkylamino" is methylamino or ethylamino.

[0034] The term of "dialkylamino" includes a group wherein two hydrogen atoms attached to a nitrogen atom of an amino group are replaced with two above "alkyl". These two alkyl groups may be the same or different. Examples are dimethylamino, diethylamino, N,N-diisopropylamino, N-methyl-N-ethylamino and N-isopropyl-N-ethylamino.

In one embodiment, "dialkylamino" is dimethylamino or diethylamino.

[0035] The term of "alkylsulfonyl" includes a group wherein a sulfonyl group is substituted with the above "alkyl". Examples are methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, tert-butylsulfonyl, isobutylsulfonyl and sec-butylsulfonyl.

In one embodiment, "alkylsulfonyl" is methylsulfonyl or ethylsulfonyl.

[0036] The term of "alkenylsulfonyl" includes a group wherein a sulfonyl group is substituted with the above "alkenyl". Examples are ethylenysulfonyl, propenylsulfonyl and butenylsulfonyl.

[0037] The term of "alkynylsulfonyl" includes a group wherein a sulfonyl group is substituted with the above "alkynyl". Examples are ethynylsulfonyl, propynylsulfonyl and butynylsulfonyl.

[0038] The term of "monoalkylcarbonylamino" includes a group wherein a hydrogen atom attached to a nitrogen atom of an amino group is replaced with the above "alkylcarbonyl". Examples are methylcarbonylamino, ethylcarbonylamino, propylcarbonylamino, isopropylcarbonylamino, tert-butylcarbonylamino, isobutylcarbonylamino and sec-butylcarbonylamino.

In one embodiment, "monoalkylcarbonylamino" is methylcarbonylamino or ethylcarbonylamino.

[0039] The term of "dialkylcarbonylamino" includes a group wherein two hydrogen atoms attached to a nitrogen atom of an amino group are replaced with two above "alkylcarbonyl". These two alkylcarbonyl groups may be the same or different. Examples are dimethylcarbonylamino, diethylcarbonylamino and N,N-diisopropylcarbonylamino. In one embodiment, "dialkylcarbonylamino" is dimethylcarbonylamino or diethylcarbonylamino.

[0040] The term of "monoalkylsulfonylamino" includes a group wherein a hydrogen atom attached to a nitrogen atom of an amino group is replaced with the above "alkylsulfonyl". Examples are methylsulfonylamino, ethylsulfonylamino, propylsulfonylamino, isopropylsulfonylamino, tert-butylsulfonylamino, isobutylsulfonylamino and sec-butylsulfonylamino. In one embodiment, "monoalkylsulfonylamino" is methylsulfonylamino or ethylsulfonylamino.

[0041] The term of "dialkylsulfonylamino" includes a group wherein two hydrogen atoms attached to a nitrogen atom of an amino group are replaced with two above "alkyl-
sulfonyl". These two alkylsulfonyl groups may be the same or different. Examples are dimethylsulfonylamino, diethylsulfonylamino and N,N-diisopropylsulfonylamino. In one embodiment, "dialkylsulfonylamino" is dimethylsulfonylamino or diethylsulfonylamino.

The term of "alkylimino" includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above "alkyl". Examples are methylimino, ethylimino, n-propylimino and isopropylimino.

The term of "alkenylimino" includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above "alkenyl". Examples are ethenylimino and propenylimino.

The term of "alkynylimino" includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above "alkynyl". Examples are ethynylimino and propynylimino.

The term of "alkylcarbonylimino" includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above "alkylcarbonyl". Examples are methylcarbonylimino, ethylcarbonylimino, n-propylcarbonylimino and isopropylcarbonylimino.

The term of "alkenylcarbonylimino" includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above "alkenylcarbonyl". Examples are ethenylcarbonylimino and propenylcarbonylimino.

The term of "alkynylcarbonylimino" includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above "alkynylcarbonyl". Examples are ethynylcarbonylimino and propynylcarbonylimino.

The term of "alkoxyimino" includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above "alkoxy". Examples are methoxyimino, ethoxyimino, n-propoxyimino and isopropoxyimino.

The term of "alkenoxyimino" includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above "alkenoxy". Examples are ethenyl oxyi

The term of "alkenylcarbonyloxy" includes a group wherein an oxygen atom is substituted with the above "alkylcarbonyl". Examples are methylcarbonyloxy, ethylcarbonyloxy, propylcarbonyloxy, isopropylcarbonyloxy, tert-buty lcarbonyloxy, isobutylcarbonyloxy and sec-buty lcarbonyloxy. In one embodiment, "alkylcarbonyloxy" is methylcarbonyloxy or ethylcarbonyloxy.

The term of "alkenylcarbonyloxy" includes a group wherein an oxygen atom is substi-
stituted with the above "alkenylcarbonyl". Examples are ethylenylcarbonyloxy and propynylcarbonyloxy.

[0053] The term "alkynylcarbonyloxy" includes a group wherein an oxygen atom is substituted with the above "alkynylcarbonyl". Examples are ethynylcarbonyloxy and propynylcarbonyloxy.

[0054] The term "alkyloxycarbonyl" includes a group wherein a carbonyl group is substituted with the above "alkoxy". Examples are methyloxycarbonyl, ethyloxycarbonyl, propyloxycarbonyl, isopropyloxycarbonyl, tert-butyloxycarbonyl, isobutyloxycarbonyl, sec-butyloxycarbonyl, pentyloxycarbonyl, isopentylxocarbonyl and hexyloxycarbonyl. In one embodiment, "alkyloxycarbonyl" includes ethoxycarbonyl, ethoxycarbonyl or propoxycarbonyl.

[0055] The term "alkenylxoxycarbonyl" includes a group wherein a carbonyl group is substituted with the above "alkenylxoxy". Examples are ethylenyloxycarbonyl, propenyloxycarbonyl and butenylxoxycarbonyl.

[0056] The term "alkynylxoxycarbonyl" includes a group wherein a carbonyl group is substituted with the above "alkynylxoxy". Examples are ethynylxoxycarbonyl, propynylxoxycarbonyl and butynylxoxycarbonyl.

[0057] The term "alkylsulfanyl" includes a group wherein a hydrogen atom attached to a sulfur atom of a sulfanyl group is replaced with the above "alkyl". Examples are methylsulfanyl, ethylsulfanyl, n-propylsulfanyl, isopropylsulfanyl, tert-butylsulfanyl and isobutylsulfanyl.

The term "cyanoalkylsulfanyl" includes a group wherein the above "alkylsulfanyl" is substituted with a cyano group. Examples are cyanomethylsulfanyl, cyanoethylsulfanyl and cyanopropylsulfanyl.

[0058] The term "alkenylsulfanyl" includes a group wherein a hydrogen atom attached to a sulfur atom of a sulfanyl group is replaced with the above "alkenyl". Examples are ethylenylsulfanyl, propenylsulfanyl and butenylsulfanyl.

[0059] The term "alkynylsulfanyl" includes a group wherein a hydrogen atom attached to a sulfur atom of a sulfanyl group is replaced with the above "alkynyl". Examples are ethynylsulfanyl, propynylsulfanyl and butynylsulfanyl.

[0060] The term "alkylsulfinyl" includes a group wherein a sulfinyl group is substituted with the above "alkyl". Examples are methylsulfinyl, ethylsulfinyl, n-propylsulfinyl and isopropylsulfinyl.

[0061] The term "alkenylsulfinyl" includes a group wherein a sulfinyl group is substituted with the above "alkenyl". Examples are ethylenylsulfinyl, propenylsulfinyl and butenylsulfinyl.

[0062] The term "alkynylsulfinyl" includes a group wherein a sulfinyl group is substituted with the above "alkynyl". Examples are ethynylsulfinyl, propynylsulfinyl and butynyl-
sulfinyl.

The term of "monoalkylcarbamoyl" includes a group wherein a hydrogen atom attached to a nitrogen atom of a carbamoyl group is replaced with the above "alkyl". Examples are methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl and isopropylcarbamoyl.

The term of "dialkylcarbamoyl" includes a group wherein two hydrogen atoms attached to a nitrogen atom of a carbamoyl group are replaced with two above "alkyl". These two alkyl groups may be the same or different. Examples are diethylcarbamoyl, diisopropylcarbamoyl and N-methyl-N-ethylcarbamoyl.

The term of "monoalkylsulfamoyl" includes a group wherein a hydrogen atom attached to a nitrogen atom of a sulfamoyl group is replaced with the above "alkyl". Examples are methylsulfamoyl, ethylsulfamoyl, n-propylsulfamoyl and isopropylsulfamoyl.

The term of "dialkylsulfamoyl" includes a group wherein two hydrogen atoms attached to a nitrogen atom of a sulfamoyl group are replaced with two above "alkyl". These two alkyl groups may be the same or different. Examples are dimethylsulfamoyl, diethylsulfamoyl and N-methyl-N-ethylsulfamoyl.

The term of "trialkylsilyl" includes a group wherein a silicon atom is substituted with three above "alkyl". These three alkyl groups may be the same or different. Examples are trimethylsilyl, triethylsilyl and tert-butyldimethylsilyl.

The term of "alkylidene" includes a divalent group derived from alkane by removing two hydrogen atoms from the same carbon atom. Examples are methylidene, ethylidene, propylidene, isopropylidene, butylidene, pentylidene and hexylidene.

The alkenyl portion of "alkenylcarbonylamino", "alkoxyalkenyloxy", "alkenylsulfanyl" and "alkenylamino" means the above "alkenyl".

The alkynyl portion of "alkynylcarbonylamino", "alkoxyalkynoxy", "alkynylsulfanyl" and "alkynylamino" means the above "alkynyl".

clylalkyloxycarbonyl", "non-aromatic carbocyclalkyloxycarbonyl", "aromatic heterocyclalkyloxycarbonyl" and "non-aromatic heterocyclalkyloxycarbonyl", "aromatic carbocyclalkyloxyalkyl", "non-aromatic carbocyclalkyloxyalkyl", "aromatic heterocyclalkyloxyalkyl" and "non-aromatic heterocyclalkyloxyalkyl", "aromatic carbocyclalkylamino", "non-aromatic carbocyclalkylamino", "aromatic heterocyclalkylamino", "non-aromatic heterocyclalkylamino", "aromatic carbocyclalkylcarbamoyl", "non-aromatic carbocyclalkylcarbamoyl", "aromatic heterocyclalkylcarbamoyl" and "non-aromatic heterocyclalkylcarbamoyl", and "cycloalkylalkyl" means the above "alkyl".

[0070] The term of "aromatic carbocyclalkyl" includes alkyl substituted with one or more above "aromatic carbocyclyl". Examples are benzyl, phenethyl, phenylpropyl, benzhydryl, trityl, naphthylmethyl and a group of the formula of

```
[Chem.11]
```

In one embodiment, "aromatic carbocyclalkyl" is benzyl, phenethyl or benzhydryl.

[0071] The term of "non-aromatic carbocyclalkyl" includes alkyl substituted with one or more above "non-aromatic carbocyclyl". Also, "non-aromatic carbocyclalkyl" includes a "non-aromatic carbocycl alkyl" wherein the alkyl portion thereof is substituted with one or more above "aromatic carbocyclyl". Examples are cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl and a group of the formula of

```
[Chem.12]
```

[0072] The term of "aromatic heterocyclalkyl" includes alkyl substituted with one or more above "aromatic heterocyclyl". Also, "aromatic heterocyclalkyl" includes "aromatic heterocycl alkyl" wherein the alkyl portion thereof is substituted with one or more above "aromatic carbocyclyl", and/or "non-aromatic carbocyclyl". Examples are pyridylmethyl, furanylmethyl, imidazolylmethyl, indolylmethyl, benzothiophenylmethyl, oxazolylmethyl, isoxazolylmethyl, thiazolylmethyl, isothiazolylmethyl, pyrazolylmethyl, isopyrazolylmethyl, pyrrolidinylmethyl, benzoxazolylmethyl and groups of the formula of
The term of "non-aromatic heterocyclylalkyl" includes alkyl substituted with one or more above "non-aromatic heterocyclyl". Also, "non-aromatic heterocyclylalkyl" includes a "non-aromatic heterocyclylalkyl" wherein the alkyl portion thereof is substituted with one or more above "aromatic carbocyclyl", "non-aromatic carbocyclyl" and/or "aromatic heterocyclyl". Examples are tetrahydropyranylmethyl, morpholinylmethyl, morpholinylethyl, piperidinylmethyl, piperazinylmethyl and groups of the formula of

The term of "aromatic carbocyclylalkyloxy" includes alkyloxy substituted with one or more above "aromatic carbocyclyl". Examples are benzyloxy, phenethyloxy, phenylpropyloxy, benzhydryloxy, trityloxy, naphthylmethyloxy and a group of the formula of

The term of "non-aromatic carbocyclylalkyloxy" includes alkyloxy substituted with one or more above "non-aromatic carbocyclyl". Also, "non-aromatic carbocyclylalkyloxy" includes a "non-aromatic carbocyclylalkyloxy" wherein the alkyl portion thereof is substituted with one or more above "aromatic carbocyclyl". Examples are cyclopropylmethyloxy, cyclobutylmethyloxy, cyclopentylmethyloxy, cyclohexylmethyloxy and a group of the formula of

The term of "aromatic heterocyclylalkyloxy" includes alkyloxy substituted with one or more above "aromatic heterocyclyl". Also, "aromatic heterocyclylalkyloxy" includes "aromatic heterocyclylalkyloxy" wherein the alkyl portion thereof is sub-
stituted with one or more above "aromatic carbocyclyl", and/or "non-aromatic carbocyclyl". Examples are pyridylmethyloxy, furanylmethyloxy, imidazolylmethyloxy, indolylmethyloxy, benzothiophenylmethyloxy, oxazolylmethyloxy, isoxazolylmethyloxy, thiazolylmethyloxy, isothiazolylmethyloxy, pyrazolylmethyloxy, isopyrazolylmethyloxy, pyrrolidinylmethyloxy, benzoxazolylmethyloxy and groups of the formula of

[Chem.17]

The term of "non-aromatic heterocyclyalkyloxy" includes alkyloxy substituted with one or more above "non-aromatic heterocyclyl". Also, "non-aromatic heterocyclylalkyloxy" includes a "non-aromatic heterocyclylalkyloxy" wherein the alkyl portion thereof is substituted with one or more above "aromatic carbocyclyl", "non-aromatic carbocyclyl" and/or "aromatic heterocyclyl". Examples are tetrahydropyranmethyloxy, morpholinylmethyloxy, piperidinylmethyloxy, piperazinylmethyloxy and groups of the formula of

[Chem.18]

The term of "aromatic carbocyclyl alkylxycarbonyl" includes alkyloxy carbonyl substituted with one or more above "aromatic carbocyclyl". Examples are benzyloxy carbonyl, phenethyloxycarbonyl, phenylpropyloxycarbonyl, benzhydryloxycarbonyl, tritylloxycarbonyl, naphthylmethyloxycarbonyl and a group of the formula of

[Chem.19]

The term of "non-aromatic carbocyclylalkyloxycarbonyl" includes alkyloxy carbonyl substituted with one or more above "non-aromatic carbocyclyl". Also, "non-aromatic carbocyclylalkyloxycarbonyl" includes "non-aromatic carbocyclylalkyloxycarbonyl" wherein the alkyl portion thereof is substituted with one or more above "aromatic carbocyclyl". Examples are cyclopentylmethyloxycarbonyl, cyclobutylmethyloxycarbonyl, cyclopropylmethyloxycarbonyl, cyclohexylmethyloxycarbonyl and a group
The term of "aromatic heterocyclyl alkyloxycarbonyl" includes alkyloxycarbonyl substituted with one or more above "aromatic heterocyclyl". Also, "aromatic heterocyclyl alkyloxycarbonyl" includes "aromatic heterocyclyl alkyloxycarbonyl" wherein the alkyl portion thereof is substituted with one or more above "aromatic carbocyclyl", and/or "non-aromatic carbocyclyl". Examples are pyridylmethyloxycarbonyl, furanymethyloxycarbonyl, imidazolylmethyloxycarbonyl, indolymethyloxycarbonyl, benzothiophenylmethyloxycarbonyl, oxazolylmethyloxycarbonyl, isoxazolylmethyloxycarbonyl, thiazolylmethyloxycarbonyl, isothiazolylmethyloxycarbonyl, pyrazolylmethyloxycarbonyl, isopyrazolylmethyloxycarbonyl, pyrrolidinylmethyloxycarbonyl, benzoxazolylmethyloxycarbonyl and groups of the formula of

The term of "non-aromatic heterocyclyl alkyloxycarbonyl" includes alkyloxycarbonyl substituted with one or more above "non-aromatic heterocyclyl". Also, "non-aromatic heterocyclyl alkyloxycarbonyl" includes "non-aromatic heterocyclyl alkyloxycarbonyl" wherein the alkyl portion thereof is substituted with one or more above "aromatic carbocyclyl", "non-aromatic carbocyclyl" and/or "aromatic heterocyclyl". Examples are tetrahydropyranmethyloxycarbonyl, morpholinylmethyloxycarbonyl, morpholinylethoxycarbonyl, piperidinylmethyloxycarbonyl, piperazinylmethyloxycarbonyl and groups of the formula of

The term of "aromatic carbocyclylalkyloxyalkyl" includes alkyloxyalkyl substituted with one or more above "aromatic carbocyclyl". Examples are benzyloxymethyl,
phenethyloxymethyl, phenylpropyloxymethyl, benzhydryloxymethyl, trityloxymethyl, naphthylmethyloxymethyl and a group of the formula of [Chem.23]

[0083] The term of "non-aromatic carbocyclalkyloxyalkyl" includes alkyloxyalkyl substituted with one or more above "non-aromatic carbocyclyl". Also, "non-aromatic carbocyclalkyloxyalkyl" includes a "non-aromatic carbocyclalkyloxyalkyl" wherein the alkyloxyalkyl portion attached to non-aromatic carbocyclyl is substituted with one or more above "aromatic carbocyclyl". Examples are cyclopropylethylmethyloxymethyl, cyclobutylethylmethyloxymethyl, cyclopentylethylmethyloxymethyl, cyclohexylethylmethyloxymethyl and a group of the formula of [Chem.24]

[0084] The term of "aromatic heterocyclalkyloxyalkyl" includes alkyloxyalkyl substituted with one or more above "aromatic heterocyclyl". Also, "aromatic heterocyclalkyloxyalkyl" includes "aromatic heterocyclalkyloxyalkyl" wherein the alkyloxyalkyl portion attached to aromatic heterocyclyl is substituted with one or more above "aromatic carbocyclyl" and/or "non-aromatic carbocyclyl". Examples are pyridylmethylmethyloxymethyl, furanylthiomethyloxymethyl, imidazolylmethyloxymethyl, indolylmethyloxymethyl, benzothiophenylmethyloxymethyl, oxazolylmethyloxymethyl, isoxazolylmethyloxymethyl, thiazolylmethyloxymethyl, isothiazolylmethyloxymethyl, pyrazolylmethyloxymethyl, isopyrazolylmethyloxymethyl, pyrrolidinylmethyloxymethyl, benzoxazolylmethyloxymethyl and groups of the formula of [Chem.25]

[0085] The term of "non-aromatic heterocyclalkyloxyalkyl" includes alkyloxyalkyl substituted with one or more above "non-aromatic heterocyclyl". Also, "non-aromatic hetero-
erocyclalkyloxyalkyl" includes "non-aromatic heterocyclylalkyloxy alkyl" wherein the alkyl portion attached to non-aromatic heterocycl is substituted with one or more above "aromatic carbocyclyl", "non-aromatic carbocyclyl" and/or "aromatic heterocyclyl". Examples are tetrahydropyranymethyloxymethyl, morpholinymethyloxymethyl, morpholinylethylloxymethyl, piperidinymethyloxymethyl and piperazinylmethyloxymethyl and groups of the formula of

[Chem.26]

The term of "aromatic carbocyclylalkylamino" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above "aromatic carbocyclylalkyl". Examples are benzylamino, phenethylamino, phenylpropylamino, benzhydrylamino, tritylamino, naphthylmethylamino and dibenzylamino.

The term of "non-aromatic carbocyclylalkylamino" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above "non-aromatic carbocyclylalkyl". Examples are cyclopropylmethylamino, cyclobutylmethylamino, cyclopentylmethylamino and cyclohexylmethylamino.

The term of "aromatic heterocyclylalkylamino" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above "aromatic heterocyclylalkyl". Examples are pyridylmethylamino, furanylmethylamino, imidazolymethylamino, indolylmethylamino, benzothiophenylmethylamino, oxazolymethylamino, thiazolymethylamino, isothiazolymethylamino, pyrazolylmethylamino, isopyrazolylmethylamino, pyrrolidinylmethylamino and benzoazolymethylamino.

The term of "non-aromatic heterocyclylalkylamino" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above "non-aromatic heterocyclylalkyl". Examples are tetrahydropyranymethylamino, morpholinylethylamino, piperidinymethylamino and piperazinylmethylamino.

The term of "aromatic carbocyclylalkylcarbamoyl" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a carbamoyl group is replaced with the above "aromatic carbocyclylalkyl". Examples are benzylcarbamoyl, phenethylcarbamoyl, phenylpropylcarbamoyl, benzhydrylcarbamoyl, tritylcarbamoyl, naphthylmethylcarbamoyl and dibenzylcarbamoyl.

The term of "non-aromatic carbocyclylalkylcarbamoyl" includes a group wherein
one or two hydrogen atoms attached to a nitrogen atom of a carbamoyl group is replaced with the above "non-aromatic carbocyclylalkyl". Examples are cyclopropylmethycarbamoyl, cyclobutylmethycarbamoyl, cyclopentylmethycarbamoyl and cyclohexylmethycarbamoyl.

[0091] The term of "aromatic heterocyclylalkylcarbamoyl" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a carbamoyl group is replaced with the above "aromatic heterocyclylalkyl". Examples are pyridylmethylcarbamoyl, furanylmethylcarbamoyl, imidazolylmethylcarbamoyl, indolylmethylcarbamoyl, benzotriphenylmethylcarbamoyl, oxazolylmethylcarbamoyl, isoxazolylmethylcarbamoyl, thiazolylmethylcarbamoyl, isothiazolylmethylcarbamoyl, pyrazolylmethylcarbamoyl, isopyrazolylmethylcarbamoyl, pyrrolidinylmethylcarbamoyl and benzoxazolylmethylcarbamoyl.

[0092] The term of "non-aromatic heterocyclylalkylcarbamoyl" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a carbamoyl group is replaced with the above "non-aromatic heterocyclylalkylcarbamoyl". Examples are tetrahydropranylmethylcarbamoyl, morpholinylethylcarbamoyl, pipendinylmethylcarbamoyl and piperazinylethylcarbamoyl.

[0093] The "aromatic carbocycle" portion of "aromatic carbocycle", "aromatic carbocyclyloxy", "aromatic carbocyclylcarbonyl", "aromatic carbocyclylcarbonyloxy", "aromatic carbocyclylamino", "aromatic carbocyclylaminoxy", "aromatic carbocyclylsulfonyl" and "aromatic carbocyclylsulfamoyl" and "aromatic carbocyclylcarbamoyl" means the above "aromatic carbocyclyl".

The term of "aromatic carbocyclyloxy" includes a group wherein an oxygen atom is substituted with the above "aromatic carbocyclyl". Examples are phenyloxoy and naphthylctryoxy.

The term of "aromatic carbocyclylcarbonyl" includes a group wherein a carbonyl group is substituted with the above "aromatic carbocyclyl". Examples are phenylcarbonyl and naphthylcarbonyl.

The term of "aromatic carbocyclylcarbonyloxy" includes a group wherein a carbonyloxy group is substituted with the above "aromatic carbocyclyl". Examples are phenylcarbonyloxy and naphthylcarbonyloxy.

The term of "aromatic carbocyclyloxyycarbonyl" includes a group wherein a carbonyl group is substituted with the above "aromatic carbocyclyloxy". Examples are phenyloxycarbonyl and naphthylcarbonyl.

The term of "aromatic carbocyclylamino" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above "aromatic carbocyclylcarbonyl". Examples are benzoamino and naphthylcarb-
bonylarnino.
The term of "aromatic carbocyclylamino" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above "aromatic carbocyclyl". Examples are phenylarnino and naphthylarnino.
The term of "aromatic carbocyclylsulfanyl" includes a group wherein a hydrogen atom attached to a sulfur atom of sulfanyl is replaced with the above "aromatic carbocyclyl". Examples are phenylsulfanyl and naphthylsulfanyl.
The term of "aromatic carbocyclylsulfonyl" includes a group wherein a sulfonyl group is substituted with the above "aromatic carbocyclyl". Examples are phenylsulfonyl and naphthylsulfonyl.
The term of "aromatic carbocyclylsulfamoyl" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a sulfamoyl group is replaced with the above "aromatic carbocyclyl". Examples are phenylsulfamoyl and naphthylsulfamoyl.
The term of "aromatic carbocyclylcarbonyl" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a carbonyl group is replaced with the above "aromatic carbocyclyl". Examples are phenylcarbonyl and naphthylcarbonyl.

The term of "non-aromatic carbocyclylcarbonyl" includes a group wherein a carbonyl group is substituted with the above "non-aromatic carbocyclyl". Examples are cyclopropylcarbonyl, cyclohexylcarbonyl and cyclohexenylcarbonyl.

The term of "non-aromatic carbocyclylcarbonyloxy" includes a group wherein a carbonyloxy group is substituted with the above "non-aromatic carbocyclyl". Examples are cyclopropylcarbonyloxy, cyclohexylcarbonyloxy and cyclohexenylcarbonyloxy.

The term of "non-aromatic carbocyclylcarbonylamino" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above "non-aromatic carbocyclylcarbonyl". Examples are cyclopropylcar-
bonylamino, cyclohexylcarbonylamino and cyclohexenylcarbonylamino.
The term of "non-aromatic carbocyclylamino" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above "non-aromatic carbocyclyl". Examples are cyclopropylamino, cyclohexylamino and cyclohexenylamino.
The term of "non-aromatic carbocyclylsulfanyl" includes a group wherein a hydrogen atom attached to a sulfur atom of a sulfanyl is replaced with the above "non-aromatic carbocyclyl". Examples are cyclopropylsulfanyl, cyclohexylsulfanyl and cyclohexenylsulfanyl.
The term of "non-aromatic carbocyclylsulfonyl" includes a group wherein a sulfonyl group is substituted with the above "non-aromatic carbocyclyl". Examples are cyclopropylsulfonyl, cyclohexylsulfonyl and cyclohexenylsulfonyl.
The term of "non-aromatic carbocyclylsulfamoyl" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a sulfamoyl group is replaced with the above "non-aromatic carbocyclyl". Examples are cyclopropylsulfamoyl, cyclohexylsulfamoyl and cyclohexenylsulfamoyl.
The term of "non-aromatic carbocyclylcarbamoyl" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a carbamoyl group is replaced with the above "non-aromatic carbocyclyl". Examples are cyclopropylcarbamoyl, cyclohexylcarbamoyl and cyclohexenylcarbamoyl.

The "aromatic heterocycle" portion of "aromatic heterocycle", "aromatic heterocyclyloxy", "aromatic heterocyclylcarbonyl", "aromatic heterocyclylcarbonyloxy", "aromatic heterocyclyloxycarbonyl", "aromatic heterocyclylcarbonylamino", "aromatic heterocyclylamino", "aromatic heterocyclylsulfanyl", "aromatic heterocyclylcarbamoyl", "aromatic heterocyclylcarbamoyl" and "aromatic heterocyclyloxycarbonyl" means the above "aromatic heterocyclyl".
Examples of "aromatic heterocycle" in ring B is pyridine, pyrazine, pyrimidine, pyridazine and oxazole.
The term of "aromatic heterocyclyloxy" includes a group wherein an oxygen atom is substituted with the above "aromatic heterocyclyl". Examples are pyridyloxy and oxazolylxy.
The term of "aromatic heterocyclylcarbonyl" includes a group wherein a carbonyl group is substituted with the above "aromatic heterocyclyl". Examples are pyridylcarbonyl and oxazolylcarbonyl.
The term of "aromatic heterocyclylcarbonyloxy" includes a group wherein a carbonyloxy group is substituted with the above "aromatic heterocyclyl". Examples are pyridylcarbonyloxy and oxazolylcarbonyloxy.
The term of "aromatic heterocyclyloxycarbonyl" includes a group wherein a
carbonyl group is substituted with the above "aromatic heterocyclyloxy". Examples are pyridyloxy carbonyl and oxazolyloxy carbonyl.

The term of "aromatic heterocyclylcarbonylamino" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above "aromatic heterocyclylcarbonyl". Examples are pyridyl carbonylamino and oxazolyl carbonylamino.

The term of "aromatic heterocyclylamino" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above "aromatic heterocyclyl". Examples are pyridylamino and oxazolylamino.

The term of "aromatic heterocyclylsulfanyl" includes a group wherein a hydrogen atom attached to a sulfur atom of sulfanyl is replaced with the above "aromatic heterocyclyl". Examples are pyridylsulfanyl and oxazolylsulfanyl.

The term of "aromatic heterocyclylsulfonyl" includes a group wherein a sulfonyl group is substituted with the above "aromatic heterocyclyl". Examples are pyridyl sulfonyl and oxazolyl sulfonyl.

The term of "aromatic heterocyclylsulfamoyl" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a sulfamoyl group is replaced with the above "aromatic heterocyclyl". Examples are pyridylsulfamoyl and oxazolylsulfamoyl.

The term of "aromatic heterocyclyl carbamoyl" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a carbamoyl group is replaced with the above "aromatic heterocyclyl". Examples are pyridyl carbamoyl and oxazolyl carbamoyl.

The "non-aromatic heterocycle" portion of "non-aromatic heterocyclyl", "non-aromatic heterocyclyloxy", "non-aromatic heterocyclyl carbonyl", "non-aromatic heterocyclyl oxacyloxy", "non-aromatic heterocyclyl carbonyloxacyloxy", "non-aromatic heterocyclylcarbonylamino", "non-aromatic heterocyclylamino", "non-aromatic heterocyclylsulfanyl", "non-aromatic heterocyclylsulfonyl", "non-aromatic heterocyclylsulfamoyl" and "non-aromatic heterocyclyl carbamoyl" means the above "non-aromatic heterocyclyl".

The term of "non-aromatic heterocyclyloxy" includes a group wherein an oxygen atom is substituted with the above "non-aromatic heterocyclyl". Examples are piperidinyloxy and tetrahydrofurlyloxy.

The term of "non-aromatic heterocyclyl carbonyl" includes a group wherein a carbonyl group is substituted with the above "non-aromatic heterocyclyl". Examples are piperidinyl carbonyl and tetrahydrofuryl carbonyl.

The term of "non-aromatic heterocyclyl oxacyloxy" includes a group wherein a car- bonyloxy group is substituted with the above "non-aromatic heterocyclyl". Examples are piperidinylcarbonyloxy and tetrahydrofurylcarbonyloxy.
The term of "non-aromatic heterocyclyloxycarbonyl" includes a group wherein a carbonyl group is substituted with the above "non-aromatic heterocycloxy". Examples are piperidinylloxycarbonyl and tetrahydrofuryloxycarbonyl.

The term of "non-aromatic heterocyclylcarbonylamino" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above "non-aromatic heterocyclylcarbonyl". Examples are piperidinylcarbonylamino and tetrahydrofurylcarbonylamino.

The term of "non-aromatic heterocyclylamino" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above "non-aromatic heterocyclyl". Examples are piperidinylamino and tetrahydrofurylamino.

The term of "non-aromatic heterocyclylsulfanyl" includes a group wherein a hydrogen atom attached to a sulfur atom of sulfanyl is replaced with the above "non-aromatic heterocyclyl". Examples are piperidinylsulfanyl and tetrahydrofurylsulfanyl.

The term of "non-aromatic heterocyclylsulfonyl" includes a group wherein a sulfonyl group is substituted with the above "non-aromatic heterocyclyl". Examples are piperidinylsulfonyl and tetrahydrofurylsulfonyl.

The term of "non-aromatic heterocyclylsulfamoyl" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a sulfamoyl group is replaced with the above "non-aromatic heterocyclyl". Examples are piperidinylsulfamoyl and tetrahydrofurylsulfamoyl.

The term of "non-aromatic heterocyclylcarbamoyl" includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a carbamoyl group is replaced with the above "non-aromatic heterocyclyl". Examples are piperidinylcarbamoyl and tetrahydrofurylcarbamoyl.

The term "R² and R² together with the carbon atom to which they are attached may form substituted cycloalkane" includes [Chem.27]

\[ \text{R}^{2a} \quad \text{R}^{2b} \quad \text{R}^{2c} \quad \text{R}^{2d} \]

wherein R is halogen or substituted or unsubstituted alkyl, and m is an integer of 1 or 2.

Examples of substituents of "substituted or unsubstituted alkyl", "substituted or unsubstituted alkenyl", and "substituted or unsubstituted alkynyl", are the group as follows. A carbon atom at any possible position(s) can be substituted with one or more
substituents selected from the following groups.
Substituent: halogen, hydroxy, carboxy, amino, imino, hydroxyamino, hydroxyimino, formyl, formyloxy, carbamoyl, sulfamoyl, sulfanyl, sulfino, sulfo, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, cyano, nitro, nitroso, azide, hydrazino, ureido, amidino, guanidino, trialkylsilyl, alklyoxy, alkenyl oxy, alkynyl oxy, haloalkyloxy, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, monoalkylamino, dialkylamino, alkylsulfonl, alkanyl sulfonl, alkynyl sulfonl, monoalkylcarbonylamino, dialkylcarbonylamino, monoalkylsulfonlamino, dialkylsulfonlamino, alkylmino, alkenylmino, alkynylmino, alkenylcarbonylimino, alkynylcarbonylimino, alkylcarbonyloxy, alkynylcarbonyloxy, alkylcarbonylcarbo nyl, alkylcarbonylcarbocyclyl, aromatic carbocyclyl, aromatic heterocyclyl, non-aromatic heterocyclyl, aromatic carbocyclyloxy, non-aromatic carbocyclyloxy, aromatic carbocyclylcarbonyl, non-aromatic carbocyclylcarbonyl, aromatic heterocyclylcarbonyl, non-aromatic heterocyclylcarbonyl, aromatic carbocyclyloxycarbonyl, non-aromatic carbocyclyloxycarbonyl, aromatic heterocyclyloxycarbonyl, non-aromatic heterocyclyloxycarbonyl, aromatic carbocyclylsulfanyl, non-aromatic carbocyclylsulfanyl, aromatic heterocyclylsulfanyl, non-aromatic heterocyclylsulfanyl, aromatic carbocyclylsulfonl, non-aromatic carbocyclylsulfonl, aromatic heterocyclylsulfonl, and non-aromatic heterocyclylsulfonl.

Examples of substituents of "substituted or unsubstituted alkyl" are one or more groups selected from the following substituent group a.

The substituent group a is a group consisting of halogen, hydroxy, alklyoxy, haloalkyloxy, hydroxalkyloxy, alkyloxalkyloxy, formyl, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, aromatic carbocyclylcarbonyl, non-aromatic carbocyclylcarbonyl, aromatic heterocyclylcarbonyl, non-aromatic heterocyclylcarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, aromatic carbocyclylcarbonyloxy, non-aromatic carbocyclyl-
cyclylcarbonyloxy, aromatic heterocyclylcarbonyloxy, non-aromatic heterocyclylcarbonyloxy, carboxy, alkylloxycarbonyl, amino, monoalkylcarbonylamino, dialkylcarbonylamino, alkenyloxycarbonylamine, alkyloxycarbonylamine, aromatic carbocyclylcarbonylamine, non-aromatic carbocyclylcarbonylamine, aromatic heterocyclylcarbonylamine, non-aromatic heterocyclylcarbonylamine, monoalkylamine, dif-alkylamine, imino, hydroxyimino, alkylloxycarbonyl, alkylsulfonylamino, carbamoylamino, dialkylcarbamoylamino, alkylloxycarbonylamino, hydrazino, ureido, amidino, guanidino, trialkylsilyl, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyimino, ring monoalkylcarbamoylamino, dialkylcarbamoylamino, hydroxyalkylcarbamoylamino, sulfamoylamino, monoalkylsulfamoylamino, dialkylsulfamoylamino, alkylsulfonylamino, diarylsulfonimino, alkylsulfonylamino, alkylsulfonylalkylamine, alkylsulfonylimino, alkyl-sulfinylamine, alkylsulfinylalkylamine, alkylsulfinylimino, cyano, nitro, aromatic carbocyclylcarbonylamino, non-aromatic carbocyclylcarbonylamino, aromatic heterocyclylcarbonylamino and non-aromatic heterocyclylcarbonylamino (each of aromatic carbocycle, non-aromatic carbocycle, aromatic heterocycle and non-aromatic heterocycle is optionally substituted with one or more selected from halogen, alkyl, hydroxy and alkoxy).

The substituents of "substituted or unsubstituted alkyl" are, for example, halogen, hydroxy and the like.

[0102] Examples of substituents of "substituted or unsubstituted alkoxy", "substituted or unsubstituted alkenyl" and "substituted or unsubstituted alkynyl" are one or more selected from the above substituent group a. Specific examples are halogen, hydroxy and the like.

[0103] Examples of substituents of "substituted or unsubstituted amino" are one or two selected from alkyl, alkenylcarbonyl, alkenyloxycarbonyl, alkynylcarbonyl, aromatic carbocyclylcarbonyl, non-aromatic carbocyclylcarbonylamino, aromatic heterocyclylcarbonylamino, non-aromatic heterocyclylcarbonylamino, hydroxy, alkyl, alkenylcarbonylamino, aromatic carbocyclylcarbonylamino, non-aromatic carbocyclylcarbonylamino, aromatic heterocyclylcarbonylamino and non-aromatic heterocyclylcarbonylamino and the like. Specific examples are alkyl, alkenylcarbonyl and the like.

[0104] Examples of substituents on "aromatic carbocycle", "non-aromatic carbocycle", "cycloalkyl", "aromatic heterocycle" and "non-aromatic heterocycle" of "substituted or unsubstituted aromatic carbocyclylcarbonyl", "substituted or unsubstituted non-aromatic carbocyclylcarbonyl", "substituted or unsubstituted cycloalkyl", "substituted or unsubstituted aromatic heterocyclylcarbonyl", and "substituted or unsubstituted non-aromatic heterocyclylcarbonyl" include the group as follows. One or more atoms at any possible position(s) on each ring can be substituted with one or more substituents selected from the following group.

Substituent: halogen, hydroxy, carboxy, amino, imino, hydroxyamino, hydroxyimino, formyl, formyloxy, carbamoyl, sulfamoyl, sulfanyl, sulfino, sulfo, thioformyl, thiocarbonyl, dithiocarbonyl, thiocarbamoyl, cyano, nitro, nitroso, azide, hydrazino, ureido, amidino, guanidino, trialkylsilyl, alkyl, alkenyl, alkynyl, haloalkyl,
alkyloxy, alkenyloxy, haloalkyloxy, alkylxyalkyloxy, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, monoalkyloxyalkylamino, alkyloxyalkylamino, alkyloxyalkyloxy, alkyloxyalkylalkyl, monoalkyloxyalkylamino, dialkylsulfonylamino, alkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, alkyloxyimino, alkenyloxyimino, alkynyloxyimino, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxycarbonyl, alkenylloxycarbonyl, alkynylloxycarbonyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, alkyloxyalkylamino, dialkylsulfonylamino, alkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, alkyloxyimino, alkenyloxyimino, alkynyloxyimino, alkyloxycarbonyl, alkenylloxycarbonyl, alkynylloxycarbonyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, monoalkylcarbamoyl, dialkylcarbamoyl, monoalkylsulfamoyl, dialkylsulfamoyl, aromatic carbocyclyl, non-aromatic carbocyclyl, aromatic heterocyclyl, non-aromatic heterocyclyl, aromatic carbocyclyloxy, non-aromatic heterocyclyloxy, aromatic carbocyclylcarbonyl, non-aromatic heterocyclylcarbonyl, aromatic carbocyclyloxy, aromatic heterocyclyloxy, aromatic carbocyclylcarbonyl, non-aromatic heterocyclylcarbonyl, aromatic carbocyclylalkyl, aromatic carbocyclylalkyl, non-aromatic carbocyclylalkyl, aromatic carbocyclylalkyloxy, non-aromatic carbocyclylalkyloxy, aromatic heterocyclylalkyl, non-aromatic heterocyclylalkyloxy, aromatic carbocyclylalkyloxy, non-aromatic carbocyclylalkyloxy, aromatic heterocyclylalkyl, non-aromatic heterocyclylalkyloxy, aromatic carbocyclylalkyloxy, non-aromatic carbocyclylalkyloxy, aromatic heterocyclylalkyl, non-aromatic heterocyclylalkyloxy, aromatic carbocyclylalkylamino, non-aromatic carbocyclylalkylamino, aromatic heterocyclylalkylamino, non-aromatic heterocyclylalkylamino, aromatic carbocyclylsulfanyl, non-aromatic carbocyclylsulfanyl, aromatic heterocyclylsulfanyl, non-aromatic heterocyclylsulfanyl, aromatic carbocyclylsulfon, non-aromatic carbocyclylsulfon, aromatic heterocyclylsulfon, and non-aromatic heterocyclylsulfon.

A "substituted or unsubstituted non-aromatic carbocyclyl" and "substituted or unsubstituted non-aromatic heterocyclyl" can be substituted with "oxo". A group wherein two hydrogen atoms attached to the same carbon atom are replaced with oxo is included: [Chem.28]
Examples of the substituent of "substituted or unsubstituted aromatic carbocycle", 
"substituted or unsubstituted non-aromatic carbocycle", "substituted or unsubstituted 
aromatic heterocycle", "substituted or unsubstituted non-aromatic heterocycle", "sub-
stituted or unsubstituted benzene", "substituted or unsubstituted pyridine", "substituted 
or unsubstituted pyrazine", "substituted or unsubstituted oxazole", "substituted or un-
substituted pyrimidine" or "substituted or unsubstituted pyridazine" in ring A and ring B include

(a) a group selected from the substituent group a, for example, halogen, hydroxy, 
alkyloxy, formyl, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, aromatic carbo-
cyclylcarbonyl, non-aromatic carbocyclylcarbonyl, aromatic heterocyclylcarbonyl, non-
aromatic heterocyclylcarbonyl, formyloxy, alkylcarbonyloxy, alkenylcarbonyloxy, 
alkynylcarbonyloxy, aromatic carbocyclylcarbonyloxy, non-aromatic carbocyclylcar-
bonyloxy, aromatic heterocyclylcarbonyloxy, non-aromatic heterocyclylcarbonyloxy, 
carboxy, alkylxycarbonyl, carbamoyl, amino, cyano, monoalkylamino, dialkylamino 
and/or alkylsulfanyl;

(b) unsubstituted alkyl or alkyl substituted with one or more groups selected from the 
substituent group a, hydroxyimino and alkyloxyimino;

(c) aminoalkyl substituted with one or more groups selected from the substituent 
group a;

(d) unsubstituted alkenyl or alkenyl substituted with one or more substituents 
selected from the substituent group a;

(e) unsubstituted alkynyl or alkynyl substituted with one or more substituents 
selected from the substituent group a;

(f) alkyloxy substituted with one or more substituents selected from the substituent 
group a;

(g) alkoxyalkyloxy substituted with one or more substituents selected from the sub-
stituent group a;

(h) unsubstituted alkenyloxy or alkenyloxy substituted with one or more substituents 
selected from the substituent group a;

(i) alkoxyalkenyloxy substituted with one or more substituents selected from the 
substituent group a;

(j) unsubstituted alkynyloxy or alkynyloxy substituted with one or more substituents 
selected from the substituent group a;

(k) alkoxyalkynyloxy substituted with one or more groups selected from the sub-
stituent group a;

(l) unsubstituted alkylsulfanyl or alkylsulfanyl substituted with one or more sub-
stituents selected from the substituent group a;

(m) unsubstituted alkenylsulfanyl or alkenylsulfanyl substituted with one or more
substituents selected from the substituent group a;
(n) unsubstituted alkynylsulfanyl or alkynylsulfanyl substituted with one or more substituents selected from the substituent group a;
(o) monoalkylamino substituted with one or more substituents selected from the substituent group a;
(p) dialkylamino substituted with one or more substituents selected from the substituent group a;
(q) alkenylamino substituted with one or more substituents selected from the substituent group a;
(r) alkynylamino substituted with one or more substituents selected from the substituent group a;
(s) unsubstituted aminooxy or aminooxy substituted with one or more substituents selected from the substituent group a and alkylidene;
(t) alkylcarbonyl substituted with one or more substituents selected from the substituent group a;
(u) alkenylcarbonyl substituted with one or more substituents selected from the substituent group a;
(v) alkynylcarbonyl substituted with one or more substituents selected from the substituent group a;
(w) aromatic carbocyclcarbonyl substituted with one or more substituents selected from the substituent group a;
(x) non-aromatic carbocyclcarbonyl substituted with one or more substituents selected from the substituent group a;
(y) aromatic heterocyclcarbonyl substituted with one or more substituents selected from the substituent group a;
(z) non-aromatic heterocyclcarbonyl substituted with one or more substituents selected from the substituent group a;
[0109] (aa) monoalkylcarbamoyl substituted with one or more substituents selected from the substituent group a;
(ab) dialkylcarbamoyl substituted with one or more substituents selected from the substituent group a;
(ac) alkoxy carbonyl substituted with one or more substituents selected from the substituent group a;
(ad) unsubstituted alkylsulfonyl or alkylsulfonyl substituted with one or more substituents selected from the substituent group a;
( ae) unsubstituted alkylsulfinyl or alkylsulfinyl substituted with one or more substituents selected from the substituent group a;
(af) monoalkylsulfamoyl substituted with one or more substituents selected from the
substituent group a;
(ag) dialkylsulfamoyl substituted with one or more substituents selected from the substituent group a;
(ah) aromatic carbocycyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
(ai) non-aromatic carbocycyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
(aj) aromatic heterocycyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

[0110] (ak) non-aromatic heterocycyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
(al) unsubstituted aromatic carbocycylalkyl or aromatic carbocycylalkyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
(am) unsubstituted non-aromatic carbocycylalkyl or non-aromatic carbocycylalkyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
(an) unsubstituted aromatic heterocycylalkyl or aromatic heterocycylalkyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
(ao) unsubstituted non-aromatic heterocycylalkyl or non-aromatic heterocycylalkyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

[0111] (ap) unsubstituted aromatic carbocyclyloxy or aromatic carbocyclyloxy substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
(aq) unsubstituted non-aromatic carbocyclyloxy or non-aromatic carbocyclyloxy substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
(ar) unsubstituted aromatic heterocyclyloxy or aromatic heterocyclyloxy substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
(as) unsubstituted non-aromatic heterocyclyloxy or non-aromatic heterocyclyloxy substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
(at) unsubstituted aromatic carbocycylalkyloxy or aromatic carbocycylalkyloxy substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
(au) unsubstituted non-aromatic carbocyclylalkyloxy or non-aromatic carbocyclylalkyloxy substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(av) unsubstituted aromatic heterocyclylalkyloxy or aromatic heterocyclylalkyloxy substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

[0112] (aw) unsubstituted non-aromatic heterocyclylalkyloxy or non-aromatic heterocyclylalkyloxy substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(ax) unsubstituted aromatic carbocyclylalkyloxy carbonyl or aromatic carbocyclylalkyloxy carbonyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(ay) unsubstituted non-aromatic carbocyclylalkyloxy carbonyl or non-aromatic carbocyclylalkyloxy carbonyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(az) unsubstituted aromatic heterocyclylalkyloxy carbonyl or aromatic heterocyclylalkyloxy carbonyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(ba) unsubstituted non-aromatic heterocyclylalkyloxy carbonyl or non-aromatic heterocyclylalkyloxy carbonyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(bb) unsubstituted aromatic carbocyclylsulfanyl or aromatic carbocyclylsulfanyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(be) unsubstituted non-aromatic carbocyclylsulfanyl or non-aromatic carbocyclylsulfanyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

[0113] (bd) unsubstituted aromatic heterocyclylsulfanyl or aromatic heterocyclylsulfanyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(be) unsubstituted non-aromatic heterocyclylsulfanyl or non-aromatic heterocyclylsulfanyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(bf) unsubstituted aromatic carbocyclylamino or aromatic carbocyclylamino substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(bg) unsubstituted non-aromatic carbocyclylamino or non-aromatic carbocyclylamino substituted with one or more substituents selected from the substituent group
α, azide, alkyl and haloalkyl;
(bh) unsubstituted aromatic heterocyclylamino or aromatic heterocyclylamino substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl;
(bi) unsubstituted non-aromatic heterocyclylamino or non-aromatic heterocyclylamino substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl;
(bj) unsubstituted aromatic carbocyclylalkylamino or aromatic carbocyclylalkylamino substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl;
(bk) unsubstituted non-aromatic carbocyclylalkylamino or non-aromatic carbocyclylalkylamino substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl;
(bl) unsubstituted aromatic heterocyclylalkylamino or aromatic heterocyclylalkylamino substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl;
(bm) unsubstituted non-aromatic heterocyclylalkylamino or non-aromatic heterocyclylalkylamino substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl;
(bn) unsubstituted aromatic carbocyclylsulfamoyl or aromatic carbocyclylsulfamoyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl;
(bo) unsubstituted non-aromatic carbocyclylsulfamoyl or non-aromatic carbocyclylsulfamoyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl;
(bp) unsubstituted aromatic heterocyclylsulfamoyl or aromatic heterocyclylsulfamoyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl;
(bq) unsubstituted non-aromatic heterocyclylsulfamoyl or non-aromatic heterocyclylsulfamoyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl;
(br) unsubstituted aromatic carbocyclylsulfonyl or aromatic carbocyclylsulfonyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl;
(bs) unsubstituted non-aromatic carbocyclylsulfonyl or non-aromatic carbocyclylsulfonyl substituted with one or more substituents selected from the substituent group α, azide, alkyl and haloalkyl;
(bt) unsubstituted aromatic heterocyclylsulfonyl or aromatic heterocyclylsulfonyl
substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(bu) unsubstituted non-aromatic heterocyclylsulfonyl or non-aromatic heterocyclylsulfonyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(bv) unsubstituted aromatic carbocyclecarbamoyl or aromatic carbocyclecarbamoyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(bw) unsubstituted non-aromatic carbocyclecarbamoyl or non-aromatic carbocyclecarbamoyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(bx) unsubstituted aromatic heterocyclylcarbamoyl or aromatic heterocyclylcarbamoyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(by) unsubstituted non-aromatic heterocyclylcarbamoyl or non-aromatic heterocyclylcarbamoyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(bz) unsubstituted aromatic carbocyclelalkylcarbamoyl or aromatic carbocyclelalkylcarbamoyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(ca) unsubstituted non-aromatic carbocyclelalkylcarbamoyl or non-aromatic carbocyclelalkylcarbamoyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(cb) unsubstituted aromatic heterocyclylalkylcarbamoyl or aromatic heterocyclylalkylcarbamoyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(cc) unsubstituted non-aromatic heterocyclylalkylcarbamoyl or non-aromatic heterocyclylalkylcarbamoyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(cd) unsubstituted aromatic carbocycleloxy carbonyl or aromatic carbocycleloxy carbonyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(ce) unsubstituted non-aromatic carbocycleloxy carbonyl or non-aromatic carbocycleloxy carbonyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;

(cf) unsubstituted aromatic heterocyclyloxy carbonyl or aromatic heterocyclyloxy carbonyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
(eg) unsubstituted non-aromatic heterocyclyloxycarbonyl or non-aromatic heterocyclyloxycarbonyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
(ch) unsubstituted alkylenedioxy or alkylenedioxy substituted with halogen;
(ci) oxo; and
(cj) azide.
Each cyclic group in "substituted or unsubstituted aromatic carbocycle", "substituted or unsubstituted non-aromatic carbocycle", "substituted or unsubstituted benzene", "substituted or unsubstituted aromatic heterocycle", "substituted or unsubstituted non-aromatic heterocycle", "substituted or unsubstituted pyridine", "substituted or unsubstituted pyrazine", "substituted or unsubstituted oxazole", "substituted or unsubstituted pyrimidine", or "substituted or unsubstituted pyridazine" may be substituted with one or more substituents selected from the above substituents.

Examples of substituents of "substituted or unsubstituted aromatic carbocycle", "substituted or unsubstituted non-aromatic carbocycle", "substituted or unsubstituted benzene", "substituted or unsubstituted aromatic heterocycle", "substituted or unsubstituted non-aromatic heterocycle", "substituted or unsubstituted pyridine", "substituted or unsubstituted pyrazine", "substituted or unsubstituted oxazole", "substituted or unsubstituted pyrimidine" or "substituted or unsubstituted pyridazine" in ring A and ring B are one or more selected from
halogen;
cyano;
hydroxy;
nitro;
carboxy;
alkyl substituted with one or more substituents selected from the substituent group a, unsubstituted alkyl;
alkenyl substituted with one or more substituents selected from the substituent group a,
unsubstituted alkenyl;
alkynyl substituted with one or more substituents selected from the substituent group a,
unsubstituted alkynyl;
alkyloxy substituted with one or more substituents selected from the substituent group a,
unsubstituted alkyloxy;
alkenyloxy substituted with one or more substituents selected from the substituent group a,
unsubstituted alkenyloxy;
alkynyloxy substituted with one or more substituents selected from the substituent
group a,
unsubstituted alkynlyloxy;
alkylsulfanyl substituted with one or more substituents selected from the substituent
group a,
unsubstituted alkylsulfanyl;
alkenylsulfanyl substituted with one or more substituents selected from the substituent
group a,
unsubstituted alkenylsulfanyl;
alkynylsulfanyl substituted with one or more substituents selected from the substituent
group a,
unsubstituted alkylnlsulfanyl;
amino substituted with one or more substituents selected from the substituent group a,
unsubstituted amino;
monoalkylamino substituted with one or more substituents selected from the substituent
group a,
unsubstituted monoalkylamino;
dialkylamino substituted with one or more substituents selected from the substituent
group a,
unsubstituted dialkylamino;
cycloalkylamino substituted with one or more substituents selected from the substituent
group a,
unsubstituted cycloalkylamino;
carbamoyl substituted with one or more substituents selected from the substituent
group a,
unsubstituted carbamoyl;
monoalkylcarbamoyl substituted with one or more substituents selected from the substituent
group a,
unsubstituted monoalkylcarbamoyl;
dialkylcarbamoyl substituted with one or more substituents selected from the substituent
group a,
unsubstituted dialkylcarbamoyl;
alkyloxycarbonyl substituted with one or more substituents selected from the substituent
group a,
unsubstituted alkyloxycarbonyl;

[0119] aromatic carbocyclyl substituted with one or more substituents selected from the substituent group a, unsubstituted alkyl, and alkyl substituted with one or more substituents selected from the substituent group a.
stituents selected from the substituent group a;
unsubstituted aromatic carbocyclyl;
non-aromatic carbocyclyl substituted with one or more substituents selected from the substituent group a, unsubstituted alkyl, and alkyl substituted with one or more substituents selected from the substituent group a;
unsubstituted non-aromatic carbocyclyl;
aparomatic heterocyclyl substituted with one or more substituents selected from the substituent group a, unsubstituted alkyl, and alkyl substituted with one or more substituents selected from the substituent group a;
unsubstituted aromatic heterocyclyl;
non-aromatic heterocyclyl substituted with one or more substituents selected from the substituent group a, unsubstituted alkyl, and alkyl substituted with one or more substituents selected from the substituent group a; and
unsubstituted non-aromatic heterocyclyl.

[0121] In one embodiment, substituents are one or more selected from halogen, cyano, hydroxy, alkyl, haloalkyl, cycloalkylalkyl, alkyloxy, haloalkyloxy, alkylalkoxy, alkylalkoxy, alkylalkylalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkenyloxy, alkynyloxy, alkylsulfanyl, cyanoalkylsulfanyl, amino, monoalkylamino, dialkylamino, cycloalkylamino and cycloalkyl.

In another embodiment, substituents are one or more selected from halogen, cyano, alkyl, haloalkyl, alkyloxy, haloalkyloxy, cycloalkylalkoxy, alkynyloxy.

In another embodiment, substituents of ring A are one or more selected from halogen.

In another embodiment, substituents of ring B are one or more selected from halogen, cyano, alkyl, haloalkyl, alkyloxy and haloalkyloxy.

[0122] In one embodiment, the substituents of "substituted or unsubstituted cycloalkyl" are one or more selected from the substituent group a, unsubstituted alkyl and alkyl substituted with one or more substituents selected from the substituent group a.

In another embodiment, "substituted or unsubstituted cycloalkyl" is unsubstituted cycloalkyl.

[0123] Specific embodiments of the present invention are illustrated below. The embodiments are the compound of the following formulas (IA) to (IO):
wherein each symbol is the same as defined above, or a pharmaceutically acceptable salt thereof.

In one embodiment of the compound of formula (IA), (IB) (IC), (IJ), or (IK), \( R^2 \) is alkyl or haloalkyloxy.

In one embodiment of the compound of formula (ID), (IE), (IJ) or (IK), \( R^2 \) is halogen.

In one embodiment of the compound of formula (IL), (IM), (IN) or (10), \( R \) is halogen and \( m \) is an integer of 2.

In one embodiment of the compound of formula (IF), \( R^5 \) is halogen and \( n \) is an integer of 1 or 2.

In one embodiment of the compound of formula (IG), (IH) or (II), \( R^2 \) is halogen.

In one embodiment of the compound of formula (IH), \( R^2 \) is alkylxy.

Specific embodiments of each symbol of the formula (I) are illustrated below. All combination of these embodiments are examples of the compounds of formula (I).

In the formula (I),

X is -0-, \( R^3 \) is haloalkyl, \( R^3b \) is alkyl, \( R^2a \) is H, \( R^3b \) is H, and \( R^1 \) is alkyl or haloalkyl (hereinafter referred to as XI),

X is -0-, \( R^3 \) is CF\(_3\), \( R^3b \) is alkyl, \( R^2a \) is H, \( R^3b \) is H, and \( R^1 \) is alkyl or haloalkyl
(hereinafter referred to as X2),
X is -0-, R^3a is CHF_2, R^3b is H, R^2a is halogen, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X3),
X is -0-, R^3a is CHFCH_3, R^3b is H, R^2a is halogen, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X4),
X is -0-, R^3a is CF_3CH_2, R^3b is H, R^2a is halogen, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X5),
X is -0-, R^3a is haloalkyl substituted with alklyoxy or cycloalkyl, R^3b is H, R^2a is halogen, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X6),
X is -0-, R^3a is haloalkyl, R^3b is alkyl, R^2a is halogen, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X7),
X is -0-, R^3a is haloalkyl, R^3b is H, R^2a is alkyl, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X8),

[0125] X is -0-, R^3a is CHF_2, R^3b is H, R^2a is CH_3, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X8),
X is -0-, R^3a is CF_3, R^3b is H, R^2a is CH_3, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X10),
X is -0-, R^3a is haloalkyl, R^3b is alkyl, R^2a is alkyl, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X11),
X is -0-, R^3a is haloalkyl, R^3b is H, R^2a is alklyoxy, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X12),
X is -0-, R^3a is CH_3F, R^3b is H, R^2a is OCH_3, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X13),
X is -0-, R^3a is CF_3, R^3b is H, R^2a is OCH_3, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X14),
X is -0-, R^3a is haloalkyl, R^3b is alkyl, R^2a is alklyoxy, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X15),
X is -0-, R^3a is haloalkyl, R^3b is H, R^2a is haloalkyloxy, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X16),

[0126] X is -0-, R^3a is CHF_2, R^3b is H, R^2a is OCH_2CF_3, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X17),
X is -0-, R^3a is haloalkyl, R^3b is alkyl, R^2a is haloalkyloxy, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X18),
X is -S-, R^3a is alkyl, R^3b is H, R^2a is halogen, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X19),
X is -S-, R^3a is CH_3 or CH_2CH_3, R^3b is H, R^2a is halogen, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X20),
X is -S-, R^3a is alkyl, R^3b is alkyl, R^2a is halogen, R^2b is H, and R^1 is alkyl or haloalkyl
(hereinafter referred to as X21),
X is -S-, R^a_ is alkyl, R^b_ is H, R^{a^b}_ is alkyloxy, R^{b^b}_ is H, and R^1_ is alkyl or haloalkyl
(herinafter referred to as X22),

[0127] X is -S-, R^a_ is alkyl, R^b_ is alkyl, R^{a^a}_ is alkyloxy, R^{b^b}_ is H, and R^1_ is alkyl or haloalkyl
(herinafter referred to as X23),
X is -S-, R^a_ is alkyl, R^b_ is H, R^{a^a}_ is haloalkyloxy, R^{b^b}_ is H, and R^1_ is alkyl or haloalkyl
(herinafter referred to as X24),
X is -S-, R^a_ is alkyl, R^b_ is alkyl, R^{a^a}_ is haloalkyloxy, R^{b^b}_ is H, and R^1_ is alkyl or haloalkyl
(herinafter referred to as X25),
X is -S-, R^a_ is haloalkyl, R^b_ is H, R^{a^a}_ is halogen, R^{b^b}_ is H, and R^1_ is alkyl or haloalkyl
(herinafter referred to as X26),
X is -S-, R^a_ is CH_2F, R^b_ is H, R^{a^a}_ is halogen, R^{b^b}_ is H, and R^1_ is alkyl or haloalkyl
(herinafter referred to as X27),
X is -S-, R^a_ is haloalkyl, R^b_ is alkyl, R^{a^a}_ is haloalkyloxy, R^{b^b}_ is H, and R^1_ is alkyl or haloalkyl
(herinafter referred to as X28),
X is -S-, R^a_ is haloalkyl, R^b_ is H, R^{a^a}_ is alkyloxy, R^{b^b}_ is H, and R^1_ is alkyl or haloalkyl
(herinafter referred to as X29),

[0128] X is -S-, R^a_ is haloalkyl, R^b_ is alkyl, R^{a^a}_ is alkyloxy, R^{b^b}_ is H, and R^1_ is alkyl or haloalkyl
(herinafter referred to as X30),
X is -S-, R^a_ is haloalkyl, R^b_ is H, R^{a^a}_ is haloalkyloxy, R^{b^b}_ is H, and R^1_ is alkyl or haloalkyl
(herinafter referred to as X31),
X is -S-, R^a_ is haloalkyl, R^b_ is alkyl, R^{a^a}_ is haloalkyloxy, R^{b^b}_ is H, and R^1_ is alkyl or haloalkyl
(herinafter referred to as X32),
X is -S-, R^a_ is haloalkyl, R^b_ is H, R^{a^a}_ is alkyl, R^{b^b}_ is H, and R^1_ is alkyl or haloalkyl
(herinafter referred to as X33),
X is -S-, R^a_ is haloalkyl, R^b_ is alkyl, R^{a^a}_ is alkyl, R^{b^b}_ is H, and R^1_ is alkyl or haloalkyl
(herinafter referred to as X34),
X is -S-, R^a_ is alkyloxyalkyl, R^b_ is H, R^{a^a}_ is halogen, R^{b^b}_ is H, and R^1_ is alkyl or haloalkyl
(herinafter referred to as X35),

[0129] X is -O-,
R₂ is H, n is 0, and R₁ is alkyl or haloalkyl (hereinafter referred to as X₃₆),
X is -0-.

R₃b is H, n is 1, R₅ is halogen, and R₁ is alkyl or haloalkyl (hereinafter referred to as X₃₈),
X is -O-.

[Chem.33]

\[ R^{3b} \text{ is alkyl, } n \text{ is 1, } R^5 \text{ is halogen, and } R^1 \text{ is alkyl or haloalkyl (hereinafter referred to as } X39), \\
X \text{ is -O-}. \]

[Chem.34]

\[ R^{3b} \text{ is H, } n \text{ is 2, } R^5 \text{ is halogen, and } R^1 \text{ is alkyl or haloalkyl (hereinafter referred to as } X40), \\
X \text{ is -O-}. \]

[Chem.35]
$R^3b$ is alkyl, $n$ is 2, $R^5$ is halogen, and $R^1$ is alkyl or haloalkyl (hereinafter referred to as $X41$),
$X$ is $-S-$,
[Chem.36]

$R^3b$ is H, $n$ is 0, and $R^1$ is alkyl or haloalkyl (hereinafter referred to as $X42$),
$X$ is $-S-$,
[Chem.37]

$R^3b$ is alkyl, $n$ is 0, and $R^1$ is alkyl or haloalkyl (hereinafter referred to as $X43$),
$X$ is $-S-$,
[Chem.38]
R\textsubscript{3b} is H, n is 1, R\textsubscript{5} is halogen, and R\textsuperscript{1} is alkyl or haloalkyl (hereinafter referred to as X44),
X is -S-,
[Chem.39]

R\textsubscript{3b} is alkyl, n is 1, R\textsubscript{5} is halogen, and R\textsuperscript{1} is alkyl or haloalkyl (hereinafter referred to as X45),
X is -S-,
[Chem.40]

R\textsubscript{3b} is H, n is 2, R\textsubscript{5} is halogen, and R\textsuperscript{1} is alkyl or haloalkyl (hereinafter referred to as X46),
X is -S-,
R³b is alkyl, n is 2, R⁵ is halogen, and R¹ is alkyl or haloalkyl (hereinafter referred to as X47),
X is -S- or -O-, R³a is H or alkyl, R⁵b is H, R⁵a and R⁵b together with the carbon atom to which they are attached may form cycloalkane substituted with 1 or 2 halogens, and R¹ is alkyl or haloalkyl (hereinafter referred to as X48),
ring A is a substituted or unsubstituted benzene and ring B is a substituted or unsubstituted pyridine (hereinafter referred to as AB1),
ring A is a substituted or unsubstituted benzene and ring B is a substituted or unsubstituted pyrazine (hereinafter referred to as AB2),
ring A is a substituted or unsubstituted benzene and ring B is a substituted or unsubstituted oxazole (hereinafter referred to as AB3),
ring A is a substituted or unsubstituted benzene and ring B is a substituted or unsubstituted pyrimidine or a substituted or unsubstituted pyridazine (hereinafter referred to as AB4),
ring A is a substituted or unsubstituted pyridine, and ring B is a substituted or unsubstituted pyridine (hereinafter referred to as AB5),
ring A is a substituted or unsubstituted pyridine, and ring B is a substituted or unsubstituted pyrazine (hereinafter referred to as AB6),
ring A is a substituted or unsubstituted pyridine, and ring B is a substituted or unsubstituted oxazole (hereinafter referred to as AB7),
ring A is a benzene substituted with halogen such as F or Cl, and ring B is a pyridine substituted with one or two substituents selected from halogen, cyano, alkyl, alkylcyloxy and haloalkyloxy (hereinafter referred to as AB8),
ring A is a benzene substituted with halogen such as F or Cl, and ring B is a pyrazine substituted with one or two substituents selected from haloalkyl, alkylcyloxy, haloalkyloxy, alkyloxy and cycloalkylalkyloxy (hereinafter referred to as AB9),
ring A is a benzene substituted with halogen such as F or Cl, and ring B is a oxazole...
substituted with one or two substituents selected from alkyl and haloalkyl (hereinafter referred to as AB10),
ring A is a benzene substituted with halogen such as F or Cl, and ring B is a pyrimidine substituted with one or two substituents selected from haloalkyloxy or a or a pyridazine substituted with one or two substituents selected from alkylloxy (hereinafter referred to as AB11),
ring A is a pyridine substituted with halogen and ring B is a pyridine substituted with one or two substituents selected from halogen and cyano (hereinafter referred to as AB12),
ring A is a pyridine substituted with halogen and ring B is a pyrazine substituted with one or two substituents selected from alkylloxy and haloalkyloxy (hereinafter referred to as AB13).

[0130] Examples of combination of "X, R^a, R^b, R^2a, R^2b and R^1v", and "ring A and ring B", (X, AB) of the compounds of formula (1) are as follows:
(X1,AB1),(X1,AB2),(X1,AB3),(X1,AB4),(X1,AB5),(X1,AB6),(X1,AB7),(X1,AB8), (X1,AB9),(X1,AB10),(X1,AB11),(X1,AB12),(X1,AB13),(X2,AB1),(X2,AB2),(X2,AB3),(X2,AB4),(X2,AB5),(X2,AB6),(X2,AB7),(X2,AB8),(X2,AB9),(X2,AB10),(X2,AB11),(X2,AB12), (X3,AB1),(X3,AB2),(X3,AB3),(X3,AB4),(X3,AB5),(X3,AB6),(X3,AB7),(X3,AB8),(X3,AB9),(X3,AB10),(X3,AB11),(X3,AB12), (X4,AB1),(X4,AB2),(X4,AB3),(X4,AB4),(X4,AB5),(X4,AB6),(X4,AB7),(X4,AB8),(X4,AB9),(X4,AB10),(X4,AB11),(X4,AB12),(X4,AB13),(X5,AB1),(X5,AB2),(X5,AB3),(X5,AB4),(X5,AB5),(X5,AB6),(X5,AB7),(X5,AB8),(X5,AB9),(X5,AB10),(X5,AB11), (X6,AB1),(X6,AB2),(X6,AB3),(X6,AB4),(X6,AB5),(X6,AB6),(X6,AB7),(X6,AB8),(X6,AB9),(X6,AB10),(X6,AB11),(X6,AB12),(X6,AB13),(X7,AB1),(X7,AB2),(X7,AB3),(X7,AB4),(X7,AB5),(X7,AB6),(X7,AB7),(X7,AB8),(X7,AB9),(X7,AB10),(X7,AB11),(X7,AB12),(X7,AB13),(X8,AB1),(X8,AB2),(X8,AB3),(X8,AB4),(X8,AB5),(X8,AB6),(X8,AB7),(X8,AB8),(X8,AB9),(X8,AB10),(X8,AB11),(X8,AB12),(X8,AB13),(X9,AB1),(X9,AB2),(X9,AB3),(X9,AB4),(X9,AB5),(X9,AB6),(X9,AB7),(X9,AB8),(X9,AB9),(X9,AB10),(X9,AB11),(X9,AB12),(X9,AB13),(X10,AB1),(X10,AB2),(X10,AB3),(X10,AB4),(X10,AB5),(X10,AB6),(X10,AB7),(X10,AB8),(X10,AB9),(X10,AB10),(X10,AB11),(X10,AB12),(X10,AB13),(X11,AB1),(X11,AB2),(X11,AB3),(X11,AB4),(X11,AB5),(X11,AB6),(X11,AB7),(X11,AB8),(X11,AB9),(X11,AB10),(X11,AB11),(X11,AB12),(X11,AB13),(X12,AB1),(X12,AB2),(X12,AB3),(X12,AB4),(X12,AB5),(X12,AB6),(X12,AB7),(X12,AB8),(X12,AB9),(X12,AB10),(X12,AB11),(X12,AB12),(X12,AB13),(X13,AB1),(X13,AB2),(X13,AB3),(X13,AB4),(X13,AB5),(X13,AB6),(X13,AB7),(X13,AB8),(X13,AB9),(X13,AB10),(X13,AB11),(X13,AB12),(X13,AB13),(X14,AB1),(X14,AB2),(X14,AB3),(X14,AB4),(X14,AB5),(X14,AB6),(X14,AB7),(X14,AB8),(X14,AB9),(X14,AB10),(X14,AB11),(X14,AB12),(X14,AB13),(X15,AB1),(X15,AB2),(X15,AB3),(X15,AB4),(X15,AB5),(X15,AB6),(X15,AB7),(X15,AB8),(X15,AB9),(X15,AB10),(X15,AB11),(X15,AB12),(X15,AB13),(X16,AB1),(X16,AB2),(X16,AB3),(X16,AB4),(X16,AB5),(X16,AB6),(X16,AB7),(X16,AB8),(X16,AB9),(X16,AB10),(X16,AB11),(X16,AB12),(X16,AB13),(X17,AB1),(X17,AB2),(X17,AB3),(X17,AB4),(X17,AB5),(X17,AB6),(X17,AB7),(X17,AB8),(X17,AB9),(X17,AB10),(X17,AB11),(X17,AB12),(X18,AB1),(X18,AB2),(X18,AB3),(X18,AB4),(X18,AB5),(X18,AB6),(X18,AB7),(X18,AB8),(X18,AB9),(X18,AB10),(X18,AB11),(X18,AB12),(X18,AB13),(X19,AB1),(X19,AB2),(X19,AB3),(X19,AB4),(X19,AB5),(X19,AB6),(X19,AB7),(X19,AB8),(X19,AB9),(X19,AB10),(X19,AB11),(X19,AB12),(X19,AB13),(X20,AB1),(X20,AB2),(X20,AB3),(X20,AB4),(X20,AB5),(X20,AB6),(X20,AB7),(X20,AB8),(X20,AB9),(X20,AB10),(X20,AB11),(X20,AB12),(X20,AB13),(X21,AB1),(X21,AB2),(X21,AB3),(X21,AB4),(X21,AB5),(X21,AB6),(X21,AB7),(X21,AB8),(X21,AB9),(X21,AB10),(X21,AB11),(X21,AB12),(X21,AB13).
The compound of formula (I) is not limited to a specific isomer, and includes all possible isomers such as keto-enol isomers, imine-enamine isomers, diastereoisomers, optical isomers and rotation isomers, racemate and the mixture thereof. For example, the compound of formula (I) includes the following tautomers.

[Chem.42]

The compound of formula (I) has an asymmetric carbon atom and the compound includes the following optical isomers.
In one embodiment, the compound of the present invention is as follows:

Optically active compounds of formula (I) can be produced by employing an optically active starting material, by obtaining an optically active intermediate by asymmetry synthesis at a suitable stage, or by performing optical resolution of an intermediate or an objective compound, each of which is a racemate, at a suitable stage. Examples of a method for optical resolution is separation of an optical isomer using an optically active column; kinetic optical resolution utilizing an enzymatic reaction; crystallization resolution of a diastereomer by salt formation using a chiral acid or a chiral base; and preferential crystallization method.

One or more hydrogen, carbon and/or other atoms of a compound of formula (I) can be replaced with an isotope of hydrogen, carbon and/or other atoms, respectively. Examples of isotopes include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, iodine and chlorine, such as $^2$H, $^3$H, $^{11}$C, $^{13}$C, $^{14}$N, $^{18}$O, $^{17}$O, $^{13}$P, $^{35}$S, $^{18}$F, $^{121}$I and $^{36}$Cl, respectively. The compound of formula (I) also includes the compound replaced with such isotopes. The compound replaced with such isotopes is useful also as a medicament, and includes all the radiolabeled compounds of the compound of formula (I). The invention includes "radiolabelling method" for manufacturing the "radiolabeled compound" and the method is useful as a tool of metabolic pharmacokinetic research, the research in binding assay and/or diagnosis.

A radiolabeled compound of the compound of formula (I) can be prepared by methods known in the art. For example, tritiated compounds of formula (I) can be prepared by introducing tritium into the particular compound of formula (I) such as by catalytic dehalogenation with tritium. This method may include reacting a suitably
halogenated precursor of a compound of formula (I) with tritium gas in the presence of a suitable catalyst such as Pd/C, in the presence or absence of a base. Other suitable methods for preparing tritiated compounds can be found in Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A), Chapter 6 (1987). A ¹⁴C-labeled compound can be prepared by employing starting materials having ¹⁴C carbon.

As pharmaceutically acceptable salt of the compound of formula (I), examples include salts with alkaline metals (e.g. lithium, sodium and potassium), alkaline earth metals (e.g. calcium and barium), magnesium, transition metal (e.g. zinc and iron), ammonia, organic bases (e.g. trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, diethanolamine, ethylenediamine, pyridine, picoline, quinoline), and amino acids, and salts with inorganic acids (e.g. hydrochloric acid, sulfuric acid, nitric acid, carbonic acid, hydrobromic acid, phosphoric acid and hydroiodic acid) and organic acids (e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, ascorbic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid and ethanesulfonic acid). Specific Examples are salts with hydrochloric acid, sulfuric acid, phosphoric acid, tartaric acid, or methanesulfonic acid. These salts can be formed by the usual method.

The compounds of the present invention represented by formula (I) or pharmaceutically acceptable salts thereof may form solvates (e.g., hydrates etc.) and/or crystal polymorphs. The present invention encompasses those various solvates and crystal polymorphs. "Solvates" may be those wherein any number of solvent molecules (e.g., water molecules etc.) are coordinated with the compounds represented by formula (I). When the compounds represented by formula (I) or pharmaceutically acceptable salts thereof are allowed to stand in the atmosphere, the compounds may absorb water, resulting in attachment of adsorbed water or formation of hydrates. Recrystallization of the compounds represented by formula (I) or pharmaceutically acceptable salts thereof may produce crystal polymorphs.

The compounds of the present invention represented by formula (I) or pharmaceutically acceptable salts thereof may form prodrugs. The present invention also encompasses such various prodrugs. Prodrugs are derivatives of the compounds of the present invention that have chemically or metabolically degradable groups and are compounds that are converted to the pharmaceutically active compounds of the present invention through solvolysis or under physiological conditions in vivo. Prodrugs include compounds that are converted to the compounds represented by formula (I) through enzymatic oxidation, reduction, hydrolysis and the like under physiological conditions in vivo and compounds that are converted to the compounds represented by
formula (I) through hydrolysis by gastric acid and the like. Methods for selecting and preparing suitable prodrug derivatives are described, for example, in the Design of Prodrugs, Elsevier, Amsterdam 1985. Prodrugs themselves may be active compounds. When the compounds of formula (I) or pharmaceutically acceptable salts thereof have a hydroxy group, prodrugs include acyloxy derivatives and sulfonloyloxy derivatives which can be prepared by reacting a compound having a hydroxy group with a suitable acid halide, suitable acid anhydride, suitable sulfonyl chloride, suitable sulfonylanhydride and mixed anhydride or with a condensing agent. Examples are CH₃COO-, C₂H₅COO-, t-BuCOO-, C₆H₅COO-, PhCOO-, (m-NaOOCPh)COO-, NaOOCCH₂CH₂ COO-, CH₃CH(NH₂) COO-, CH₂N(CH₃)₂COO-, CH₃SO₃⁻, CH₃CH₂SO₃⁻, CF₃SO₃⁻, CH₂FSO₃⁻, CF₃CH₂SO₃⁻, p-CH₃-0-PhSO₃⁻, PhSO₃⁻ and p-CH₃PhSO₃⁻.

The compounds of formula (I) may be prepared by the methods described below, together with synthetic methods known to a person skilled in the art.

The starting materials are commercially available or may be prepared in accordance with known methods.

During any of the following synthesis, it may be necessary or preferable to protect sensitive or reactive groups on any of molecules. In such case, these protection can be achieved by means of conventional protective groups such as those described in Greene's Protective Group in Organic Synthesis, John Wiley & Sons, 2007.

It will be understood by a person skilled in the art that the compounds described below will be generated a mixture of diastereomers and/or enantiomers, which may be separated at relevant stages of the following procedures using conventional techniques such as crystallization, silica gel chromatography, chiral or achiral high performance liquid chromatography (HPLC), and chiral supercritical fluid (SFC) chromatography to provide the single enantiomers of the invention.

During all the following steps, the order of the steps to be performed may be appropriately changed. In each step, an intermediate may be isolated and then used in the next step. All of reaction time, reaction temperature, solvents, reagents, protecting groups, etc. are mere exemplification and not limited as long as they do not cause an adverse effect on a reaction.

General procedure A:
wherein P1 is alkyl, each of P2 is hydrogen or protective groups such as alkyl, benzoyl, benzyl, 4-methoxybenzyl or 2,4-dimethoxybenzyl, Y is halogen (e.g., Br, I), nitro, or trifluoroacetylamino (-NHCOCF₃), and other symbols are the same as defined above.

[0137] General Procedure A is a method for preparing compounds of formula (la) from compounds of formula (Al) through multiple steps of Step 1 to Step 7. Those skilled in the art will be appreciate that protective groups P1 and P2 can be chosen depending on the reaction conditions used in later steps. The starting material of formula (Al) can be prepared in a manner similar to the conditions described in Chem. Rev. 2010, 110, 3600-3740.

[0138] Step 1:
Compounds of formula (A2) can be prepared by Mannich reaction of sulfinyl imine (Al) with enolates derived from the corresponding esters. This type of reactions can be conducted using the conditions described in Chem. Rev. 2010, 110, 3600-3740. Preferably, the enolates can be prepared from the corresponding esters, lithium diisopropylamide (LDA), and TiCl(Oi-Pr)₃, which can be then reacted with (Al) to give compounds of formula (A2). The solvent used in this step is not particularly limited in so far as it does not interfere with the reaction. Examples of the solvent include tetrahydrofuran, 1,4-dioxanne, 1,2-dimethoxyethane, diethyl ether, toluene, and
benzene. The reaction temperature is preferably -78 °C to -30 °C. The reaction time is not particularly limited and is usually 5 minutes to 24 hours, preferably 30 minutes to 24 hours.

[0139] Step 2:
Compounds of formula (A3) can be prepared by deprotection of (A2). This deprotection reaction is known to a person skilled in the art and can be performed under the conditions described in Chem. Rev. 2010, 110, 3600-3740. The reaction can be conducted under acidic conditions using e.g. hydrochloric acid at room temperature to 60 °C. Examples of the solvent include methanol, 1,4-dioxane, and ethyl acetate. The reaction time is not particularly limited and is usually 1 hour to 24 hours, preferably 1 hour to 6 hours.

[0140] Step 3:
Compounds of formula (A4) can be prepared by reaction of (A3) with reagents such as benzoyl isothiocyanate and benzyl isothiocyanate. Those skilled in the art will appreciate that the isothiocyanate generated from (A3) and reagents such as thiophosgene and thiocarbonyl diimidazole can be reacted with primary or secondary amines to afford compounds of formula (A4). The solvent used in this step is not particularly limited in so far as it does not interfere with the reaction. Examples of the solvent include dichloromethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, and toluene. The reaction time is not particularly limited and is usually 1 hour to 24 hours, preferably 3 hours to 6 hours. The reaction temperature is usually 0 °C to 60 °C, preferably 0 °C to room temperature. Reagents for the thiourea formation in this step are not particularly limited if these can be deprotected in Step 6, and a preferable reagent is benzoyl isothiocyanate.

[0141] Step 4:
Compounds of formula (A5) can be prepared by reaction of (A4) with Grignard reagents such as methyl magnesium bromide and ethyl magnesium bromide and alkyl lithium reagents such as methyl lithium, butyllithium, and phenyllithium. Stepwise addition of these nucleophiles can allow for compounds of formula (A5) with various substituents of R⁻³ and R⁻⁸. The solvent used is not particularly limited in so far as it does not interfere with the reaction. Preferable examples of the solvent include tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, diethyl ether, toluene, and benzene. The reaction temperature is not particularly limited and is usually 5 minutes to 24 hours, preferably 5 minutes to 6 hours. The reaction temperature is usually -100 °C to room temperature, preferably -78 °C to 0 °C.

[0142] Step 5:
Compounds of formula (A6) can be prepared by cyclization reaction of (A5) using reagents such as m-CPBA, hydrogen peroxide, and carbodiimide reagents (e.g.
l-ethyl-3-(3-dimethylaminopropyl)carbodiimide. Alternatively, compounds of formula (A6) can be obtained by reacting (A5) with alkylating reagents followed by cyclization reaction under basic conditions. In the former case, suitable reagents include m-CPBA, and the reaction temperature is usually 0 °C to room temperature and preferably room temperature. Preferable solvents include dichloromethane and chloroform. In the latter case, suitable alkylating reagents include methyl iodide, and suitable bases include sodium hydride, sodium bicarbonate, and potassium carbonate.

[0143] Step 6:
Compounds of formula (la) can be prepared by the following reaction sequence: 1) \( Y = H \); deprotection of P2 in formula (A6), nitration, protection, reduction, followed by amide coupling reaction with amines to afford compounds of formula (la), 2) \( Y = \text{Br or I; Buchwald-Hartwig reaction of formula (A6) with amines followed by deprotection of P2 to afford compounds of formula (la),} \) 3) \( Y = \text{trifluoroacetylamino; deprotection of the trifluoroacetylamino, amide coupling reaction, followed by deprotection of P2 to afford compounds of formula (la). Examples of reaction conditions for 1) – 3) are described below:}

1) \( Y = H \):
Compounds of formula (A6) can be deprotected under the conditions described in Greene's Protective Groups in Organic Synthesis. When P2 is benzoyl, the de-protection can be conducted with bases such as hydrazine hydrate or potassium carbonate using the solvent such as methanol and ethanol at room temperature to 80 °C.

Nitration of the deprotected compounds can be conducted by methods known to a person skilled in the art. For example, the nitrated compounds can be obtained by use of nitric acid or nitrate in solvents such as sulfuric acid or mixed solvent of sulfuric and trifluoroacetic acid. The reaction temperature is usually -20 °C to 0 °C. The reaction time is usually 1 minute to 1 hour.

The amidine group in the deprotected compounds can be protected by Boc under the conditions described in Greene's Protective Groups in Organic Synthesis. For example, the Boc protection can be conducted using Boc₂O and a catalytic amount of N,N-dimethyl-4-aminopyridine in solvents such as dichloromethane and tetrahydrofuran at room temperature to 50 °C.

Reduction of the nitrated compounds can be conducted by methods known to a person skilled in the art to afford the corresponding anilines; the following conditions can be used: 1) a method using iron powder in the presence of hydrochloric acid or ammonium chloride; 2) a method using palladium on carbon under hydrogen atmosphere. Examples of the solvent include solvents such as water, methanol, ethanol, ethyl acetate, tetrahydrofuran, and mixtures of those solvents.
Amide coupling reaction of the aniline with amines can be conducted by a method known to a person skilled in the art, and suitable coupling conditions can be found in Chem. Rev. 2011, 111, 6557-6602, which includes: a) reactions using condensation reagents; b) reactions using acid chlorides or fluorides.

Reaction a) can be conducted by use of condensation reagents such as dicyclohexyl-carbodiimide (DCC), diisopropylcarbodiimide (DIC), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC hydrochloride), 0-(7-aza-lH-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), and lH-Benzotriazol-l-yl-oxy-tri(pyrrUdino) phosphonium hexafluorophosphate (PyBOP). When using uronium or phosphonium salts such as HATU and PyBOP, the reaction can be performed in the presence of bases such as triethylamine and diisopropylethylamine. The reaction may be accelerated by use of catalysts such as 1-hydroxy-benzotriazole (HOBt) and 1-hydroxy-7-aza-benzotriazole (HOAt). The solvent used in the reaction is not particularly limited in so far as it does not interfere with the reaction. Examples of the solvent include dichromethane, N,N-dimethylformamide, N-methylpyrrolidone, and tetrahydrofuran. The reaction temperature is usually 0 °C to 50 °C and is preferably room temperature.

Reaction b) can be performed by use of commercially available acid chlorides or those synthesized by known methods to a person skilled in the art in solvents such as dichromethane, tetrahydrofuran, and ethyl acetate in the presence of bases such as triethylamine, diisopropylethylamine, pyridine, and N,N-dimethyl-4-aminopyridine. The reaction temperature is usually 0 °C to 60 °C and is preferably 0 °C to room temperature. The reaction time is not particularly limited and is usually 5 minutes to 24 hours, preferably 20 minutes to 6 hours.

2) Y = Br or I:

Buchwald-Hartwig reaction of compounds of formula (A6) with amide derivatives can be conducted by a method described in Metal-Catalyzed Cross-Coupling Reactions, 2nd ed. For example, this reaction can be performed by use of transition metal catalysts such as tris(dibenzyldieneacetone) dipalladium and palladium acetate and ligands such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP), 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos), and 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (X-Phos) in the presence of bases such as sodium tert-butoxide, cesium carbonate, and potassium phosphate. The reaction temperature is usually 40 °C to 150 °C and is preferably 60 °C to 100 °C. This reaction may be accelerated by microwave irradiation. Examples of the solvent include toluene, benzene, xylene, tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane.

After the Buchwald-Hartwig reaction, the deprotection of P2 in the resulting compound can be performed under the conditions described above.
3) \( Y = \text{trifluoroacetylamino} \):

Deprotection of the trifluoroacetylamino group in compounds of formula (A6) can be conducted by methods known to a person skilled in the art. Suitable conditions can be found in Greene's Protective Groups in Organic Synthesis. For example, use of potassium carbonate in methanol at room temperature may be a usual method, but not limited to. The following amide coupling reaction and deprotection of P2 can be conducted under the same conditions described above.

General procedure B:

wherein the symbols are the same as defined in General Procedure A.

General Procedure B is a method for preparing compounds of formula (lb) from compounds of formula (A5) through multiple steps. Using compounds of formula (B1), compounds of formula (lb) can be prepared according to the methods described in General Procedure A.

Step 1:

Compounds of formula (B1) can be prepared by cyclization reaction of compounds of formula (A5) by converting the hydroxy group into leaving groups such as Cl, Br, and triflate. The reaction conditions are known to those skilled in the art. For example, chlorination followed by cyclization may be achieved using reagents such as 1-chloro-N,N,2-trimethylpropenylamine. Alternatively, triflic anhydride may be used in the presence of bases such as N,N-dimethyl-4-aminopyridine and pyridine. Examples of the solvent include dichloromethane and tetrahydrofuran. The reaction temperature is usually 0 °C to room temperature and preferably 0 °C. The reaction time is not particularly limited and is usually 0.5 to 3 hours.
wherein Hal is halogen, R^{3a'} and R^b are each independently hydrogen or alkyl, and other symbols are the same as defined in General Procedure A.

General Procedure C is a method for preparing compounds of formula (Ic) from compounds of formula (A3) through multiple steps. Using compounds of formula (C6), compounds of formula (Ic) can be prepared according to the methods described in General procedure A.

Step 1: Compounds of formula (C1) can be prepared by urea formation of compounds of formula (A3). This type of reaction is known to those skilled in the art and is usually performed by treatment of compounds of formula (A3) with reagents such as triphosgene, 4-nitrophenyl chloroformate, and carbonyl diimidazole followed by addition of amines such as bis(2,4-dimethoxybenzyl)amine. Preferable combination of these reagents may be 4-nitrophenyl chloroformate and bis(2,4-dimethoxybenzyl)amine. In such case, the reaction can be performed in the presence of bases such as sodium bicarbonate in solvents such as water, tetrahydrofuran, ethyl acetate, and mixture of these solvents. The reaction temperature is usually 0 °C to room temperature. The reaction time is not particularly limited and is
usually 1 to 12 hours.

Step 2:
Compounds of formula (C2) can be prepared by reduction of compounds of formula (C1). This reaction is known to those skilled in the art and is usually preformed using diisobutylaluminium hydride (DIBAL-H). Examples of the solvents include dichloromethane, tetrahydrofuran, and toluene. The reaction temperature is usually below -60 °C and preferably below -70 °C. The reaction time is not particularly limited and is usually 1 to 12 hours.

Step 3:
Compounds of formula (C3) can be prepared by Wittig reaction of compounds of formula (C2) with the corresponding phosphonium ylides. Alternatively, Peterson olefination, Horner-Wadsworth-Emmons reaction, Julia coupling, and Knoevenagel condensation may be considered. These reactions are known to those skilled in the art. For example, Wittig reaction can be generally conducted by treatment of the corresponding alkyl halide with triphenylphosphine followed by bases such as n-butyl lithium, which can be then added to compounds of formula (C3) in solvents such as tetrahydrofuran. The reaction time is not particularly limited and is usually 1 to 12 hours.

Step 4:
Compounds of formula (C4) can be prepared by cyclization of compounds of formula (C3) using iodine. Examples of the solvent include acetonitrile, tetrahydrofuran, and dichloromethane. The reaction temperature is usually 0 °C to 50 °C and preferably room temperature. The reaction time is not particularly limited and is usually 1 to 12 hours.

Step 5:
Compounds of formula (C5) can be prepared by 1) halogenation of compounds of formula (C4); 2) hydroxylation of compounds of formula (C4) followed by deoxohalogenation of the corresponding alcohol.

As for 1), halogenation, e.g., fluorination, of compounds of formula (C4) can be performed with reagents such as tetrabutylammonium fluoride (TBAF). Examples of the solvent include acetonitrile and tetrahydrofuran. The reaction temperature is usually 0 °C to 50 °C and preferably room temperature. The reaction time is not particularly limited and is usually 1 to 12 hours.

As for 2), hydroxylation of compounds of formula (C4) can be conducted with reagents such as potassium superoxide (K02), silver trifluoroacetate, and silver trifluoroborate. Preferable examples of the solvent include dimethyl sulfoxide (DMSO) for K02, nitromethane-water for silver trifluoroacetate, and DMSO-water for silver trifluoroborate. The reaction temperature is not particularly limited and is preferably room temperature for K02, 60 °C to 80 °C for silver trifluoroacetate, and 60 °C to 80 °C for...
silver trifluoroborate. The following deoxohalogenation, e.g., deoxofluorination, can be conducted with reagents such as N,N-diethylaminosulfur trifluoride (DAST), and bis(2-methoxyethyl)aminosulfur trifluoride (Deoxofluor; Trademark). Examples of the solvent include dichloromethane, acetonitrile, and tetrahydrofuran. The reaction temperature is usually -78 °C to room temperature and is preferably -78 °C to 0 °C. Alternative conditions can be found in Synthesis 2002, 2561-2578.

[0155] General procedure D:

\[ \text{[Chem.48]} \]\n
\[ (A5) \] \n
wherein the symbols are the same as defined in General Procedure A.

[0156] General Procedure D is a method for preparing compounds of formula (I) from compounds of formula (Dl) through multiple steps. Using compounds of formula (A5), compounds of formula (I) can be prepared according to the methods described in General procedure A and B. The starting material of formula (Dl) can be prepared in a manner similar to the conditions described in Chem. Rev. 2010, 110, 3600-3740.

[0157] Step 1:

Compounds of formula (D2) can be prepared by addition of compound of formula (Dl) to ketones of formula (R^aCOR^b). This reaction can be performed under conditions similar to those described in Chem. Rev. 2010, 110, 3600-3740. For example, the ketimines derived from formula (Dl) can be prepared using lithium diisopropylamide followed by addition of ketones (R^aCOR^b) to afford (D2). Examples of the solvent include tetrahydrofuran and toluene. The reaction temperature is usually below -60 °C and preferably below -70 °C. The reaction time is not particularly limited and is usually 1 to 12 hours.

[0158] Step 2:

Compounds of formula (D3) can be prepared by reaction of (D2) with Grignard reagents such as methyl magnesium bromide and ethyl magnesium bromide and alkyl lithium reagents such as methylithium, butyllithium, and phenyllithium. The solvent is not particularly limited in so far as it does not interfere with the reaction. Preferable
examples of the solvent include tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, diethyl ether, toluene, and benzene. The reaction temperature is not particularly limited and is usually 5 minutes to 24 hours, preferably 5 minutes to 6 hours. The reaction temperature is usually -78 °C to room temperature and is preferably -78 °C to -40 °C.

Step 3:
Compounds of formula (D4) can be prepared according to the method described in Step 2 of General Procedure A.

Step 4:
Compounds of formula (A5) can be prepared according to the method described in Step 3 of General Procedure A.

[0159] General procedure E:

wherein P is a protective group for the hydroxy group such as benzyl and tert-butyldimethylsilyl. R is alkyl or haloalkyl, and the other symbols are the same as defined in General Procedure A.

General Procedure E is a method for preparing compounds of formula (I) from compounds of formula (El) through multiple steps. Using compounds of formula (E8), compounds of formula (I) can be prepared according to the methods described in General procedure A and B.

[0161] Step 1:
Compounds of formula (E2) can be prepared by addition reaction of such as Me₃SiCF₃, Me₃SiCHF₂, and Me₃SiCH₂F in the presence of a catalytic amount of bases such as TBAF, cesium fluoride, and potassium fluoride. Examples of the solvent include
tetrahydrofuran, N,N-dimethylformamide (DMF), acetonitrile, and toluene. The reaction temperature is usually -20 °C to room temperature and is preferably room temperature. Alternatively, this reaction can be performed by use of alkyl or haloalkyl cerium reagents prepared by cerium (III) chloride and alkyl lithium or Grignard reagents to afford compounds of formula (E2). Use of alkyl or haloalkyl lithium or Grignard reagents without cerium (III) chloride may provide (E2) according to a method known to a person skilled in the art.

Step 2:

Compounds of formula (E3) can be prepared by epoxidation of compounds of formula (E2). Epoxidation is known to a person skilled in the art and is performed by use of oxidants such as m-CPBA and tert-butyl hydroperoxide in solvents such as dichloromethane and chloroform. The reaction time is not particularly limited and is usually 0.5 to 3 hours. The reaction temperature is usually -50 °C to room temperature. Asymmetric epoxidation such as Sharpless asymmetric epoxidation can be also applied to this step using methods known to those skilled in the art, which may be helpful to synthesize chiral compounds without chiral separation. Suitable conditions can be found in Comprehensive Organic Synthesis 1991, 7, 389.

Step 3:

Compounds of formula (E4) can be prepared by ring opening reaction of compounds of formula (E3) using sodium azide in the presence of Lewis acids such as Ti(OEt)4. Examples of the solvent include solvents such as tetrahydrofuran, toluene, and ethyl ether. The reaction time is not particularly limited and is usually 1 to 24 hours. The reaction temperature is usually room temperature.

Step 4:

Protection of compounds of formula (E4) can be conducted by benzyl bromide or tert-butyldimethylsilyl chloride to afford compounds of formula (E5). When protecting by benzyl, the protection may be conducted using benzyl bromide in the presence of dibutyltin oxide. Examples of the solvent include toluene, methanol, DMF, and these mixed solvents. The reaction temperature is usually 60 °C to 100 °C. When protecting by tert-butyldimethylsilyl, suitable conditions can be found in Greene's Protective Groups in Organic Synthesis. For example, the protection may be conducted using tert-butyldimethylsilyl chloride in the presence of imidazole as a base. Examples of the solvent include tetrahydrofuran, dichloromethane, and DMF. The reaction temperature is usually 0 °C to room temperature.

Step 5:

Compounds of formula (E6) can be prepared by alkylation of compounds of formula (E5). This reaction is known to a person skilled in the art and is usually performed using alkylation reagents such as alkyl iodide, alkyl bromide, and alkyl triflate in the
presence of bases such as sodium hydride, potassium carbonate, and sodium carbonate. Examples of the solvent include tetrahydrofuran, DMF, toluene, acetone, and acetonitrile. The reaction temperature is usually 0 °C to room temperature.

[0166] Step 6:
Compounds of formula (E7) can be deprotected under conditions similar to those described in Greene's Protective Groups in Organic Synthesis. For example, when P is benzyl, the deprotection can be performed by hydrogenation in the presence of a catalytic amount of palladium carbon or palladium hydroxide. When P is tert-butyldimethylsilyl, the deprotection can be performed by TBAF in solvents such as tetrahydrofuran at 0 °C to room temperature.

[0167] General procedure F:

wherein P1 is alkyl; P2 is a protective group for the hydroxy group such as tert-butyldimethylsilyl; P3 is methanesulfonyl or toluenesulfonyl, and the other symbols are the same as defined in General Procedure A.

[0169] General Procedure F is a method for preparing compounds of formula (If) from compounds of formula (El) through multiple steps. Using compounds of formula (F9),
compounds of formula (I) can be prepared according to the methods described in
General procedure A and B.

[0170] Step 1:
Compounds of formula (Fl) can be prepared by Reformatsky reaction of compounds
of formula (El) with α-haloesters. This reaction is known to a person skilled in the art
and is usually performed under conditions described in Tetrahedron 2004, 42,
9325-9374. For example, a mixture of compounds of formula (Fl) and α-haloesters in
solvents such as tetrahydrofuran, acetonitrile, and toluene is reacted in the presence of
zinc powder at room temperature to 100 °C. The reaction time is not particularly
limited and is usually 1 hour to 12 hours.

[0171] Step 2:
Compounds of formula (F2) can be prepared by the method described in Step 2 of
General Procedure C.

[0172] Step 3:
Compounds of formula (F3) can be prepared by protection of the alcohol of formula
(F2). The protective group can be selected depending on reaction conditions used in
the next step. Suitable protective groups can be found in Greene's Protective Groups in
Organic Synthesis. For example, when tert-butyldimethylsilyl group is selected, the
protection can be performed using tert-butyldimethylsilyl chloride in the presence of
bases such as imidazole and sodium hydride in solvents such as DMF, tetrahydrofuran,
and acetonitrile at 0 °C to room temperature. The reaction time is not particularly
limited and is usually 0.5 to 6 hours. If the yield is low, use of tert-butyldimethylsilyl
triflate instead of the corresponding chloride may be a proper choice.

[0173] Step 4:
Compounds of formula (F4) can be prepared according to the conditions described in
Step 2 of General Procedure E.

[0174] Step 5:
Compounds of formula (F5) can be prepared by deprotection of compounds of
formula (F4). Depending on the protective group in formula (F4), a deprotection
condition can be selected according to Greene's Protective Groups in Organic
Synthesis. When P2 is tert-butyldimethylsilyl, the deprotection can be conducted using
TBAF in solvents such as tetrahydrofuran, DMF, and acetonitrile at 0 °C to room
temperature. The reaction time is not particularly limited and is usually 0.5 to 6 hours.

[0175] Step 6:
Compounds of formula (F6) can be prepared according to the conditions described in
Step 3 of General Procedure E.

[0176] Step 7:
The terminal alcohol of compounds of formula (F6) can be converted into the corre-
sponding leaving group such as methanesulfonate or toluenesulfonate in this step. This reaction is known to a person skilled in the art and is usually conducted according to the method described in Greene's Protective Groups in Organic Synthesis. For example, protection of toluenesulfonyl can be performed using toluenesulfonyl chloride in the presence of bases such as N,N-dimethylamino-4-pyridine, pyridine, and triethylamine in solvents such as dichloromethane, tetrahydrofuran, and acetonitrile at 0 °C to room temperature. The reaction time is not particularly limited and is usually 0.5 to 6 hours.

[0177] Step 8

Compounds of formula (F8) can be prepared by cyclization of compounds of formula (F7). This reaction can be achieved by use of bases such as potassium carbonate and sodium carbonate in solvents such as methanol, ethanol, and acetone at room temperature. The reaction time is not particularly limited and is usually 1 to 6 hours.

[0178] Step 9:

Compounds of formula (F9) can be prepared according to the conditions described in Step 4 of General Procedure E.

[0179] The compounds of the present invention have BACE1 inhibitory activity and are effective in treatment and/or prevention, symptom improvement, and prevention of the progression of disease induced by the production, secretion or deposition of-amyloid β protein, such as Alzheimer's disease, Alzheimer dementia, senile dementia of Alzheimer type, mild cognitive impairment (MCI), prodromal Alzheimer's disease (e.g., MCI due to Alzheimer's disease), Down's syndrome, memory impairment, prion disease (Creutzfeldt-Jakob disease), Dutch type of hereditary cerebral hemorrhage with amyloidosi, cerebral amyloid angiopathy, other type of degenerative dementia, mixed dementia such as coexist Alzheimer's disease with vascular type dementia, dementia with Parkinson's Disease, dementia with progressive supranuclear palsy, dementia with Cortico-basal degeneration, Alzheimer's disease with diffuse Lewy body disease, age-related macular degeneration, Parkinson's Disease, amyloid angiopathy or the like.

Furthermore, the compounds of the present invention are effective in preventing the progression in a patient asymptomatic at risk for Alzheimer dementia (preclinical Alzheimer's disease).

"A patient asymptomatic at risk for Alzheimer dementia" includes a subject who is cognitively and functionally normal but has potential very early signs of Alzheimer's disease or typical age related changes (e.g., mild white matter hyper intensity on MRI), and/or have evidence of amyloid deposition as demonstrated by low cerebrospinal fluid Aβ1-42 levels. For example, "a patient asymptomatic at risk for Alzheimer dementia" includes a subject whose score of the Clinical Dementia Rating (CDR) or Clinical Dementia Rating -Japanese version (CDR-J) is 0, and/or whose stage of the
Functional Assessment Staging (FAST) is stage 1 or stage 2.

[0180] The compound of the present invention has not only BACE1 inhibitory activity but the beneficialness as a medicament. The compound has any or all of the following superior properties.

a) The compound has weak inhibitory activity for CYP enzymes such as CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4.

b) The compound show excellent pharmacokinetics profiles such as high bioavailability or low clearance.

c) The compound has a high metabolic stability.

d) The compound does not show irreversible inhibitions to CYP enzymes such as CYP3A4 in the range of the concentrations of the measurement conditions described in this description.

e) The compound does not show a mutagenesis.

f) The compound is at a low risk for cardiovascular systems.

g) The compound shows a high solubility.

h) The compound shows a high brain distribution.

i) The compound has a high oral absorption.

j) The compound has a long half-life period.

k) The compound has a high protein unbinding ratio.

l) The compound is negative in the Ames test.

m) The compound has a high BACE1 selectivity over BACE2.

Since the compound of the present invention has high inhibitory activity on BACE1 and/or high selectivity on other enzymes, for example, BACE2, it can be a medicament with reduced side effect. Further, since the compound has high effect of reducing amyloid β production in a cell system, particularly, has high effect of reducing amyloid β production in brain, it can be an excellent medicament. In addition, by converting the compound into an optically active compound having suitable stereochemistry, the compound can be a medicament having a wider safety margin on the side effect.

[0181] When a pharmaceutical composition of the present invention is administered, it can be administered orally or parenterally. The composition for oral administration can be administered in usual dosage forms such as oral solid formulations (e.g., tablets, powders, granules, capsules, pills, films or the like), oral liquid formulations (e.g., suspension, emulsion, elixir, syrup, lemonade, spirit, aromatic water, extract, decoction, tincture or the like) and the like may prepared according to the usual method and administered. The tablets can be sugar-coated tablets, film-coated tablets, enteric-coating tablets, sustained-release tablets, troche tablets, sublingual tablets, buccal tablets, chewable tablets or orally disintegrated tablets. Powders and granules can be dry syrups. Capsules can be soft capsules, micro capsules or sustained-release
capsules.
The composition for parenteral administration can be administered suitably in usual
parenteral dosage forms such as dermal, subcutaneous, intravenous, intraperitoneal, intra-
muscular, intraperitoneal, transmucosal, inhalation, transnasal, ophthalmic, inner ear or vaginal administration and the like. In case of parenteral administration, any forms, which are usually used, such as injections, drips, external preparations (e.g., ophthalmic drops, nasal drops, ear drops, aerosols, inhalations, lotion, infusion, liniment, mouthwash, enema, ointment, plaster, jelly, cream, patch, cataplasm, external powder, suppository or the like) and the like can be preferably administered. Injections can be emulsions whose type is O/W, W/O, O/W/O, W/O/W or the like.
The compounds of the present invention can be preferably administered in an oral dosage form because of their high oral absorbability.
A pharmaceutical composition can be formulated by mixing various additive agents for medicaments, if needed, such as excipients, binders, disintegrating agents, and lubricants which are suitable for the formulations with an effective amount of the compound of the present invention. Furthermore, the pharmaceutical composition can be for pediatric patients, geriatric patients, serious cases or operations by appropriately changing the effective amount of the compound of the present invention, formulation and/or various pharmaceutical additives. The pediatric pharmaceutical compositions are preferably administered to patients under 12 or 15 years old. In addition, the pediatric pharmaceutical compositions can be administered to patients who are under 27 days old after the birth, 28 days to 23 months old after the birth, 2 to 11 years old, 12 to 16 years old, or 18 years old. The geriatric pharmaceutical compositions are preferably administered to patients who are 65 years old or over.

[0182] The dosage of a pharmaceutical composition of the present invention should be determined in consideration of the patient's age and body weight, the type and degree of diseases, the administration route and the like. The usual oral dosage for adults is in the range of 0.05 to 100 mg/kg/day and preferable is 0.1 to 10 mg/kg/day. For parenteral administration, the dosage highly varies with administration routes and the usual dosage is in the range of 0.005 to 10 mg/kg/day and preferably 0.01 to 1 mg/kg/day. The dosage may be administered once or several times per day.
The compound of the present invention can be used in combination with other drugs for treating Alzheimer's disease, Alzheimer dementia or the like such as acetylcholinesterase inhibitor (hereinafter referred to as a concomitant medicament) for the purpose of enforcement of the activity of the compound or reduction of the amount of medication of the compound or the like. In this case, timing of administration of the compound of the present invention and the concomitant medicament is not limited and these may be administered to the subject simultaneously or at regular intervals. Fur-
thermore, the compound of the present invention and concomitant medicament may be administered as two different compositions containing each active ingredient or as a single composition containing both active ingredients.

The dose of the concomitant medicament can be suitably selected on the basis of the dose used on clinical. Moreover, the mix ratio of the compound of the present invention and a concomitant medicament can be suitably selected in consideration of the subject of administration, administration route, target diseases, symptoms, combinations, etc. For example, when the subject of administration is human, the concomitant medicament can be used in the range of 0.01 to 100 parts by weight relative to 1 part by weight of the compounds of the present invention.

Examples of a concomitant medicament are Donepezil hydrochloride, Tacrine, Galanthamine, Rivastigmine, Zanapezil, Memantine and Vinpocetine.

[0183] Following examples and test examples illustrate the present invention in more detail, but the present invention is not limited by these examples.

In examples, the meaning of each abbreviation is as follows:

Ac acetyl
Et ethyl
Boc tert-butoxycarbonyl
Bn benzyl
Bz benzoyl
Me methyl
Ph phenyl
t-Bu tert-butyl
TBS tert-butyldimethylsilyl
TMS trimethylsilyl
AIBN azobisisobutyronitrile
DAST N,N-diethylaminosulfur trifluoride
DIBAL diisobutyaluminium hydride
DIPEA N,N-diisopropylethylamine
DMF N,N-dimethylformamide
DMAP 4-dimethylaminopyridine
DMSO dimethylsulf oxide
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
HATU 1-[4is(dimethylamino)methylene]-IH-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
LHMDS lithium hexamethyldisilazide
m-CPBA meta-chloroperbenzoic acid
TFA trifluoroacetic acid
THF tetrahydrofuran  
TBAF tetrabutylammonium fluoride  
WSCD l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride  

[0184] 1H NMR spectra were recorded on Bruker Advance 400 MHz spectrometer with chemical shift reported relative to tetramethylsilane or the residual solvent peak (CDCl$_3$ = 7.26 ppm, DMSO-d$_6$ = 2.50 ppm).  
Analytical LC/MS (ESI positive or negative, retention time (RT)) data were recorded on Shimadzu UFLC or Waters UPLC system under the following conditions:  
Column: Shim-pack XR-ODS (2.2 µm, i.d. 50 x 3.0 mm) (Shimadzu)  
Flow rate: 1.6 mL/min  
Column oven: 50 °C  
UV detection wavelength: 254 nm  
Mobile phase: [A] 0.1% formic acid-containing aqueous solution; [B] 0.1% formic acid-containing acetonitrile solution  
Gradient: linear gradient from 10% to 100% solvent [B] for 3 minutes and 100% solvent [B] for 1 minute  

Example 1  
[0185] Synthesis of compound 1-5
[0186] Step 1

A stirred suspension of zinc (1.40 g, 1.4 mmol) in THF (80 ml) was heated to reflux. To the suspension were added a solution of compound 1-1 (8.46 g, 19.4 mmol) in THF (20 ml) and a solution of ethyl 2-bromo-2-fluoroacetate (3.95 g, 21.4 mmol) in THF (10 ml). After stirring for 3 h at the same temperature, the reaction mixture was treated with saturated aqueous NH₄Cl and the aqueous layer was extracted with AcOEt. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated. The crude product was added to a silica gel column and eluted with Hexane/EtOAc 25%. Collected fractions were evaporated to afford compound 1-2 (5.76 g, 10.6 mmol, 55%) as a brown oil.

1H-NMR (400 MHz, CDCl₃) δ: 0.84-0.89 (m, 6H), 0.94-0.98 (m, 9H), 1.24 (s, 9H), 1.29 (t, J = 7.2 Hz, 3H), 1.96 (s, 3H), 4.26 (m, 2H), 5.16 (s, 1H), 5.34 (d, J = 46.4 Hz, 1H), 7.37 (d, J = 2.6 Hz, 1H).

Step 2

KF (1.24 g, 21.3 mmol) was added to a solution of compound 1-2 (5.76 g, 10.6 mmol) and AcOH (1.22 ml, 21.3 mmol) in THF (30 ml). DMF (30 ml) was added, and the mixture was stirred at room temperature. After stirring for 2.5 h at the same temperature, the reaction mixture was treated with saturated aqueous NaHCO₃, and the aqueous layer was extracted with AcOEt. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated. The crude product was added to a silica gel column and eluted with Hexane/EtOAc 30% to 50%. Collected fractions were evaporated to afford compound 1-3 (4.01 g, 9.38 mmol, 88%) as a brown oil.

1H-NMR (400 MHz, CDCl₃) δ: 1.25 (s, 9H), 1.30 (t, J = 7.2 Hz, 3H), 1.97 (s, 3H), 4.27 (m, 2H), 5.14 (s, 1H), 5.35 (d, J = 46.4 Hz, 1H), 7.29 (dd, J = 10.8, 8.4 Hz, 1H), 7.45 (dd, J = 8.4, 2.9 Hz, 1H).

[0187] Step 3

To a solution of compound 1-3 (3.94 g, 9.22 mmol) in CH₂Cl₂ (40 ml) was added 1.02 mol/L DIBAL (27.1 ml, 27.7 mmol) at -78 °C. After stirring for 15 min at the same temperature, the mixture was treated with saturated aqueous Rochelle's salt and stirred for 2.5 h. The aqueous layer was extracted with AcOEt, and the combined organic layers were washed with brine, dried over Na₂SO₄, and filtered. The filtrate was concentrated under vacuum to give compound 1-4 as a yellow amorphous that was used for the next step without purification.

To a solution of methyltriphenylphosphonium bromide (8.23 g, 23.0 mmol) in toluene (85 ml) was added 1.00 mol/L t-BuOK solution in THF (21.2 ml, 21.2 mmol) at room temperature. After stirring for 1 h at the same temperature, a solution of compound 1-4 in toluene (30 ml) was added at 0 °C. After stirring for 90 min at room
temperature, the reaction mixture was treated with saturated aqueous \( \text{NH}_4\text{Cl} \), and the aqueous layer was extracted with AcOEt. The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The crude product was added to a silica gel column and eluted with Hexane/EtOAc 10% to 50%. Collected fractions were evaporated to afford compound 1-5 (1.57 g, 4.12 mmol, 45%) as a white amorphous.

\[ \text{1H-NMR (400 MHz, CDC13) } \delta: 1.24 (s, 9H), 1.85 (t, J = 1.8 Hz, 3H), 5.11 (s, 1H), 5.17-5.32 (m, 2H), 5.34 (d, J = 1.1 Hz, 1H), 5.91-6.04 (m, 1H), 7.29 (dd, J = 10.7, 8.5 Hz, 1H), 7.43 (dd, J = 3.0, 8.5 Hz, 1H). \]

Step 4
To a solution of compound 1-5 (1.57 g, 4.12 mmol) in MeOH (16 ml) was added 4 mol/L HCl in Dioxane (1.54 ml, 6.18 mmol) at room temperature. After stirring for 30 min at the same temperature, the reaction mixture was treated with aqueous NaHC03 and the aqueous layer was extracted with AcOEt. The combined organic layers were washed with \( \text{H}_2\text{O} \) and brine, dried over Na2SO4, filtered and concentrated to give compound 1-6, which was used for the next step without purification.

To a solution of 1-6 in \( \text{CH}_2\text{Cl}_2 \) (11 ml) was added benzyol isothiocyanate (0.848 ml, 2.58 mmol) at 0°C. After stirring for 30 min at room temperature, the reaction mixture was concentrated, and the resulting residue was added to a silica gel column and eluted with Hexane/EtOAc 0% to 25%. Collected fractions were evaporated to afford compound 1-7 (1.81 g, 4.12 mmol, quant) as a yellow oil.

\[ \text{1H-NMR (400 MHz, CDC13) } \delta: 2.12 (d, J = 0.9 Hz, 3H), 5.43-5.61 (m, 3H), 5.90-6.03 (m, 1H), 7.19 (dd, J = 10.6, 8.5 Hz, 1H), 7.40 (dd, J = 8.5, 3.0 Hz, 1H), 7.52 (t, J = 7.7 Hz, 2H), 7.63 (t, J = 7.7 Hz, 1H), 7.85 (d, J = 7.7 Hz, 2H), 8.83 (s, 1H), 11.53 (s, 1H). \]

Step 5
To a solution of iodine (2.09 g, 8.24 mmol) in MeCN (40 ml) was added compound 1-7 (1.81 g, 4.12 mmol) in MeCN (14 ml) at 0°C. After stirring for 20 min at the same temperature, the reaction mixture was treated with aqueous NaHC03 and Na2SO203. The aqueous layer was extracted with AcOEt. The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 35%. Collected fractions were evaporated to afford compound 1-8 (2.18 g, 3.85 mmol, 94%) as a yellow amorphous.

\[ \text{1H-NMR (400 MHz, CDC13) } \delta: 1.90 (s, 3H), 3.29 (dd, J = 10.4, 5.0 Hz, 1H), 3.58 (t, J = 10.4 Hz, 1H), 3.94-3.79 (m, 1H), 5.75 (d, J = 47.3 Hz, 1H), 7.52-7.32 (m, 6H), 8.16 (d, J = 6.9 Hz, 2H). \]

Step 6
To a solution of compound 1-8 (1.52 g, 2.68 mmol) in DMSO (1 ml) and \( \text{H}_2\text{O} \) (0.1
ml) was added AgBF4 (1.05 g, 5.37 mmol) at room temperature. After stirring for 2 h at the same temperature, the reaction mixture was treated with aqueous NaHCO3. The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na2SO4, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 50%. Collected fractions were evaporated to afford compound 1-12 (346 mg, 0.611 mmol, 91%) as a white amorphous.

Step 7
To a solution of compound 1-9 (325 mg, 0.712 mmol) in DMF (4 ml) were added imidazole (194 mg, 2.85 mmol) and TBSCl (215 mg, 1.42 mmol) at 0 °C. After stirring for 20 min at room temperature, the reaction mixture was treated with H2O. The aqueous layer was extracted with AcOEt, and the organic layers were dried over Na2SO4, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 30%. Collected fractions were evaporated to afford compound 1-10 (384 mg, 0.673 mmol, 95%) as a white amorphous.

1H-NMR (400 MHz, CDC13) δ: 0.11 (s, 3H), 0.12 (s, 3H), 0.92 (s, 9H), 1.87 (s, 3H), 3.64-3.69 (m, 1H), 3.72-3.79 (m, 1H), 4.03-4.09 (m, 1H), 5.60 (dd, J = 46.9, 1.3 Hz, 1H), 7.30-7.30 (m, 5H), 8.20 (d, J = 7.3 Hz, 2H).

Step 8
To a solution of compound 1-10 (384 mg, 0.673 mmol) in THF (4 ml) were added Boc2O (0.234 ml, 1.01 mmol) and DMAP (32.9 mg, 0.269 mmol) at room temperature. After stirring for 20 min at the same temperature, the mixture was concentrated under vacuum. The crude product was added to a silica gel column and eluted with Hexane/EtOAc 0% to 30%. Collected fractions were evaporated to afford compound 1-11 (451 mg, 0.672 mmol, quant) as a white amorphous.

1H-NMR (400 MHz, CDC13) δ: 0.08 (s, 3H), 0.09 (s, 3H), 0.90 (s, 9H), 1.39 (s, 9H), 1.62 (d, J = 2.4 Hz, 3H), 3.71-3.76 (m, 1H), 3.89 (dt, J = 30.3, 7.7 Hz, 1H), 4.06 (dd, J = 9.8, 7.7 Hz, 1H), 5.33 (dd, J = 47.4, 1.6 Hz, 1H), 7.19 (t, J = 9.2 Hz, 1H), 7.33-7.40 (m, 3H), 7.48 (t, J = 7.3 Hz, 1H), 7.76 (d, J = 7.3 Hz, 2H).

Step 9
To a solution of compound 1-11 (451 mg, 0.672 mmol) in THF (2 ml), MeOH (2 ml) and H2O (2 ml) was added K2CO3 (279 mg, 2.02 mmol) at room temperature. After stirring for 2 h at 50 °C, the reaction mixture was treated with H2O. The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na2SO4, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 30%. Collected fractions were evaporated to afford compound 1-12 (346 mg, 0.611 mmol, 91%) as a white amorphous.
1H-NMR (400 MHz, CDC13) δ: 0.07 (s, 3H), 0.08 (s, 3H), 0.89 (s, 9H), 1.50 (s, 9H), 1.79 (s, 3H), 3.49-3.70 (m, 2H), 3.99 (t, J = 9.0 Hz, 1H), 5.53 (d, J = 47.2 Hz, 1H), 7.30 (t, J = 9.4 Hz, 1H), 7.45-7.41 (m, 1H).

Step 10
To a solution of compound 1-12 (346 mg, 0.611 mmol) in THF (4 ml) were added Boc₂O (0.213 ml, 0.916 mmol) and DMAP (29.8 mg, 0.244 mmol) at room temperature. After stirring for 30 min at the same temperature, the mixture was concentrated under vacuum. The crude product was added to a silica gel column and eluted with Hexane/EtOAc 0% to 30%. Collected fractions were evaporated to afford compound 1-13 (370 mg, 0.555 mmol, 91%) as a white solid.

1H-NMR (400 MHz, CDC13) δ: 0.11 (s, 3H), 0.11 (s, 3H), 0.92 (s, 9H), 1.42 (s, 18H), 1.82 (d, J = 1.9 Hz, 3H), 3.73-3.79 (m, 1H), 3.97-4.15 (m, 2H), 5.45 (d, J = 47.7 Hz, 1H), 7.25-7.31 (m, 1H), 7.39 (dd, J = 8.4, 3.0 Hz, 1H).

Step 11
To a solution of compound 1-13 (400 mg, 0.600 mmol) in THF (8 ml) were added AcOH (0.0510 ml, 0.900 mmol) and TBAF (1.00 mol/L solution in THF, 1.80 ml, 1.80 mmol) at room temperature. After stirring for 1 h at the same temperature, the reaction mixture was treated with H₂O. The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na₂SO₄, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 10% to 50%. Collected fractions were evaporated to afford compound 1-14 (323 mg, 0.585 mmol, 98%) as a white amorphous.

1H-NMR (400 MHz, CDC13) δ: 1.43 (s, 9H), 1.84 (s, 3H), 3.84-3.95 (m, 1H), 4.04-4.19 (m, 2H), 5.51 (d, J = 47.4 Hz, 1H), 7.27-7.42 (m, 2H).

Step 12
To a solution of compound 1-14 (323 mg, 0.585 mmol) in CH₂Cl₂ (10 ml) was added DAST (0.257 ml, 1.75 mmol) at -78 °C. After stirring for 40 min at room temperature, the reaction mixture was treated with aqueous NaHCO₃. The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na₂SO₄, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 30%. Collected fractions were evaporated to afford compound 5-15 (310 mg, 0.559 mmol, 96%) as a white amorphous.

1H-NMR (400 MHz, CDC13) δ: 1.42 (s, 18H), 1.85 (d, J = 2.1 Hz, 3H), 4.28-4.61 (m, 2H), 4.90 (dt, J = 46.6, 8.4 Hz, 1H), 5.50 (dd, J = 47.1, 1.8 Hz, 1H), 7.30 (t, J = 9.0 Hz, 1H), 7.42 (dd, J = 9.0, 3.1 Hz, 1H).

Step 13
A degassed mixture of Pd2(dbaz)₃ (11.6 mg, 0.0130 mmol) and xantphos (21.9 mg, 0.0380 mmol) in dioxane (1 ml) was stirred for 1 h at room temperature. To this
mixture were added dioxane (3 ml), compound 1-15 (70.0 mg, 0.126 mmol), 5-(fluoromethoxy)pyrazine-2-carboxamide (25.9 mg, 0.152 mmol) and cesium carbonate (49.4 mg, 0.152 mmol). After stirring for 6 h at 90 °C, to the reaction mixture were further added 5-(fluoromethoxy)pyrazine-2-carboxamide (25.9 mg, 0.152 mmol) and cesium carbonate (49.4 mg, 0.152 mmol). After stirring for additional 11 h, the reaction mixture was treated with aqueous citric acid and filtered. The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na2S04, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 35%. Collected fractions were evaporated to afford compound 1-16 (55.0 mg, 0.0850 mmol, 68%) as a yellow oil.

1H-NMR (400 MHz, CDC13) δ: 1.48 (s, 18H), 1.89 (s, 3H), 3.99-4.11 (m, 1H), 4.37-4.53 (m, 1H), 4.85 (dt, J = 47.0, 8.8 Hz, 1H), 5.49 (d, J = 48.4 Hz, 1H), 6.16 (d, J = 50.9 Hz, 2H), 7.52 (t, J = 9.3 Hz, 1H), 8.31 (s, 1H), 8.39 (dd, J = 9.3, 3.0 Hz, 1H), 9.09 (s, 1H), 10.01 (s, 1H).

Step 14
A solution of compound 1-16 (55.0 mg, 0.0850 mmol) in formic acid (0.982 ml) was stirred for 22 h at room temperature. The reaction mixture was treated with aqueous K2 CO3. The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na2S04, filtered and concentrated to afford compound 1-5 (24.0 mg, 0.0540 mmol, 63%) as a tan solid.

Example 2

[0193] Synthesis of compound 1-7
Step 1
To a solution of compound 2-1 (2.00 g, 8.29 mmol) in THF (20 ml) was added a solution of LHMDS (1.00 mmol/L in THF, 16.6 mL, 16.6 mmol) at -78 °C. After stirring for 40 min, a solution of 1,1,1-trifluoropropan-2-one (1.48 ml, 16.6 mmol) in THF (5 ml) was added and the mixture was stirred for 20 min at the same temperature. The reaction mixture was treated with aqueous NH₄Cl. The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na₂S⁰⁴, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/
EtOAc 0% to 20%. Collected fractions were evaporated to afford compound 2-2 (1.79 g, 5.07 mmol, 61%) as a yellow solid.

1H-NMR (400 MHz, CDC13) δ: 1.04 (s, 3H), 1.39 (s, 9H), 3.45 (d, J = 12.7 Hz, 1H), 3.80 (d, J = 12.7 Hz, 1H), 6.31 (s, 1H), 7.15 (dd, J = 11.4, 8.3 Hz, 1H), 7.24 (t, J = 8.3 Hz, 1H), 7.55-7.44 (m, 2H).

Step 2
To a solution of compound 2-2 (896 mg, 2.54 mmol) in MeOH (12 ml) was added 4 mol/L HCl in H2O (6.34 ml, 12.7 mmol) at room temperature. After stirring for 1 h at the same temperature, the reaction mixture was treated with aqueous NaHC03, and the aqueous layer was extracted with AcOEt. The combined organic layer was washed with H2O and brine, dried over Na2SO4, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 20%. Collected fractions were evaporated to afford compound 2-3 (603 mg, 2.41 mmol, 95%) as a white solid.

1H-NMR (400 MHz, CDC13) δ: 1.50 (s, 3H), 3.17 (d, J = 17.8 Hz, 1H), 3.53 (d, J = 17.8 Hz, 1H), 5.06 (s, 1H), 7.18 (t, J = 9.8 Hz, 1H), 7.26-7.31 (m, 1H), 7.63-7.56 (m, 1H), 7.86 (t, J = 7.5 Hz, 1H).

[0194] Step 3
To a solution of compound 2-3 (500 mg, 2.00 mmol) in toluene (5 ml) were added titanium ethoxide (0.836 ml, 4.00 mmol) and (S)-2-methylpropane-2-sulfinamide (363 mg, 3.00 mmol). After stirring for 15 min at 80 °C, the reaction mixture were added MeCN (10 ml) and H2O (0.25 mL) at room temperature, and the insoluble material was removed by filtration. The filtrate was evaporated under reduced pressure. The crude product was added to a silica gel column and eluted with hexane/EtOAc 30%. Collected fractions were evaporated to afford compound 2-4 (588 mg, 1.66 mmol, 83%) as a white solid.

1H-NMR (400 MHz, CDC13) δ: 1.33 (s, 3H), 1.37 (s, 9H), 3.35 (d, J = 13.0 Hz, 1H), 3.95 (d, J = 13.0 Hz, 1H), 5.89 (s, 1H), 7.07-7.25 (m, 2H), 7.54-7.40 (m, 2H).

Step 4
To a solution of compound 2-4 (550 mg, 1.56 mmol) in DMF (5 ml) were added imidazole (318 mg, 4.67 mmol), TMSC1 (338 mg, 3.11 mmol) and DMAP (95.0 mg, 0.778 mmol) at room temperature. After stirring for 40 min at the same temperature, the reaction mixture was treated with H2O. The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na2SO4, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 20%. Collected fractions were evaporated to afford compound 2-5 (406 mg, 0.954 mmol, 61%) as a yellow oil.

1H-NMR (400 MHz, CDC13) δ: -0.14 (s, 9H), 1.30 (s, 9H), 1.42 (s, 3H), 3.61 (d, J =
13.2 Hz, 1H), 3.99 (d, J = 13.2 Hz, 1H), 7.07 (dd, J = 8.4, 10.7 Hz, 1H), 7.17 (t, J = 7.4 Hz, 1H), 7.43-7.35 (m, 1H), 7.46-7.53 (m, 1H).

[0195] Step 5

To a solution of compound 2-5 (200 mg, 0.470 mmol) in THF (3 ml) was added a solution of MeLi (1.13 mmol/L in ethyl ether, 1.25 mL, 1.41 mmol) at -78 °C. After stirring for 30 min at 0 °C, the reaction mixture was treated with aqueous NH₄Cl. The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na₂SO₄, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 30%. Collected fractions were evaporated to afford compound 2-6 (18.0 mg, 0.0408 mmol, 8.7%) as a colorless oil.

1H-NMR (400 MHz, CDC13) δ: 0.01 (s, 9H), 1.06 (s, 3H), 1.28 (s, 9H), 1.69 (s, 3H), 2.30 (d, J = 15.1 Hz, 1H), 2.53 (d, J = 15.1 Hz, 1H), 5.54 (s, 1H), 6.96-7.03 (m, 1H), 7.24-7.17 (m, 2H), 8.14 (t, J = 8.0 Hz, 1H).

Step 6

To a solution of compound 2-6 (86.0 mg, 0.195 mmol) in MeOH (1 ml) was added 4 mol/L HC1 in Dioxane (0.292 ml, 1.17 mmol) at room temperature. After stirring for 17 h at the same temperature, the reaction mixture was treated with aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃. The combined organic layer was dried over Na₂SO₄, filtered and concentrated to give compound 2-7, which was used for the next step without purification.

To a solution of 2-7 in CH₂Cl₂ (1 ml) was added benzoyl isothiocyanate (0.0400 ml, 0.292 mmol) at 0 °C. After stirring for 2.5 h at room temperature, the reaction mixture was concentrated. The resulting residue was added to a silica gel column and eluted with hexane/EtOAc 0% to 25%. Collected fractions were evaporated to afford 2-8 (72.0 mg, 0.168 mmol, 86%) as a yellow oil.

1H-NMR (400 MHz, CDC13) δ: 1.31 (s, 3H), 2.25 (s, 3H), 2.66 (d, J = 15.2 Hz, 1H), 2.98 (d, J = 15.2 Hz, 1H), 7.02-7.09 (m, 1H), 7.16 (t, J = 7.1 Hz, 1H), 7.27-7.33 (m, 1H), 7.45 (t, J = 7.7 Hz, 1H), 7.52 (t, J = 7.7 Hz, 2H), 7.63 (t, J = 7.7 Hz, 1H), 7.86 (d, J = 7.7 Hz, 2H), 8.83 (s, 1H), 11.65 (s, 1H).

[0196] Step 7

To a solution of compound 2-8 (72.0 mg, 0.168 mmol) in MeCN (1 ml) was added WSCD HCl (64.4 mg, 0.336 mmol) at room temperature. After stirring for 20 h at the same temperature, the reaction mixture was concentrated. The resulting residue was added to a silica gel column and eluted with hexane/EtOAc 0% to 20%. Collected fractions were evaporated to afford compound 2-9 (55.0 mg, 0.139 mmol, 83%) as a colorless oil.

1H-NMR (400 MHz, CDC13) δ: 1.11 (s, 3H), 1.82 (s, 3H), 2.43 (d, J = 14.3 Hz, 1H), 3.06 (d, J = 14.3 Hz, 1H), 7.10-7.21 (m, 2H), 7.32-7.47 (m, 4H), 7.52 (t, J = 7.3 Hz,
1H), 8.28 (d, J = 7.3 Hz, 2H), 11.94 (s, 1H).

Step 8  
To a solution of compound 2-9 (55.0 mg, 0.139 mmol) in MeOH (1 ml) was added K₂C₃O₂ (57.8 mg, 0.418 mmol) at room temperature. After stirring for 4 h at 50 °C, the reaction mixture was treated with H₂O, and the aqueous layer was extracted with AcOEt. The combined organic layers were dried over Na₂SO₄, filtered and concentrated to give compound 2-10, which was used for the next step without purification.

To a solution of 2-10 in TFA (1 ml) was added sulfuric acid (0.245 ml, 4.60 mmol) at -20 °C. After stirring for 5 min at 0 °C, the reaction mixture was added to HNO₃ (0.00935 ml, 0.209 mmol) at -20 °C. After stirring for 15 min at 0 °C, the reaction mixture was treated with aqueous K₂C₃O₂. The aqueous layer was extracted with AcOEt and the organic layer was dried over Na₂SO₄. The filtrate was concentrated under vacuum to give compound 2-11 as a yellow oil that was used for the next step without purification.

To a solution of 2-11 in THF (1 ml) were added Boc₂O (0.0970 ml, 0.419 mmol) and DMAP (6.82 mg, 0.0560 mmol) at room temperature. After stirring for 1 h at the same temperature, the mixture was concentrated under vacuum. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 20%. Collected fractions were evaporated to afford compound 2-12 (70.0 mg, 0.131 mmol, 94%) as a white solid.

1H-NMR (400 MHz, CDCl₃) δ: 1.09 (s, 3H), 1.53 (s, 18H), 1.66 (s, 3H), 2.19 (d, J = 14.8 Hz, 1H), 2.90 (d, J = 14.8 Hz, 1H), 7.28-7.24 (m, 1H), 8.19-8.24 (m, 1H), 8.59 (dd, J = 6.9, 2.9 Hz, 1H).

[0197] Step 9  
A suspension of 2-12 (70.0 mg, 0.131 mmol) and 10% Pd/C (7.05 mg) in MeOH (3 ml) was stirred under a hydrogen atmosphere at room temperature. After stirring for 1.5 h at the same temperature, the mixture was filtrated through a pad of Celite (Registered trademark). The filtrate was concentrated under vacuum to give compound 2-13 (57.0 mg, 0.113 mmol, 86%) as a white solid that was used for the next step without purification.

1H-NMR (400 MHz, CDCl₃) δ: 1.14 (s, 3H), 1.52 (s, 18H), 1.61 (s, 3H), 2.04 (d, J = 14.2 Hz, 1H), 2.93 (d, J = 14.2 Hz, 1H), 3.51 (s, 2H), 6.55-6.50 (m, 1H), 6.89-6.81 (m, 2H).

Step 10  
To a solution of 2-13 (57.0 mg, 0.113 mmol) in DMF (1 ml) were added 5-cyanopicolinic acid hydrate (18.7 mg, 0.113 mmol), HATU (51.4 mg, 0.135 mmol) and DIPEA (0.0390 ml, 0.226 mmol) at room temperature. After stirring for 1 h at the
same temperature, the reaction mixture was treated with \( \text{H}_2\text{O} \). The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na2SO4, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 30%. Collected fractions were evaporated to afford compound 2-14 (70.0 mg, 0.110 mmol, 98%) as a white amorphous.

\[ \delta: 1.11 \ (s, 3H), \ 1.54 \ (s, 18H), \ 1.67 \ (s, 3H), \ 2.12 \ (d, J = 14.3 \ Hz, 1H), \ 2.94 \ (d, J = 14.3 \ Hz, 1H), \ 7.13 \ (dd, J = 11.5, 9.0 \ Hz, 1H), \ 7.53 \ (dd, J = 7.0, 2.6 \ Hz, 1H), \ 8.21 \ (dd, J = 8.2, 1.8 \ Hz, 1H), \ 8.32-8.27 \ (m, 1H), \ 8.43 \ (d, J = 8.2 \ Hz, 1H), \ 8.80 \ (s, 1H), \ 9.91 \ (s, 1H). \]

**Step 11**

A solution of compound 2-14 (70.0 mg, 0.110 mmol) in formic acid (0.972 ml) was stirred for 19 h at room temperature. The reaction mixture was treated with aqueous \( \text{K}_2\text{CO}_3 \). The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na2SO4, filtered and concentrated to afford compound 1-7 (40.0 mg, 0.0920 mmol, 83%) as a white solid.

**Example 3**

[0198] Synthesis of compound 1-8
Chem. 53

Step 1
To a solution of compound 3-1 (373 mg, 1.24 mmol) in MeOH (4 ml) was added 4 mol/L HCl in dioxane (0.464 ml, 1.86 mmol) at room temperature. After stirring for 30 min at the same temperature, the reaction mixture was treated with aqueous NaHCO$_3$ and the aqueous layer was extracted with AcOEt. The combined organic layers were washed with H$_2$O and brine, dried over Na$_2$SO$_4$ and filtered. The filtrate was concentrated under vacuum to give compound 3-2 as a brown oil that was used for the next step without purification.

To a solution of compound 3-2 in CH$_2$Cl$_2$ (3 ml) was added benzoyl isothiocyanate (0.255 ml, 1.86 mmol) at 0 °C. After stirring for 30 min at room temperature the reaction mixture was concentrated. The resulting residue was added to a silica gel column and eluted with Hexane/EtOAc 0% to 25%. Collected fractions were
evaporated to afford compound 3-3 (397 mg, 1.10 mmol, 89%) as a white amorphous.

1H-NMR (400MHz, CDC13) δ: 2.13 (s, 3H), 5.48 (d, J = 10.6 Hz, 1H), 5.60-5.76 (m, 2H), 5.82-5.96 (m, 1H), 7.00-7.07 (m, 1H), 7.16 (t, J = 7.7 Hz, 1H), 7.27-7.33 (m, 1H), 7.44 (t, J = 7.7 Hz, 1H), 7.51 (t, J = 7.7 Hz, 2H), 7.63 (t, J = 7.7 Hz, 1H), 7.85 (d, J = 7.7 Hz, 2H), 8.82 (s, 1H), 11.50 (s, 1H).

Step 2
To a solution of iodine (559 mg, 2.20 mmol) in MeCN (30 ml) was added compound 3-3 (397 mg, 1.10 mmol) in MeCN (10 ml) at 0 °C. After stirring for 20 min at the same temperature, the reaction mixture was treated with aqueous NaHCO₃ and Na2S2O3. The aqueous layer was extracted with AcOEt. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 20%. Collected fractions were evaporated to afford compound 3-4 (489 mg, 1.01 mmol, 91%) as a white amorphous.

1H-NMR (400 MHz, CDC13) δ: 1.90 (s, 3H), 3.14-3.28 (m, 2H), 3.50 (t, J = 9.3 Hz, 1H), 5.70 (d, J = 47.3 Hz, 1H), 7.12-7.23 (m, 2H), 7.31-7.48 (m, 4H), 7.53 (t, J = 7.3 Hz, 1H), 8.21 (d, J = 7.3 Hz, 2H).

[0200]
Step 3
To a solution of compound 3-4 (489 mg, 1.01 mmol) in toluene (5 ml) were added Bu3SnH (0.320 ml, 1.21 mmol) and AIBN (8.26 mg, 0.0500 mmol) at room temperature. After stirring for 100 min at 80 °C the reaction mixture was concentrated. The resulting residue was added to an amino silica gel column and eluted with Hexane/EtOAc 0% to 20%. Collected fractions were evaporated to afford compound 3-5 (336 mg, 0.932 mmol, 93%) as a white amorphous.

1H-NMR (400 MHz, CDC13) δ: 1.40 (d, J = 6.7 Hz, 3H), 1.88 (s, 3H), 3.13 (dq, J = 31.4, 6.7 Hz, 1H), 5.25 (d, J = 47.2 Hz, 1H), 7.11 (dd, J = 12.3, 8.0 Hz, 1H), 7.20 (t, J = 7.5 Hz, 1H), 7.33-7.46 (m, 4H), 7.51 (t, J = 7.5 Hz, 1H), 8.22 (d, J = 7.5 Hz, 2H), 12.13 (br s, 1H).

Step 4
To a solution of compound 3-5 (336 mg, 0.932 mmol) in EtOH (3 ml) was added hydrazine hydrate (0.226 ml, 4.66 mmol) at room temperature. After stirring for 14 h at the same temperature, the reaction mixture was concentrated. The resulting residue was added to an amino silica gel column and eluted with Hexane/EtOAc 10% to 50%. Collected fractions were evaporated to afford compound 3-6 (195 mg, 0.761 mmol, 82%) as a white solid.

1H-NMR (400 MHz, CDC13) δ: 1.32 (d, J = 6.8 Hz, 3H), 3.08-2.94 (m, 1H), 5.09 (d, J = 47.4 Hz, 1H), 6.99-7.07 (m, 1H), 7.12 (t, J = 7.4 Hz, 1H), 7.23-7.31 (m, 2H).
To a solution of compound 3-6 in TFA (2 ml) was added sulfuric acid (0.507 ml, 9.51 mmol) at -20 °C. After stirring for 5 min at 0 °C, the reaction mixture was added to HNO₃ (0.0510 ml, 1.14 mmol) at -20 °C. After stirring for 20 min at 0 °C, the reaction mixture was treated with aqueous K₂C₇O₃. The aqueous layer was extracted with AcOEt and the organic layer was dried over Na₂SO₄. The filtrate was concentrated under vacuum to give compound 3-7 as a yellow oil that was used for the next step without purification.

To a solution of compound 3-7 in THF (2 ml) were added Boc₂O (0.529 ml, 2.28 mmol) and DMAP (37.1 mg, 0.304 mmol) at room temperature. After stirring for 50 min at the same temperature, the mixture was concentrated under vacuum. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 40%. Collected fractions were evaporated to afford compound 3-8 (381 mg, 0.760 mmol, quant) as a white amorphous.

1H-NMR (400 MHz, CDC13) δ: 1.37 (d, J = 6.8 Hz, 3H), 1.55 (s, 18H), 1.82 (s, 3H), 3.09 (dq, J = 29.6, 6.8 Hz, 1H), 5.12 (d, J = 46.7 Hz, 1H), 7.23 (dd, J = 10.9, 9.1 Hz, 1H), 8.23-8.18 (m, 1H), 8.52 (dd, J = 6.6, 2.8 Hz, 1H).

[0201] Step 6

To a solution of compound 3-8 (381 mg, 0.760 mmol) in EtOH (4 ml), THF (2 ml) and H₂O (2 ml) were added NH₄Cl (488 mg, 9.12 mmol) and iron powder (339 mg, 6.08 mmol) at room temperature. After stirring for 90 min at 60 °C, the mixture was treated with H₂O and filtrated through a pad of Celite (Registered trademark). The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na₂SO₄, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 40%. Collected fractions were evaporated to afford compound 3-9 (247 mg, 0.524 mmol, 69%) as a white amorphous.

1H-NMR (400 MHz, CDC13) δ: 1.33 (d, J = 7.0 Hz, 3H), 1.54 (s, 18H), 1.80 (t, J = 2.0 Hz, 3H), 3.19 (dq, J = 29.6, 7.0 Hz, 1H), 3.57 (s, 2H), 5.05 (d, J = 48.2 Hz, 1H), 6.55-6.51 (m, 1H), 6.88-6.80 (m, 2H).

Step 7

To a solution of compound 3-9 (60.0 mg, 0.127 mmol) in DMF (1 ml) were added 5-methoxypyrazine-2-carboxylic acid (20.6 mg, 0.134 mmol), HATU (58.1 mg, 0.153 mmol) and DIPEA (0.0440 ml, 0.254 mmol) at room temperature. After stirring for 20 min at the same temperature, the reaction mixture was treated with H₂O. The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na₂SO₄, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 30%. Collected fractions were evaporated to afford compound 3-10 (70.0 mg, 0.115 mmol, 91%) as a white solid.

1H-NMR (400 MHz, CDC13) δ: 1.35 (d, J = 7.0 Hz, 3H), 1.58 (s, 18H), 1.86 (s, 3H),
3.17 (dq, J = 30.5, 7.0 Hz, 1H), 4.06 (s, 3H), 5.09 (d, J = 46.8 Hz, 1H), 7.10 (dd, J = 9.3, 11.7 Hz, 1H), 7.51 (d, J = 6.7 Hz, 1H), 8.06 (s, 1H), 8.44-8.39 (m, 1H), 9.01 (s, 1H), 9.69 (s, 1H).

Step 8
A solution of compound 3-10 (70.0 mg, 0.115 mmol) in formic acid (0.972 ml) was stirred for 19 h at room temperature. The reaction mixture was treated with aqueous K$_2$CO$_3$. The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na$_2$SO$_4$, filtered and concentrated to afford compound 1-8 (35.0 mg, 0.0860 mmol, 75%) as a white solid.

**Example 4**

[0202] Synthesis of compound 1-13

[Chem.54]
Step 1
To a solution of compound 4-1 (15.0 g, 43.2 mmol) in methanol (150 ml) was added
HCl-dioxane (4M, 15.1 ml, 60.4 mmol). After stirring for 1 h at room temperature, the reaction mixture was quenched with saturated aqueous NaHCO₃ solution. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated to afford compound 4-2 (10.5 g, quant), which was used in the next reaction without further purification.

LC/MS (Shimadzu): RT 0.83, MS calcd for 244.10 (M+H+), found 244.30.

Step 2

To a solution of compound 4-2 (10.5 g, 43.2 mmol) and NaHCO₃ (12.7 g, 151 mmol) in AcOEt (100 ml) and H₂O (50 ml) was added 4-nitrophenyl carbonochloridate (8.71 g, 43.2 mmol) at 0 °C. After being stirred for 1 h at 0 °C, bis(2,4-dimethoxybenzyl)amine (13.7 g, 43.2 mmol) was added. After an additional stirring for 1 h at 0 °C, the reaction mixture was quenched with H₂O, and the aqueous phase was extracted with AcOEt. The organic phase was washed with aqueous K₂CO₃ and H₂O in twice to remove 4-nitrophenol. The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 4-3 (25.3 g, 43.1 mmol, 100%, including small amount of 4-nitrophenol).

1H-NMR (CDCl₃) δ: 0.97 (t, J = 7.2 Hz, 3H), 1.95 (s, 3H), 3.80 (s, 6H), 3.81 (s, 6H), 3.87 (dq, J = 10.6, 7.2 Hz, 1H), 4.01 (dq, J = 10.6, 7.2 Hz, 1H), 4.33 (d, J = 16.2 Hz, 2H), 4.42 (d, J = 16.2 Hz, 2H), 5.58 (d, J = 47.8 Hz, 1H), 6.07 (s, 1H), 6.42-6.49 (m, 4H), 7.00 (m, 1H), 7.08 (m, 1H), 7.18 (d, J = 8.8 Hz, 2H), 7.24 (m, 1H), 7.36 (m, 1H).

[0204] Step 3

To a solution of compound 4-3 (25.3 g, 43.2 mmol, including small amount of 4-nitrophenol) in CH₂Cl₂ (125 ml) was added DIBAL (1.02 mol/L in toluene, 127 ml, 130 mmol) at -65 °C. After being stirred for 1 h at -65 °C, the reaction mixture was quenched with AcOEt and Rochelle's salt (98 g, 346 mmol) in H₂O. After an additional stirring for 2 h at room temperature, the aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 4-4 (19.5 g, 35.9 mmol, 83% in 3 steps).

1H-NMR (CDCl₃) δ: 1.67 (s, 3H), 3.80 (s, 6H), 3.81 (s, 6H), 4.36 (d, J = 15.9 Hz, 2H), 4.43 (d, J = 15.9 Hz, 2H), 5.76 (d, J = 46.9 Hz, 1H), 5.77 (s, 1H), 6.43-6.51 (m, 4H), 7.00-7.20 (m, 4H), 7.22-7.35 (m, 2H), 9.51 (d, J = 10.0 Hz, 1H).

Step 4

To a solution of ethyltriphenylphosphonium bromide (28.2 g, 76.0 mmol) in THF (129 ml) was added KHMDS (0.5 mol/L in toluene, 143 ml, 71.3 mmol) at 0 °C. After dropwise of KHMDS, compound 4-4 (12.9 g, 23.8 mmol) in THF (80 ml) was added rapidly to the reaction mixture. After being stirred for 30 min at 0 °C, the temperature was warmed to 50 °C. After an additional stirring for 1 h, the reaction mixture was
cooled to 0 °C and quenched with H$_2$O. The aqueous phase was extracted with AcOEt, and the organic layer was dried over Na$_2$SO$_4$ and concentrated. The residue was purified by silica gel chromatography to afford compound 4-5 and 4-6 as a mixture (12.4 g, 22.4 mmol, 94%, compound 4-5:compound 4-6 = 1.5:1).

**compound 4-5:**
1H-NMR (CDC13) δ: 1.54 (m, 3H), 1.87 (s, 3H), 3.78 (s, 6H), 3.81 (s, 6H), 4.31-4.47 (m, 4H), 5.31 (m, 1H), 5.58-5.83 (m, 3H), 6.42-6.48 (m, 4H), 6.97 (m, 1H), 7.07 (m, 1H), 7.10-7.17 (m, 2H), 7.19 (m, 1H), 7.37 (m, 1H).

**compound 4-6:**
1H-NMR (CDC13) δ: 1.57 (m, 3H), 1.82 (s, 3H), 3.78 (s, 6H), 3.81 (s, 6H), 4.37 (m, 4H), 5.30 (m, 1H), 5.45 (dd, J = 47.3, 6.8 Hz, 1H), 5.60 (s, 1H), 5.71 (m, 1H), 6.40-6.49 (m, 4H), 6.98 (dd, J = 12.5, 8.2 Hz, 1H), 7.08 (m, 1H), 7.13 (d, J = 8.5 Hz, 2H), 7.21 (m, 1H), 7.38 (dd, J = 8.2, 8.0 Hz, 1H).

**Step 5**
To a solution of iodine (11.4 g, 44.7 mmol) in acetonitrile (500 ml) was added compounds 4-5 and 4-6 (12.4 g, 22.4 mmol) in acetonitrile (125 ml) at 0 °C. After being stirred for 1.5 h at 0 °C, the reaction mixture was quenched with aqueous Na$_2$S$_2$O$_4$ and saturated aqueous NaHCO$_3$. After removal of acetonitrile in vacuo, the aqueous phase was extracted with AcOEt. The organic layer was dried over Na$_2$SO$_4$ and concentrated. The residue was purified by silica gel chromatography to afford compound 4-7 (8.81 g, 13.0 mmol, 58%) and recovered compound 4-6 (3.17 g, 5.72 mmol, 26%).

1H-NMR (CDC13) δ: 1.63 (s, 3H), 1.84 (d, J = 7.0 Hz, 3H), 3.63 (dd, J = 28.6, 9.2 Hz, 1H), 3.75 (s, 6H), 3.82 (s, 6H), 4.12 (m, 1H), 4.49 (d, J = 15.9 Hz, 2H), 4.65 (d, J = 15.9 Hz, 2H), 5.37 (d, J = 48.8 Hz, 1H), 6.41-6.50 (m, 4H), 7.00 (dd, J = 11.9, 8.3 Hz, 1H), 7.06 (dd, J = 7.4, 7.4 Hz, 1H), 7.16-7.28 (m, 3H), 7.42 (dd, J = 8.3, 7.4 Hz, 1H).

**Step 6**
To a solution of 18-crown-6 (5.45 g, 20.6 mmol) and K$_2$O$_2$ (1.47 g, 20.6 mmol) in DMSO (40 ml) was added compound 4-7 (3.51 g, 5.16 mmol) in DMSO (25 ml) at room temperature. After being stirred for 25 min, the reaction mixture was quenched with saturated aqueous Na$_2$S$_2$O$_3$. The aqueous phase was extracted with AcOEt, and the organic layer was dried over Na$_2$SO$_4$. This reaction was repeated 3 times (300 mg, 2.0 g and 3.0 g of 4-7 were used in each step). The combined organic layers obtained in each step were concentrated, and the residue was purified by silica gel chromatography to afford compound 4-8 (2.05 g, 3.59 mmol, 28%, 7.6:1 diastereomeric mixture at C7 position).

1H-NMR (CDC13) δ: 1.07 (d, J = 6.3 Hz, 3H), 1.66 (s, 3H), 3.35 (dd, J = 30.4, 7.8 Hz, 1H), 3.75 (s, 6H), 3.81 (s, 6H), 3.85 (m, 1H), 4.45 (d, J = 15.9 Hz, 2H), 4.61 (d, J = 15.9 Hz, 2H), 5.38 (d, J = 48.6 Hz, 1H), 6.41-6.50 (m, 4H), 6.98 (dd, J = 12.0, 8.2 Hz,
1H), 7.05 (dd, J = 7.7, 7.3 Hz, 1H), 7.17-7.28 (m, 3H), 7.42 (dd, J = 8.2, 7.7 Hz, 1H).

[0206] Step 7

To a solution of compound 4-8 (1.42 g, 2.49 mmol) and nonafluorobutanesulfonfyl fluoride (1.61 ml, 8.96 mmol) in toluene (28 ml) was added DBU (1.34 ml, 8.96 mmol) at room temperature. After being stirred for 12 h at room temperature, the reaction mixture was quenched with saturated aqueous NH₄Cl, water and 2 mol/L aqueous HCl. The aqueous phase was extracted with AcOEt and the organic phase was washed with 2 mol/L aqueous NaOH. The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography to afford a mixture of compound 4-9 and the corresponding exo olefin (1.0 g, compound 4-9:exo olefin = 1:1, inseparable mixture).

LC/MS(Shimadzu): RT 1.98, MS calcd for 573.26 (M+H+), found 573.25.

Step 8

To a mixture of compound 4-9 and exo olefin (1.0 g, compound 4-9:exo olefin = 1:1, inseparable mixture) and anisole (1.34 ml, 12.2 mmol) was added TFA (6.73 ml, 87.0 mmol) at room temperature. After being stirred for 13.5 h at 80 °C, the reaction mixture was cooled to 0 °C and quenched with aqueous K₂CO₃. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 4-10 (251.8 mg, 925 μmol, 37%, 2 steps).

1H-NMR (CDCl₃) δ: 1.40 (dd, J = 24.1, 6.4 Hz, 3H), 1.77 (s, 3H), 3.89 (ddd, J = 30.2, 12.9, 7.8 Hz, 1H), 4.88 (ddq, J = 49.0, 7.8, 6.4 Hz, 1H), 5.25 (d, J = 47.2 Hz, 1H), 7.10 (dd, J = 12.3, 8.2 Hz, 1H), 7.24 (m, 1H), 7.32-7.45 (m, 2H).

[0207] Step 9

To a solution of compound 4-10 (251.8 mg, 925 μmol) in TFA (2.4 ml) was added H₂SO₄ (0.6 ml) at -20 °C. After being stirred for 5 min at 0 °C, the reaction mixture was cooled to -20 °C and HNO₃ (62 μl, 1.39 mmol) was added. After an additional stirring for 30 min at 0 °C, the reaction mixture was quenched with aqueous K₂CO₃. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 4-11 (240.1 mg, 757 μmol, 82%).

1H-NMR (CDCl₃) δ: 1.39 (ddd, J = 24.2, 6.4 Hz, 3H), 1.65 (s, 3H), 3.67 (ddd, J = 30.9, 13.2, 7.4 Hz, 1H), 4.42 (brs, 2H), 4.86 (ddq, J = 48.8, 7.4, 6.4 Hz, 1H), 5.15 (d, J = 47.7 Hz, 1H), 7.23 (m, 1H), 8.22 (m, 1H), 8.45 (m, 1H).

Step 10

To a solution of compound 4-11 (240.1 mg, 757 μmol) and DMAP (18.5 mg, 151 μmol) in CH₂Cl₂ (2.4 ml) was added Boc₃O (439 μl, 1.89 mmol) at room temperature. After being stirred for 35 min at room temperature, the reaction mixture was con-
centrated. The residue was purified by silica gel chromatography to afford compound 4-12. The residue was triturated from AcOEt/hexane to give compound 4-12 (244.6 mg, 473 \( \mu \text{mol} \), 62%). The stereochemistry at C7 position of compound 4-12 was determined by X-ray crystallographic analysis.

1H-NMR (CDC13) \( \delta \): 1.40 (dd, \( J = 24.1, 6.5 \text{ Hz}, 3H \)), 1.52 (s, 18H), 1.72 (s, 3H), 3.80 (ddd, \( J = 29.9, 12.9, 7.2 \text{ Hz}, 1H \)), 4.91 (ddq, \( J = 48.1, 7.2, 6.5 \text{ Hz}, 1H \)), 5.19 (d, \( J = 47.2 \text{ Hz}, 1H \)), 7.28 (m, 1H), 8.26 (m, 1H), 8.57 (m, 1H).

**Example 5**

**Synthesis of compound 1-16**

To a solution of compound 4-12 (241.2 mg, 466 \( \mu \text{mol} \)) in THF (3 ml) and MeOH (1.5 ml) was added Pd/C (24.8 mg) at room temperature. After being stirred for 2 h under H2 atmosphere at room temperature, the reaction mixture was filtered through a pad of Celite (Registered trademark) and washed with AcOEt. The filtrate was concentrated, and the residue was purified by silica gel chromatography to afford compound 4-13 (214.2 mg, 439 \( \mu \text{mol} \), 94%).

1H-NMR (CDC13) \( \delta \): 1.39 (dd, \( J = 24.1, 6.4 \text{ Hz}, 3H \)), 1.52 (s, 18H), 1.68 (s, 3H), 3.58 (brs, 2H), 3.91 (ddd, \( J = 30.0, 13.4, 7.4 \text{ Hz}, 1H \)), 4.88 (ddq, \( J = 48.8, 7.4, 6.4 \text{ Hz}, 1H \)), 5.16 (d, \( J = 47.7 \text{ Hz}, 1H \)), 6.56 (m, 1H), 6.82-6.91 (m, 2H).

**Step 12**

To a solution of compound 4-13 (70.0 mg, 144 \( \mu \text{mol} \)), 5-cyanopicolinic acid hydrate (28.6 mg, 172 \( \mu \text{mol} \)) and diisopropylethylamine (50 \( \mu \text{l}, 287 \mu \text{mol} \)) in DMF (1 ml) was added HATU (65.5 mg, 172 \( \mu \text{mol} \)) at room temperature. After being stirred for 1.5 h at room temperature, the reaction mixture was quenched with saturated aqueous \( \text{NH}_4\text{Cl} \). The aqueous phase was extracted with AcOEt, and the organic phase was washed with \( \text{H}_2\text{O} \). The organic layer was dried over Na2SO4 and concentrated. The residue was purified by silica gel chromatography to afford compound 4-14 (90.0 mg, quant.).

1H-NMR (CDC13) \( \delta \): 1.40 (dd, \( J = 24.0, 6.4 \text{ Hz}, 3H \)), 1.56 (s, 18H), 1.75 (s, 3H), 3.90 (ddd, \( J = 30.6, 13.2, 7.4 \text{ Hz}, 1H \)), 4.89 (ddq, \( J = 48.8, 7.4, 6.4 \text{ Hz}, 1H \)), 5.18 (d, \( J = 47.3 \text{ Hz}, 1H \)), 7.15 (m, 1H), 7.60 (m, 1H), 8.21 (d, \( J = 8.3 \text{ Hz}, 1H \)), 8.40 (m, 1H), 8.43 (d, \( J = 8.3 \text{ Hz}, 1H \)), 8.80 (s, 1H), 9.99 (s, 1H).

**Step 13**

Compound 4-14 (90.0 mg, 144 \( \mu \text{mol} \)) was solved in formic acid (1 ml) and stirred for 16 h at room temperature. The reaction mixture was quenched with aqueous \( \text{K}_2\text{C}_3\text{O}_4 \), and the aqueous phase was extracted with AcOEt. The organic layer was dried over Na2SO4 and concentrated. The residue was triturated from AcOEt/hexane to give compound 1-13 (48.8 mg, 117 \( \mu \text{mol} \), 81% in 2 steps).

**Example 5**

**Synthesis of compound 1-16**
To a solution of iodine (1.05 g, 4.15 mmol) in acetonitrile (45 ml) was added compound 4-6 (1.15 g, 2.07 mmol) in acetonitrile (15 ml) at 0 °C. After being stirred
for 3 d at 0 °C, the reaction mixture was quenched with saturated aqueous NaHCO₃ followed by addition of aqueous Na₂S₂O₃. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂S₂O₃ and concentrated. The residue was purified by silica gel chromatography to afford compound 5-1 (1.20 g, 1.76 mmol, 85%).

1H-NMR (CDCl₃) δ: 1.65 (s, 3H), 1.74 (d, J = 6.8 Hz, 3H), 3.61 (dd, J = 27.5, 10.0 Hz, 1H), 3.74 (s, 6H), 3.81 (s, 6H), 4.10 (m, 1H), 4.45 (d, J = 16.1 Hz, 2H), 4.61 (d, J = 16.1 Hz, 2H), 5.66 (d, J = 48.3 Hz, 1H), 6.41-6.49 (m, 4H), 7.03 (m, 1H), 7.06 (m,-1H), 7.19 (d, J = 8.2 Hz, 2H), 7.22 (m, 1H), 7.41 (m, 1H).

Step 2
To a solution of 18-crown-6 (1.62 g, 6.11 mmol) and K₂O₂ (435 mg, 6.11 mmol) in DMSO (25 ml) was added compound 5-1 (1.04 g, 1.53 mmol) in DMSO (15 ml) at room temperature. After being stirred for 30 min, the reaction mixture was quenched with saturated aqueous Na₂S₂O₃ at 0 °C. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂S₂O₃ and concentrated. The residue was purified by silica gel chromatography to afford compound 5-2 (291 mg, 510 µmol, 33%).

1H-NMR (CDCl₃) δ: 1.07 (d, J = 6.3 Hz, 3H), 1.62 (s, 3H), 2.25 (brs, 1H), 3.34 (dd, J = 30.9, 8.0 Hz, 1H), 3.76 (s, 6H), 3.81 (s, 6H), 3.83 (m, 1H), 4.49 (d, J = 15.9 Hz, 2H), 4.67 (d, J = 15.9 Hz, 2H), 5.14 (d, J = 48.8 Hz, 1H), 6.42-6.51 (m, 4H), 6.98 (m, 1H), 7.03 (m, 1H), 7.17-7.29 (m, 3H), 7.37 (m, 1H).

[0211] Step 3
To a solution of compound 5-2 (290 mg, 508 µmol) in CH₂Cl₂ (6 ml) was added DAST (537 µl, 4.06 mmol) at -65 °C. After being stirred for 22.5 h at room temperature, the reaction mixture was quenched with saturated aqueous NaHCO₃ at 0 °C. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂S₂O₃ and concentrated. The residue was purified by silica gel chromatography to afford a mixture of compound 5-3 and the corresponding endo olefin (212 mg, compound 5-3:endo olefin = 2.5:1, inseparable mixture). The yield of compound 5-3 was calculated by 1H NMR ratio to be 53%.

1H-NMR (CDCl₃) δ: 1.17 (dd, J = 25.5, 6.1 Hz, 3H), 1.66 (s, 3H), 3.53 (m, 1H), 3.75 (s, 6H), 3.81 (s, 6H), 4.38-4.75 (m, 5H), 5.30 (d, J = 48.3 Hz, 1H), 6.40-6.50 (m, 4H), 7.00 (m, 1H), 7.06 (m, 1H), 7.15-7.29 (m, 3H), 7.41 (m, 1H).

Step 4
To a mixture of compound 5-3 and exo olefin (net weight of 5-3: 172 mg, 300 µmol) and anisole (316 µl, 2.89 mmol) was added TFA (1.59 ml, 20.7 mmol) at room temperature. After being stirred for 17 h at 80 °C, the reaction mixture was cooled to 0 °C and quenched with aqueous K₂CO₃. The aqueous phase was extracted with AcOEt.
The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 5-4 (103 mg, quant.).

1H-NMR (CDCl₃) δ: 1.44 (dd, J = 25.3, 6.0 Hz, 3H), 1.85 (s, 3H), 3.84 (m, 1H), 4.86 (m, 1H), 5.44 (d, J = 46.4 Hz, 1H), 7.12 (m, 1H), 7.26 (m, 1H), 7.33-7.43 (m, 2H).

Step 5

To a solution of compound 5-4 (103 mg, 300 µmol) in TFA (1.2 ml) was added H₂SO₄ (0.3 ml) at -20 °C. After being stirred for 5 min at 0 °C, the reaction mixture was cooled to -20 °C and HN₃ (25 µl, 567 µmol) was added. After being stirred for 30 min at 0 °C, the reaction mixture was quenched with aqueous K₂CO₃. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 5-5 (86.3 mg, 272 µmol, 91%, 2 steps).

1H-NMR (CDCl₃) δ: 1.40 (dd, J = 25.5, 6.1 Hz, 3H), 1.67 (s, 3H), 3.53 (m, 1H), 4.29 (brs, 2H), 4.81 (m, 1H), 5.30 (d, J = 47.2 Hz, 1H), 7.23 (m, 1H), 8.21 (m, 1H), 8.44 (m, 1H).

Step 6

To a solution of compound 5-5 (86.3 mg, 272 µmol) and DMAP (16.6 mg, 135 µmol) in CH₂Cl₂ (2 ml) was added Boc₂O (158 µl, 680 µmol) at room temperature. After being stirred for 50 min at room temperature, the reaction mixture was concentrated. The residue was purified by silica gel chromatography to afford compound 5-6 (129 mg, 248 µmol, 91%).

1H-NMR (CDCl₃) δ: 1.41 (dd, J = 25.5, 6.1 Hz, 3H), 1.53 (s, 18H), 1.74 (s, 3H), 3.65 (ddd, J = 27.4, 8.3, 4.8 Hz, 1H), 4.87 (ddq, J = 46.7, 8.3, 6.1 Hz, 1H), 5.35 (d, J = 46.9 Hz, 1H), 7.27 (m, 1H), 8.26 (m, 1H), 8.52 (m, 1H).

Step 7

To a solution of compound 5-6 (129 mg, 248 µmol) in THF (2 ml) and MeOH (1 ml) was added Pd/C (26.4 mg) at room temperature. After being stirred for 7.5 h under H₂ atmosphere at room temperature, the reaction mixture was filtered through a pad of Celite (Registered trademark) and washed with AcOEt. The filtrate was concentrated, and the residue was purified by silica gel chromatography to afford compound 5-7 (104 mg, 214 µmol, 86%).

1H-NMR (CDCl₃) δ: 1.40 (dd, J = 25.4, 6.1 Hz, 3H), 1.53 (s, 18H), 1.70 (s, 3H), 3.56 (brs, 2H), 3.80 (m, 1H), 4.84 (m, 1H), 5.33 (d, J = 47.3 Hz, 1H), 6.56 (m, 1H), 6.83 (m, 1H), 6.86 (m, 1H).

Step 8

To a solution of compound 5-7 (44.2 mg, 90.7 µmol), 5-(fluoromethoxy)pyrazine-2-carboxylic acid (18.7 mg, 109 µmol) and diisopropylethylamine (32 µl, 181 µmol) in DMF (1 ml) was added HATU (41.4 mg, 109 µmol)
at room temperature. After being stirred for 50 min at room temperature, the reaction mixture was quenched with saturated aqueous \( \text{NH}_4\text{Cl} \). The aqueous phase was extracted with AcOEt. The organic layer was dried over Na\( _2\text{SO}_4 \) and concentrated. The residue was purified by silica gel chromatography to afford compound 5-8 (51.6 mg, 80.4 \( \mu \)mol, 89%).

1H-NMR (CDCl\( _3 \)) \( \delta \): 1.40 (dd, \( J = 25.3, 6.1 \text{ Hz} \), 3H), 1.54 (s, 18H), 1.76 (s, 3H), 3.78 (m, 1H), 4.85 (m, 1H), 5.36 (dd, \( J = 51.1, 14.8 \text{ Hz} \), 1H), 7.14 (dd, \( J = 51.1, 14.8 \text{ Hz} \), 2H), 7.47 (m, 1H), 8.20 (s, 1H), 8.35 (m, 1H), 9.08 (s, 1H), 9.62 (s, 1H).

Step 9

Compound 5-8 (51.6 mg, 80.4 \( \mu \)mol) was solved in formic acid (0.75 ml) and stirred for 18.5 h at room temperature. The reaction mixture was quenched with aqueous \( \text{K}_2\text{CO}_3 \) at 0 °C, and the aqueous phase was extracted with AcOEt. The organic layer was dried over Na\( _2\text{SO}_4 \) and concentrated. The residue was triturated from AcOEt/hexane to give compound 1-16 (31.0 mg, 70.2 \( \mu \)mol, 87%).

Example 6

[0214] Synthesis of compound 1-28

[Chem.57]
The reaction mixture was stirred for 30 min at -78 °C. The reaction was quenched with a saturated solution of ammonium chloride. The resulting mixture was filtered through Celite (Registered trademark), and the filtrate was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated, and the crude product was purified by flash column chromatography (silica gel, gradient from 3:1 to 1:1 hexane:ethyl acetate) to give compound 6-2 (24.8 g, 82%) as a tan oil. This material was obtained as a mixture of diastereomers.

1H NMR (400 MHz, CDCl3) (major isomer) 1.14 (d, J = 7.0 Hz, 3H), 1.28 (s, 9H), 1.95 (s, 3H), 3.14 (q, J = 7.0 Hz, 1H), 3.98-4.04 (m, 1H), 4.89 (s, 1H), 7.01-7.43 (m, 5H).

Step 2

To a stirred solution of diisopropylamine (37.7 mL, 0.265 mol) in THF (260 mL) was added dropwise n-butyl lithium (2.65 mol/L in hexane, 100 mL, 0.265 mol) at -78 °C. After being stirred for 25 min at 0 °C, ethyl to the mixture were added dropwise ethyl propionate (30.4 mL, 0.265 mol) followed by chlorotrisopropoxytitanium (IV) (84.0 mL, 0.353 mol) in THF (70 mL) at -78 °C. After being stirred for 30 min, compound 6-1 (21.3 g, 0.088 mol) in THF (70 mL) was added dropwise to the mixture at -78 °C. The reaction mixture was stirred for 30 min at -78 °C. The reaction was quenched with a saturated solution of ammonium chloride. The resulting mixture was filtered through Celite (Registered trademark), and the filtrate was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated, and the crude product was purified by flash column chromatography (silica gel, gradient from 3:1 to 1:1 hexane:ethyl acetate) to give compound 6-2 (24.8 g, 82%) as a tan oil. This material was obtained as a mixture of diastereomers.

1H NMR (400 MHz, CDCl3) 1.06 (d, J = 7.5 Hz, 3H), 1.20 (s, 9H), 1.84 (s, 3H), 3.36 (q, J = 7.5 Hz, 1H), 4.99 (s, 1H), 7.02-7.45 (m, 4H), 9.76 (s, 1H).

[0216] Under a nitrogen atmosphere, to a stirred solution of compound 6-3 (1.04 g, 3.47 mmol) in THF (20 mL) were added trimethyl(trifluoromethyl)silane (1.05 mL, 6.95 mmol) and TBAF (1 mol/L in THF, 0.243 mL, 0.243 mmol) at 0 °C. After being stirred for 1 h at 0 °C, the reaction was quenched with water. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated to give the crude product, which was used for the next reaction without further purification.

To a stirred solution of the crude product in methanol (15 mL) was added hydrogen chloride (4 mol/L in dioxane, 1.30 mL, 5.20 mmol) at 0 °C. After being stirred for 20 h at room temperature, the reaction was quenched with a saturated solution of sodium
hydrogen carbonate. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated to give the crude product, which was used for the next reaction without further purification.

To a stirred solution of the crude product in dichloromethane (15 mL) was added benzoyl isothiocyanate (0.559 mL, 4.16 mmol) at 0 °C. After being stirred for 2.5 h at room temperature, the mixture was evaporated. The crude product was purified by flash column chromatography (silica gel, 3:1 hexane:ethyl acetate) to give compound 6-4 (620 mg, 42%) as a yellow amorphous. This material was obtained as a mixture of diastereomers. MS: m/z = 395.10 [M+H]+.

Step 4
A suspension of compound 6-4 (620 mg, 1.45 mmol) and WSCD HCl (555 mg, 2.89 mmol) in acetonitrile (12 mL) was stirred for 20 h at room temperature. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated, and the crude product was purified by flash column chromatography (silica gel, 85:15 hexane:ethyl acetate) to give compound 6-5 (258 mg, 45%) as a colorless oil.

1H NMR (400 MHz, CDC13) 1.30 (d, J = 6.9 Hz, 3H), 1.79 (s, 3H), 2.96 (q, J = 6.9 Hz, 1H), 4.35-4.39 (m, 1H), 7.13-7.55 (m, 7H), 8.27 (d, J = 8.0 Hz, 2H), 11.6 (s, 1H).

[0217] Step 5
A suspension of compound 6-5 (258 mg, 0.654 mmol) and potassium carbonate (271 mg, 1.96 mmol) in methanol (5 mL) was stirred for 3 days at room temperature. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated to give the crude product, which was used for the next reaction without further purification.

To a stirred solution of the crude product in TFA (1.1 mL) were added sulfuric acid (0.28 mL, 5.25 mmol), followed by nitric acid (0.044 mL, 0.982 mmol) at -20 °C. After being stirred at -20 °C to -10 °C for 75 min, the reaction was quenched with a saturated solution of potassium carbonate. The mixture was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated, and the crude product was purified by flash column chromatography (silica gel, gradient from 2:1 to 1:1 hexane:ethyl acetate) to give compound 6-6 (149 mg, 68%) as a colorless amorphous.

1H NMR (400 MHz, CDC13) 1.19 (d, J = 7.0 Hz, 3H), 2.74 (q, J = 7.0 Hz, 1H), 3.99-4.04 (m, 1H), 7.22 (t, J = 9.9 Hz, 1H), 8.17-8.21 (m, 1H), 8.35 (dd, J = 6.7, 2.8 Hz, 1H).
Step 6
A suspension of compound 6-6 (85.7 mg, 0.256 mmol), iron powder (114 mg, 2.05 mmol), and ammonium chloride (164 mg, 3.07 mmol) in ethanol (0.8 mL)/THF (0.4 mL)/water (0.4 mL) was stirred at 60 °C for 2.5 h. The mixture was cooled to room temperature and filtered through a pad of Celite (Registered trademark). The filtrate was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated to give the crude product, which was used for the next reaction without further purification.

To a stirred solution of the crude product and aqueous hydrochloric acid solution (2 mol/L, 0.081 mL, 0.161 mmol) in methanol (1 mL) were added 5-cyanopicolinic acid hydrate (29.5 mg, 0.177 mmol) and WSCD HCl (37.1 mg, 0.161 mmol) at room temperature. After being stirred for 1 h at room temperature, the reaction was quenched with aqueous sodium hydroxide solution. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated, and the crude product was purified by flash column chromatography (amino silica gel, gradient from 1:1 to 0:1 hexane:ethyl acetate) to give compound 1-28 (58.1 mg, 74%) as an off-white solid.

Example 7
[0218] Synthesis of compound 1-33
Step 1
A solution of compound 7-1 (6.2 g, 18.1 mmol) (an intermediate for the synthesis of 1-28) and hydrogen chloride solution (4 mol/L in dioxane, 6.77 mL, 27.1 mmol) in methanol (45 mL) was stirred at room temperature for 75 min. The reaction was quenched with a saturated solution of sodium hydrogen carbonate. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated to give the crude product, which was used for the next reaction without further purification.

A solution of the crude product and Boc₂O (5.79 mL, 27.1 mmol) in THF (40 mL)
was stirred at room temperature for 16 h and then heated to 50 °C for 24 h. The mixture was cooled to room temperature and evaporated. The crude product was purified by flash column chromatography (silica gel, 9:1 hexane:ethyl acetate) to give compound 7-2 (5.7 g, 93%) as a tan oil. This material was obtained as a mixture of diastereomers.

1H NMR (400 MHz, CDC13) (major isomer) 0.96 (d, J = 7.0 Hz, 3H), 1.23 (t, J = 6.4 Hz), 1.40 (s, 9H), 1.81 (s, 3H), 3.01 (q, J = 7.0 Hz, 1H), 4.10-4.16 (m, 3H), 5.95 (1H, brs), 6.97-7.31 (m, 5H).

Step 2
To a stirred solution of compound 7-2 (5.12 g, 15.1 mmol) in THF (25 mL) and methanol (25 mL) was added slowly sodium borohydride (2.85 g, 75.0 mmol) at 0 °C. After being stirred at 0 °C for 2 h, sodium borohydride (2.85 g, 75.0 mmol) was added slowly to the mixture at 0 °C. The resulting mixture was stirred at room temperature for 16.5 h. The reaction was quenched with an aqueous solution of hydrogen chloride. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated to give the crude product, which was used for the next reaction without further purification.

Under a nitrogen atmosphere, to a stirred solution of the crude product in dichloromethane (50 mL) was added Dess-Martin periodinane (9.54 g, 22.5 mmol) at 0 °C. After being stirred for 4.5 h at room temperature, the reaction was quenched with a saturated solution of sodium hydrogen carbonate and sodium thiosulfate. The mixture was extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, and filtered. The solvent was evaporated, and the crude product was purified by flash column chromatography (silica gel, gradient from 1:1 to 1:2 hexane:ethyl acetate) to give compound 7-3 (2.15 g, 49%) as a colorless gum. This material was obtained as a mixture of diastereomers.

1H NMR (400 MHz, CDC13) (major isomer) 1.02 (d, J = 6.9 Hz, 3H), 1.97 (s, 3H), 3.15-3.20 (m, 1H), 5.16 (s, 1H), 7.00-7.33 (5H, m), 9.71 (s, 1H).

[0220] Step 3
A solution of compound 7-3 (2.15 g, 7.28 mmol) and Hunig's base (6.36 mL, 36.4 mmol) in THF (10 mL) was stirred at reflux for 25.5 h. The mixture was cooled to room temperature, and the solvent was evaporated. The crude product was purified by flash column chromatography (silica gel, gradient from 87:13 to 85:15 hexane:ethyl acetate) to give compound 7-4 (1.81 g, 84%) as a colorless gum. This material was obtained as a mixture of diastereomers.

1H NMR (400 MHz, CDC13) (major isomer) 1.12 (d, J = 6.9 Hz, 3H), 1.76 (s, 3H), 3.09-3.14 (m, 1H), 5.17 (s, 1H), 7.02-7.33 (5H, m), 9.57 (s, 1H).
Step 4
To a stirred solution of compound 7-4 (1.81 g, 6.13 mmol) in DMF (18 mL) were added difluoromethyl trimethylsilane (3.35 mL, 24.5 mmol) and cesium fluoride (279 mg, 1.84 mmol) at 0 °C. After being stirred for 4.5 days at room temperature, TBAF (1 mol/L in THF, 6.13 mL, 6.13 mmol) was added to the mixture at 0 °C. The resulting mixture was stirred at 0 °C for 1 h, and water was added to the mixture. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated, and the residue was filtered through a pad of silica gel with aid of hexane and ethyl acetate (1:1). The filtrate was evaporated to give the crude product, which was used for the next reaction without further purification.

To a stirred solution of the crude product in dichloromethane (15 mL) was added TFA (1.73 mL, 22.5 mmol) at 0 °C. After being stirred for 2.5 h at room temperature, the reaction was quenched with a saturated solution of sodium hydrogen carbonate. The mixture was extracted with dichloromethane. The combined organic layer was dried over sodium sulfate, and filtered. The solvent was evaporated to give the crude product, which was used for the next reaction without further purification.

To a stirred solution of the crude product in dichloromethane (15 mL) was added benzyol isothiocyanate (0.724 mL, 5.39 mmol) at 0 °C. After being stirred for 100 min at room temperature, the solvent was evaporated. The crude product was purified by flash column chromatography (silica gel, 3:1 hexane:ethyl acetate) to give compound 7-5 (749 mg, 41%) as an orange amorphous. This material was obtained as a mixture of diastereomers. MS: m/z = 411.15 [M+H]+.  

[0221] Step 5
A suspension of compound 7-5 (749 mg, 1.83 mmol) and WSCD HCl (700 mg, 3.65 mmol) in acetonitrile (7 mL) was stirred for 15 h at room temperature. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated, and the crude product was purified by flash column chromatography (silica gel, gradient from 5:1 to 3:1 to 2:1 hexane:ethyl acetate) to give compound 7-6 (248 mg, 36%) as a yellow amorphous. This material was obtained as a mixture of diastereomers. MS: m/z = 377.15 [M+H]+.

Step 6
A solution of compound 7-6 (248 mg, 0.659 mmol), Boc₂O (0.214 mL, 0.988 mmol) and DMAP (16.1 mg, 0.132 mmol) in THF (3 mL) was stirred at room temperature for 3 h. The solvent was evaporated, and the crude product was purified by flash column chromatography (silica gel, gradient from 91:9 to 84:16 hexane:ethyl acetate) to give compound 7-7 (140 mg, 45%) as a colorless gum.
1H NMR (400 MHz, CDCl3) 1.19 (d, J = 7.0 Hz, 3H), 1.41 (s, 9H), 1.54 (s, 3H), 2.67 (q, J = 7.0 Hz, 1H), 4.00-4.05 (m, 1H), 5.82 (ddt, J = 55.1, 6.5, 2.6 Hz, 1H), 7.06 (dd, J = 12.5, 7.9 Hz, 1H), 7.14 (t, J = 7.6 Hz), 7.46 (dd, J = 15.4, 7.9 Hz, 2H), 7.56 (t, J = 7.6 Hz, 1H), 7.77 (d, J = 8.2 Hz, 1H).

[0222] Step 7

A suspension of compound 7-7 (140 mg, 0.294 mmol) and potassium carbonate (122 mg, 0.881 mmol) in methanol (2 mL) was stirred for 2 h at room temperature. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated to give the crude product, which was used for the next reaction without further purification.

A solution of the crude product and TFA (0.226 mL, 2.93 mmol) in dichloromethane (2 mL) was stirred at room temperature for 6.5 h. The reaction was quenched with a saturated solution of potassium carbonate, which was then extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, and filtered. The solvent was evaporated to give the crude product, which was used for the next reaction without further purification.

To a stirred solution of the crude product in TFA (1 mL) were added sulfuric acid (0.12 mL, 2.25 mmol), followed by nitric acid (0.020 mL, 0.441 mmol) at -25 °C. After being stirred at -25 °C to -15 °C for 1.5 h, the reaction was quenched with a saturated solution of potassium carbonate. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated, and the crude product was purified by flash column chromatography (amino silica gel, gradient from 2:1 to 1:1 hexane:ethyl acetate) to give compound 7-8 (82.6 mg, 89%) as a colorless amorphous.

1H NMR (400 MHz, CDCl3) 1.14 (d, J = 7.0 Hz, 3H), 1.54 (s, 3H), 2.64 (q, J = 7.0 Hz, 1H), 3.74-3.79 (m, 1H), 5.76 (ddt, J = 55.3, 6.3, 1.9 Hz, 1H), 7.21 (t, J = 9.9 Hz, 1H), 8.16-8.20 (m, 1H), 8.35 (dd, J = 6.8, 2.6 Hz, 1H).

Step 8

A suspension of compound 7-8 (82.6 mg, 0.260 mmol), iron powder (116 mg, 2.08 mmol), and ammonium chloride (167 mg, 3.12 mmol) in ethanol (0.8 mL), THF (0.4 mL), and water (0.4 mL) was stirred at 60 °C for 100 min. The mixture was cooled to room temperature, filtered through a pad of Celite (Registered trademark). The filtrate was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated to give the crude product (77.7 mg), which was used for the next reaction without further purification.

To a stirred solution of the crude product (18.8 mg) and aqueous hydrochloric acid solution (2 mol/L, 0.033 mL, 0.065 mmol) in methanol (1 mL) were added
5-(fluoromethoxy)pyrazine-2-carboxylic acid (12.4 mg, 0.072 mmol) and WSCD HCl (15.1 mg, 0.079 mmol) at room temperature. After being stirred for 1 h at room temperature, the reaction was quenched with aqueous sodium hydroxide solution. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated, and the crude product was purified by flash column chromatography (amino silica gel, gradient from 1:1 to 0:1 hexane:ethyl acetate) to give compound 1-33 (25.0 mg, 87%) as an off-white solid.

**Example 8**

Synthesis of compound 1-34
[0224]  Step 1

To a solution of compound 8-1 (4.59 g, 23.63 mmol) in THF (45 ml) was added 1.04 mol/L of DIBAL (56.8 ml, 59.1 mmol) in toluene at 0 °C. After stirring for 2 h at the same temperature, the mixture was treated with saturated aqueous Rochelle's salt and
stirred for 1.5 h. The aqueous layer was extracted with AcOEt, and the combined organic layer was washed with brine. The organic layer was dried over MgSO₄, filtered and concentrated. The crude compound was dissolved in CH₂C₁₂ (30 mL), and Dess-Martin periodinane (11.94 g, 28.2 mmol) was added at 0 °C. After stirring for 2 h at room temperature, the mixture was treated with saturated aqueous NaHCO₃ and stirred for 0.5 h. The aqueous layer was extracted with AcOEt, and the combined organic layers were washed with brine, dried over MgSO₄ and filtered. The filtrate was concentrated in vacuo. The crude product was added to a silica gel column and eluted with Hexane/EtOAc 0% to 40%. Collected fractions were evaporated to afford compound 8-2 (3.67 g, 22.35 mmol, 95%) as a colorless oil.

1H-NMR (400 MHz, CDC13) δ: 2.56 (s, 3H), 6.22 (d, J = 8.0 Hz, 1H), 7.11 (dd, J = 12.0, 8.0 Hz, 1H), 7.18 (t, J = 8.0 Hz, 1H), 7.32 (m, 1H), 7.37 (m, 1H), 10.18 (d, J = 8.0 Hz, 1H).

Step 2
To a solution of compound 8-2 (2.01 g, 12.25 mmol) and (trifluoromethyl)trimethylsilane (2.61 g, 2.72 mmol) in THF (30 ml) was added 1.00 mol/L of TBAF in THF (0.123ml, 0.123 mmol) at -10 °C. After stirring for 1 h at 0 °C, to the mixture was added 1.00 mol/L of TBAF (1.23 ml, 1.23 mmol in THF, and the mixture was stirred for 1 h at room temperature. The reaction mixture was diluted with H₂O, and the aqueous layer was extracted with AcOEt. The combined organic layers were washed with H₂O and brine, dried over MgSO₄ and filtered. The filtrate was concentrated in vacuo. The crude product was added to a silica gel column and eluted with Hexane/EtOAc 0% to 30%. Collected fractions were evaporated to afford compound 8-3 (2.81 g, 12.00 mmol, 98%) as a yellow oil.

1H-NMR (400 MHz, CDC13) δ: 2.19 (d, J = 8.0 Hz, 1H), 2.20 (s, 3H), 4.86 (m, 1H), 5.67 (d, J = 8.0 Hz, 1H), 7.06 (dd, J = 8.0, 4.0 Hz, 1H), 7.12 (m, 1H), 7.25 (m, 1H), 7.29 (m, 1H).

Step 3
To a solution of compound 8-3 (3.2 g, 13.66 mmol) in CH₂C₁₂ (40 ml) was added m-CPBA (6.74g, 27.3 mmol) at 0 °C. After stirring for 2 h at room temperature, the mixture was treated with 2 mol/L NaOH (20.5 ml) and stirred for 0.5 h. The aqueous layer was extracted with AcOEt, and the combined organic layers were washed with brine, dried over MgSO₄ and filtered. The filtrate was concentrated in vacuo. The crude product was used for next reaction without further purification.

1H-NMR (400 MHz, CDC13) δ: 1.72 (s, 3H), 2.72 (d, J = 8.0 Hz, 1H), 3.20 (d, J = 8.0 Hz, 1H), 4.15 (m, 1H), 7.05 (m, 1H), 7.14 (m, 1H), 7.31 (m, 1H), 7.37 (m, 1H).

Step 4
To a solution of compound 8-4 (3.42 g, 13.67 mmol) and Ti(OEt)₄ (18.71 g, 82
mmol) in DMF (30 ml) was added NaN₃ (3.55 mg, 54.7 mmol) at room temperature. After stirring for 20 h at the same temperature, the mixture was treated with saturated aqueous citric acid and stirred for 1 h. The aqueous layer was extracted with AcOEt, and the combined organic layers were washed with brine, dried over MgSO₄ and filtered. The filtrate was concentrated in vacuo. The crude product was added to a silica gel column and eluted with Hexane/EtOAc 20% to 60%. Collected fractions were evaporated to afford compound 8-5 (3.03 g, 11.26 mmol, 82%) as a yellow solid. 

1H-NMR (400 MHz, CDC13) δ: 1.93 (s, 3H), 2.85 (d, J = 8.0 Hz, 1H), 3.19 (d, J = 4.0 Hz, 1H), 3.75 (m, 1H), 4.47 (d, J = 8.0 Hz, 1H), 7.11 (m, 1H), 7.22 (m, 1H), 7.37 (m, 1H), 7.58 (m, 1H).

Step 5

To a solution of compound 8-5 (3.03 g, 11.25 mmol) in toluene (30 ml) and MeOH (30 ml) was added dibutyltin oxide (3.36 g, 13.51 mmol) at room temperature. After stirring for 3 h at 110 °C, the reaction mixture was concentrated. Dry toluene (30 ml) was added to the residue, and the mixture was evaporated and dried in vacuo. The residue was dissolved in toluene (30 ml), and tetrabutylammonium bromide (0.726 g, 2.251 mmol) and benzyl bromide (3.34 ml, 28.1 mmol) were added at room temperature. After being stirred for 20 h at 110 °C, the reaction mixture was diluted with H₂O and extracted with AcOEt. The organic layers were dried over MgSO₄, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/ethyl acetate 0% to 30%. Collected fractions were evaporated to afford compound 8-6 (3.1 g, 8.09 mmol, 72%) as a colorless oil.

1H-NMR (400 MHz, CDC13) δ: 1.93 (s, 3H), 3.29 (d, J = 12.0 Hz, 1H), 3.47 (q, J = 8.0 Hz, 1H), 4.43 (d, J = 8.0 Hz, 1H), 4.75 (m, 2H), 7.09 (m, 1H), 7.20 (m, 1H), 7.32-7.41 (m, 6H), 7.56 (m, 1H).

Step 6

To a suspension of NaH (939 mg, 23.48 mmol) in THF (40 ml) was added compound 8-6 (3.0 g, 7.83 mmol) at 0°C. After stirring for 30 min at room temperature, the mixture was added Mel (2.45 ml, 39.1 mmol), and the mixture was stirred for 30 min at room temperature. The reaction mixture was treated with saturated aqueous NH₄Cl, and the aqueous layer was extracted with AcOEt. The combined organic layers were washed with brine, dried over MgSO₄ and filtered. The filtrate was concentrated in vacuo. The crude product was added to a silica gel column and eluted with Hexane/EtOAc 0% to 30%. Collected fractions were evaporated to afford compound 8-7 (3.03 g, 7.63 mmol, 97%) as a colorless oil.

1H-NMR (400 MHz, CDC13) δ: 1.91 (s, 3H), 3.54 (s, 3H), 3.61 (s, 1H), 4.08 (s, 1H), 4.72 (s, 2H), 7.07 (m, 1H), 7.15 (m, 1H), 7.29-7.41 (m, 6H), 7.51 (m, 1H).
A suspension of compound 8-7 (3.0 g, 7.55 mmol) and 10% Pd/C (600 mg) in MeOH (40 ml) was stirred under a hydrogen atmosphere at room temperature. After stirring for 24 h at the same temperature, the mixture was filtrated through a pad of Celite (Registered trademark). The filtrate was concentrated under vacuum to give compound 8-8 (2.13 g, 7.57 mmol, 100%) as a white solid, which was used for the next step without purification.

1H-NMR (400 MHz, CDC13) δ: 1.65 (s, 3H), 3.17 (s, 1H), 3.61 (s, 3H), 3.65 (m, 1H),
3.99 (s, 1H), 7.07 (m, 1H), 7.20 (m, 1H), 7.31 (m, 1H), 7.56 (m, 1H).

Step 8

To a stirred solution of compound 8-8 (2.13 g, 7.57 mmol) in CH₂Cl₂ (30 mL) was added benzoyl isothiocyanate (1.22 mL, 6.82 mmol) at 0 °C. After being stirred for 2 h at room temperature, the reaction mixture was concentrated, and the resulting residue was added to a silica gel column and eluted with hexane/ethyl acetate 0% to 50%. Collected layers were evaporated to afford compound 8-9 (3.03 g, 6.82 mmol, 90%) as a yellow amorphous.

1H-NMR (400 MHz, CDC13) δ: 2.32 (s, 3H), 3.48 (s, 1H), 3.56 (s, 3H), 3.95 (m, 1H),
7.09 (m, 1H), 7.18 (m, 1H), 7.32 (m, 1H), 7.41 (m, 1H), 7.52 (m, 2H), 7.63 (m, 1H),
7.87 (m, 2H), 8.88 (m, 1H), 11.66 (m, 1H).

[0228] Step 9

To a stirred solution of compound 8-9 (3.03 g, 6.84 mmol) in acetonitrile (30 mL) was added EDC (3.93 g, 20.52 mmol) at room temperature. After being stirred for 20 h at the same temperature, the reaction mixture was diluted with H₂O and extracted with ethyl acetate. The organic layers were combined and washed with brine. The organic layer was dried over MgSO₄, filtered and concentrated. The crude product was used for next reaction without further purification.

1H-NMR (400 MHz, CDC13) δ: 1.87 (s, 3H), 3.71 (s, 3H), 4.23 (s, 1H), 4.31 (m, 1H),
7.15 (m, 1H), 7.23 (m, 1H), 7.35-7.55 (m, 5H), 8.28 (m, 2H), 11.64 (m, 1H).

Step 10

To a stirred solution of compound 8-10 (2.81 g, 6.85 mmol) in THF (40 mL) were added Boc₂O (2.385 mL, 10.27 mmol) and DMAP (251 mg, 2.05 mmol) at room temperature under nitrogen. After being stirred for 1 h, the reaction mixture was diluted with H₂O and extracted with ethyl acetate. The organic layers were combined and washed with brine. The organic layer was dried over MgSO₄, filtered and concentrated. The crude compound was dissolved in methanol (40 mL), and K₂CO₃ (2.50 g, 18.1 mmol) was added at 0 °C. After being stirred for 2 h at room temperature, the reaction mixture was diluted with H₂O and extracted with ethyl acetate. The organic layer was dried over MgSO₄, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/ethyl acetate 0% to 30%. Collected
fractions were evaporated to afford the Boc-protected compound. The compound was dissolved in CH$_2$Cl$_2$ (15 mL), and TFA (4 ml) was added at 0 °C. After being stirred for 2 h at r.t., the reaction mixture was quenched with 20% aq. Na$_2$CO$_3$ and extracted with ethyl acetate. The organic layer was dried over MgSO$_4$ and filtered. The filtrate was concentrated under vacuum to give compound 8-11 (1.16 g, 3.79 mmol, 55%) as a white amorphous, which was used for the next step without purification.

1H-NMR (400 MHz, CDC13) δ: 1.69 (s, 3H), 3.66 (s, 3H), 3.99 (m, 1H), 4.16 (s, 1H), 7.07 (dd, J = 12.0. 8.0 Hz, 1H), 7.17 (t, J = 8.0 Hz, 1H), 7.30 (m, 1H), 7.39 (t, J = 8.0 Hz, 1H).

Step 11
To a solution of compound 8-11 (1.14 g, 3.72 mmol) in TFA (4.9 ml) was added sulfuric acid (1.25 ml, 23.5 mmol) at -10 °C. After stirring for 5 min at -10 °C, to the reaction mixture was added HN0$_3$ (0.36 ml, 5.58 mmol) at -10 °C. After stirring for 30 min at -10 °C, the reaction mixture was treated with aqueous K$_2$C0$_3$. The aqueous layer was extracted with AcOEt, and the organic layer was dried over MgSO$_4$, filtered and concentrated. The filtrate was concentrated under vacuum to give compound 8-12 (1.23 g, 3.50 mmol, 94%) as a white amorphous.

1H-NMR (400 MHz, CDC13) δ: 1.67 (s, 3H), 3.67 (s, 3H), 3.93 (m, 1H), 4.13 (m, 1H), 7.07 (m, 1H), 8.21 (m, 1H), 8.39 (m, 1H).

Step 12
To a solution of compound 8-12 (1.2 g, 3.42 mmol) and DMAP (125 mg, 1.027 mmol) in THF (10 ml) was added Boc$_2$O (2.38 ml, 10.3 mmol) at room temperature. After stirring for 2 h at the same temperature, the mixture was concentrated under vacuum. The crude product was added to a silica gel column and eluted with hexane/ EtOAc 0% to 30%. Collected fractions were evaporated to afford compound 8-13 (1.73 g, 3.14 mmol, 92%) as a white amorphous.

1H-NMR (400 MHz, CDC13) δ: 1.53 (s, 18H), 1.57 (s, 3H), 3.64 (s, 3H), 4.02 (m, 1H), 4.15 (s, 1H), 7.27 (m, 1H), 8.25 (m, 1H), 8.50 (m, 1H).

Step 13
A suspension of compound 8-13 (1.73 g, 3.14 mmol) 10% Pd/C (300 mg) in MeOH (8 ml) and THF (6ml) was stirred under a hydrogen atmosphere at room temperature. After stirring for 2 h at the same temperature, the mixture was filtrated through a pad of Celite (Registered trademark). The filtrate was concentrated under vacuum to give compound 8-14 (1.63 g, 3.13 mmol, 99%) as a white amorphous, which was used for the next step without purification.

1H-NMR (400 MHz, CDC13) δ: 1.52 (s, 18H), 1.57 (s, 3H), 3.59 (s, 3H), 4.13 (m, 1H), 4.14 (m, 1H), 6.55 (m, 1H), 6.83 (m, 1H), 6.87 (m, 1H).
To a solution of compound 8-14 (201mg, 0.385 mmol) in CH$_2$Cl$_2$ (2 ml) were added 5-cyanopicolinic acid hydrate (70.4 mg, 0.424 mmol), HATU (161 mg, 0.424 mmol) and DIPEA (0.101 ml, 0.578 mmol) at room temperature. After stirring for 18 h at the same temperature, the reaction mixture was treated with H$_2$O. The aqueous layer was extracted with AcOEt, and the organic layer was dried over MgSO$_4$, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 50%. Collected fractions were evaporated to afford compound 8-15 (245 mg, 0.376 mmol, 98%) as a white amorphous.

IH-NMR (400 MHz, CDC13) $\delta$: 1.56 (s, 18H), 1.75 (s, 3H), 3.63 (s, 3H), 4.11 (m, 1H), 4.16 (m, 1H), 7.16 (dd, $J = 12.0, 8.0$ Hz, 1H), 7.55 (dd, $J = 8.0, 4.0$ Hz, 1H), 8.22 (dd, $J = 8.0, 4.0$ Hz, 1H), 8.39 (m, 1H), 8.43 (d, $J = 8.0$ Hz, 1H), 8.79 (m, 1H), 9.98 (s, 1H).

Step 15

To a solution of compound 8-15 (44 mg, 0.073 mmol) in CH$_2$Cl$_2$ (1.5 ml) was added TFA (0.5ml) at 0 °C. After being stirred for 2 h at r.t., the reaction mixture was quenched with 20% aq. K$_2$C0$_3$. The aqueous layer was extracted with AcOEt and the organic layers were combined and washed with brine. The organic layer was dried over MgSO$_4$, filtered and concentrated. The crude product was purified by supercritical fluid chromatography (SFC) (Chiralpak (Registered trademark) IB; 5-40% ethyl alcohol with 0.1% diethylamine) to give compound 1-34 (58mg, 0.128 mmol, 34%) as a white solid.

Example 9

Synthesis of compound 1-35
Step 1
To a suspension of zinc (1.20 g, 18.27 mmol) in THF (10 ml) were added a solution of ethylbromodifluoroacetate (5.19 g, 25.6 mmol) in THF (10 ml) and a solution of compound 9-1 (1.2 g, 7.31 mmol) in THF (10 ml) at room temperature. After stirring for 2 h at the same temperature, the reaction mixture was treated with saturated aqueous \( \text{NH}_4\text{Cl} \), and the aqueous layer was extracted with AcOEt. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The crude product was added to a silica gel column and eluted with Hexane/EtOAc 0% to 40%. Collected fractions were evaporated to afford compound 9-2 (1.91 g, 6.63 mmol, 91%) as a colorless oil.

**1H-NMR** (400 MHz, CDC13) \( \delta \): 1.37 (t, \( J = 8.0 \) Hz, 3H), 2.15 (s, 3H), 2.21 (d, \( J = 4.0 \) Hz, 1H), 4.38 (q, \( J = 8.0 \) Hz, 2H), 4.98 (m, 1H), 5.67 (d, \( J = 8.0 \) Hz, 1H), 7.04 (m, 1H), 7.11 (t, \( J = 8.0 \) Hz, 1H), 7.24 (m, 1H), 7.28 (m, 1H).

**Step 2**

To a solution of compound 9-2 (2.09 g, 7.24 mmol) in MeOH (80 ml) was added NaBH4 (822 mg, 21.7 mmol) at 0 °C. After stirring for 0.5 h at the same temperature, the mixture was treated with saturated aqueous \( \text{NH}_4\text{Cl} \) and stirred for 0.5 h. The aqueous layer was extracted with AcOEt, and the combined organic layers were washed with brine. The organic layer was dried over MgSO4, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 40%. Collected fractions were evaporated to afford compound 9-3 (1.70 g, 6.91 mmol, 95%) as a colorless oil.

**1H-NMR** (400 MHz, CDC13) \( \delta \): 2.14 (s, 3H), 2.32 (t, \( J = 8.0 \) Hz, 1H), 2.39 (d, \( J = 8.0 \) Hz, 1H), 3.92 (m, 1H), 4.02 (m, 1H), 4.88 (m, 1H), 5.72 (d, \( J = 12.0 \) Hz, 1H), 7.04 (m, 1H), 7.10 (t, \( J = 8.0 \) Hz, 1H), 7.25 (m, 1H), 7.27 (m, 1H).

**[0233]**

**Step 3**

To a solution of compound 9-3 (1.71 g, 6.94 mmol) in \( \text{CH}_2\text{Cl}_2 \) (30 ml) were added TBSCl (2.09 g, 13.89 mmol) and imidazole (0.946 g, 13.89 mmol) at room temperature. After stirring for 0.5 h at the same temperature, the mixture was treated with water and stirred for 0.5 h. The aqueous layer was extracted with AcOEt, and the combined organic layers were washed with brine. The organic layer was dried over MgSO4, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 20%. Collected fractions were evaporated to afford compound 9-4 (1.95 g, 5.42 mmol, 78%) as a colorless oil.

**1H-NMR** (400 MHz, CDC13) \( \delta \): 0.10 (s, 3H), 0.12 (s, 3H), 0.92 (s, 9H), 2.13 (s, 3H), 2.31 (d, \( J = 4.0 \) Hz, 1H), 3.87 (m, 1H), 3.99 (m, 1H), 4.88 (m, 1H), 5.70 (d, \( J = 12.0 \) Hz, 1H), 7.04 (dd, \( J = 12.0, 8.0 \) Hz, 1H), 7.10 (t, \( J = 8.0 \) Hz, 1H), 7.24 (m, 1H), 7.26 (m, 1H).

**Step 4**
To a solution of compound 9-4 (1.95 g, 5.42 mmol) in CH₂Cl₂ (30 ml) was added m-
CPBA (2.67 g, 10.8 mmol) at 0 °C. After stirring for 2 h at room temperature, the
mixture was treated with 2 mol/L NaOH (20.5 ml) and stirred for 0.5 h. The aqueous
layer was extracted with AcOEt, and the combined organic layer was washed with
brine, dried over MgSO₄ and filtered. The crude product was added to a silica gel
column and eluted with Hexane/EtOAc 0% to 30%. Collected fractions were
evaporated to afford compound 9-5 (1.92 g, 5.10 mmol, 94%) as a colorless oil.

1H-NMR (400 MHz, CDC13) δ: 0.11 (s, 6H), 0.90 (s, 9H), 1.71 (s, 3H), 2.61 (d, J =
8.0 Hz, 1H), 3.28 (d, J = 8.0 Hz, 1H), 3.94 (m, 1H), 4.03 (m, 1H), 4.10 (m, 1H), 7.03
(m, 1H), 7.12 (t, J = 8.0 Hz, 1H), 7.27 (m, 1H), 7.38 (m, 1H).

[0234] Step 5
To a solution of compound 9-5 (1.92 g, 5.10 mmol) in THF (25 ml) was added 1.00
mol/L of TBAF in THF (5.61 ml, 5.61 mmol) at 0 °C. After stirring for 2 h at the same
temperature, the mixture was treated with saturated aqueous NaHCO₃ and stirred for
0.5 h. The aqueous layer was extracted with AcOEt, and the combined organic layer
was washed with brine. The organic layer was dried over MgSO₄, filtered and con-
centrated. The crude product was added to a silica gel column and eluted with Hexane/ EtOAc 10% to 50%. Collected fractions were evaporated to afford compound 9-6 (1.31
g, 5.00 mmol, 98%) as a colorless oil.

1H-NMR (400 MHz, CDC13) δ: 1.72 (s, 3H), 2.09 (t, J = 4.0 Hz, 1H) 2.63 (d, J = 4.0
Hz, 1H), 3.31 (d, J = 8.0 Hz, 1H), 3.97-4.18 (m, 3H), 7.05 (m, 1H), 7.13 (t, J = 8.0 Hz,
1H), 7.29 (m, 1H), 7.39 (t, J = 8.0 Hz, 1H).

Step 6
To a solution of 9-6 (1.31 g, 5.00 mmol) and Ti(OEt)₄ (6.85 g, 30.0 mmol) in DMF
(12 ml) was added NaN₃ (1.30 g, 20.0 mmol) at room temperature. After stirring for
20 h at the same temperature, the mixture was treated with saturated aqueous citric
acid and stirred for 1 h. The aqueous layer was extracted with AcOEt, and the
combined organic layers were washed with brine, dried over MgSO₄ and filtered. The
filtrate was concentrated in vacuo. The crude product was added to a silica gel column
and eluted with hexane/EtOAc 20% to 60%. Collected fractions were evaporated to
afford compound 9-7 (1.38 g, 4.52 mmol, 90%) as a white solid.

1H-NMR (400 MHz, CDC13) δ: 1.93 (s, 3H), 2.70 (br, 1H), 3.22 (d, J = 8.0 Hz, 1H),
3.38 (br, 1H), 3.67 (m, 1H), 3.77 (m, 1H), 3.90 (m, 1H), 4.50 (s, 1H), 7.10 (dd, J =
12.0, 8.0 Hz, 1H), 7.20 (t, J = 8.0 Hz, 1H), 7.35 (m, 1H), 7.58 (t, J = 8.0 Hz, 1H).

[0235] Step 7
To a solution of compound 9-7 (1.38 g, 4.52 mmol) and p-toluenesulfonyl chloride
(0.95 g, 4.97 mmol) in CH₂Cl₂ (26 ml) was added DMAP (1.11 g, 9.04 mmol) at 0 °C.
After stirring for 2 h at the same temperature, the mixture was treated with saturated
aqueous NaHCO₃ and stirred for 0.5 h. The aqueous layer was extracted with AcOEt, and the combined organic layers were washed with 0.1 mol/L aqueous HCl and brine, dried over MgSO₄ and filtered. The filtrate was concentrated in vacuo. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 30%. Collected fractions were evaporated to afford compound 9-8 (1.92 g, 4.18 mmol, 92%) as a colorless oil.

1H-NMR (400 MHz, CDC13) δ: 1.90 (s, 3H), 2.46 (s, 3H), 2.83 (d, J = 8.0 Hz, 1H), 3.05 (d, J = 8.0 Hz, 1H), 3.61 (s, 1H), 4.20 (m, 1H), 4.28 (m, 1H), 4.42 (d, J = 8.0 Hz, 1H), 7.08 (dd, J = 12.0, 8.0 Hz, 1H), 7.20 (t, J = 8.0 Hz, 1H), 7.34 (m, 4H), 7.54 (m, 1H), 7.72 (m, 2H).

Step 8
To a solution of compound 9-8 (1.92 g, 4.18 mmol) in MeOH (30 ml) was added K₂CO₃ (1.16 g, 8.36 mmol) at room temperature. After stirring for 20 h at the same temperature, the mixture was treated with water and stirred for 0.5 h. The aqueous layer was extracted with AcOEt, and the combined organic layers were washed with brine, dried over MgSO₄ and filtered. The filtrate was concentrated in vacuo. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 30%. Collected fractions were evaporated to afford compound 9-9 (1.10 g, 3.84 mmol, 92%) as a colorless oil.

1H-NMR (400 MHz, CDC13) δ: 1.92 (s, 3H), 3.72 (m, 1H), 3.78 (m, 1H), 4.04 (m, 1H), 4.28 (m, 1H), 4.74 (m, 1H), 7.09 (dd, J = 12.0, 8.0 Hz, 1H), 7.19 (t, J = 8.0 Hz, 1H), 7.33 (m, 1H), 7.67 (m, 1H).

[0236] Step 9
A suspension of compound 9-9 (1.05 g, 3.66 mmol) in MeOH (25 ml) and 10% Pd/C (200 mg) was stirred under a hydrogen atmosphere at room temperature. After stirring for 24 h at the same temperature, the mixture was filtrated through a pad of Celite (Registered trademark). The filtrate was concentrated under vacuum to give compound 9-10 (0.9 g, 3.47 mmol, 95%) as a white solid, which was used for the next step without purification.

1H-NMR (400 MHz, CDC13) δ: 1.70 (s, 3H), 3.67 (dd, J = 8.0, 4.0 Hz, 1H), 4.04 (m, 1H), 4.25 (m, 1H), 4.54 (m, 1H), 7.09 (dd, J = 12.0, 8.0 Hz, 1H), 7.20 (t, J = 8.0 Hz, 1H), 7.33 (m, 1H), 7.55 (m, 1H).

Step 10
To a stirred solution of compound 9-10 (750 mg, 2.87 mmol) in CH₂Cｌ₂ (15 mL) was added benzoyl isothiocyanate (0.579 mL, 4.31 mmol) at 0 °C. After being stirred for 6 h at room temperature, the reaction mixture was concentrated, and the resulting residue was added to a silica gel column and eluted with hexane/ethyl acetate 0% to 35%. Collected fractions were evaporated to afford compound 9-11 (1.07 g, 2.51 mmol,
87%) as a colorless amorphous.
1H-NMR (400 MHz, CDC13) δ: 2.28 (s, 3H), 3.96 ( , 1H), 4.14 (m, 1H), 4.46 (m, 1H), 4.80 (m, 1H), 7.06 (dd, J = 12.0, 8.0 Hz, 1H), 7.14 (t, J = 8.0 Hz, 1H), 7.29 (m, 1H), 7.52 (m, 3H), 7.62 (t, J = 8.0 Hz, 1H), 7.87 (d, J = 4.0 Hz, 1H), 8.86 (s, 1H), 11.81 (s, 1H).

**Step 11**
To a stirred solution of compound 9-11 (1.156 g, 2.72 mmol) in acetonitrile (15 mL) was added EDC (1.04 g, 5.45 mmol) at room temperature. After being stirred for 20 h at the same temperature, the reaction mixture was diluted with H2O and extracted with ethyl acetate. The organic layers were combined and washed with brine. The organic layer was dried over MgS04, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/ethyl acetate 0% to 40%. Collected fractions were evaporated to afford compound 9-12 (853 mg, 2.19 mmol, 80%) as a white solid.

1H-NMR (400 MHz, CDC13) δ: 1.86 (s, 3H), 4.13-4.33 (m, 3H), 4.87 (s, 1H), 7.15 (m, 1H), 7.18 (m, 1H), 7.30 (m, 1H), 7.38 (m, 1H), 7.44 (t, J = 8.0 Hz, 2H), 7.53 (t, J = 8.0 Hz, 1H), 8.28 (d, J = 8.0 Hz, 2H), 11.62 (s, 1H).

**Step 12**
To a stirred solution of compound 9-12 (853 mg, 2.19 mmol) in THF (10 mL) were added Boc2O (0.761 mL, 3.28 mmol) and DMAP (80 mg, 0.656 mmol) at room temperature. After being stirred for 1 h, the reaction mixture was diluted with H2O and extracted with ethyl acetate. The organic layers were combined and washed with brine. The organic layer was dried over MgSO4, filtered and concentrated. The crude compound was dissolved in methanol (15 mL), and K2C03 (904 mg, 6.54 mmol) was added at 0 °C. After being stirred for 2 h at room temperature, the reaction mixture was diluted with H2O and extracted with ethyl acetate. The organic layer was dried over MgSO4, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/ethyl acetate 0% to 30%. Collected fractions were evaporated to afford the Boc-protected compound. The compound was dissolved in CH2Cl2 (5 mL) and TFA (1.5 ml) was added at 0 °C. After being stirred for 2 h at r.t., the reaction mixture was quenched with 20% aq. Na2C03 and extracted with ethyl acetate. The organic layer was dried over MgSO4 and filtered. The filtrate was concentrated under vacuum to give compound 9-13 (538 mg, 1.88 mmol, 86%) as a white amorphous, which was used for the next step without purification.

1H-NMR (400 MHz, CDC13) δ: 1.65 (s, 3H), 4.00-4.23 (m, 3H), 4.70 (s, 1H), 7.06 (dd, J = 12.0, 8.0 Hz, 1H), 7.14 (t, J = 8.0 Hz, 1H), 7.28 (m, 1H), 7.36 (t, J = 8.0 Hz, 1H).

**Step 13**
To a solution of compound 9-13 (538 mg, 1.88 mmol) in TFA (2.2 ml) was added sulfuric acid (0.65 ml, 12.2 mmol) at -10 °C. After stirring for 5 min at -10 °C, to the reaction mixture was added HN0₃ (0.18 ml, 2.82 mmol) at -10 °C. After stirring for 30 min at -10 °C, the reaction mixture was treated with aqueous K₂C0₃. The aqueous layer was extracted with AcOEt, and the organic layer was dried over MgSO₄, filtered, and concentrated. The crude product was purified by supercritical fluid chromatography (SFC) (Chiralpak (Registered trademark) IC; 0-65% methyl alcohol with 0.1% diethylamine) to give compound 9-14 (300 mg, 0.91 mmol, 48%) as a white amorphous solid.

IH-NMR (400 MHz, CDC13) δ: 1.66 (s, 3H), 4.04 (m, 1H), 4.05-4.24 (m, 2H), 4.68 (s, 1H), 7.23 (m, 1H), 8.21 (m, 1H), 8.34 (m, 1H).

Step 14
A suspension of compound 9-14 (71 mg, 0.21 mmol) 10% Pd/C (20 mg) in MeOH (2 ml) was stirred under a hydrogen atmosphere at room temperature. After stirring for 2 h at the same temperature, the mixture was filtrated through a pad of Celite (Registered trademark). The filtrate was concentrated under vacuum to give compound 9-15 (63 mg, 0.21 mmol, 98%) as a white amorphous, which was used for the next step without purification.

IH-NMR (400 MHz, CDC13) δ: 1.61 (s, 3H), 4.02-4.33 (m, 3H), 4.69 (s, 1H), 6.52 (m, 1H), 6.64 (m, 1H), 6.84 (m, 1H).

Step 15
To a solution of compound 9-15 (63 mg, 0.21 mmol) in CH₂Cl₂ (2 ml) were added 5-cyanopicolinic acid hydrate (38.2 mg, 0.23 mmol), EDC (48 mg, 0.25 mmol) and 2 mmol/L HCl (aqueous solution, 0.11 ml, 0.209 mmol) at room temperature. After stirring for 1 h at the same temperature, the reaction mixture was treated with H₂O. The aqueous layer was extracted with AcOEt, and the organic layer was dried over MgSO₄, filtered, and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 30% to 70%. Collected fractions were evaporated to afford compound 1-35 (66 mg, 0.153 mmol, 73%) as a white solid.

Example 10

[0239] Synthesis of compound 1-63
[Chem.61]
Step 1: Synthesis of compound 10-4

To a solution of 3,3-difluorocyclobutanecarboxylic acid (compound 10-1, 3.00 g, 22.0 mmol) in DMF (30 ml) were added Cs$_2$CO$_3$ (14.4 g, 44.1 mmol) and BnBr (2.62 ml, 22.0 mmol) at room temperature. After stirring for 20 min at 50 °C, the mixture was treated with H$_2$O, and the aqueous layer was extracted with AcOEt. The combined organic layer was washed with H$_2$O and brine, dried over Na$_2$SO$_4$ and filtered. The filtrate was concentrated under vacuum to give compound 10-2 as a yellow oil, which was used for the next step without purification.

To a solution of diisopropylamine (2.91 ml, 20.5 mmol) in THF (25 ml) was added 1.6 mol/L of n-BuLi (12.2 ml, 19.5 mmol) at -78 °C. After stirring for 30 min at the same temperature, compound 10-2 (3.30 g, 14.6 mmol) in THF (10 ml) was added, and this was stirred for 1 h followed by addition of Ti(OiPr)$_3$Cl (4.89 ml, 20.5 mmol) in THF (10 ml). After stirring for 10 min at the same temperature, to the mixture was added 10-3 (2.35 g, 9.74 mmol) in THF (10 ml). The mixture was stirred for 1 h at the same temperature and was treated with saturated aqueous NH$_4$Cl. The aqueous layer was extracted with AcOEt, and the combined organic layers were washed with brine, dried over Na$_2$SO$_4$ and filtered. The filtrate was concentrated in vacuo. The crude
product was added to a silica gel column and eluted with hexane/EtOAc 30%.
Collected fractions were evaporated to afford compound 10-4 (1.24 g, 2.65 mmol, 27%) as a yellow oil.

1H-NMR (400 MHz, CDC13) δ: 1.24 (s, 9H), 1.94 (s, 3H), 2.87-3.33 (m, 4H), 4.79 (s, 2H), 5.15 (s, 1H), 6.94-7.01 (m, 1H), 7.03-7.08 (m, 1H), 7.09-7.14 (m, 2H), 7.22-7.39 (m, 5H).

[0242] Step 2: Synthesis of compound 10-6
To a solution of compound 10-4 (1.24 g, 2.65 mmol) in MeOH (8 ml) was added 4 mol/L of HCl in dioxane (0.995 ml, 3.98 mmol) at room temperature. After stirring for 1 h at the same temperature, the reaction mixture was treated with aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃. The combined organic layer was washed with H₂O and brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated under vacuum to give compound 10-5 as a brown oil, which was used for the next step without purification.

To a solution of compound 10-5 in MeOH (10 ml) was added Boc₂O (1.85 ml, 7.96 mmol) at room temperature. After stirring for 16 h at 60 °C the reaction mixture was concentrated. The resulting residue was added to a silica gel column and eluted with Hexane/EtOAc 0% to 10%. Collected fractions were evaporated to afford 10-6 (914 mg, 1.97 mmol, 74%) as a colorless oil.

1H-NMR (400 MHz, CDC13) δ: 1.24 (s, 9H), 1.94 (s, 3H), 2.88-3.32 (m, 4H), 4.79 (s, 2H), 5.15 (s, 1H), 6.94-7.01 (m, 1H), 7.03-7.08 (m, 1H), 7.10-7.14 (m, 2H), 7.39-7.22 (m, 5H).

[0243] Step 3: Synthesis of compound 10-7
To a solution of compound 10-6 (914 mg, 1.97 mmol) in THF (9 ml) were added 3 mol/L of LiBH₄ in THF (1.97 ml, 5.92 mmol) and MeOH (0.240 ml, 5.92 mmol) at 0 °C. After stirring for 30 min at room temperature, the mixture was treated with H₂O and AcOH. The aqueous layer was extracted with AcOEt, and the combined organic layers were washed with brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated in vacuo. The crude product was added to a silica gel column and eluted with hexane/EtOAc 20%. Collected fractions were evaporated to afford compound 10-7 (693 mg, 1.93 mmol, 98%) as a white solid.

1H-NMR (400 MHz, CDC13) δ: 1.38 (s, 9H), 1.99 (d, J = 2.5 Hz, 3H), 2.04-2.19 (m, 1H), 2.46-2.60 (m, 1H), 2.78 (q, J = 14.4 Hz, 1H), 2.92 (q, J = 14.4 Hz, 1H), 3.60 (d, J = 10.5 Hz, 1H), 3.77 (d, J = 10.5 Hz, 1H), 6.51 (s, 1H), 6.99-7.06 (m, 1H), 7.11-7.16 (m, 1H), 7.30-7.23 (m, 1H), 7.35 (t, J = 7.3 Hz, 1H).

[0244] Step 4: Synthesis of compound 10-8
To a solution of compound 10-7 (693 mg, 1.93 mmol) in CH₂Cl₂ (7 ml) was added DMP (2.13 g, 5.01 mmol) at room temperature. After stirring for 16 h at the same temper-
perature, the mixture was treated with aqueous NaHC\textsubscript{3} and aqueous NaHSO\textsubscript{3}. The aqueous layer was extracted with CHCl\textsubscript{3}, and the combined organic layers were washed with brine, dried over Na\textsubscript{2}SO\textsubscript{4} and filtered. The filtrate was concentrated in vacuo. The crude product was added to a silica gel column and eluted with hexane/EtOAc 20\%. Collected fractions were evaporated to afford compound 10-8 (356 mg, 0.996 mmol, 52\%) as a white solid.

1H-NMR (400 MHz, CDCl\textsubscript{3}) \(\delta\): 1.56 (s, 9H), 2.16 (d, \(J = 2.3\) Hz, 3H), 2.56-2.73 (m, 4H), 5.11 (s, 1H), 7.03-7.11 (m, 1H), 7.13-7.20 (m, 1H), 7.34-7.22 (m, 2H), 9.57 (s, 1H).

[0245] Step 5: Synthesis of compound 10-9

To a solution of methyltriphenylphosphonium bromide (890 mg, 2.49 mmol) in toluene (8 ml) was added 1.00 mol/L of t-BuOK solution in THF (2.29 ml, 2.29 mmol) at room temperature. After stirring for 1 h at the same temperature, the mixture was added a solution of compound 10-8 (356 mg, 0.996 mmol) in toluene (4 ml) at 10 °C, and the mixture was stirred for 1 h at room temperature. The reaction mixture was treated with saturated aqueous NH\textsubscript{4}Cl, and the aqueous layer was extracted with AcOEt. The combined organic layers were washed with brine, dried over Na\textsubscript{2}SO\textsubscript{4} and filtered. The filtrate was concentrated in vacuo. The crude product was added to a silica gel column and eluted with Hexane/EtOAc 0\% to 20\%. Collected fractions were evaporated to afford compound 10-9 (304 mg, 0.855 mmol, 86\%) as a colorless oil.

1H-NMR (400 MHz, CDCl\textsubscript{3}) \(\delta\): 1.35 (s, 9H), 1.90 (d, \(J = 2.4\) Hz, 3H), 2.41-2.59 (m, 2H), 2.82-3.01 (m, 2H), 4.99 (s, 1H), 5.23 (d, \(J = 17.2\) Hz, 1H), 5.35 (d, \(J = 10.5\) Hz, 1H), 5.76 (dd, \(J = 17.2, 10.5\) Hz, 1H), 7.02 (dd, \(J = 13.1, 8.2\) Hz, 1H), 7.11 (t, \(J = 7.1\) Hz, 1H), 7.29-7.19 (m, 2H).

[0246] Step 6: Synthesis of compound 10-11

A solution of compound 10-9 (304 mg, 0.855 mmol) in 4 mol/L HCl in dioxane (2.14 ml, 8.55 mmol) was stirred for 30 min at room temperature. The reaction mixture was treated with aqueous NaHC\textsubscript{3} and the aqueous layer was extracted with AcOEt. The combined organic layers were washed with H\textsubscript{2}O and brine, dried over Na\textsubscript{2}SO\textsubscript{4} and filtered. The filtrate was concentrated under vacuum to give compound 10-10 as a brown oil that was used for the next step without purification.

To a solution of compound 10-10 in CH\textsubscript{2}Cl\textsubscript{2} (2 ml) was added benzoyle isothiocyanate (0.176 ml, 1.28 mmol) at room temperature. After stirring for 15 h at the same temperature the reaction mixture was concentrated. The resulting residue was added to a silica gel column and eluted with Hexane/EtOAc 0\% to 20\%. Collected fractions were evaporated to afford compound 10-11 (347 mg, 0.829 mmol, 97\%) as a white amorphous.

1H-NMR (400MHz, CDCl\textsubscript{3}) \(\delta\): 1.56 (s, 9H), 2.16 (d, \(J = 2.3\) Hz, 3H), 2.56-2.73 (m,
2H), 2.85-3.01 (m, 2H), 5.42 (d, J = 17.3 Hz, 1H), 5.46 (d, J = 10.5 Hz, 1H), 5.89 (dd, J = 17.3, 10.5 Hz, 1H), 7.02-7.08 (m, 1H), 7.14-7.19 (m, 1H), 7.21-7.34 (m, 2H), 7.52 (t, J = 7.4 Hz, 2H), 7.63 (t, J = 7.4 Hz, 1H), 7.86 (d, J = 7.4 Hz, 2H), 8.85 (s, 1H), 11.55 (s, 1H).

[0247] Step 7: Synthesis of compound 10-12

To a solution of Iodine (421 mg, 1.66 mmol) in MeCN (9 ml) was added compound 10-11 (347 mg, 0.829 mmol) in MeCN (5 ml) at 0 °C. After stirring for 2 h at the same temperature, the reaction mixture was treated with aqueous NaHCO₃ and Na₂S₂O₃. The aqueous layer was extracted with AcOEt. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 15%. Collected fractions were evaporated to afford compound 10-12 (343 mg, 0.630 mmol, 76%) as a white amorphous.

1H-NMR (400 MHz, CDC13) δ: 1.83 (s, 3H), 2.74-2.99 (m, 3H), 3.29 (t, J = 11.1 Hz, 1H), 3.36-3.47 (m, 2H), 3.74 (dd, J = 10.0, 2.5 Hz, 1H), 7.12 (dd, J = 12.7, 8.2 Hz, 1H), 7.20 (t, J = 7.7 Hz, 1H), 7.29-7.41 (m, 2H), 7.44 (t, J = 7.5 Hz, 2H), 7.52 (t, J = 7.5 Hz, 1H), 8.22 (d, J = 7.5 Hz, 2H).

[0248] Step 8: Synthesis of compound 10-13

To a solution of compound 10-12 (343 mg, 0.630 mmol) in toluene (5 ml) were added Bu₃SnH (0.251 ml, 0.945 mmol) and AIBN (10.4 mg, 0.0630 mmol) at room temperature. After stirring for 1 h at 80 °C the reaction mixture was concentrated. The resulting residue was added to an amino silica gel column and eluted with Hexane/EtOAc 0% to 20%. Collected fractions were evaporated to afford compound 10-13 (212 mg, 0.507 mmol, 80%) as a white amorphous.

1H-NMR (400 MHz, CDC13) δ: 1.33 (d, J = 6.9 Hz, 3H), 1.85 (s, 3H), 2.81 (q, J = 12.5 Hz, 1H), 2.88-3.01 (m, 1H), 3.23 (q, J = 6.9 Hz, 1H), 3.35 (q, J = 12.5 Hz, 1H), 7.10 (dd, J = 12.5, 8.2 Hz, 1H), 7.17 (t, J = 7.6 Hz, 1H), 7.32-7.38 (m, 2H), 7.43 (t, J = 7.5 Hz, 2H), 7.51 (t, J = 7.5 Hz, 1H), 8.22 (d, J = 7.5 Hz, 2H), 12.02 (br s, 1H).

[0249] Step 9: Synthesis of compound 10-14

To a solution of 1-5 (212 mg, 0.507 mmol) in MeOH (1 ml) and THF (1 ml) was added hydrazine hydrate (0.246 ml, 5.07 mmol) at room temperature. After stirring for 13 h at the same temperature, the reaction mixture was concentrated. The resulting residue was added to an amino silica gel column and eluted with Hexane/EtOAc 10% to 50%. Collected fractions were evaporated to afford compound 10-14 (150 mg, 0.477 mmol, 94%) as a white amorphous.

1H-NMR (400 MHz, CDC13) δ: 1.24 (d, J = 6.8 Hz, 3H), 1.72 (s, 3H), 2.67-2.81 (m, 3H), 3.20 (q, J = 6.8 Hz, 1H), 3.27-3.42 (m, 1H), 7.02 (dd, J = 12.7, 8.0 Hz, 1H), 7.11 (t, J = 7.5 Hz, 1H), 7.22-7.28 (m, 1H), 7.32 (t, J = 8.0 Hz, 1H).
[0250] Step 10: Synthesis of compound 10-16

To a solution of 1-6 in TFA (1.3 ml) was added sulfuric acid (0.318 ml, 5.96 mmol) at -20 °C. After stirring for 5 min at 0 °C, to the reaction mixture was added to HN03 (0.0320 ml, 0.716 mmol) at -20 °C. After stirring for 20 min at 0 °C, the reaction mixture was treated with aqueous K₂C₃O₃. The aqueous layer was extracted with AcOEt and the organic layer was dried over Na2S04. The filtrate was concentrated under vacuum to give 1-15 as a yellow oil that was used for the next step without purification.

To a solution of compound 10-15 in THF (2 ml) were added Boc₂0 (0.331 ml, 1.43 mmol) and DMAP (23.3 mg, 0.190 mmol) at room temperature. After stirring for 30 min at the same temperature, the mixture was concentrated under vacuum. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 20%. Collected fractions were evaporated to afford compound 10-16 (252 mg, 0.450 mmol, 95%) as a white amorphous.

1H-NMR (400 MHz, CDC13) δ: 1.36 (d, J = 6.9 Hz, 3H), 1.55 (s, 18H), 1.85 (d, J = 1.6 Hz, 3H), 2.71-2.94 (m, 3H), 3.21 (q, J = 15.7 Hz, 1H), 3.33 (q, J = 6.9 Hz, 1H), 7.20 (dd, J = 11.2, 9.0 Hz, 1H), 8.22-8.15 (m, 1H), 8.57 (dd, J = 6.8, 2.8 Hz, 1H).

[0251] Step 11: Synthesis of compound 10-17

To a solution of compound 10-16 (252 mg, 0.450 mmol) in EtOH (2 ml), THF (1 ml) and H₂O (1 ml) were added NH₄Cl (289 mg, 5.40 mmol) and Fe (201 mg, 3.60 mmol) at room temperature. After stirring for 1 h at 60 °C, the mixture was treated with H₂O and filtrated through a pad of Celite (Registered trademark). The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na2S04, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 30%. Collected fractions were evaporated to afford compound 10-17 (177 mg, 0.334 mmol, 74%) as a white amorphous.

1H-NMR (400 MHz, CDC13) δ: 1.27 (d, J = 7.0 Hz, 3H), 1.54 (s, 18H), 1.86 (d, J = 2.5 Hz, 3H), 2.63-2.87 (m, 3H), 3.28-3.47 (m, 2H), 3.61 (s, 2H), 6.56-6.50 (m, 1H), 6.82 (dd, J = 12.5, 8.5 Hz, 1H), 7.03 (dd, J = 7.0, 2.8 Hz, 1H).

[0252] Step 10: Synthesis of compound 10-18

To a solution of compound 10-17 (50.0 mg, 0.0940 mmol) in DMF (1 ml) were added 5-fluoropicolinic acid (13.3 mg, 0.0940 mmol), HATU (43.1 mg, 0.113 mmol) and DIPEA (0.0330 ml, 0.189 mmol) at room temperature. After stirring for 30 min at the same temperature, the reaction mixture was treated with H₂O. The aqueous layer was extracted with AcOEt, and the organic layer was dried over Na2S04, filtered and concentrated. The crude product was added to a silica gel column and eluted with hexane/EtOAc 0% to 30%. Collected fractions were evaporated to afford compound 10-18 (58.0 mg, 0.0890 mmol, 94%) as a colorless oil.
1H-NMR (400 MHz, CDC13) δ: 1.29 (d, J = 7.0 Hz, 3H), 1.60 (s, 18H), 1.92 (s, 3H), 2.70-2.93 (m, 3H), 3.33-3.49 (m, 2H), 7.08 (dd, J = 12.2, 8.8 Hz, 1H), 7.58 (td, J = 8.8, 2.8 Hz, 1H), 7.72 (dd, J = 7.1, 2.8 Hz, 1H), 8.44-8.31 (m, 3H), 10.03 (s, 1H).

Step 11: Synthesis of compound 1-63

To a solution of compound 10-18 (58.0 mg, 0.0890 mmol) in CH2Cl2 (0.7 ml) was added TFA (0.226 ml, 2.93 mmol) at room temperature. After stirring for 17 h at the same temperature, the reaction mixture was treated with aqueous K2CO3. The aqueous layer was extracted with AcOEt and the organic layer was dried over Na2SO4, filtered and concentrated to afford compound 1-63 (34.0 mg, 0.0750 mmol, 85%) as a white solid.

1H-NMR (400 MHz, CDC13) δ: 1.27 (d, J = 7.0 Hz, 3H), 1.74 (s, 3H), 2.67-2.85 (m, 3H), 3.24-3.42 (m, 2H), 7.06 (dd, J = 11.9, 8.7 Hz, 1H), 7.44 (dd, J = 7.0, 2.6 Hz, 1H), 7.59 (td, J = 8.7, 2.6 Hz, 1H), 7.93-7.87 (m, 1H), 8.33 (dd, J = 8.7, 4.6 Hz, 1H), 8.46 (d, J = 2.6 Hz, 1H), 9.76 (s, 1H).

Example 11

Synthesis of compound 1-40
Step 1
To a solution of compound 11-1 (16.1 g, 46.5 mmol) in methanol (160 ml) was added HCl-dioxane (4M, 16.3 ml, 65.0 mmol) at room temperature. After being stirred for 1.5 h at room temperature, the reaction mixture was concentrated and quenched with saturated aqueous NaHCO₃. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated to afford compound 11-2 (12.8 g, quant). The obtained compound 11-2 was used in the next reaction without further purification.

LC/MS(Shimadzu): RT 0.80, MS calcd for 244.11 (M+H+), found 244.00.

Step 2
To a solution of compound 11-2 (12.8 g, 46.5 mmol) in methanol (55 ml) was added Boc₂O (32.4 ml, 140 mmol) at room temperature. After being stirred for 4 h at 60 °C, the reaction mixture was concentrated. The residue was purified by silica gel chromatography to afford compound 11-3 (21.35 g, quant., including Boc₂O, compound 3:Boc₂O = 1:0.8).

1H-NMR (CDCl₃) δ: 1.03 (brs, 3H), 1.39 (brs, 9H), 1.96 (brs, 3H), 4.06 (brs, 2H), 5.34 (d, J = 47.2 Hz, 1H), 5.70 (brs, 1H), 7.04 (m, 1H), 7.11 (m, 1H), 7.25-7.35 (m, 2H).

Step 3
To a solution of compound 11-3 (11.4 g, 24.7 mmol, including Boc₂O) in CH₂Cl₂ (110 ml) was added DffiAL (1.02 M in toluene, 107 ml, 109 mmol) at -65 °C. After being stirred for 50 min at -65 °C, the reaction mixture was quenched with AcOEt and Rochelle's salt (93 g, 331 mmol) in H₂O. After being stirred for 1.5 h at room temperature, the aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 11-7 (1.07 g, quant). The obtained compound 11-4 was used in the next reaction without further purification.

1H-NMR (CDCl₃) δ: 1.39 (s, 9H), 1.74 (s, 3H), 5.07 (s, 1H), 5.53 (d, J = 46.8 Hz, 1H), 7.08 (m, 1H), 7.16 (m, 1H), 7.30 (m, 1H), 7.37 (m, 1H), 9.55 (d, J = 9.0 Hz, 1H).

[0258] Step 4

To a solution of compound 11-4 (7.87 g, 24.7 mmol) and ethyl 2-bromo-2,2-difluoroacetate (15.0 g, 74.1 mmol) in THF (150 ml) was added zinc (4.84 g, 74.1 mmol) at room temperature. After being stirred for 1.5 h at 70 °C, the reaction mixture was cooled to 0 °C and quenched with saturated aqueous NH₄Cl. The resulting mixture was filtered through a pad of Celite (registered trademark) and washed with AcOEt. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 11-5 (1.40 g, 4.01 mmol, 16%, 4 steps).

1H-NMR (CDCl₃) δ: 1.34 (t, J = 7.2 Hz, 3H), 1.78 (s, 3H), 4.34 (q, J = 7.2 Hz, 2H), 4.40 (ddd, J = 28.5, 13.7, 6.3 Hz, 1H), 5.49 (d, J = 47.4 Hz, 1H), 5.83 (s, 1H), 7.15 (m, 1H), 7.28 (m, 1H), 7.42 (m, 1H), 7.51 (m, 1H).

[0259] Step 5

To a solution of compound 11-5 (1.40 g, 4.01 mmol) in THF (28 ml) was added LiBH₄ (175 mg, 8.02 mmol) at room temperature. After being stirred for 45 min at room temperature, the reaction mixture was quenched with saturated aqueous NH₄Cl. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 11-6 (740 mg, 2.41 mmol, 60%).

1H-NMR (CDCl₃) δ: 1.79 (s, 3H), 1.97 (t, J = 7.1 Hz, 1H), 3.84-4.11 (m, 2H), 4.28 (ddd, J = 30.0, 13.2, 6.4 Hz, 1H), 5.47 (d, J = 46.9 Hz, 1H), 5.69 (s, 1H), 7.15 (m, 1H), 7.27 (m, 1H), 7.41 (m, 1H), 7.50 (m, 1H).

[0260] Step 6

To a solution of compound 11-6 (850 mg, 2.77 mmol), PPh₃ (2.90 mg, 11.1 mmol) and imidazole (753 mg, 11.1 mmol) in THF (17 ml) was added iodine (2.81 g, 11.1 mmol) at room temperature. After being stirred for 16 h at 80 °C, the reaction mixture was cooled to 0 °C and quenched with aqueous Na₂S₂O₃. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 11-7 (1.07 g, quant).
g, 2.57 mmol, 93%).
1H-NMR (CDCl₃) δ: 1.79 (s, 3H), 3.56-3.74 (m, 2H), 4.29 (dt, J = 29.5, 7.6 Hz, 1H), 5.41 (d, J = 47.2 Hz, 1H), 5.72 (s, 1H), 7.16 (m, 1H), 7.29 (m, 1H), 7.43 (m, 1H), 7.50 (m, 1H).

[0261] Step 7
To a solution of compound 11-7 (1.07 g, 2.57 mmol) and Boc₂O (1.19 ml, 5.13 mmol) in CH₂Cl₂ (20 ml) was added DMAP (157 mg, 1.28 mmol) at room temperature. After being stirred for 45 min at room temperature, the reaction mixture was concentrated and quenched with saturated NaOH solution. The residue was purified by silica gel chromatography to afford compound 11-8 (1.33 g, 2.57 mmol, 100%).
1H-NMR (CDCl₃) δ: 1.52 (s, 9H), 1.97 (s, 3H), 3.56-3.74 (m, 2H), 4.31 (dt, J = 30.6, 7.6 Hz, 1H), 5.32 (d, J = 46.9 Hz, 1H), 7.14 (m, 1H), 7.27 (m, 1H), 7.41 (m, 1H), 7.48 (m, 1H).

[0262] Step 8
To a solution of compound 11-8 (1.33 g, 2.57 mmol) and n-Bu₃SnH (1.64 ml, 6.16 mmol) in toluene (26 ml) was added AIBN (63.2 mg, 385 µmol) at room temperature. After being stirred for 1 h at 80 °C, the reaction mixture was cooled to room temperature and concentrated. The residue was purified by silica gel chromatography to afford compound 11-9 (717.1 mg, 1.83 mmol, 71%).
1H-NMR (CDCl₃) δ: 1.52 (s, 9H), 1.75 (t, J = 19.8 Hz, 3H), 1.97 (s, 3H), 4.05 (ddd, J = 30.7, 10.4, 4.8 Hz, 1H), 5.27 (d, J = 46.9 Hz, 1H), 7.13 (m, 1H), 7.25 (m, 1H), 7.39 (m, 1H), 7.48 (m, 1H).

[0263] Step 9
To a solution of compound 11-9 (717.1 mg 1.83 mmol) in EtOH (12 ml) and H₂O (6 ml) was added Ba(OH)₂·8H₂O (1.73 g, 5.50 mmol) at room temperature. After being stirred for 1.5 h at room temperature, the reaction mixture was quenched with aqueous citric acid. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated. The residue was washed with AcOEt and hexane and insoluble matter was filtered. The filtrate was concentrated and the residue was purified by silica gel chromatography to afford compound 11-10 (630.1 mg, 1.73 mmol, 94%).
1H-NMR (CDCl₃) δ: 1.42 (s, 9H), 1.61 (t, J = 19.3 Hz, 3H), 2.02 (s, 3H), 2.67 (dd, J = 9.3, 3.8 Hz, 1H), 3.62 (brs, 1H), 5.14 (d, J = 44.5 Hz, 1H), 6.27 (brs, 1H), 7.05 (m, 1H), 7.16 (m, 1H), 7.29 (m, 1H), 7.39 (m, 1H).

[0264] Step 10
To a solution of compound 11-10 (630.1 mg, 1.73 mmol) and in MeOH (6 ml) was added HCl-dioxane (4M, 1.73 ml, 6.90 mmol) at room temperature. After being stirred for 2.5 h at 50 °C, the reaction mixture was concentrated and quenched with saturated
aqueous NaHCO$_3$. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na$_2$SO$_4$ and concentrated. The obtained compound 11-11 was used in the next reaction without further purification.

1H-NMR (CDC$_3$) $\delta$: 1.64 (td, $J = 19.6, 1.5$ Hz, 3H), 1.76 (s, 3H), 3.46 (dt, $J = 29.9, 9.5$ Hz, 1H), 5.19 (d, $J = 45.7$ Hz, 1H), 7.09 (m, 1H), 7.23 (m, 1H), 7.35 (m, 1H), 7.57 (m, 1H).

[0265] Step 11

To a solution of compound 11-11 in CH$_2$Cl$_2$ (3 ml) was added BzNCS (348 $\mu$L, 2.59 mmol) at room temperature. After being stirred for 2.5 h at room temperature, the reaction mixture was quenched with H$_2$O. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na$_2$SO$_4$ and concentrated. The residue was purified by silica gel chromatography to afford compound 11-12 (630.9 mg, 1.47 mmol, 85%, 2 steps).

1H-NMR (CDC$_3$) $\delta$: 1.69 (t, $J = 19.2$ Hz, 3H), 2.31 (s, 3H), 2.74 (dd, $J = 9.9, 2.9$ Hz, 1H), 3.85 (m, 1H), 5.41 (d, $J = 44.4$ Hz, 1H), 7.08 (m, 1H), 7.18 (m, 1H), 7.33 (m, 1H), 7.47 (m, 1H), 7.52 (m, 2H), 7.63 (m, 1H), 7.87 (m, 2H), 8.91 (s, 1H), 11.80 (s, 1H).

[0266] Step 12

To a solution of compound 11-12 (630.9 mg, 1.47 mmol) in CH$_3$CN (12 ml) was added WSCD hydrochloride (565 mg, 2.95 mmol) at room temperature. After being stirred for 1.5 h at 50 °C, the reaction mixture was cooled to room temperature and quenched with H$_2$O. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na$_2$SO$_4$ and concentrated. The residue was purified by silica gel chromatography to afford compound 11-13 (564.0 mg, 1.43 mmol, 97%).

1H-NMR (CDC$_3$) $\delta$: 1.83 (td, $J = 19.7, 1.9$ Hz, 3H), 1.89 (s, 3H), 4.11 (ddd, $J = 29.1, 10.0, 5.0$ Hz, 1H), 5.52 (d, $J = 47.2$ Hz, 1H), 7.17 (m, 1H), 7.24 (m, 1H), 7.38-7.48 (m, 4H), 7.53 (m, 1H), 8.27 (m, 2H), 11.80 (s, 1H).

[0267] Step 13

To a solution of compound 11-13 (554.0 mg, 1.40 mmol) in MeOH (22 ml) was added K$_2$CO$_3$ (1.17 g, 8.43 mmol) at room temperature. After being stirred for 3 h at 80 °C, the reaction mixture was cooled to room temperature and quenched with H$_2$O. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na$_2$SO$_4$ and concentrated. The residue was purified by silica gel chromatography to afford compound 11-14 (374.5 mg, 1.29 mmol, 92%).

1H-NMR (CDC$_3$) $\delta$: 1.66 (s, 3H), 1.71 (t, $J = 19.7$ Hz, 3H), 3.83 (ddd, $J = 30.0, 10.8, 4.4$ Hz, 1H), 4.29 (brs, 2H), 5.35 (d, $J = 48.2$ Hz, 1H), 7.05 (m, 1H), 7.17 (m, 1H), 7.29 (m, 1H), 7.44 (m, 1H).

[0268] Step 14

To a solution of compound 11-14 (360.0 mg, 1.24 mmol) in TFA (4 ml) was added H$_2$SO$_4$ (1 ml) at -20 °C. After being stirred for 5 min at 0 °C, the reaction mixture was
cooled to -20 °C and HNO₃ (83 µℓ, 1.86 mmol) was added. After being stirred for 15 min at 0 °C, the reaction mixture was quenched with aqueous K₂C₇O₃. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 11-15 (530 mg, quant.).

1H-NMR (CDCl₃): δ: 1.77 (t, J = 19.7 Hz, 3H), 1.87 (s, 3H), 4.05 (m, 1H), 5.46 (d, J = 46.6 Hz, 1H), 7.34 (m, 1H), 8.27-8.36 (m, 2H).

Step 15
To a solution of compound 11-15 (530 mg, quant.) and Boc₂O (864 µℓ, 3.72 mmol) in CH₂Cl₂ (7 ml) was added DMAP (182 mg, 1.49 mmol) at room temperature. After being stirred for 1 h at room temperature, the reaction mixture was concentrated. The residue was purified by silica gel chromatography to afford compound 11-16 (603.8 mg, 1.13 mmol, 91%, 2 steps).

1H-NMR (CDCl₃): δ: 1.52 (s, 18H), 1.73 (s, 3H), 1.74 (m, 3H), 3.88 (ddd, J = 28.9, 10.3, 4.3 Hz, 1H), 5.39 (d, J = 47.4 Hz, 1H), 7.29 (m, 1H), 8.27 (m, 1H), 8.51 (m, 1H).

Step 16
To a solution of compound 11-16 (603.8 mg, 1.13 mmol) in THF (8 ml) and MeOH (4 ml) was added Pd/C (60.0 mg) at room temperature. After being stirred for 3.5 h under H₂ atmosphere at room temperature, the reaction mixture was filtered through a pad of Celite (Registered trademark), and the residue was washed with AcOEt. The filtrate was concentrated, and the residue was purified by silica gel chromatography to afford compound 11-17. The obtained compound 11-17 was further purified by trituration from AcOEt/hexane to give compound 11-17 (482.9 mg, 955 µmol, 85%).

1H-NMR (CDCl₃): δ: 1.52 (s, 18H), 1.69 (s, 3H), 1.72 (t, J = 19.6 Hz, 3H), 3.56 (brs, 2H), 4.02 (m, 1H), 5.37 (d, J = 47.8 Hz, 1H), 6.57 (m, 1H), 6.81 (m, 1H), 6.87 (m, 1H).

Step 17
To a solution of compound 11-17 (70.0 mg, 138 µmol), 5-cyanopicolinic acid hydrate (27.6 mg, 166 µmol) and diisopropylethylamine (48 µℓ, 277 µmol) in DMF (2 ml) was added HATU (63.2 mg, 166 µmol) at room temperature. After being stirred for 50 min at room temperature, the reaction mixture was quenched with saturated aqueous NH₄Cl. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 11-18 (91.6 mg, quant.).

1H-NMR (CDCl₃): δ: 1.56 (s, 18H), 1.73 (t, J = 19.7 Hz, 3H), 1.76 (s, 3H), 4.01 (ddd, J = 29.6, 10.2, 4.4 Hz, 1H), 5.40 (d, J = 47.6 Hz, 1H), 7.16 (m, 1H), 7.53 (m, 1H), 8.21 (d, J = 8.2 Hz, 1H), 8.37 (m, 1H), 8.43 (d, J = 8.2 Hz, 1H), 8.80 (s, 1H), 9.96 (s, 1H).
Compound 11-18 (91.6 mg) was solved in formic acid (1 ml, 26.1 mmol) at room temperature. After being stirred for 8 h at room temperature, the reaction mixture was quenched with aqueous K$_2$CO$_3$. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na$_2$SO$_4$ and concentrated. The residue was purified by trituration from AcOEt/hexane to give pure compound 1-40 (52.2 mg, 120 µmol, 87%, 2 steps).

1H-NMR (CDCl$_3$) δ: 1.67 (s, 3H), 1.72 (t, J = 19.7 Hz, 3H), 3.88 (ddd, J = 29.9, 10.8, 4.4 Hz, 1H), 4.33 (brs, 2H), 5.38 (d, J = 48.1 Hz, 1H), 7.12 (m, 1H), 7.55 (m, 1H), 8.02 (m, 1H), 8.21 (d, J = 8.3 Hz, 1H), 8.43 (d, J = 8.3 Hz, 1H), 8.90 (s, 1H), 9.87 (s, 1H).

Example 12

[0273] Synthesis of compound 1-82
Step 1
To a solution of compound 12-1 (1.50 g, 4.88 mmol) and imidazole (798 mg, 11.7 mmol) in DMF (15 ml) was added TBSCl (883 mg, 5.86 mmol) at room temperature. After stirring for 45 min at room temperature, the reaction mixture was quenched with saturated aqueous NaHCO₃. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated to afford compound 12-2. The obtained compound 12-2 was used in the next reaction without further purification.

LC/MS (Shimadzu): RT 2.59, MS calc for 422.18 (M+H+), found 422.00.

Step 2
To a solution of compound 12-2 and Boc₂O (6.57 ml, 28.3 mmol) in CH₂Cl₂ (20 ml) was added DMAP (238 mg, 1.95 mmol) at room temperature. After being stirred for 1 h at room temperature, the reaction mixture was concentrated. The residue was purified
by silica gel chromatography to afford compound 12-3 (2.60 g, quant.)

1H-NMR (CDC13) δ: -0.04 (s, 3H), -0.02 (s, 3H), 0.69 (s, 9H), 1.52 (s, 9H), 1.98 (m, 3H), 3.76 (m, 1H), 3.94 (ddd, J = 24.1, 11.8, 6.0 Hz, 1H), 4.34 (m, 1H), 5.38 (d, J = 46.9 Hz, 1H), 7.09 (m, 1H), 7.23 (m, 1H), 7.36 (m, 1H), 7.48 (m, 1H).

[0276]

Step 3

To a solution of compound 12-3 (2.60 g) in MeOH (25 ml) was added K2CO3 (2.70 g, 19.5 mmol) at room temperature. After being stirred for 45 min at room temperature, the reaction mixture was quenched with saturated aqueous NH4Cl. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na2SO4 and concentrated to afford compound 12-4. The obtained compound 12-4 was used in the next reaction without further purification.

LC/MS(Shimadzu): RT 2.94, MS calcd for 496.25 (M+H+), found 496.25.

[0277]

Step 4

To a solution of compound 12-4 in CH2Cl2 (50 ml) was added TFA (5 ml, 64.9 mmol) at room temperature. After being stirred for 1 h at room temperature, the reaction mixture was quenched with saturated aqueous NaHCO3 and K2CO3. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na2SO4 and concentrated. The residue was purified by silica gel chromatography to afford compound 12-5 (1.53 g, 3.87 mmol, 79%, 4 steps).

1H-NMR (CDC13) δ: -0.05 (s, 3H), -0.02 (s, 3H), 0.74 (s, 9H), 1.74 (s, 3H), 3.61-3.77 (m, 2H), 3.91 (ddd, J = 23.5, 11.5, 7.7 Hz, 1H), 5.29 (d, J = 45.8 Hz, 1H), 7.06 (m, 1H), 7.20 (m, 1H), 7.32 (m, 1H), 7.59 (m, 1H).

[0278]

Step 5

To a solution of compound 12-5 (1.53 g, 3.87 mmol) in CH2Cl2 (6 ml) was added BzNCS (780 µl, 5.80 mmol) at room temperature. After being stirred for 1 h at room temperature, the reaction mixture was concentrated. The residue was purified by silica gel chromatography to afford compound 12-6 (2.07 g, including compound 12-7).

1H-NMR (CDC13) δ: 0.01 (s, 3H), 0.04 (s, 3H), 0.81 (s, 9H), 2.35 (brs, 3H), 3.22 (dd, J = 11.0, 2.5 Hz, 1H), 3.76 (td, J = 11.8, 5.5 Hz, 1H), 3.96-4.15 (m, 2H), 5.38 (d, J = 44.2 Hz, 1H), 7.06 (m, 1H), 7.16 (m, 1H), 7.31 (m, 1H), 7.48 (m, 1H), 7.52 (m, 2H), 7.63 (m, 1H), 7.86 (m, 2H), 8.89 (s, 1H), 11.92 (s, 1H).

[0279]

Step 6

To a solution of compound 12-6 (2.07 g) in CH3CN (21 ml) was added WSCD hydrochloride (1.42 g, 7.41 mmol) at room temperature. After being stirred for 1.5 h at 50 °C, the reaction mixture was cooled to room temperature and quenched with H2O. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na2SO4 and concentrated to afford compound 12-7. The obtained compound 12-7 was used in the next reaction without further purification.
LC/MS(Shimadzu): RT 3.06, MS calcd for 525.22 (M+H+), found 525.20.

Step 7
To a solution of compound 12-7 in THF (20 ml) was added TBAF (1 M in THF, 7.41 ml, 7.41 mmol) at room temperature. After being stirred for 10 min at room temperature, the reaction mixture was quenched with saturated aqueous NH₄Cl. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na2SO4 and concentrated. The residue was purified by silica gel chromatography to afford compound 12-8 (1.55 g, 3.78 mmol, 98%, 3 steps)

1H-NMR (CDCl₃) δ: 1.90 (s, 3H), 3.96 (ddd, J = 15.7, 13.3, 7.9 Hz, 1H), 4.14 (m, 1H), 4.35 (ddd, J = 29.5, 12.9, 6.4 Hz, 1H), 5.62 (d, J = 46.9 Hz, 1H), 7.17 (m, 1H), 7.24 (m, 1H), 7.38-7.48 (m, 4H), 7.53 (m, 1H), 8.24 (m, 2H), 11.77 (brs, 1H).

Step 8
To a solution of compound 12-8 (500 mg, 1.22 mmol) in CH₂Cl₂ (10 ml) was added Dess-Martin periodinane (1.03 g, 2.44 mmol) at room temperature. After being stirred for 1 h at room temperature, the reaction mixture was quenched with saturated aqueous NaHCO₃ and Na₂S₂O₃. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na2SO4 and concentrated to afford compound 12-9. The obtained compound 12-9 was used in the next reaction without further purification.

LC/MS(Shimadzu): RT 1.86, MS calcd for 427.13 (M+H+), found 427.10.

Step 9
To a suspension of methyltriphenylphosphonium bromide (1.39 g, 3.90 mmol) in THF (8 ml) was added KHMDS (0.5 M in toluene, 7.31 ml, 3.65 mmol) at 0 °C. After being stirred for 20 min at 0 °C, compound 12-9 in THF (8 ml) was added. After being stirred for 3 h at room temperature, the reaction mixture was quenched with H₂O. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na2SO4 and concentrated. The residue was purified by silica gel chromatography to afford compound 12-10 (255.3 mg, 628 μg, 52%).

1H-NMR (CDCl₃) δ: 1.88 (s, 3H), 4.18 (ddd, J = 28.9, 9.3, 6.0 Hz, 1H), 5.54 (d, J = 47.2 Hz, 1H), 5.64 (d, J = 11.0 Hz, 1H), 5.87 (m, 1H), 6.08 (m, 1H), 7.17 (m, 1H), 7.24 (m, 1H), 7.38-7.48 (m, 4H), 7.52 (m, 1H), 8.27 (m, 2H), 11.78 (brs, 1H).

Step 10
To a solution of compound 12-10 (225.3 mg, 554 μmol) and Boc₂O (257 μl, 1.11 mmol) in CH₂Cl₂ (4.6 ml) was added DMAP (13.6 mg, 111 μmol) at room temperature. After being stirred for 40 min at room temperature, the reaction mixture was concentrated. The residue was purified by silica gel chromatography to afford compound 12-11 (289.6 mg, quant).

1H-NMR (CDCl₃) δ: 1.38 (m, 3H), 1.48 (s, 9H), 4.05 (ddd, J = 28.6, 9.9, 6.3 Hz, 1H), 5.31 (d, J = 47.8 Hz, 1H), 5.60 (d, J = 11.0 Hz, 1H), 5.77 (m, 1H), 5.99 (m, 1H), 6.3 Hz,
7.06 (m, 1H), 7.17 (m, 1H), 7.31 (m, 1H), 7.40-7.47 (m, 3H), 7.55 (m, 1H), 7.76 (m, 2H).

[0284] Step 11

In a test tube, to a mixture of aqueous NaOH (30%, 2 ml) and Et2O (6 ml) was added 1-methyl-1-nitrosourea (571 mg, 2.77 mmol) at 0 °C. After being stirred for 20 min at 0 °C, the color of organic phase was turned to yellow, which indicated that an Et2O solution of diazomethane was able to be prepared. In a separate flask, to a suspension of compound 12-11 (289.6 mg) and Pd(OAc)2 (24.9 mg, 111 μmol) in Et2O (6 ml) was added the Et2O solution of diazomethane at 0 °C. After being stirred for 15 min at 0 °C, the reaction mixture was quenched with H2O and AcOH. Saturated aqueous NaHCO3 was added, and the aqueous phase was extracted with AcOEt. The organic layer was dried over Na2SO4 and concentrated. The residue was purified by silica gel chromatography to afford compound 12-12 (275.7 mg, 530 μmol, 96%, 2 steps).

1H-NMR (CDCl3) δ: 0.59-0.78 (m, 4H), 1.33-1.44 (m, 4H), 1.48 (s, 9H), 4.02 (ddd, J = 28.9, 9.5, 7.4 Hz, 1H), 5.34 (d, J = 47.6 Hz, 1H), 7.05 (m, 1H), 7.17 (m, 1H), 7.30 (m, 1H), 7.40-7.49 (m, 3H), 7.54 (m, 1H), 7.79 (m, 2H).

[0285] Step 12

To a solution of compound 12-12 (313.6 mg, 602 μmol) in MeOH (3 ml) was added K2C03 (416 mg, 3.01 mmol) at room temperature. After being stirred for 40 min at room temperature, the reaction mixture was quenched with H2O. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na2SO4 and concentrated. The residue was purified by silica gel chromatography to afford compound 12-13 (233.1 mg, 560 μmol, 93%).

1H-NMR (CDCl3) δ: 0.58-0.78 (m, 4H), 1.45 (m, 1H), 1.53 (s, 9H), 1.84 (s, 3H), 4.04 (dt, J = 29.1, 8.0 Hz, 1H), 5.47 (d, J = 47.2 Hz, 1H), 7.14 (m, 1H), 7.25 (m, 1H), 7.36-7.44 (m, 2H), 10.05 (brs, 1H).

[0286] Step 13

Compound 12-13 (233.1 mg, 560 μmol) was solved in TFA (2 ml) at room temperature. After being stirred for 45 min at room temperature, the reaction mixture was cooled to -20 °C and H2SO4 (0.5 ml) was added. After being stirred for 5 min at 0 °C, the reaction mixture was cooled to -20 °C and HNO3 (75 μl, 1.68 mmol) was added. After being stirred for 50 min at 0 °C, the reaction mixture was quenched with aqueous K2C03. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na2SO4 and concentrated to afford compound 12-14 (326.3 mg, quant.). The obtained compound 12-14 was used in the next reaction without further purification.

1H-NMR (CDCl3) δ: 0.60-0.78 (m, 4H), 1.39 (m, 1H), 1.69 (s, 3H), 3.85 (ddd, J = 29.6, 9.2, 7.4 Hz, 1H), 5.41 (d, J = 47.4 Hz, 1H), 7.25 (dd, J = 10.7, 8.9 Hz, 1H), 8.23 (ddd, J = 8.9, 4.1, 2.9 Hz, 1H), 8.45 (dd, J = 6.7, 2.9 Hz, 1H).
[0287] Step 14
To a solution of compound 12-14 (326.3 mg, quant.) and Boc₂O (325 µι, 1.40 mmol) in CH₂Cl₂ (6 ml) was added DMAP (103 mg, 840 µηοι) at room temperature. After being stirred for 40 min at room temperature, the reaction mixture was concentrated. The residue was purified by silica gel chromatography to afford compound 12-15 (276.1 mg, 492 µηοι, 88%, 2 steps).
1H-NMR (CDCl₃) δ: 0.59-0.80 (m, 4H), 1.40 (m, 1H), 1.52 (s, 18H), 1.74 (m, 3H), 3.93 (ddd, J = 28.6, 8.9, 7.0 Hz, 1H), 5.44 (d, J = 47.2 Hz, 1H), 7.29 (dd, J = 10.8, 9.0 Hz, 1H), 8.27 (ddd, J = 9.0, 4.2, 2.9 Hz, 1H), 8.53 (dd, J = 6.7, 2.9 Hz, 1H).

[0288] Step 15
To a solution of compound 12-15 (276.1 mg, 492 µηοι) in THF (3 ml) and MeOH (1.5 ml) was added Pd/C (52.4 mg) at room temperature. After being stirred for 6.5 h under H₂ atmosphere at room temperature, the reaction mixture was filtered through a pad of Celite (Registered trademark), and the residue was washed with AcOEt. The filtrate was concentrated, and the residue was purified by silica gel chromatography to afford compound 12-16 (240.9 mg, 453 µηοι, 92%).
1H-NMR (CDCl₃) δ: 0.58-0.77 (m, 4H), 1.39 (m, 1H), 1.52 (s, 18H), 1.71 (m, 3H), 3.57 (brs, 2H), 4.07 (ddd, J = 28.7, 9.7, 6.9 Hz, 1H), 5.43 (d, J = 47.7 Hz, 1H), 6.57 (ddd, J = 8.7, 3.8, 3.0 Hz, 1H), 6.83 (dd, J = 6.5, 3.0 Hz, 1H), 6.87 (dd, J = 11.7, 8.7 Hz, 1H).

[0289] Step 16
To a solution of compound 12-16 (70.0 mg, 132 µηοι). 5-(fluoromethoxy)pyrazine-2-carboxylic acid (27.2 mg, 158 µηοι) and diisopropylethylamine (46 µι, 263 µηοι) in DMF (2 ml) was added HATU (60.1 mg, 158 µηοι) at room temperature. After being stirred for 50 min at room temperature, the reaction mixture was quenched with saturated aqueous NH₄Cl. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 12-17 (86.6 mg, 126 µηοι, 96%).
1H-NMR (CDCl₃) δ: 0.59-0.77 (m, 4H), 1.38 (m, 1H), 1.54 (s, 18H), 1.76 (m, 3H), 4.05 (m, 1H), 5.45 (d, J = 47.4 Hz, 1H), 6.15 (ddd, J = 50.9, 11.5, 2.0 Hz, 2H), 7.15 (dd, J = 11.5, 8.8 Hz, 1H), 7.48 (dd, J = 6.8, 2.8 Hz, 1H), 8.20 (d, J = 1.5 Hz, 1H), 8.37 (ddd, J = 8.8, 4.0, 2.8 Hz, 1H), 9.08 (d, J = 1.5 Hz, 1H), 9.63 (s, 1H).

[0290] Step 17
Compound 12-17 (86.6 mg, 126 µηοι) was solved in formic acid (1 ml, 26.1 mmol) at room temperature. After being stirred for 15 h at room temperature, the reaction mixture was quenched with aqueous K₂CO₃. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated. The residue was
purified by trituration from hexane to give pure compound 1-82 (52.8 mg, 109 \(\mu\)mol, 86%).

\[\text{1H-NMR (CDCl}_3\text{)} \delta: 0.64 (m, 2H), 0.73 (m, 2H), 1.38 (m, 1H), 1.67 (s, 3H), 3.95 (\text{ddd}, J = 29.9, 10.0, 7.3 \text{Hz}, 1H), 4.37 (\text{brs}, 2H), 5.45 (d, J = 48.1 \text{Hz}, 1H), 6.15 (m, 2H), 7.11 (dd, J = 11.3, 8.9 \text{Hz}, 1H), 7.50 (dd, J = 6.8, 2.8 \text{Hz}, 1H), 8.03 (\text{ddd}, J = 8.9, 4.1, 2.8 \text{Hz}, 1H), 8.29 (d, J = 1.4 \text{Hz}, 1H), 9.08 (d, J = 1.4 \text{Hz}, 1H), 9.52 (s, 1H).

**Example 13**

[0291] Synthesis of compound 1-109

[Chem.67]

![Diagram of chemical structures](image-url)

[0292] **Step 1**

A solution of compound 3-4 (1.25 g, 2.57 mmol) and silver (I) tetrafluoroborate (1.00 g, 5.14 mmol) in DMSO (6.3 mL) and water (0.63 mL) was stirred for 3.5 h at room temperature. The reaction was quenched with a saturated solution of sodium hydrogen carbonate. The resulting mixture was filtered through celite (Registered trademark) pad and the filtrate was extracted with ethyl acetate. The combined organic layers were washed with water and evaporated. The crude product was purified by flash column chromatography (silica gel, 2:1 hexane:ethyl acetate) to give compound 13-1 (560 mg, 58%) as a colorless amorphous.
IH NMR (400 MHz, CDCl3) δ: 1.89 (s, 3H), 3.17-3.29 (m, 1H), 3.80 (dd, J = 10.8, 7.9 Hz, 1H), 4.04 (dd, J = 10.8, 7.2 Hz, 1H), 5.60 (dd, J = 47.3, 1.6 Hz, 1H), 7.12 (dd, J = 12.2, 8.2 Hz, 1H), 7.20 (t, J = 7.7 Hz, 1H), 7.35-7.54 (m, 5H), 8.23 (d, J = 7.3 Hz, 2H).

Step 2
To a stirred suspension of compound 13-1 (560 mg, 0.84 mmol) and sodium hydride (179 mg, 4.46 mmol, 60% in oil) in THF (6 mL) was added iodomethane (0.465 mL, 7.44 mmol) at 0 °C. After being stirred for 2 h at 0 °C, the reaction was quenched with a saturated solution of ammonium chloride. The mixture was extracted with ethyl acetate and the combined organic layers were washed with water. The solvent was evaporated and the crude product was purified by flash column chromatography (silica gel, gradient from 4:1 to 3:1 hexane:ethyl acetate) to give compound 13-2 (326 g, 56%) as a colorless amorphous.

IH NMR (400 MHz, CDCl3) δ: 1.88 (s, 3H), 3.21-3.33 (m, 1H), 3.35 (s, 3H), 3.44-3.48 (m, 1H), 3.81 (dd, J = 9.3, 7.3 Hz, 1H), 5.52 (dd, J = 47.2, 2.0 Hz, 1H), 7.12 (dd, J = 12.3, 8.0 Hz, 1H), 7.19 (td, J = 7.6, 1.2 Hz, 1H), 7.34-7.53 (m, 5H), 8.23 (d, J = 7.0 Hz, 2H).

Step 3
A solution of compound 13-2 (326 mg, 0.84 mmol) and hydrazine monohydrate (0.405 mL, 8.35 mmol) in ethanol (5 mL) was stirred for 18 h at room temperature. The mixture was evaporated, and the crude product was purified by flash column chromatography (amino silica gel, 1:1 hexane:ethyl acetate) to give compound 13-3 (210 mg, 88%) as a colorless gum.

IH NMR (400 MHz, CDCl3) δ: 1.75 (t, J = 1.5 Hz, 3H), 3.21-3.33 (m, 1H), 3.32 (s, 3H), 3.40-3.44 (m, 1H), 3.77 (dd, J = 9.4, 6.7 Hz, 1H), 5.33 (dd, J = 47.7, 1.8 Hz, 1H), 7.03 (ddd, J = 12.4, 8.2, 1.3 Hz, 1H), 7.12 (td, J = 7.5, 1.3 Hz, 1H), 7.23-7.30 (m, 2H).

Step 4
To a stirred suspension of compound 13-3 (210 mg, 0.73 mmol) and sulfuric acid (0.520 mL, 9.76 mmol) in trifluoroacetic acid (2.1 mL) was added nitric acid (0.049 mL, 1.10 mmol) at -20 °C. After being stirred for 30 min at between -20 °C and -10 °C, the reaction was quenched with a solution of potassium carbonate. The mixture was extracted with ethyl acetate, and the combined organic layers were washed with water. The solvent was evaporated to give compound 13-4 (231 mg) as a crude product, which was used for the next reaction without further purification.

Step 5
A suspension of compound 13-4 (231 mg), iron (311 mg, 5.58 mmol), and ammonium chloride (447 mg, 8.37 mmol) in toluene (2 mL) and water (2 mL) was stirred for 2 h at 80 °C. After being cooled to room temperature, the reaction was quenched with a solution of potassium carbonate. The mixture was filtered through
celite (Registered trademark) pad, and the filtrate was extracted with ethyl acetate. The combined organic layers were washed with water and evaporated to give compound 13-5 (206 mg) as a crude product, which was used for the next reaction without further purification.

[0297] Step 6
To a stirred solution of compound 13-5 (55.6 mg) in dichloromethane (1.1 mL) was added boron tribromide (0.922 mL, 0.922 mmol, 1 mol/L in dichloromethane) at -78 °C. After being stirred at 0 °C for 3 h, boron tribromide (0.553 mL, 0.553 mmol) was added to the mixture at -78 °C. After being stirred at 0 °C for 1 h, the reaction was quenched with a saturated solution of sodium hydrogen carbonate. The mixture was extracted with ethyl acetate, and the combined organic layers were washed with water. The solvent was evaporated to give compound 13-6 (58.1 mg) as a crude product, which was used for the next reaction without further purification.

[0298] Step 7
To a stirred solution of compound 13-6 (58.1 mg) and hydrogen chloride (0.092 mL, 0.184 mmol, 2 mol/L in water) were added 5-(fluoromethoxy)pyrazine-2-carboxylic acid (31.7 mg, 0.184 mmol) and WSCD (38.9 mg, 0.203 mmol) at room temperature. After being stirred for 45 min at room temperature, the reaction was quenched with a saturated solution of sodium hydrogen carbonate. The mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The solvent was evaporated, and the crude product was triturated with hexane to give 1-109 (64.5 mg, 74% over 4 steps).

1H NMR (400 MHz, CDC13) δ: 1.77 (s, 3H), 3.23-3.35 (m, 1H), 3.75 (dd, J = 11.0, 7.3 Hz, 1H), 4.00 (dd, J = 11.0, 7.3 Hz, 1H), 5.44 (d, J = 46.7 Hz, 1H), 6.15 (d, J = 50.2 Hz, 2H), 7.09 (dd, J = 11.5, 8.8 Hz, 1H), 7.34 (dd, J = 6.7, 2.9 Hz, 1H), 7.95-7.99 (m, 1H), 8.30 (s, 1H), 9.08 (s, 1H), 9.48 (s, 1H).

Example 14

1H NMR (400 MHz, CDC13) δ: 1.77 (s, 3H), 3.23-3.35 (m, 1H), 3.75 (dd, J = 11.0, 7.3 Hz, 1H), 4.00 (dd, J = 11.0, 7.3 Hz, 1H), 5.44 (d, J = 46.7 Hz, 1H), 6.15 (d, J = 50.2 Hz, 2H), 7.09 (dd, J = 11.5, 8.8 Hz, 1H), 7.34 (dd, J = 6.7, 2.9 Hz, 1H), 7.95-7.99 (m, 1H), 8.30 (s, 1H), 9.08 (s, 1H), 9.48 (s, 1H).

Example 14

Synthesis of compound 1-94
Step 1
To a suspension of compound 14-1 (537.7 mg, 1.29 mmol) in dimethylacetamide (2.5 ml) and H₂O (2.5 ml) was added zinc (421 mg, 6.45 mmol) at room temperature. After being stirred for 2 h at 80 °C, the reaction mixture was cooled to 0 °C and quenched with aqueous Na₂S₂O₃. The resulting mixture was filtered through a pad of Celite (Registered trademark), and the residue was washed with AcOEt. The aqueous phase was extracted with AcOEt. The organic phase was dried over Na₂SO₄ and concentrated to afford compound 14-2. The obtained compound 14-2 was used in the next reaction without further purification.

1H-NMR (CDCl₃) δ: 1.80 (s, 3H), 4.45 (d, J = 28.2 Hz, 1H), 4.91 (ddd, J = 17.8, 3.9, 1.3 Hz, 1H), 5.00 (ddd, J = 14.8, 3.9, 1.3 Hz, 1H), 5.29 (d, J = 46.6 Hz, 1H), 6.02 (s, 1H), 7.15 (m, 1H), 7.27 (m, 1H), 7.41 (m, 1H), 7.53 (m, 1H).

Step 2
To a solution of compound 14-2 and Boc₂O (748 µl, 3.22 mmol) in CH₂Cl₂ (3.5 ml) was added DMAP (79 mg, 645 µmol) at room temperature. After being stirred for 1.5 h at room temperature, the reaction mixture was concentrated. The residue was purified by silica gel chromatography to afford compound 14-3 (436.3 mg, 1.17 mmol, 91%, 2 steps).

1H-NMR (CDCl₃) δ: 1.52 (s, 9H), 1.97 (m, 3H), 4.46 (d, J = 29.3 Hz, 1H), 4.91 (ddd, J = 20.2, 4.0, 1.3 Hz, 1H), 4.99 (ddd, J = 12.3, 4.0, 1.3 Hz, 1H), 5.21 (d, J = 46.3 Hz, 1H), 7.13 (m, 1H), 7.25 (m, 1H), 7.39 (m, 1H), 7.50 (m, 1H).

Step 3
To a solution of compound 14-3 (456.3 mg, 1.23 mmol) in MeOH (5 ml) was added K₂CO₃ (679 mg, 4.91 mmol) at room temperature. After being stirred for 15 min at
room temperature, the reaction mixture was quenched with saturated aqueous NH₄Cl. The aqueous phase was extracted with AcOEt. The organic layer was dried over Na₂SO₄ and concentrated to afford compound 14-4. The obtained compound 14-4 was used in the next reaction without further purification.

LC/MS(Shimadzu): RT 2.15, MS calcd for 346.16 (M+H+), found 346.15.

[0303] Step 4
To a solution of compound 14-4 in CH₂Cl₂ (5 ml) was added TFA (1 ml, 13.0 mmol) at room temperature. After being stirred for 1 h at room temperature, the reaction mixture was quenched with saturated aqueous NaHC0₃ and K₂C0₃ solutions. The aqueous phase was extracted with AcOEt. The organic phase was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 14-5 (254.6 mg, 1.04 mmol, 84%, 2 steps).

1H-NMR (CDCl₃) δ: 1.77 (s, 3H), 3.89 (d, J = 31.0 Hz, 1H), 4.71 (ddd, J = 22.2, 2.9, 1.4 Hz, 1H), 4.79 (ddd, J = 10.9, 2.9, 1.4 Hz, 1H), 5.09 (dd, J = 44.9, 1.1 Hz, 1H), 7.10 (m, 1H), 7.22 (m, 1H), 7.35 (m, 1H), 7.58 (m, 1H).

[0304] Step 5
To a solution of compound 14-5 (254.6 mg, 1.04 mmol) in CH₂Cl₂ (2.5 ml) was added BzNCS (209 µl, 1.56 mmol) at room temperature. After being stirred for 2.5 h at room temperature, the reaction mixture was concentrated. The residue was purified by silica gel chromatography to afford compound 14-6 (375.5 mg, 919 µmol, 89%).

1H-NMR (CDCl₃) δ: 2.30 (s, 3H), 2.56 (d, J = 9.5 Hz, 1H), 4.36 (ddd, J = 25.2, 9.5, 5.0 Hz, 1H), 4.76 (dd, J = 48.9, 3.5 Hz, 1H), 4.85 (dd, J = 17.7, 3.5 Hz, 1H), 5.37 (d, J = 43.9 Hz, 1H), 7.08 (m, 1H), 7.18 (m, 1H), 7.33 (m, 1H), 7.46-7.56 (m, 3H), 7.63 (m, 1H), 7.87 (m, 2H), 8.89 (s, 1H), 11.85 (s, 1H).

[0305] Step 6
To a solution of compound 14-6 (375.5 mg, 919 µmol) in CH₃CN (7 ml) was added WSCD hydrochloride (352 mg, 1.84 mmol) at room temperature. After being stirred for 1 h at 50 °C, the reaction mixture was cooled to room temperature and quenched with H₂O. The aqueous phase was extracted with AcOEt. The organic phase was dried over Na₂SO₄ and concentrated to afford compound 14r7. Obtained compound 14r7 was used in the next reaction without further purification.

1H-NMR (CDCl₃) δ: 1.91 (s, 3H), 4.52 (d, J = 27.7 Hz, 1H), 5.01 (dd, J = 9.0, 4.0 Hz, 1H), 5.09 (dd, J = 23.7, 4.0 Hz, 1H), 5.43 (d, J = 46.4 Hz, 1H), 7.17 (m, 1H), 7.24 (m, 1H), 7.38-7.49 (m, 4H), 7.53 (m, 1H), 8.27 (m, 2H), 11.81 (s, 1H).

[0306] Step 7
To a solution of compound 14-7 and Boc₂O (427 µl, 1.84 mmol) in CH₂Cl₂ (3.5 ml) was added DMAP (22.5 mg, 184 µmol) at room temperature. After being stirred for 30 min at room temperature, the reaction mixture was concentrated. The residue was
purified by silica gel chromatography to afford compound 14-8 (416.5 mg, 878 µmol, 95%).

1H-NMR (CDCl₃) δ: 1.47 (s, 9H), 1.55 (s, 3H), 4.40 (dd, J = 27.5, 2.8 Hz, 1H), 4.80 (dd, J = 49.4, 3.6 Hz, 1H), 4.95 (dd, J = 17.8, 3.6 Hz, 1H), 5.23 (d, J = 47.2 Hz, 1H), 7.06 (m, 1H), 7.17 (m, 1H), 7.30 (m, 1H), 7.41-7.53 (m, 3H), 7.55 (m, 1H), 7.78 (m, 2H).

[0307] Step 8

In a test tube, to a mixture of aqueous NaOH (30%, 4 ml) and Et₂O (4 ml) was added 1-methyl-1-nitrosourea (905 mg, 4.39 mmol, 5 eq.) at 0 °C. After being stirred for 20 min at 0 °C, the color of organic phase was turned to yellow, which indicated that an Et₂O solution of diazomethane was able to be prepared. In a separate flask, to a suspension of compound 14-8 (416.5 mg, 878 µmol) and Pd(OAc)₂ (39.4 mg, 176 µmol, 0.2 eq.) in Et₂O (4 ml) was added the Et₂O solution of diazomethane at -30 °C. The reaction mixture was stirred at -20 °C, and the Et₂O solution of diazomethane (5x5 eq.) prepared above and Pd(OAc)₂ (0.2x2 eq.) were added in several batches till the compound 14-8 was consumed completely. After being stirred for 3 h at -20 °C from the first addition of the diazomethane solution, the reaction mixture was quenched with H₂O and AcOH. Saturated aqueous NaHCO₃ was added and the resulting mixture was filtered through a pad of Celite (Registered trademark). The filtrate was washed with AcOEt. The aqueous phase was extracted with AcOEt. The organic phase was dried over Na₂S0₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 14-9 (259.2 mg, 531 µmol, 60%).

1H-NMR (CDCl₃) δ: 0.75-1.20 (m, 4H), 1.43 (s, 3H), 1.47 (s, 9H), 4.25 (dd, J = 28.5, 10.7 Hz, 1H), 5.27 (d, J = 47.6 Hz, 1H), 7.05 (m, 1H), 7.17 (m, 1H), 7.29 (m, 1H), 7.40-7.61 (m, 4H), 7.76 (m, 2H).

[0308] Step 9

To a solution of compound 14-9 (259.2 mg, 531 µmol) in MeOH (5 ml) was added K₂CO₃ (367 mg, 2.65 mmol) at room temperature. After being stirred for 20 min at room temperature, the reaction mixture was quenched with H₂O. The aqueous phase was extracted with AcOEt. The organic phase was dried over Na₂S0₄ and concentrated. The residue was purified by silica gel chromatography to afford compound 14-10 (117.4 mg, 305 µmol, 58%).

1H-NMR (CDCl₃) δ: 0.84-1.17 (m, 4H), 1.52 (s, 9H), 1.85 (s, 3H), 4.35 (dd, J = 28.1, 5.3 Hz, 1H), 5.48 (d, J = 46.9 Hz, 1H), 7.14 (m, 1H), 7.24 (m, 1H), 7.35-7.44 (m, 2H), 10.00 (brs, 1H).

[0309] Step 10

Compound 14-10 (117.4 mg, 305 µmol) was solved in TFA (1 ml) at room temperature. After being stirred for 1 h at room temperature, the reaction mixture was
cooled to -20 °C and then H2SO4 (250 µl) was added. After being stirred for 5 min at 0 °C, the reaction mixture was cooled to -20 °C then HNO3 (41 µl, 916 µmol) was added. After being stirred for 25 min at 0 °C, the reaction mixture was quenched with aqueous K2CO3. The aqueous phase was extracted with AcOEt. The organic phase was dried over Na2SO4 and concentrated. The residue was purified by silica gel chromatography to afford compound 14-11 (82.8 mg, 251 µmol, 82%).

1H-NMR (CDCl3) δ: 0.75-1.22 (m, 4H), 1.55 (s, 18H), 1.76 (m, 3H), 4.29 (dd, J = 7.28 Hz, 1H), 8.21 (dd, J = 9.0, 4.1, 2.9 Hz, 1H), 8.46 (dd, J = 6.7, 2.9 Hz, 1H).

[0310] Step 11
To a solution of compound 14-11 (82.8 mg, 251 µmol) and Boc2O (175 µl, 754 µmol) in CH2Cl2 (1 ml) was added DMAP (30.7 mg, 251 µmol) at room temperature. After being stirred for 30 min at room temperature, the reaction mixture was concentrated. The residue was purified by silica gel chromatography to afford compound 14-12 (83.8 mg, 158 µmol, 63%).

1H-NMR (CDCl3) δ: 0.80 (m, 1H), 0.92-1.09 (m, 2H), 1.16 (m, 1H), 1.53 (s, 18H), 1.74 (s, 3H), 4.23 (dd, J = 28.2, 8.2 Hz, 1H), 5.39 (d, J = 47.1 Hz, 1H), 7.28 (m, 1H), 8.26 (m, 1H), 8.56 (dd, J = 6.7, 2.9 Hz, 1H).

[0311] Step 12
To a solution of compound 14-12 (83.8 mg, 158 µmol) in THF (0.5 ml) and MeOH (1 ml) was added Pd/C (8.4 mg) at room temperature. After being stirred for 4.5 h under H2 atmosphere at room temperature, the reaction mixture was filtered through a pad of Celite (Registered trademark), and the residue was washed with AcOEt. The filtrate was concentrated, and the residue was purified by silica gel chromatography to afford compound 14-13 (65.4 mg, 131 µmol, 83%).

1H-NMR (CDCl3) δ: 0.75-1.20 (m, 4H), 1.52 (s, 18H), 1.70 (m, 3H), 3.57 (brs, 2H), 4.31 (dd, J = 28.6, 10.0 Hz, 1H), 5.35 (d, J = 47.7 Hz, 1H), 6.56 (m, 1H), 6.83-6.90 (m, 2H).

[0312] Step 13
To a solution of compound 14-13 (41.0 mg, 82 µmol), 5-(fluoromethoxy)pyrazine-2-carboxylic acid (17.0 mg, 98 µmol) and diisopropylethylamine (29 µl, 164 µmol) in DMF (2 ml) was added HATU (37.5 mg, 98 µmol) at room temperature. After being stirred for 1 h at room temperature, the reaction mixture was quenched with saturated aqueous NH4Cl. The aqueous phase was extracted with AcOEt. The organic phase was dried over Na2SO4 and concentrated. The residue was purified by silica gel chromatography to afford compound 14-14 (49.4 mg, 76 µmol, 92%).

1H-NMR (CDCl3) δ: 0.75-1.22 (m, 4H), 1.55 (s, 18H), 1.76 (m, 3H), 4.29 (dd, J =
Step 14

Compound 14-14 (49.4 mg, 76 µmol) was solved in formic acid (1 ml, 26.1 mmol) at room temperature. After being stirred for 16.5 h at room temperature, the reaction mixture was quenched with aqueous K₂CO₃. The aqueous phase was extracted with AcOEt. The organic phase was dried over Na₂SO₄ and concentrated. The residue was purified by solidification from hexane to give pure 1-94 (25.9 mg, 57 µmol, 76%).

1H-NMR (CDCl₃) δ: 0.76-1.20 (m, 4H), 1.67 (s, 3H), 4.11 (dd, J = 29.2, 11.8 Hz, 1H), 5.35 (d, J = 47.9 Hz, 1H), 6.15 (m, 2H), 7.11 (dd, J = 11.3, 8.9 Hz, 1H), 7.50 (dd, J = 6.8, 2.6 Hz, 1H), 8.02 (m, 1H), 8.29 (s, 1H), 9.08 (s, 1H), 9.52 (s, 1H).

The following compounds are prepared in a manner similar to the above. In the tables, RT means LC/MS retention time (minute).
<table>
<thead>
<tr>
<th>No.</th>
<th>Structure</th>
<th>NMR (solvent: dimethyl sulfoxide-&lt;sup&gt;d6&lt;/sup&gt;)</th>
<th>MS-ESI (m/z)</th>
<th>LC-MS RT</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td><img src="image1" alt="Structure 11" /></td>
<td>1H-NMR (CDCl&lt;sub&gt;3&lt;/sub&gt;) δ 1.30 (d, J = 6.9 Hz, 3H), 1.81 (s, 3H), 3.23-3.38 (m, 1H), 5.05 (d, J = 47.6, 1.5 Hz, 1H), 7.51-7.46 (m, 1H), 8.22 (dd, J = 8.1, 1.9 Hz, 1H), 8.33 (dd, J = 9.0, 2.9 Hz, 1H), 8.43 (d, J = 8.1 Hz, 1H), 8.95 (d, J = 1.9 Hz, 1H), 10.25 (s, 1H)</td>
<td>403</td>
<td>1.05</td>
</tr>
<tr>
<td>12</td>
<td><img src="image2" alt="Structure 12" /></td>
<td>1H-NMR (CDCl&lt;sub&gt;3&lt;/sub&gt;) δ 1.30 (d, J = 7.0 Hz, 3H), 1.81 (s, 3H), 3.26-3.41 (m, 1H), 5.05 (dd, J = 47.7, 1.8 Hz, 1H), 7.46 (dd, J = 10.5, 8.9 Hz, 1H), 7.84-7.98 (m, 1H), 8.36-8.29 (m, 2H), 8.50 (d, J = 2.8 Hz, 1H), 10.20 (s, 1H)</td>
<td>306</td>
<td>1.17</td>
</tr>
<tr>
<td>13</td>
<td><img src="image3" alt="Structure 13" /></td>
<td>1H-NMR (CDCl&lt;sub&gt;3&lt;/sub&gt;) δ 1.30 (d, J = 7.6 Hz, 3H), 1.81 (s, 3H), 3.24-3.38 (m, 1H), 5.04 (dd, J = 1.5, 47.7 Hz, 1H), 6.16 (d, J = 50.9 Hz, 2H), 7.47 (dd, J = 10.5, 9.0 Hz, 1H), 8.34-8.30 (m, 2H), 9.09 (d, J = 1.6 Hz, 1H), 9.83 (s, 1H)</td>
<td>427</td>
<td>1.15</td>
</tr>
<tr>
<td>14</td>
<td><img src="image4" alt="Structure 14" /></td>
<td>1H-NMR (CDCl&lt;sub&gt;3&lt;/sub&gt;) δ 1.61 (s, 3H), 3.76-3.52 (m, 1H), 4.32-4.48 (m, 1H), 4.74-4.91 (m, 1H), 5.45 (dd, J = 48.1, 2.7 Hz, 1H), 7.47-7.53 (m, 1H), 8.22 (dd, J = 8.2, 1.9 Hz, 1H), 8.35 (dd, J = 8.8, 3.0 Hz, 1H), 8.44 (d, J = 8.2 Hz, 1H), 8.95 (d, J = 1.1 Hz, 1H), 10.24 (s, 1H)</td>
<td>421</td>
<td>1.06</td>
</tr>
<tr>
<td>15</td>
<td><img src="image5" alt="Structure 15" /></td>
<td>1H-NMR (CDCl&lt;sub&gt;3&lt;/sub&gt;) δ 1.61 (s, 3H), 3.78-3.93 (m, 1H), 4.32-4.48 (m, 1H), 4.82 (dd, J = 47.1, 8.8 Hz, 1H), 5.44 (dd, J = 48.2, 2.5 Hz, 1H), 6.16 (dd, J = 50.9, 2.5 Hz, 2H), 7.52-7.45 (m, 1H), 8.36-8.32 (m, 2H), 9.69 (d, J = 1.3 Hz, 1H), 9.92 (s, 1H)</td>
<td>445</td>
<td>1.14</td>
</tr>
<tr>
<td>16</td>
<td><img src="image6" alt="Structure 16" /></td>
<td>1H-NMR (CDCl&lt;sub&gt;3&lt;/sub&gt;) δ 1.61 (s, 3H), 4.74-4.91 (m, 1H), 5.45 (dd, J = 48.1, 2.3 Hz, 1H), 7.45-7.53 (m, 1H), 7.80 (dd, J = 8.7, 2.3 Hz, 1H), 8.25 (d, J = 8.7 Hz, 1H), 8.34 (dd, J = 8.7, 3.1 Hz, 1H), 8.62 (s, 1H), 10.22 (s, 1H)</td>
<td>430</td>
<td>1.29</td>
</tr>
<tr>
<td>17</td>
<td><img src="image7" alt="Structure 17" /></td>
<td>1H-NMR (CDCl&lt;sub&gt;3&lt;/sub&gt;) δ 1.65 (s, 3H), 3.14 (d, J = 14.1 Hz, 1H), 2.00 (d, J = 14.1 Hz, 1H), 7.11 (d, J = 10.0 Hz, 1H), 7.57 (d, J = 6.8 Hz, 1H), 8.00-8.00 (m, 1H), 8.21 (d, J = 8.5 Hz, 1H), 8.43 (d, J = 8.5 Hz, 1H), 8.91 (s, 1H), 9.88 (s, 1H)</td>
<td>430</td>
<td>1.33</td>
</tr>
<tr>
<td>Compound</td>
<td>1H-NMR (CDCl3) δ</td>
<td>ppm (J, Hz)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>------------------</td>
<td>-------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-8</td>
<td>1.35 (s, 3H)</td>
<td>1.79 (s, 3H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.07 (s, 3H)</td>
<td>5.13 (d, J = 6.9 Hz, 3H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.08 (dd, J = 11.2, 5.9 Hz, 1H)</td>
<td>7.30 (dd, J = 6.7, 2.1 Hz, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.07-7.82 (m, 1H)</td>
<td>8.16 (s, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9.01 (s, 1H)</td>
<td>9.51 (s, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-9</td>
<td>1.35 (s, 3H)</td>
<td>1.79 (s, 3H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5.13 (d, J = 6.9 Hz, 3H)</td>
<td>7.05 (dd, J = 9.0, 11.3 Hz, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.25-7.32 (m, 1H)</td>
<td>8.02-7.97 (m, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8.30 (s, 1H)</td>
<td>9.06 (s, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9.49 (s, 1H)</td>
<td>1.20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-10</td>
<td>1.65 (s, 3H)</td>
<td>3.99 (m, 2H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.11 (m, 2H)</td>
<td>4.16-4.32 (m, 4H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5.15 (dd, J = 51.3, 3.1 Hz, 2H)</td>
<td>7.09 (dd, J = 9.0, 11.3 Hz, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.25-7.32 (m, 1H)</td>
<td>8.02-7.97 (m, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8.30 (s, 1H)</td>
<td>9.06 (s, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9.49 (s, 1H)</td>
<td>1.20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-11</td>
<td>1.65 (s, 3H)</td>
<td>3.99-4.12 (m, 2H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.17-4.37 (m, 4H)</td>
<td>4.50 (m, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.61 (m, 1H)</td>
<td>7.09 (dd, J = 11.6, 8.9 Hz, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.47 (dd, J = 6.9, 2.8 Hz, 1H)</td>
<td>7.60 (dd, J = 8.7, 8.0, 2.8 Hz, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8.03 (ddd, J = 8.6, 4.2, 2.8 Hz, 1H)</td>
<td>8.32 (dd, J = 8.7, 4.5 Hz, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8.45 (d, J = 2.8 Hz, 1H)</td>
<td>9.62 (s, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-12</td>
<td>1.65 (s, 3H)</td>
<td>3.99-4.12 (m, 2H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.16-4.35 (m, 4H)</td>
<td>4.50 (m, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.61 (m, 1H)</td>
<td>7.10 (dd, J = 11.5, 8.8 Hz, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.46 (dd, J = 6.5, 2.8 Hz, 1H)</td>
<td>8.62 (ddd, J = 8.8, 4.0, 2.8 Hz, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8.29 (brs, 1H)</td>
<td>9.05 (brs, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9.51 (s, 1H)</td>
<td>1.34</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-13</td>
<td>1.38 (dd, J = 24.3, 6.4 Hz, 3H)</td>
<td>1.64 (s, 3H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3.76 (ddd, J = 30.7, 13.5, 7.6 Hz, 1H)</td>
<td>4.37 (brs, 2H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.88 (ddd, J = 46.2, 7.6, 4.4 Hz, 1H)</td>
<td>5.18 (d, J = 48.1 Hz, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.12 (m, 1H)</td>
<td>8.06 (m, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8.21 (dd, J = 6.2, 1.8 Hz, 1H)</td>
<td>8.43 (d, J = 8.2 Hz, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8.91 (s, 1H)</td>
<td>9.83 (s, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-14</td>
<td>1.38 (dd, J = 24.2, 6.4 Hz, 3H)</td>
<td>1.65 (s, 3H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3.77 (ddd, J = 30.9, 13.4, 7.7 Hz, 1H)</td>
<td>4.35 (brs, 2H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.88 (ddd, J = 46.1, 7.7, 4.4 Hz, 1H)</td>
<td>5.18 (d, J = 47.9 Hz, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.11 (m, 1H)</td>
<td>8.15 (d, J = 51.1 Hz, 2H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.71 (d, J = 11.4, 8.9 Hz, 1H)</td>
<td>7.66 (dd, J = 6.6, 2.5 Hz, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8.06 (m, 1H)</td>
<td>8.30 (s, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9.08 (s, 1H)</td>
<td>9.52 (s, 1H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compound</td>
<td>1H-NMR (CDCl3) δ (ppm)</td>
<td>Anal. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>------------------------</td>
<td>-----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-15</td>
<td>1.30 (dd, J = 25.6, 6.0 Hz, 3H), 1.68 (s, 3H), 3.66 (m, 1H), 4.81 (m, 1H), 5.35 (d, J = 17.4 Hz, 1H), 7.11 (m, 1H), 7.56 (m, 1H), 8.03 (m, 1H), 8.21 (d, J = 8.3 Hz, 1H), 8.90 (s, 1H), 9.88 (s, 1H)</td>
<td>418 1.29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-16</td>
<td>1.30 (dd, J = 25.3, 6.1 Hz, 3H), 1.68 (s, 3H), 3.66 (m, 1H), 4.80 (m, 1H), 5.35 (d, J = 17.4 Hz, 1H), 6.50 (dd, J = 51.0, 5.9 Hz, 2H), 7.10 (m, 1H), 7.51 (m, 1H), 7.96 (m, 1H), 8.29 (s, 1H), 9.09 (s, 1H), 9.52 (s, 1H)</td>
<td>442 1.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-17</td>
<td>1.30 (dd, J = 24.2, 6.4 Hz, 3H), 1.65 (s, 3H), 3.77 (dd, J = 10.7, 13.2, 7.5 Hz, 1H), 4.07 (s, 3H), 4.36 (m, 1H), 4.65 (dd, J = 49.1, 7.5, 6.4 Hz, 1H), 5.12 (d, J = 17.9 Hz, 1H), 7.10 (m, 1H), 7.43 (m, 1H), 8.00 (m, 1H), 8.10 (s, 1H), 9.02 (s, 1H), 9.53 (s, 1H)</td>
<td>424 1.18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-18</td>
<td>1.83 (s, 3H), 3.69 (s, 3H), 3.94-4.03 (m, 1H), 4.58-4.52 (br m, 2H), 4.58-4.68 (m, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.62 (s, 1H), 8.05 (d, J = 8.3 Hz, 1H), 8.21 (d, J = 8.0 Hz, 1H), 8.42 (d, J = 8.0 Hz, 1H), 8.51 (s, 1H), 9.51 (s, 1H)</td>
<td>432 1.16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-19</td>
<td>1.82 (s, 3H), 3.69 (s, 3H), 3.97-4.03 (m, 1H), 4.59-4.53 (br m, 2H), 4.61-4.63 (m, 1H), 6.09 (d, J = 4.5 Hz, 1H), 6.21 (d, J = 4.9 Hz, 1H), 7.40 (d, J = 8.5 Hz, 1H), 7.57 (m, 1H), 8.00 (d, J = 8.5 Hz, 1H), 8.29 (m, 1H), 9.07 (s, 1H), 9.57 (s, 1H)</td>
<td>456 1.21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-20</td>
<td>1.86 (s, 3H), 3.69 (s, 3H), 4.03-4.08 (m, 1H), 4.51-4.55 (m, 2H), 4.61-4.64 (m, 1H), 7.41 (d, J = 8.5 Hz, 1H), 7.56-7.62 (m, 2H), 8.08 (d, J = 8.3 Hz, 1H), 8.52 (d, J = 8.0, 4.3 Hz, 1H), 8.47 (s, 1H), 9.90 (s, 1H)</td>
<td>425 1.21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-21</td>
<td>2.07 (s, 3H), 3.72 (s, 3H), 4.28-4.33 (m, 1H), 4.53-4.61 (m, 1H), 4.64-4.73 (m, 2H), 7.47 (d, J = 8.8 Hz, 1H), 7.59 (s, 1H), 7.69 (d, J = 8.3 Hz, 1H), 8.15-8.29 (m, 3H), 8.60 (s, 1H), 10.12 (s, 1H)</td>
<td>441 1.3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[0317]
<table>
<thead>
<tr>
<th></th>
<th>Structure</th>
<th>NMR Data (CDCl₃)</th>
<th>ppm</th>
<th>1H NMR (CDCl₃)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-22</td>
<td><img src="image" alt="Structure" /></td>
<td>2.06 (s, 3H), 3.72 (s, 3H), 4.27-4.33 (m, 1H), 4.53-4.62 (m, 1H), 4.64-4.74 (m, 2H), 7.43-7.48 (m, 3H), 7.96 (s, 1H), 8.16 (s, 1H), 8.32 (d, 1H)</td>
<td>475</td>
<td>1.32</td>
</tr>
<tr>
<td>I-23</td>
<td><img src="image" alt="Structure" /></td>
<td>1.87 (s, 2H), 3.60 (s, 3H), 4.06 (s, 1H), 4.27-4.33 (m, 1H), 4.51-4.59 (m, 1H), 4.62-4.71 (m, 1H), 7.15 (d, J = 8.3 Hz, 1H), 7.68 (d, J = 8.3 Hz, 1H), 8.12 (d, J = 8.3 Hz, 1H), 8.23 (d, J = 8.3 Hz, 1H), 8.50 (s, 1H), 9.20 (s, 1H)</td>
<td>425</td>
<td>1.14</td>
</tr>
<tr>
<td>I-24</td>
<td><img src="image" alt="Structure" /></td>
<td>1.96 (s, 3H), 3.60 (s, 3H), 4.06 (s, 1H), 4.27-4.33 (m, 1H), 4.51-4.59 (m, 1H), 4.62-4.71 (m, 1H), 7.16 (d, J = 8.3 Hz, 1H), 7.18 (t, J = 8.3 Hz, 1H), 7.34 (t, J = 8.3 Hz, 1H), 7.93 (d, J = 8.3 Hz, 1H), 8.33 (s, 1H), 8.50 (s, 1H), 9.09 (s, 1H)</td>
<td>440</td>
<td>1.06</td>
</tr>
<tr>
<td>I-25</td>
<td><img src="image" alt="Structure" /></td>
<td>1.73 (s, 3H), 3.60 (s, 3H), 4.06 (s, 1H), 4.27-4.33 (m, 1H), 4.51-4.59 (m, 1H), 4.62-4.71 (m, 1H), 7.11 (d, J = 8.3 Hz, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.60 (t, J = 8.3 Hz, 1H), 8.07 (m, 1H), 8.32 (d, J = 8.3 Hz, 1H), 4.46 (s, 1H), 9.09 (s, 1H)</td>
<td>406</td>
<td>1.06</td>
</tr>
<tr>
<td>I-26</td>
<td><img src="image" alt="Structure" /></td>
<td>1.66 (s, 3H), 3.60 (s, 3H), 4.06 (s, 1H), 4.27-4.33 (m, 1H), 4.51-4.59 (m, 1H), 4.62-4.71 (m, 1H), 7.09 (d, J = 8.3 Hz, 1H), 7.26-7.28 (m, 2H), 7.93 (s, 1H), 8.15-8.18 (m, 1H), 8.40 (s, 1H), 9.01 (s, 1H)</td>
<td>450</td>
<td>1.16</td>
</tr>
<tr>
<td>I-27</td>
<td><img src="image" alt="Structure" /></td>
<td>1.01 (d, J = 6.8 Hz, 3H), 1.77 (s, 3H), 2.09-2.16 (m, 1H), 4.04-4.08 (m, 1H), 4.58-4.65 (m, 1H), 7.09 (d, J = 11.2 Hz, 1H), 7.30-7.52 (m, 1H), 7.79-7.80 (m, 1H), 8.21 (d, J = 7.8 Hz, 1H), 8.44 (d, J = 7.8 Hz, 1H), 8.91 (s, 1H)</td>
<td>436</td>
<td>1.27</td>
</tr>
<tr>
<td>I-28</td>
<td><img src="image" alt="Structure" /></td>
<td>1.17 (d, J = 6.8 Hz, 3H), 1.57 (s, 3H), 2.78 (s, J = 6.8 Hz, 1H), 4.12-4.14 (m, 1H), 7.11 (d, J = 11.2 Hz, 1H), 7.30-7.52 (m, 1H), 7.79-7.80 (m, 1H), 8.21 (d, J = 7.8 Hz, 1H), 8.44 (d, J = 7.8 Hz, 1H), 8.91 (s, 1H)</td>
<td>436</td>
<td>1.27</td>
</tr>
</tbody>
</table>

[0318]
[Table 1-5]

<table>
<thead>
<tr>
<th>Compound</th>
<th>1H-NMR (400 MHz, CDCl₃) δ</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-29</td>
<td>6.7 Hz, 3H, 1.60 (s, 3H), 2.58-2.99 (m, 1H), 4.33-4.80 (m, 1H), 7.08 (dd, J = 11.6, 6.7 Hz, 1H), 7.73-7.80 (m, 2H), 8.21 (dd, J = 8.1, 1.9 Hz, 1H), 8.43 (d, J = 8.1 Hz, 1H), 8.90 (s, J = 1.0 Hz, 1H), 9.05 (s, 1H).</td>
<td>436 1.27</td>
</tr>
<tr>
<td>I-30</td>
<td>7.0 Hz, 3H, 1.60 (s, 3H), 2.77 (q, J = 7.0 Hz, 1H), 6.15 (d, J = 50.9 Hz, 1H), 7.10 (dd, J = 10.7, 9.4 Hz, 1H), 7.42 (d, J = 8.8 Hz, 1H), 7.96-7.98 (m, 1H), 8.29 (s, 1H), 9.06 (s, 1H), 9.50 (s, 1H).</td>
<td>460 1.33</td>
</tr>
<tr>
<td>I-31</td>
<td>6.9 Hz, 3H, 1.56 (s, 3H), 2.88-3.58 (m, 1H), 5.75 (ddt, J = 55.2, 6.5, 2.3 Hz, 1H), 7.10 (dd, J = 11.2, 9.0 Hz, 1H), 7.46 (dd, J = 8.9, 2.3 Hz, 1H), 7.97-7.99 (m, 1H), 8.21 (d, J = 8.0 Hz, 1H), 8.43 (d, J = 8.0 Hz, 1H), 8.90 (s, 1H), 9.86 (s, 1H).</td>
<td>418 1.25</td>
</tr>
<tr>
<td>I-32</td>
<td>6.8 Hz, 3H, 1.56 (s, 3H), 2.52 (s, 3H), 2.76 (q, J = 6.8 Hz, 1H), 4.13-4.15 (m, 1H), 7.07 (dd, J = 11.3, 9.3 Hz, 1H), 7.36-7.38 (m, 1H), 7.98-8.01 (m, 1H), 8.17 (s, 1H), 8.67 (s, 1H).</td>
<td>415 1.13</td>
</tr>
<tr>
<td>I-33</td>
<td>6.9 Hz, 3H, 1.60 (s, 3H), 2.67-2.72 (m, 1H), 3.80-3.94 (m, 1H), 5.75 (ddt, J = 55.4, 6.1, 2.4 Hz, 1H), 6.15 (d, J = 50.9 Hz, 2H), 7.09 (dd, J = 11.4, 9.0 Hz, 1H), 7.40 (dd, J = 6.9, 2.4 Hz, 1H), 7.98-8.01 (m, 1H), 8.29 (s, 1H), 9.08 (s, 1H), 9.50 (s, 1H).</td>
<td>442 1.28</td>
</tr>
<tr>
<td>I-34</td>
<td>6.0 Hz, 3H, 3.90 (s, 3H), 4.05-4.09 (m, 1H), 4.19 (s, 1H), 7.13 (dd, J = 12.0, 8.0 Hz, 1H), 7.49 (dd, J = 8.0, 4.0 Hz, 1H), 8.03 (m, 1H), 8.21 (dd, J = 8.0, 4.0 Hz, 1H), 8.42 (d, J = 8.0 Hz, 1H), 8.50 (m, 1H), 9.07 (s, 1H).</td>
<td>413 1.18</td>
</tr>
<tr>
<td>I-35</td>
<td>6.0 Hz, 3H, 3.90 (s, 3H), 4.05-4.09 (m, 1H), 4.19 (s, 1H), 7.13 (dd, J = 12.0, 8.0 Hz, 1H), 7.49 (dd, J = 8.0, 4.0 Hz, 1H), 8.03 (m, 1H), 8.21 (dd, J = 8.0, 4.0 Hz, 1H), 8.42 (d, J = 8.0 Hz, 1H), 8.50 (m, 1H), 9.07 (s, 1H).</td>
<td>413 1.18</td>
</tr>
</tbody>
</table>

[0319]
<table>
<thead>
<tr>
<th><strong>Table 1-6</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="Structure I-36" /></td>
</tr>
<tr>
<td>1H-NMR (400 MHz, CDCl3) δ: 1.66 (s, 3H); 1.72 (t, J = 19.6 Hz, 3H); 3.89 (ddd, J = 29.4, 10.7, 4.6 Hz, 1H); 4.38 (t, J = 19.5 Hz, 1H); 5.38 (d, J = 51.1 Hz, 2H); 7.11 (m, 1H); 7.51 (m, 1H); 8.01 (m, 1H); 8.29 (s, 1H); 9.08 (s, 1H); 9.51 (s, 1H).</td>
</tr>
<tr>
<td><img src="image" alt="Structure I-37" /></td>
</tr>
<tr>
<td><img src="image" alt="Structure I-38" /></td>
</tr>
<tr>
<td><img src="image" alt="Structure I-39" /></td>
</tr>
<tr>
<td><img src="image" alt="Structure I-40" /></td>
</tr>
<tr>
<td><img src="image" alt="Structure I-41" /></td>
</tr>
<tr>
<td><img src="image" alt="Structure I-42" /></td>
</tr>
</tbody>
</table>

[0320]
| I43 | \[
\begin{align*}
N\text{NN} & \text{N} \\
\text{H} & \text{H}
\end{align*}
\] | 1H-NMR (400 MHz, CDCl₃) & 1.73 (d, J = 3.1 Hz, 3H), 2.10-2.20 (m, 1H), 2.30-2.42 (m, 1H), 2.74 (dd, J = 29.4, 14.6 Hz, 1H), 2.94 (dd, J = 29.4, 14.6 Hz, 1H), 4.03 (d, J = 10.8 Hz, 1H), 4.19 (d, J = 10.8 Hz, 1H), 7.11 (dd, J = 11.9, 8.8 Hz, 1H), 7.63 (dd, J = 7.2, 2.6 Hz, 1H), 7.85-7.90 (m, 1H), 8.21 (dd, J = 8.1, 1.9 Hz, 1H), 8.43 (d, J = 8.1 Hz, 1H), 8.90 (s, 1H), 9.86 (s, 1H). | 430 | 1.17 |
| I44 | \[
\begin{align*}
\text{F} & \text{O} \\
\text{N} & \text{H} \\
\text{N} & \text{H}
\end{align*}
\] | 1H-NMR (400 MHz, CDCl₃) & 1.76 (s, 3H), 2.08-2.21 (m, 1H), 2.31-2.45 (m, 1H), 2.73-3.02 (m, 2H), 4.08 (d, J = 11.0 Hz, 1H), 4.21 (d, J = 11.0 Hz, 1H), 6.15 (d, J = 51.2 Hz, 2H), 7.06-7.14 (m, 1H), 7.61 (d, J = 7.0 Hz, 1H), 7.85-7.79 (m, 1H), 8.30 (s, 1H), 9.08 (s, 1H), 9.52 (s, 1H). | 454 | 1.25 |
| I45 | \[
\begin{align*}
\text{F} & \text{N} \\
\text{H} & \text{N}
\end{align*}
\] | 1H-NMR (400 MHz, CDCl₃) & 1.80 (s, 3H), 2.09-2.21 (m, 1H), 2.34-2.46 (m, 1H), 2.78-3.03 (m, 2H), 4.12 (d, J = 10.8 Hz, 1H), 4.23 (d, J = 10.8 Hz, 1H), 7.07-7.14 (m, 1H), 7.57-7.67 (m, 2H), 7.84-7.77 (m, 1H), 8.33 (dd, J = 8.9, 4.6 Hz, 1H), 8.47 (s, 1H), 9.84 (s, 1H). | 423 | 1.24 |
| I46 | \[
\begin{align*}
\text{F} & \text{O} \\
\text{N} & \text{H} \\
\text{S} & \text{N}
\end{align*}
\] | 1H-NMR (400 MHz, CDCl₃) & 1.34 (d, J = 7.0 Hz, 3H), 1.76 (s, 3H), 3.09 (dq, J = 31.0, 7.0 Hz, 1H), 4.87 (q, J = 8.2 Hz, 2H), 5.11 (d, J = 47.4 Hz, 1H), 7.08 (dd, J = 11.4, 8.9 Hz, 1H), 7.30 (dd, J = 6.7, 2.6 Hz, 1H), 8.01-7.95 (m, 1H), 8.31 (s, 1H), 9.02 (s, 1H), 9.45 (s, 1H). | 476 | 1.48 |
| I47 | \[
\begin{align*}
\text{F} & \text{O} \\
\text{N} & \text{H} \\
\text{S} & \text{N}
\end{align*}
\] | 1H-NMR (400 MHz, CDCl₃) & 1.35 (d, J = 7.0 Hz, 3H), 1.78 (s, 3H), 3.10 (dq, J = 30.7, 7.0 Hz, 1H), 5.12 (d, J = 47.3 Hz, 1H), 7.10 (dd, J = 11.4, 8.8 Hz, 1H), 7.34-7.29 (m, 1H), 7.60 (d, J = 71.4 Hz, 1H), 7.96-8.00 (m, 1H), 8.34 (s, 1H), 9.07 (s, 1H), 9.45 (s, 1H). | 444 | 1.33 |

[0321]
<table>
<thead>
<tr>
<th>Table 1-8</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>I48</strong></td>
<td><strong>I49</strong></td>
</tr>
<tr>
<td>1H-NMR (400 MHz, CDCl3) δ: 1.45 (d, J = 7.0 Hz, 3H), 1.93 (s, 3H), 3.30 (dq, J = 30.0, 7.0 Hz, 1H), 4.65 (td, J = 13.3, 4.0 Hz, 2H), 5.26 (d, J = 46.4 Hz, 1H), 6.16 (tt, J = 55.0, 4.0 Hz, 1H), 7.14 (dd, J = 11.5, 9.0 Hz, 1H), 7.39 (dd, J = 6.6, 2.4 Hz, 1H), 8.04-7.98 (m, 1H), 8.29 (s, 1H), 8.98 (s, 1H), 9.55 (s, 1H).</td>
<td>1H-NMR (400 MHz, CDCl3) δ: 1.34 (d, J = 6.9 Hz, 3H), 1.76 (s, 3H), 3.09 (dq, J = 30.9, 6.9 Hz, 1H), 5.10 (d, J = 47.4 Hz, 1H), 5.44 (d, J = 47.1 Hz, 2H), 7.07 (dd, J = 11.4, 8.9 Hz, 1H), 7.24-7.30 (m, 1H), 7.85-7.91 (m, 1H), 8.34 (s, 1H), 8.66 (s, 1H).</td>
</tr>
<tr>
<td><strong>I50</strong></td>
<td><strong>I51</strong></td>
</tr>
<tr>
<td>1H-NMR (400 MHz, CDCl3) δ: 1.34 (d, J = 7.0 Hz, 3H), 1.77 (s, 3H), 3.11 (dq, J = 31.2, 7.0 Hz, 1H), 3.94 (s, 3H), 5.11 (d, J = 48.2 Hz, 1H), 7.06 (dd, J = 11.7, 8.9 Hz, 1H), 7.25-7.36 (m, 2H), 7.98-8.05 (m, 1H), 8.30-8.40 (m, 2H), 9.82 (s, 1H).</td>
<td>1H-NMR (400 MHz, CDCl3) δ: 1.34 (d, J = 6.8 Hz, 3H), 1.77 (s, 3H), 3.11 (dq, J = 31.4, 6.8 Hz, 1H), 5.12 (d, J = 48.4 Hz, 1H), 5.81 (d, J = 53.5 Hz, 2H), 7.07 (dd, J = 11.5, 8.7 Hz, 1H), 7.24-7.33 (m, 1H), 7.57 (dd, J = 8.7, 2.6 Hz, 1H), 7.98-8.04 (m, 1H), 8.29 (d, J = 8.7 Hz, 1H), 8.42 (d, J = 2.6 Hz, 1H), 9.81 (s, 1H).</td>
</tr>
<tr>
<td><strong>I52</strong></td>
<td><strong>I53</strong></td>
</tr>
<tr>
<td>1H-NMR (400 MHz, CDCl3) δ: 1.34 (d, J = 6.9 Hz, 3H), 1.76 (s, 3H), 2.85 (s, 3H), 3.10 (dq, J = 30.3, 6.9 Hz, 1H), 5.12 (dd, J = 47.4, 1.4 Hz, 1H), 7.08 (dd, J = 11.5, 8.9 Hz, 1H), 7.19 (dd, J = 6.7, 2.7 Hz, 1H), 7.94 (s, 1H), 8.07-8.02 (m, 1H), 8.73 (d, J = 1.4 Hz, 1H), 9.97 (s, 1H).</td>
<td>1H-NMR (400 MHz, CDCl3) δ: 1.34 (d, J = 6.9 Hz, 3H), 1.76 (s, 3H), 2.85 (s, 3H), 3.10 (dq, J = 30.3, 6.9 Hz, 1H), 5.12 (dd, J = 47.4, 1.4 Hz, 1H), 7.08 (dd, J = 11.5, 8.9 Hz, 1H), 7.19 (dd, J = 6.7, 2.7 Hz, 1H), 7.94 (s, 1H), 8.07-8.02 (m, 1H), 8.73 (d, J = 1.4 Hz, 1H), 9.97 (s, 1H).</td>
</tr>
<tr>
<td>Compound</td>
<td>1H-NMR (400 MHz, CDCl₃) δ</td>
</tr>
<tr>
<td>----------</td>
<td>----------------</td>
</tr>
<tr>
<td>153</td>
<td>(d, J = 7.0 Hz, 3H), 1.77 (s, 3H), 3.10</td>
</tr>
<tr>
<td></td>
<td>(dq, J = 30.9, 7.0 Hz, 1H), 4.58 (q, J = 7.8 Hz, 2H), 5.11 (d, J = 48.4 Hz, 1H), 7.09 (dd, J = 11.5, 8.8 Hz, 1H), 7.38 (dd, J = 6.8, 2.6 Hz, 1H), 7.98-8.03 (m, 1H), 8.62 (s, 2H), 9.72 (s, 1H)</td>
</tr>
<tr>
<td>154</td>
<td>(d, J = 7.0 Hz, 3H), 1.77 (s, 3H), 3.10</td>
</tr>
<tr>
<td></td>
<td>(dq, J = 31.6, 7.0 Hz, 1H), 4.49 (q, J = 7.8 Hz, 2H), 5.12 (d, J = 47.4 Hz, 1H), 7.07 (dd, J = 11.7, 8.9 Hz, 1H), 7.31 (dd, J = 7.0, 2.9 Hz, 1H), 7.40 (dd, J = 8.9, 2.9 Hz, 1H), 7.97-8.02 (m, 1H), 8.28 (d, J = 8.9 Hz, 1H), 8.35 (d, J = 2.9 Hz, 1H), 9.78 (s, 1H)</td>
</tr>
<tr>
<td>155</td>
<td>(d, J = 2.8 Hz, 3H), 2.30-2.42 (m, 1H), 2.44-2.55 (m, 1H), 2.82 (q, J = 14.6 Hz, 1H), 2.93-3.07 (m, 2H), 3.17 (d, J = 12.8 Hz, 1H), 4.07 (s, 3H), 7.07 (dd, J = 11.8, 8.8 Hz, 1H), 7.56 (dd, J = 7.0, 2.9 Hz, 1H), 7.88-7.83 (m, 1H), 8.16 (d, J = 1.3 Hz, 1H), 9.02 (d, J = 1.3 Hz, 1H), 9.49 (s, 1H)</td>
</tr>
<tr>
<td>156</td>
<td>(d, J = 2.8 Hz, 3H), 2.31-2.42 (m, 1H), 2.44-2.55 (m, 1H), 2.82 (q, J = 14.1 Hz, 1H), 2.92-3.07 (m, 2H), 3.18 (d, J = 12.3 Hz, 1H), 6.15 (d, J = 51.2 Hz, 2H), 7.06 (dd, J = 11.9, 8.7 Hz, 1H), 7.57 (dd, J = 7.0, 2.8 Hz, 1H), 7.90-7.91 (m, 1H), 8.29 (d, J = 1.3 Hz, 1H), 9.09 (d, J = 1.3 Hz, 1H), 9.48 (s, 1H)</td>
</tr>
<tr>
<td>157</td>
<td>(d, J = 2.8 Hz, 3H), 2.30-2.41 (m, 1H), 2.43-2.56 (m, 1H), 2.82 (q, J = 15.1 Hz, 1H), 2.94-3.08 (m, 2H), 3.16 (d, J = 13.1 Hz, 1H), 3.94 (s, 3H), 7.06 (dd, J = 11.9, 8.9 Hz, 1H), 7.34 (dd, J = 8.9, 2.8 Hz, 1H), 7.57 (dd, J = 7.2, 2.8 Hz, 1H), 7.85-7.91 (m, 1H), 8.24 (d, J = 8.9 Hz, 1H), 8.27 (d, J = 2.8 Hz, 1H), 9.82 (s, 1H)</td>
</tr>
</tbody>
</table>

[0323]
<table>
<thead>
<tr>
<th>Table 1-10</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Image" /></td>
</tr>
<tr>
<td><img src="image2.png" alt="Image" /></td>
</tr>
<tr>
<td><img src="image3.png" alt="Image" /></td>
</tr>
<tr>
<td><img src="image4.png" alt="Image" /></td>
</tr>
<tr>
<td><img src="image5.png" alt="Image" /></td>
</tr>
</tbody>
</table>

[0324]
<table>
<thead>
<tr>
<th>1H-NMR (400 MHz, CDCl₃) δ: 1.27 (d, J = 7.0 Hz, 3H), 1.74 (s, 3H), 2.67-2.85 (m, 3H), 3.24-3.42 (m, 2H), 7.06 (dd, J = 11.5, 8.7 Hz, 1H), 7.44 (dd, J = 7.0, 2.6 Hz, 1H), 7.50 (td, J = 8.7, 2.6 Hz, 1H), 7.93-7.87 (m, 1H), 8.33 (dd, J = 8.7, 4.6 Hz, 1H), 8.46 (d, J = 2.6 Hz, 1H), 9.76 (s, 1H).</th>
<th>453</th>
<th>1.39</th>
</tr>
</thead>
<tbody>
<tr>
<td>1H-NMR (400 MHz, CDCl₃) δ: 1.35 (d, J = 7.0 Hz, 3H), 1.75 (s, 3H), 3.09 (dq, J = 29.7, 7.0 Hz, 1H), 5.12 (d, J = 47.4 Hz, 1H), 7.06-7.18 (m, 2H), 8.13-8.08 (m, 1H), 8.17 (d, J = 1.8 Hz, 1H), 8.79 (d, J = 1.8 Hz, 1H).</td>
<td>436</td>
<td>1.28</td>
</tr>
<tr>
<td>1H-NMR (400 MHz, CDCl₃) δ: 1.35 (d, J = 6.9 Hz, 3H), 1.77 (s, 3H), 3.10 (dq, J = 30.7, 6.9 Hz, 1H), 5.12 (d, J = 48.4 Hz, 1H), 6.80 (t, J = 54.4 Hz, 1H), 7.11 (dd, J = 11.5, 8.8 Hz, 1H), 7.35 (dd, J = 6.7, 2.7 Hz, 1H), 8.02-7.96 (m, 1H), 8.93 (s, 1H), 9.53 (s, 1H), 9.62 (s, 1H).</td>
<td>428</td>
<td>1.22</td>
</tr>
<tr>
<td>1H-NMR (400 MHz, CDCl₃) δ: 0.94 (t, J = 7.4 Hz, 3H), 1.61-1.70 (m, 1H), 1.76 (s, 3H), 1.82-1.91 (m, 1H), 2.93 (dt, J = 31.4, 8.0 Hz, 1H), 5.25 (d, J = 48.7 Hz, 1H), 6.15 (dd, J = 51.4, 2.9 Hz, 2H), 7.10 (dd, J = 11.4, 8.9 Hz, 1H), 7.26-7.30 (m, 1H), 8.05-7.99 (m, 1H), 8.30 (s, 1H), 9.08 (s, 1H), 9.48 (s, 1H).</td>
<td>440</td>
<td>1.36</td>
</tr>
<tr>
<td>1H-NMR (400 MHz, CDCl₃) δ: 0.94 (t, J = 7.4 Hz, 3H), 1.61-1.70 (m, 1H), 1.76 (s, 3H), 1.82-1.89 (m, 1H), 2.94 (dt, J = 31.4, 7.5 Hz, 1H), 5.25 (d, J = 48.9 Hz, 1H), 5.81 (d, J = 53.5 Hz, 2H), 7.08 (dd, J = 11.7, 8.9 Hz, 1H), 7.27-7.31 (m, 1H), 7.57 (dd, J = 8.4, 2.9 Hz, 1H), 8.01-8.06 (m, 1H), 8.29 (d, J = 8.4 Hz, 1H), 8.42 (d, J = 2.9 Hz, 1H), 9.82 (s, 1H).</td>
<td>439</td>
<td>1.40</td>
</tr>
<tr>
<td>Table 1-12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><img src="image1" alt="Structure I-68" /></td>
<td>1H-NMR (400 MHz, CDCl3) δ: 0.94 (t, J = 7.4 Hz, 3H), 1.62-1.71 (m, 1H), 1.75 (s, 3H), 1.83-1.90 (m, 1H), 3.00-3.24 (m, 4H), 5.26 (d, J = 47.2 Hz, 1H), 7.09 (dd, J = 11.7, 8.7 Hz, 1H), 7.19 (dd, J = 6.5, 2.8 Hz, 1H), 7.95 (s, 1H), 8.05-8.03 (m, 1H), 8.73 (s, 1H), 9.98 (s, 1H).</td>
<td></td>
</tr>
<tr>
<td><img src="image2" alt="Structure I-69" /></td>
<td>1H-NMR (400 MHz, CDCl3) δ: 0.94 (t, J = 7.5 Hz, 3H), 1.61-1.70 (m, 1H), 1.76 (s, 3H), 1.81-1.92 (m, 1H), 2.93 (dd, J = 31.4, 7.1 Hz, 1H), 5.25 (d, J = 47.3 Hz, 1H), 7.11 (dd, J = 11.5, 8.8 Hz, 1H), 7.34 (dd, J = 6.7, 2.8 Hz, 1H), 7.99-8.05 (m, 1H), 8.21 (dd, J = 8.1, 1.9 Hz, 1H), 8.43 (d, J = 8.1 Hz, 1H), 8.91 (s, 1H), 9.84 (s, 1H).</td>
<td></td>
</tr>
<tr>
<td><img src="image3" alt="Structure I-70" /></td>
<td>1H-NMR (400 MHz, CDCl3) δ: 0.94 (t, J = 7.4 Hz, 3H), 1.61-1.72 (m, 1H), 1.76 (s, 3H), 1.81-1.91 (m, 1H), 2.94 (dd, J = 30.9, 7.2 Hz, 1H), 5.25 (d, J = 47.6 Hz, 1H), 7.09 (dd, J = 11.5, 8.9 Hz, 1H), 7.30 (dd, J = 6.7, 2.8 Hz, 1H), 7.63-7.57 (m, 1H), 7.99-8.05 (m, 1H), 8.33 (dd, J = 8.7, 4.6 Hz, 1H), 8.48 (d, J = 2.6 Hz, 1H), 9.79 (s, 1H).</td>
<td></td>
</tr>
<tr>
<td><img src="image4" alt="Structure I-71" /></td>
<td>1H-NMR (400 MHz, CDCl3) δ: 1.39 (dd, J = 25.6, 6.3 Hz, 3H), 1.68 (s, 3H), 3.67 (m, 1H), 4.07 (s, 3H), 4.80 (m, 1H), 5.36 (d, J = 47.7 Hz, 1H), 7.09 (dd, J = 11.3, 8.8 Hz, 1H), 7.48 (dd, J = 7.0, 2.8 Hz, 1H), 8.00 (m, 1H), 8.16 (d, J = 1.3 Hz, 1H), 9.02 (d, J = 1.3 Hz, 1H), 9.52 (s, 1H).</td>
<td></td>
</tr>
<tr>
<td><img src="image5" alt="Structure I-75" /></td>
<td>1H-NMR (400 MHz, CDCl3) δ: 1.66 (s, 3H), 1.72 (t, J = 19.7 Hz, 3H), 3.09 (ddd, J = 29.7, 10.8, 4.8 Hz, 1H), 4.32 (bs, 2H), 4.85 (d, J = 8.3 Hz, 1H), 4.89 (d, J = 8.3 Hz, 1H), 5.38 (d, J = 48.1 Hz, 1H), 7.11 (dd, J = 11.3, 8.9 Hz, 1H), 7.52 (dd, J = 6.7, 2.6 Hz, 1H), 7.59 (m, 1H), 8.31 (bs, 1H), 9.02 (bs, 1H), 9.50 (s, 1H).</td>
<td></td>
</tr>
</tbody>
</table>

[0326]
| I76 | 1H-NMR (400 MHz, CDCl3) δ: 1.67 (s, 3H), 1.72 (t, J = 19.6 Hz, 3H), 1.83 (t, J = 2.3 Hz, 3H), 3.89 (dd, J = 29.7, 10.7, 4.8 Hz, 1H), 4.38 (bs, 2H), 5.05 (q, J = 2.3 Hz, 2H), 5.36 (d, J = 47.9 Hz, 1H), 7.10 (dd, J = 11.4, 8.9 Hz, 1H), 7.49 (dd, J = 6.8, 2.7 Hz, 1H), 8.00 (m, 1H), 8.20 (bs, 1H), 9.03 (bs, 1H), 9.51 (s, 1H). |
| I77 | 1H-NMR (400 MHz, CDCl3) δ: 1.66 (s, 3H), 1.72 (t, J = 19.6 Hz, 3H), 3.89 (dd, J = 29.6, 10.8, 4.9 Hz, 1H), 4.38 (bs, 2H), 4.66 (td, J = 13.4, 4.0 Hz, 2H), 5.38 (d, J = 48.2 Hz, 1H), 6.16 (tt, J = 55.1, 4.0 Hz, 1H), 7.11 (dd, J = 11.4, 8.8 Hz, 1H), 7.50 (dd, J = 6.8, 2.8 Hz, 1H), 8.00 (dd, J = 8.8, 4.3, 2.8 Hz, 1H), 8.27 (d, J = 1.3 Hz, 1H), 9.02 (d, J = 1.3 Hz, 1H), 9.50 (s, 1H). |
| I78 | 1H-NMR (400 MHz, CDCl3) δ: 1.67 (s, 3H), 3.39 (s, 3H), 3.74 (m, 2H), 4.07 (m, 1H), 4.37 (bs, 2H), 5.48 (d, J = 48.1 Hz, 1H), 7.12 (dd, J = 11.2, 9.0 Hz, 1H), 7.54 (m, 1H), 8.04 (m, 1H), 8.21 (dd, J = 8.2, 2.0 Hz, 1H), 8.43 (dd, J = 8.2, 0.8 Hz, 1H), 8.90 (bs, 1H), 9.88 (s, 1H). |
| I79 | 1H-NMR (400 MHz, CDCl3) δ: 1.66 (s, 3H), 3.39 (s, 3H), 3.74 (m, 2H), 4.08 (m, 1H), 4.36 (bs, 2H), 5.47 (d, J = 48.1 Hz, 1H), 6.15 (m, 2H), 7.11 (dd, J = 11.4, 8.9 Hz, 1H), 7.50 (dd, J = 6.7, 2.6 Hz, 1H), 8.03 (m, 1H), 8.29 (d, J = 1.3 Hz, 1H), 9.08 (d, J = 1.3 Hz, 1H), 9.52 (s, 1H). |
| I80 | 1H-NMR (400 MHz, CDCl3) δ: 1.66 (s, 3H), 3.39 (s, 3H), 3.74 (m, 2H), 4.07 (s, 3H), 4.07 (m, 1H), 4.35 (bs, 2H), 5.47 (d, J = 48.1 Hz, 1H), 7.10 (dd, J = 11.4, 8.9 Hz, 1H), 7.48 (dd, J = 6.8, 2.6 Hz, 1H), 8.03 (dd, J = 8.9, 4.4, 2.6 Hz, 1H), 8.16 (d, J = 1.3 Hz, 1H), 9.02 (d, J = 1.3 Hz, 1H), 9.52 (s, 1H). |

[0327]
<table>
<thead>
<tr>
<th>Table</th>
<th>Structure</th>
<th>NMR Data</th>
<th>ppm</th>
<th>Hz</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-81</td>
<td><img src="image" alt="Structure" /></td>
<td>1H-NMR (400 MHz, CDCl3) δ: 0.64 (m, 2H), 0.73 (m, 2H), 1.38 (m, 1H), 1.68 (s, 3H), 3.94 (dd, J = 29.9, 10.0, 7.2 Hz, 1H), 4.38 (brs, 2H), 5.45 (d, J = 48.1 Hz, 1H), 7.12 (dd, J = 11.3, 8.9 Hz, 1H), 7.55 (dd, J = 6.7, 2.6 Hz, 1H), 8.04 (dd, J = 8.9, 4.1, 2.6 Hz, 1H), 8.21 (dd, J = 6.2, 2.0 Hz, 1H), 8.43 (dd, J = 8.2, 0.8 Hz, 1H), 8.90 (dd, J = 2.0, 0.8 Hz, 1H), 9.88 (s, 1H).</td>
<td>462</td>
<td>1.44</td>
</tr>
<tr>
<td>I-82</td>
<td><img src="image" alt="Structure" /></td>
<td>1H-NMR (400 MHz, CDCl3) δ: 0.64 (m, 2H), 0.73 (m, 2H), 1.38 (m, 1H), 1.67 (s, 3H), 3.95 (dd, J = 29.9, 10.0, 7.3 Hz, 1H), 4.37 (brs, 2H), 5.45 (d, J = 48.1 Hz, 1H), 6.15 (m, 2H), 7.11 (dd, J = 11.3, 8.9 Hz, 1H), 7.50 (dd, J = 6.8, 2.8 Hz, 1H), 8.03 (dd, J = 8.9, 4.1, 2.6 Hz, 1H), 8.29 (d, J = 1.4 Hz, 1H), 9.08 (d, J = 1.4 Hz, 1H), 9.52 (s, 1H).</td>
<td>486</td>
<td>1.48</td>
</tr>
<tr>
<td>I-83</td>
<td><img src="image" alt="Structure" /></td>
<td>1H-NMR (400 MHz, CDCl3) δ: 0.64 (m, 2H), 0.72 (m, 2H), 1.36 (m, 1H), 1.67 (s, 3H), 3.95 (dd, J = 29.9, 10.0, 7.4 Hz, 1H), 4.07 (s, 3H), 4.36 (brs, 2H), 5.45 (d, J = 48.1 Hz, 1H), 7.10 (dd, J = 11.3, 8.9 Hz, 1H), 7.49 (dd, J = 6.7, 2.6 Hz, 1H), 8.04 (m, 1H), 8.16 (brs, 1H), 9.02 (brs, 1H), 9.53 (s, 1H).</td>
<td>468</td>
<td>1.45</td>
</tr>
<tr>
<td>I-84</td>
<td><img src="image" alt="Structure" /></td>
<td>1H-NMR (CDCl3) δ: 1.34 (d, J = 6.9 Hz, 3H), 1.46 (t, J = 7.0 Hz, 3H), 1.77 (s, 3H), 3.10 (dq, J = 30.5, 6.8 Hz, 1H), 4.49 (q, J = 7.1 Hz, 2H), 5.12 (d, J = 47.4 Hz, 1H), 7.07 (dd, J = 11.5, 8.8 Hz, 1H), 7.26-7.30 (m, 1H), 7.97-8.01 (m, 1H), 8.12 (d, J = 1.1 Hz, 1H), 8.95 (d, J = 1.1 Hz, 1H), 9.46 (s, 1H).</td>
<td>422</td>
<td>1.28</td>
</tr>
<tr>
<td>I-85</td>
<td><img src="image" alt="Structure" /></td>
<td>1H-NMR (CDCl3) δ: 0.40 (d, J = 10.5, 4.8 Hz, 2H), 0.66-0.68 (m, 2H), 1.29-1.36 (m, 3H), 1.76 (s, 3H), 3.10 (dq, J = 30.5, 6.7 Hz, 1H), 4.27 (d, J = 7.3 Hz, 2H), 5.11 (dd, J = 47.6, 1.1 Hz, 1H), 7.07 (dd, J = 11.5, 8.9 Hz, 1H), 7.28 (dd, J = 6.8, 2.7 Hz, 1H), 7.96-8.00 (m, 1H), 8.16 (d, J = 1.3 Hz, 1H), 8.97 (d, J = 1.3 Hz, 1H), 9.47 (s, 1H).</td>
<td>448</td>
<td>1.48</td>
</tr>
</tbody>
</table>

[0328]
| I-86 | ![Chemical Structure](image) | 1H-NMR (400 MHz, CDCl3) δ 1.16 (d, J = 6.8 Hz, 3H), 1.65 (s, 3H), 2.76-2.78 (m, 1H), 4.01-4.07 (m, 4H), 5.79 (td, J = 56.4, 6.4 Hz, 1H), 7.09-7.14 (m, 1H), 7.36-7.38 (m, 1H), 8.02-8.05 (m, 1H), 8.18 (s, 1H), 8.56 (s, 1H), 9.02 (s, 1H), 9.54 (s, 1H). | 424 | 1.28 |
| I-87 | ![Chemical Structure](image) | 1H-NMR (400 MHz, CDCl3) δ 1.29 (d, J = 8.9 Hz, 3H), 1.75 (s, 3H), 3.03-3.07 (m, 1H), 3.71 (s, 3H), 3.88 (d, J = 1.6 Hz, 1H), 6.15 (dd, J = 51.5, 2.5 Hz, 2H), 7.08 (dd, J = 11.7, 8.8 Hz, 1H), 7.18 (dd, J = 6.8, 2.8 Hz, 1H), 8.02-8.06 (m, 1H), 8.29 (d, J = 1.3 Hz, 1H), 9.08 (d, J = 1.3 Hz, 1H), 9.46 (s, 1H). | 438 | 1.19 |
| I-88 | ![Chemical Structure](image) | 1H-NMR (400 MHz, CDCl3) δ 1.30 (d, J = 8.8 Hz, 3H), 1.76 (s, 3H), 3.02-3.07 (m, 1H), 3.72 (s, 3H), 3.88 (d, J = 1.8 Hz, 1H), 7.09 (dd, J = 11.5, 8.8 Hz, 1H), 7.24 (dd, J = 6.9, 2.8 Hz, 1H), 8.01-8.05 (m, 1H), 8.20 (dd, J = 8.1, 1.9 Hz, 1H), 8.42 (d, J = 8.2 Hz, 1H), 8.90 (d, J = 1.1 Hz, 1H), 9.82 (s, 1H). | 414 | 1.15 |
| I-89 | ![Chemical Structure](image) | 1H-NMR (400 MHz, CDCl3) δ 1.29 (d, J = 8.8 Hz, 3H), 1.75 (s, 3H), 3.04-3.06 (m, 1H), 3.72 (s, 3H), 3.87 (d, J = 2.0 Hz, 1H), 7.07 (dd, J = 11.7, 8.9 Hz, 1H), 7.20 (dd, J = 6.9, 2.9 Hz, 1H), 7.59 (td, J = 8.3, 2.8 Hz, 1H), 8.01-8.05 (m, 1H), 8.32 (dd, J = 8.8, 4.5 Hz, 1H), 8.46 (d, J = 2.8 Hz, 1H), 9.77 (s, 1H). | 407 | 1.24 |
| I-90 | ![Chemical Structure](image) | 1H-NMR (400 MHz, CDCl3) δ 1.29 (d, J = 6.9 Hz, 3H), 1.75 (s, 3H), 3.03-3.08 (m, 1H), 3.72 (s, 3H), 3.87 (d, J = 1.6 Hz, 1H), 4.07 (s, 3H), 7.07 (dd, J = 11.7, 8.8 Hz, 1H), 7.17 (dd, J = 6.9, 2.6 Hz, 1H), 8.03 (ddd, J = 8.7, 4.0, 3.0 Hz, 1H), 8.16 (d, J = 1.1 Hz, 1H), 9.01 (d, J = 1.1 Hz, 1H), 9.47 (s, 1H). | 420 | 1.23 |

[0329]
| I-91 | 1H-NMR (400 MHz, CDCl3) δ 1.76 (s, 3H), 3.29-3.45 (m, 1H), 3.53 (s, 3H), 3.70 (dd, J = 9.3, 8.5 Hz, 1H), 5.36 (dd, J = 47.8, 1.6 Hz, 1H), 6.16 (dd, J = 51.2, 0.8 Hz, 2H), 7.00 (dd, J = 11.3, 8.8 Hz, 1H), 7.32 (dd, J = 6.7, 2.6 Hz, 1H), 7.98 (dd, J = 6.8, 4.1, 2.9 Hz, 1H), 8.29 (d, J = 1.3 Hz, 1H), 9.08 (d, J = 1.3 Hz, 1H), 9.47 (s, 1H). | 456 | 1.20 |
| I-92 | 1H-NMR (400 MHz, CDCl3) δ 1.76 (s, 3H), 3.28-3.45 (m, 1H), 3.33 (s, 3H), 3.78 (dd, J = 9.2, 6.5 Hz, 1H), 5.36 (dd, J = 47.8, 1.5 Hz, 1H), 7.10 (dd, J = 11.4, 8.8 Hz, 1H), 7.36 (dd, J = 6.7, 2.8 Hz, 1H), 8.00 (dt, J = 8.8, 3.5 Hz, 1H), 8.20 (dd, J = 8.2, 2.0 Hz, 1H), 8.43 (d, J = 8.2 Hz, 1H), 8.90 (d, J = 1.1 Hz, 1H), 9.82 (s, 1H). | 432 | 1.25 |
| I-93 | 1H-NMR (CDCl3) δ: 0.64 (m, 2H), 0.72 (m, 2H), 1.38 (m, 1H), 1.67 (s, 3H), 3.94 (s, 3H), 3.95 (m, 1H), 4.36 (bs, 2H), 5.45 (d, J = 48.2 Hz, 1H), 7.09 (dd, J = 11.4, 8.8 Hz, 1H), 7.34 (ddd, J = 8.7, 2.8 Hz, 1H), 7.50 (dd, J = 6.8, 2.8 Hz, 1H), 8.05 (ddd, J = 8.8, 4.3, 2.8 Hz, 1H), 8.24 (d, J = 8.7 Hz, 1H), 8.27 (d, J = 2.8 Hz, 1H), 9.86 (s, 1H). | 467 | 1.52 |
| I-94 | 1H-NMR (CDCl3) δ: 0.76-1.20 (m, 4H), 1.67 (s, 3H), 4.11 (dd, J = 29.2, 11.8 Hz, 1H), 5.35 (d, J = 47.9 Hz, 1H), 6.15 (m, 2H), 7.11 (dd, J = 11.3, 8.9 Hz, 1H), 7.50 (dd, J = 6.8, 2.6 Hz, 1H), 8.02 (m, 1H), 8.29 (s, 1H), 9.08 (s, 1H), 9.52 (s, 1H). | 454 | 1.39 |
| I-95 | 1H-NMR (CDCl3) δ: 0.64 (m, 2H), 0.73 (m, 2H), 1.39 (m, 1H), 1.68 (s, 3H), 3.94 (dd, J = 30.0, 9.9, 7.0 Hz, 1H), 4.24 (s, 3H), 5.43 (d, J = 48.2 Hz, 1H), 7.11 (dd, J = 11.4, 8.9 Hz, 1H), 7.17 (d, J = 9.1 Hz, 1H), 7.51 (dd, J = 6.8, 2.8 Hz, 1H), 8.05 (m, 1H), 8.28 (d, J = 9.1 Hz, 1H), 9.31 (s, 1H). | 468 | 1.45 |

[0330]
| I-96 | 1H-NMR (CDCl₃) δ: 0.76-1.20 (m, 4H), 1.67 (s, 3H), 4.12 (dd, J = 29.2, 11.5 Hz, 1H), 5.35 (d, J = 47.9 Hz, 1H), 7.12 (dd, J = 11.3, 8.9 Hz, 1H), 7.55 (dd, J = 8.8, 2.8 Hz, 1H), 8.03 (m, 1H), 8.21 (dd, J = 8.2, 2.0 Hz, 1H), 8.43 (d, J = 8.2 Hz, 1H), 8.91 (d, J = 2.0 Hz, 1H), 9.88 (s, 1H). | 430 | 1.32 |
| I-97 | 1H-NMR (CDCl₃) δ: 0.75-1.20 (m, 4H), 1.67 (s, 3H), 4.07 (s, 3H), 4.11 (dd, J = 29.5, 11.9 Hz, 1H), 5.35 (d, J = 47.9 Hz, 1H), 7.10 (dd, J = 11.3, 8.9 Hz, 1H), 7.48 (dd, J = 6.8, 2.6 Hz, 1H), 8.03 (m, 1H), 8.16 (d, J = 1.1 Hz, 1H), 9.02 (d, J = 1.1 Hz, 1H), 9.53 (s, 1H). | 436 | 1.33 |
| I-99 | 1H-NMR (CDCl₃) δ: 0.76-1.20 (m, 4H), 1.66 (s, 3H), 2.86 (s, 3H), 4.12 (dd, J = 29.4, 11.8 Hz, 1H), 5.35 (d, J = 47.9 Hz, 1H), 7.10 (dd, J = 11.3, 8.8 Hz, 1H), 7.43 (dd, J = 6.8, 2.5 Hz, 1H), 7.95 (d, J = 1.5 Hz, 1H), 8.06 (m, 1H), 8.73 (d, J = 1.5 Hz, 1H), 10.03 (s, 1H). | 444 | 1.40 |
| I-100 | 1H-NMR (CDCl₃) δ: 0.74-1.20 (m, 4H), 1.68 (s, 3H), 3.94 (s, 3H), 4.11 (dd, J = 29.4, 11.9 Hz, 1H), 5.35 (d, J = 47.9 Hz, 1H), 7.09 (dd, J = 11.4, 8.9 Hz, 1H), 7.34 (dd, J = 8.7, 2.8 Hz, 1H), 7.49 (dd, J = 6.8, 2.6 Hz, 1H), 8.05 (m, 1H), 8.24 (d, J = 8.7 Hz, 1H), 8.27 (d, J = 2.8 Hz, 1H), 9.86 (s, 1H). | 435 | 1.38 |

[0331]
<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>1H-NMR (CDCl₃) δ:</th>
<th>ppm</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-101</td>
<td><img src="image" alt="I-101" /></td>
<td>0.75-1.20 (m, 4H), 1.67 (s, 3H), 4.11 (dd, J = 29.4, 11.9 Hz, 1H), 5.35 (d, J = 47.9 Hz, 1H), 5.81 (d, J = 53.5 Hz, 2H), 7.10 (dd, J = 11.4, 8.9 Hz, 1H), 7.51 (dd, J = 6.7, 2.6 Hz, 1H), 7.58 (dd, J = 8.7, 2.6 Hz, 1H), 8.04 (m, 1H), 8.29 (dd, J = 8.7, 1H), 8.42 (d, J = 2.6 Hz, 1H), 9.86 (s, 1H).</td>
<td>1.39</td>
</tr>
<tr>
<td>I-102</td>
<td><img src="image" alt="I-102" /></td>
<td>1.29 (d, J = 6.9 Hz, 3H), 1.74 (d, J = 2.1 Hz, 3H), 3.02-3.14 (m, 1H), 4.65 (dd, J = 47.9, 1.1 Hz, 1H), 7.10 (d, J = 8.0 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.60 (s, 1H), 7.76 (dd, J = 8.0, 1.1 Hz, 1H), 8.22 (dd, J = 8.2, 2.0 Hz, 1H), 8.44 (d, J = 8.2 Hz, 1H), 8.91 (d, J = 1.1 Hz, 1H), 9.88 (s, 1H).</td>
<td>1.08</td>
</tr>
<tr>
<td>I-103</td>
<td><img src="image" alt="I-103" /></td>
<td>1.29 (d, J = 7.0 Hz, 3H), 1.74 (d, J = 2.0 Hz, 4H), 3.09 (dq, J = 30.5, 7.0 Hz, 1H), 4.07 (s, 3H), 4.65 (d, J = 47.9 Hz, 1H), 7.05 (d, J = 7.9 Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 7.59 (s, 1H), 7.72 (d, J = 7.9 Hz, 1H), 8.17 (d, J = 1.1 Hz, 1H), 9.03 (d, J = 1.1 Hz, 1H), 9.53 (s, 1H).</td>
<td>1.11</td>
</tr>
<tr>
<td>I-104</td>
<td><img src="image" alt="I-104" /></td>
<td>1.29 (d, J = 6.9 Hz, 3H), 1.74 (d, J = 2.0 Hz, 3H), 3.09 (dq, J = 30.5, 6.9 Hz, 1H), 4.65 (dd, J = 47.9, 0.9 Hz, 1H), 6.16 (dd, J = 51.1, 1.3 Hz, 2H), 7.07 (d, J = 8.0 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.58 (s, 1H), 7.73 (d, J = 8.0 Hz, 1H), 8.30 (d, J = 1.1 Hz, 1H), 9.09 (d, J = 1.1 Hz, 1H), 9.53 (s, 1H).</td>
<td>1.10</td>
</tr>
<tr>
<td>I-105</td>
<td><img src="image" alt="I-105" /></td>
<td>1.29 (d, J = 7.0 Hz, 3H), 1.74 (d, J = 2.1 Hz, 4H), 2.87 (s, 3H), 3.08 (ddd, J = 30.2, 13.7, 7.0 Hz, 1H), 4.48 (s, 2H), 4.66 (d, J = 48.8 Hz, 1H), 7.07 (d, J = 8.0 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.49 (s, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.95 (s, 1H), 8.74 (d, J = 1.1 Hz, 1H), 10.03 (s, 1H).</td>
<td>1.17</td>
</tr>
</tbody>
</table>

[0332]
<table>
<thead>
<tr>
<th>Table 1-19</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="Chemical Structure I-106" /></td>
</tr>
<tr>
<td><img src="image" alt="Chemical Structure I-107" /></td>
</tr>
<tr>
<td><img src="image" alt="Chemical Structure I-108" /></td>
</tr>
<tr>
<td><img src="image" alt="Chemical Structure I-109" /></td>
</tr>
<tr>
<td><img src="image" alt="Chemical Structure I-110" /></td>
</tr>
</tbody>
</table>

[0333]
Test Examples for the compounds of the present invention are mentioned below.

<table>
<thead>
<tr>
<th>Compound</th>
<th>NMR Data</th>
<th>Purity</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-111</td>
<td>1H-NMR (400 MHz, CDCl₃) δ: 1.34 (d, J = 7.0 Hz, 3H), 1.76 (s, 3H), 3.10 (dq, J = 29.9, 7.0 Hz, 1H), 5.11 (d, J = 48.7 Hz, 1H), 7.08 (dd, J = 11.5, 8.9 Hz, 1H), 7.25-7.29 (m, 1H), 8.03-7.98 (m, 1H), 8.16 (d, J = 1.3 Hz, 1H), 9.02 (d, J = 1.3 Hz, 1H), 9.47 (s, 1H).</td>
<td>411 1.20</td>
</tr>
<tr>
<td>I-112</td>
<td>1H-NMR (CDCl₃) δ: 1.46 (d, J = 7.0 Hz, 3H), 1.52 (s, 3H), 3.68-3.83 (m, 1H), 4.42 (s, 2H), 5.01 (dd, J = 46.9, 1.8 Hz, 1H), 6.15 (dq, J = 51.2, 2.0 Hz, 2H), 7.09 (dd, J = 12.0, 8.8 Hz, 1H), 7.77 (dd, J = 7.0, 2.8 Hz, 1H), 8.09-8.13 (m, 1H), 8.28 (d, J = 1.5 Hz, 1H), 9.08 (d, J = 1.3 Hz, 1H), 9.53 (s, 1H).</td>
<td>426 1.18</td>
</tr>
<tr>
<td>I-113</td>
<td>1H-NMR (CDCl₃) δ: 1.46 (d, J = 6.8 Hz, 3H), 1.53 (s, 3H), 3.69-3.83 (m, 1H), 5.01 (dd, J = 46.9, 1.8 Hz, 1H), 7.10 (dd, J = 12.0, 8.8 Hz, 1H), 7.82 (dd, J = 7.0, 2.8 Hz, 1H), 8.19 (dd, J = 8.0, 2.0 Hz, 1H), 8.42 (dd, J = 8.2, 0.8 Hz, 1H), 8.73 (dd, J = 2.0, 0.8 Hz, 1H), 9.89 (s, 1H).</td>
<td>402 1.13</td>
</tr>
<tr>
<td>I-114</td>
<td>1H-NMR (CDCl₃) δ: 1.29 (d, J = 7.0 Hz, 3H), 1.74 (d, J = 2.1 Hz, 3H), 3.09 (dq, J = 29.9, 7.0 Hz, 1H), 4.65 (d, J = 48.7 Hz, 1H), 7.05 (dd, J = 7.9 Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 7.59 (s, 1H), 7.72 (d, J = 7.9 Hz, 1H), 8.17 (d, J = 1.0 Hz, 1H), 9.03 (d, J = 1.0 Hz, 1H), 9.53 (s, 1H).</td>
<td>393 1.1</td>
</tr>
<tr>
<td>I-115</td>
<td>1H-NMR (CDCl₃) δ: 1.29 (d, J = 7.0 Hz, 3H), 1.74 (d, J = 2.1 Hz, 3H), 3.03-3.15 (m, 1H), 4.65 (dd, J = 47.9, 2.1 Hz, 1H), 7.06 (dd, J = 8.0 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.58-7.64 (m, 2H), 7.74 (dd, J = 8.0, 1.1 Hz, 1H), 8.34 (dd, J = 8.7, 4.6 Hz, 1H), 8.47 (d, J = 2.8 Hz, 1H), 9.83 (s, 1H).</td>
<td>377 1.14</td>
</tr>
<tr>
<td>I-116</td>
<td>1H-NMR (400 MHz, CDCl₃) δ: 1.34 (d, J = 7.0 Hz, 3H), 1.77 (s, 3H), 3.10 (dq, J = 29.7, 7.0 Hz, 1H), 5.12 (dd, J = 47.4, 1.5 Hz, 1H), 7.08 (dd, J = 11.5, 8.8 Hz, 1H), 7.30 (dd, J = 6.8, 2.8 Hz, 1H), 7.62-7.57 (m, 1H), 7.96-8.03 (m, 1H), 8.33 (dd, J = 8.8, 4.6 Hz, 1H), 8.46 (d, J = 2.8 Hz, 1H), 9.78 (s, 1H).</td>
<td>395 1.2</td>
</tr>
</tbody>
</table>

Test Examples for the compounds of the present invention are mentioned below.
Example 15

[0334] (Test Example 1-1: Assay of BACE1 inhibitory activity: 96-well)

48.5 µL of substrate peptide solution (Biotin-XSEVNLDAEFRHDSGC-Eu: Xα-ε-amino-n-capronic acid, Eu=Europium cryptate) was added to each well of 96-hole half-area plate (a black plate: Costar), and after addition of 0.5 µL of the compound of the present invention (DMSO solution) and 1 µL of Recombinant human BACE1(R&D Systems), the reaction mixture was incubated at 30 °C for 3.5 hours. The substrate peptide was synthesized by reacting Cryptate TBPCOOH mono SMP (CIS bio international) with Biotin-XSEVNLDAEFRHDSGC (Peptide Institute, Inc.). The final concentrations of the substrate peptide and Recombinant human BACE1 were adjusted to 9.7 nmol/L and 500 nmol/L, respectively, and the reaction was performed in sodium acetate buffer (50 mmol/L sodium acetate, pH 5.0, 0.008% Triton X-100).

After the incubation for reaction, 50 µL of 8.0 µg/ml Streptavidin-XL665 (CIS bio international) dissolved in phosphate buffer (150 mmol/L K2HPO4-KH2P04, pH 7.0, 0.008% Triton X-100, 0.8 mol/L KF) was added to each well and left stand at 30 °C for 45 minutes. After then, fluorescence intensity was measured (excitation wavelength: 320 nm, measuring wavelength: 620 nm and 665 nm) using ARVO-X4 2030 Multilabel Reader (Perkin Elmer life sciences). Enzymatic activity was determined from counting ratio of each wavelength (10,000 x Count 665/Count 620) and 50% inhibitory concentration against the enzymatic activity (IC50) was calculated.

[0335] (Test Example 1-2: Assay of BACE1 inhibitory activity: 384-well)

5 µL of substrate peptide solution (Biotin-XSEVNLDAEFRHDSGC-Eu: X=ε-amino-n-capronic acid, Eu=Europium cryptate) was added to each well of 384-well plate (a black plate: Corning), and after addition of 0.1 µL of the compound of the present invention (DMSO solution) and 5 µL of Recombinant human BACE1(R&D Systems), the reaction mixture was incubated at 25 °C for 2 hours. The substrate peptide was synthesized by reacting Cryptate TBPCOOH mono SMP (CIS bio international) with Biotin-XSEVNLDAEFRHDSGC (Peptide Institute, Inc.). The final concentrations of the substrate peptide and Recombinant human BACE1 were adjusted to 9.7 nmol/L and 500 nmol/L, respectively, and the reaction was performed in sodium acetate buffer (50 mmol/L sodium acetate, pH 5.0, 0.008% Triton X-100).

After the incubation for reaction, 10 µL of 8.0 µg/ml Streptavidin-XL665 (CIS bio international) dissolved in phosphate buffer (150 mmol/L K2HPO4·4KH2P04·4·pH 7.0, 0.008% Triton X-100, 0.8 mol/L KF) was added to each well and left stand at 25 °C for 30 minutes. After then, fluorescence intensity was measured (excitation wavelength: 320 nm, measuring wavelength: 620 nm and 665 nm) using RUBYstar (BMG LABTECH). Enzymatic activity was determined from counting ratio of each
wavelength (10,000 x Count 665/Count 620) and 50% inhibitory concentration against the enzymatic activity (IC\(_{50}\)) was calculated.

[Table 2-1]

<table>
<thead>
<tr>
<th>No.</th>
<th>IC(_{50}) value nmol/L</th>
<th>Assay format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-1</td>
<td>13.3</td>
<td>96-well</td>
</tr>
<tr>
<td>1-2</td>
<td>67.9</td>
<td>96-well</td>
</tr>
<tr>
<td>1-3</td>
<td>61.3</td>
<td>96-well</td>
</tr>
<tr>
<td>1-4</td>
<td>11.5</td>
<td>96-well</td>
</tr>
<tr>
<td>1-5</td>
<td>29.9</td>
<td>96-well</td>
</tr>
<tr>
<td>1-6</td>
<td>15</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-7</td>
<td>47.5</td>
<td>96-well</td>
</tr>
<tr>
<td>1-8</td>
<td>11.8</td>
<td>96-well</td>
</tr>
<tr>
<td>1-9</td>
<td>10.3</td>
<td>96-well</td>
</tr>
<tr>
<td>1-10</td>
<td>25.8</td>
<td>96-well</td>
</tr>
<tr>
<td>1-11</td>
<td>102</td>
<td>96-well</td>
</tr>
<tr>
<td>1-12</td>
<td>56.8</td>
<td>96-well</td>
</tr>
<tr>
<td>1-13</td>
<td>32</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-14</td>
<td>52.2</td>
<td>96-well</td>
</tr>
<tr>
<td>1-15</td>
<td>15.2</td>
<td>96-well</td>
</tr>
<tr>
<td>1-16</td>
<td>30.3</td>
<td>96-well</td>
</tr>
<tr>
<td>1-17</td>
<td>59.7</td>
<td>96-well</td>
</tr>
<tr>
<td>1-18</td>
<td>18</td>
<td>96-well</td>
</tr>
<tr>
<td>1-19</td>
<td>46.5</td>
<td>96-well</td>
</tr>
<tr>
<td>1-20</td>
<td>72.7</td>
<td>96-well</td>
</tr>
<tr>
<td>1-21</td>
<td>26.9</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-22</td>
<td>23</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-23</td>
<td>34.4</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-24</td>
<td>97</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-25</td>
<td>156</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-26</td>
<td>33.9</td>
<td>96-well</td>
</tr>
<tr>
<td>1-27</td>
<td>40.5</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-28</td>
<td>22.6</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-29</td>
<td>1560</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-30</td>
<td>52.1</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-31</td>
<td>22.3</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-32</td>
<td>43.6</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-33</td>
<td>49.2</td>
<td>96-well</td>
</tr>
<tr>
<td>1-34</td>
<td>16.5</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-35</td>
<td>13.1</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-36</td>
<td>22</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-40</td>
<td>21.1</td>
<td>384-well</td>
</tr>
<tr>
<td>1-41</td>
<td>14.6</td>
<td>384-well</td>
</tr>
<tr>
<td>1-42</td>
<td>14.7</td>
<td>384-well</td>
</tr>
<tr>
<td>1-43</td>
<td>21.8</td>
<td>96-well</td>
</tr>
<tr>
<td>1-44</td>
<td>69.6</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-45</td>
<td>134</td>
<td>96-wellU</td>
</tr>
<tr>
<td>1-46</td>
<td>23.6</td>
<td>384-well</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>1-47</td>
<td>4.77</td>
<td>384-well</td>
</tr>
<tr>
<td>1-48</td>
<td>7.49</td>
<td>384-well</td>
</tr>
<tr>
<td>1-49</td>
<td>3.13</td>
<td>384-well</td>
</tr>
<tr>
<td>1-50</td>
<td>7.77</td>
<td>384-well</td>
</tr>
<tr>
<td>1-51</td>
<td>17.5</td>
<td>384-well</td>
</tr>
<tr>
<td>1-52</td>
<td>7.62</td>
<td>384-well</td>
</tr>
<tr>
<td>1-53</td>
<td>14.5</td>
<td>384-well</td>
</tr>
<tr>
<td>1-54</td>
<td>13</td>
<td>384-well</td>
</tr>
<tr>
<td>1-55</td>
<td>19.8</td>
<td>384-well</td>
</tr>
<tr>
<td>1-56</td>
<td>11.9</td>
<td>384-well</td>
</tr>
<tr>
<td>1-57</td>
<td>1G.1</td>
<td>384-well</td>
</tr>
<tr>
<td>1-58</td>
<td>13.7</td>
<td>384-well</td>
</tr>
<tr>
<td>1-59</td>
<td>10.9</td>
<td>384-well</td>
</tr>
<tr>
<td>1-60</td>
<td>6.62</td>
<td>384-well</td>
</tr>
<tr>
<td>1-61</td>
<td>15.4</td>
<td>384-well</td>
</tr>
<tr>
<td>1-62</td>
<td>7.74</td>
<td>384-well</td>
</tr>
<tr>
<td>1-63</td>
<td>11.9</td>
<td>384-well</td>
</tr>
<tr>
<td>1-64</td>
<td>7.06</td>
<td>384-well</td>
</tr>
<tr>
<td>1-65</td>
<td>21.9</td>
<td>384-well</td>
</tr>
<tr>
<td>1-66</td>
<td>5.62</td>
<td>384-well</td>
</tr>
<tr>
<td>1-67</td>
<td>5.47</td>
<td>384-well</td>
</tr>
<tr>
<td>1-68</td>
<td>11.6</td>
<td>384-well</td>
</tr>
<tr>
<td>1-69</td>
<td>9.24</td>
<td>384-well</td>
</tr>
<tr>
<td>1-70</td>
<td>10.6</td>
<td>384-well</td>
</tr>
<tr>
<td>1-71</td>
<td>12</td>
<td>384-well</td>
</tr>
<tr>
<td>1-75</td>
<td>15.6</td>
<td>384-well</td>
</tr>
<tr>
<td>1-76</td>
<td>3.77</td>
<td>384-well</td>
</tr>
<tr>
<td>1-77</td>
<td>45.8</td>
<td>384-well</td>
</tr>
<tr>
<td>1-78</td>
<td>7.35</td>
<td>384-well</td>
</tr>
<tr>
<td>1-79</td>
<td>13.2</td>
<td>384-well</td>
</tr>
<tr>
<td>1-80</td>
<td>35.5</td>
<td>384-well</td>
</tr>
<tr>
<td>1-81</td>
<td>16.9</td>
<td>384-well</td>
</tr>
<tr>
<td>1-82</td>
<td>25.1</td>
<td>384-well</td>
</tr>
<tr>
<td>1-83</td>
<td>30.3</td>
<td>384-well</td>
</tr>
<tr>
<td>1-84</td>
<td>12.9</td>
<td>384-well</td>
</tr>
<tr>
<td>1-85</td>
<td>15.4</td>
<td>384-well</td>
</tr>
<tr>
<td>1-86</td>
<td>101</td>
<td>384-well</td>
</tr>
<tr>
<td>1-87</td>
<td>21.4</td>
<td>384-well</td>
</tr>
<tr>
<td>1-88</td>
<td>14.4</td>
<td>384-well</td>
</tr>
<tr>
<td>1-89</td>
<td>15.1</td>
<td>384-well</td>
</tr>
<tr>
<td>1-90</td>
<td>15.3</td>
<td>384-well</td>
</tr>
<tr>
<td>1-91</td>
<td>6.37</td>
<td>384-well</td>
</tr>
<tr>
<td>1-92</td>
<td>8.27</td>
<td>384-well</td>
</tr>
</tbody>
</table>
89 μL of substrate peptide solution (SEVNLADEFRHDSGYEK-biotin) is added to each well of 96-well plate (a black plate: Costar), and after addition of 1 μL of the compound of the present invention (DMSO solution) and 10 μμ of the human BACE2 which purified FreeStyle TM293-F cells condition medium that expression human BACE2 ectodomain, the reaction mixture is incubated at 37 °C for 1 hours. The final concentrations of the substrate peptide and human BACE2 are adjusted to 1000 nmol/L and 20 ng/mL, respectively, and the reaction is performed in sodium acetate buffer (50 mmol/L sodium acetate, pH 4.5, 0.25 mg/mL bovine serum albumin).

After the incubation for reaction, 30 μL of 1 M Tris-HCL (pH 7.6) is added to reaction mixtures. The reaction mixtures added to each well coated with 82E1 (anti-amyloid β antibody; Immuno-Biological Laboratories) and incubated overnight at 4 °C. After the incubation and five wash, Neutravidin-Horseradish Peroxidase conjugated (Thermo Fisher) is added to each wells and incubated for 1 hour at room
temperature. After five washes, 45 µL of mixture of Supersignal pico solution A and B (Thermo Fisher) is added to each wells. The count of chemi-luminescence in each well is measured by ARVO MX 1420 Multilabel Reader (Perkin Elmer life sciences). Enzymatic activity is determined from counting ratio of each wavelength (10,000 x Count 665/Count 620) and 50% inhibitory concentration against the enzymatic activity (IC$_{50}$) is calculated.

**Example 16**  
(Test Example 2-1: Measurement of β-amyloid (Aβ) production inhibitory effect in cell: 96-well)

Neuroblastoma SH-SY5Y cells (SH/APPwt) with human wild-type β-APP excessively expressed therein were prepared at 8 x 10$^5$ cells/mL, and 150 µµ portions thereof were inoculated into each well of a 96-well culture plate (Falcon). The cells were cultured for 2 hours at 37 °C in a 5% gaseous carbon dioxide incubator. Then, a solution which have been preliminarily prepared by adding and suspending the compound of the present invention (DMSO (dimethyl sulfoxide) solution) so as to be 2 µl/50 µ medium was added to the cell sap. Namely, the final DMSO concentration was 1%, and the amount of the cell culture was 200 µµ. After the incubation was performed for 24 hours from the addition of the test compound, 100 µµ of the culture supernatant was-collected from each fraction. The amount of the Aβ in each fraction was measured.

The Aβ amount was measured as follows. 10 µµ of a homogeneous time resolved fluorescence (HTRF) measurement reagent (Amyloid β 1-40 peptide; CIS bio international) and 10 µµ of the culture supernatant were put into a 384-well half area microplate (black microplate, Costar) and mixed with each other, and then left standing overnight at 4 °C while the light was shielded. Then, the fluorescence intensity (excitation wavelength: 337 nm, measurement wavelength: 620 nm and 665 nm) was measured with a micro plate reader (Artemis K-101; FURUNO ELECTRIC). The Aβ amount was determined from the count rate at each measurement wavelength (10000 X Count 665/Count 620), and the amount needed to inhibit Aβ production by 50 % (IC$_{50}$) was calculated from at least six different dosages.

(Test Example 2-2: Measurement of β-amyloid (Aβ) production inhibitory effect in cell: 384-well)

Neuroblastoma SH-SY5Y cells (SH/APPwt) with human wild-type β-APP excessively expressed therein were prepared at 4 x 10$^5$ cells/mL, and 50 µµ portions thereof were inoculated into each well of a 384-well culture plate (Corning) added 0.5 µµ of the test compound of the present invention (DMSO solution). The final DMSO concentration was 1%, and the amount of the cell culture was 50 µµ. After the in-
Cubation was performed for 24 hours from the cell seeding. 5 µl of the culture supernatant was collected from each fraction. The amount of the Aβ in each fraction was measured.

The Aβ amount was measured as follows. 5 µl of a homogeneous time resolved fluorescence (HTRF) measurement reagent (Amyloid β1-40 peptide; CIS bio international) and 5 µl of the culture supernatant were put into a 384-well plate (a black plate: Corning) and mixed with each other, and then left standing overnight at 4 °C while the light was shielded. Then, the fluorescence intensity (620 nm and 665 nm) was measured with EnVision (Perkin Elmer life sciences). The Aβ amount was determined from the count rate at each measurement wavelength (Count 665/Count 620), and the amount needed to inhibit Aβ production by 50% (IC50) was calculated from at least six different dosages.
<table>
<thead>
<tr>
<th>No.</th>
<th>IC₅₀ value</th>
<th>Assay format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-1</td>
<td>0.504</td>
<td>96-well</td>
</tr>
<tr>
<td>1-2</td>
<td>3.73</td>
<td>96-well</td>
</tr>
<tr>
<td>1-3</td>
<td>3.59</td>
<td>96-well</td>
</tr>
<tr>
<td>1-4</td>
<td>0.697</td>
<td>96-well</td>
</tr>
<tr>
<td>1-5</td>
<td>2.88</td>
<td>96-well</td>
</tr>
<tr>
<td>1-6</td>
<td>1.29</td>
<td>96-well</td>
</tr>
<tr>
<td>1-7</td>
<td>2.52</td>
<td>96-well</td>
</tr>
<tr>
<td>1-8</td>
<td>0.26</td>
<td>96-well</td>
</tr>
<tr>
<td>1-9</td>
<td>0.235</td>
<td>96-well</td>
</tr>
<tr>
<td>1-10</td>
<td>0.708</td>
<td>96-well</td>
</tr>
<tr>
<td>1-11</td>
<td>4.21</td>
<td>96-well</td>
</tr>
<tr>
<td>1-12</td>
<td>1.88</td>
<td>96-well</td>
</tr>
<tr>
<td>1-13</td>
<td>1.12</td>
<td>96-well</td>
</tr>
<tr>
<td>1-14</td>
<td>2.09</td>
<td>96-well</td>
</tr>
<tr>
<td>1-15</td>
<td>0.65</td>
<td>96-well</td>
</tr>
<tr>
<td>1-16</td>
<td>1.12</td>
<td>96-well</td>
</tr>
<tr>
<td>1-17</td>
<td>3.23</td>
<td>96-well</td>
</tr>
<tr>
<td>1-18</td>
<td>0.573</td>
<td>96-well</td>
</tr>
<tr>
<td>1-19</td>
<td>1.2</td>
<td>96-well</td>
</tr>
<tr>
<td>1-20</td>
<td>4.19</td>
<td>96-well</td>
</tr>
<tr>
<td>1-21</td>
<td>2.93</td>
<td>96-well</td>
</tr>
<tr>
<td>1-22</td>
<td>4.22</td>
<td>96-well</td>
</tr>
<tr>
<td>1-23</td>
<td>1.53</td>
<td>96-well</td>
</tr>
<tr>
<td>1-24</td>
<td>2.28</td>
<td>96-well</td>
</tr>
<tr>
<td>1-25</td>
<td>4.31</td>
<td>96-well</td>
</tr>
<tr>
<td>1-26</td>
<td>1.76</td>
<td>96-well</td>
</tr>
<tr>
<td>1-27</td>
<td>6.7</td>
<td>96-well</td>
</tr>
<tr>
<td>1-28</td>
<td>1.5</td>
<td>96-well</td>
</tr>
<tr>
<td>1-29</td>
<td>93.5</td>
<td>96-well</td>
</tr>
<tr>
<td>1-30</td>
<td>2.33</td>
<td>96-well</td>
</tr>
<tr>
<td>1-31</td>
<td>0.668</td>
<td>96-well</td>
</tr>
<tr>
<td>1-32</td>
<td>2.39</td>
<td>96-well</td>
</tr>
<tr>
<td>1-33</td>
<td>1.07</td>
<td>96-well</td>
</tr>
<tr>
<td>1-34</td>
<td>1.85</td>
<td>96-well</td>
</tr>
<tr>
<td>1-35</td>
<td>0.391</td>
<td>96-well</td>
</tr>
<tr>
<td>1-36</td>
<td>2.29</td>
<td>96-well</td>
</tr>
<tr>
<td>1-40</td>
<td>6</td>
<td>384-well</td>
</tr>
<tr>
<td>1-41</td>
<td>15</td>
<td>384-well</td>
</tr>
<tr>
<td>1-42</td>
<td>21</td>
<td>384-well</td>
</tr>
<tr>
<td>1-43</td>
<td>0.615</td>
<td>96-well</td>
</tr>
<tr>
<td>1-44</td>
<td>2.11</td>
<td>96-well</td>
</tr>
</tbody>
</table>
[Table 3-2]
| I-45 | 5.71 | 96-well |
| I-46 | 2.4  | 384-well|
| I-47 | 1.2  | 384-well|
| I-48 | 5.4  | 384-well|
| I-49 | 0.025| 384-well|
| I-50 | 0.39 | 384-well|
| I-51 | 0.41 | 384-well|
| I-52 | 0.42 | 384-well|
| I-53 | 0.89 | 384-well|
| I-54 | 7.2  | 384-well|
| I-55 | 0.3  | 384-well|
| I-56 | 0.53 | 384-well|
| I-57 | 0.68 | 384-well|
| I-58 | 0.68 | 384-well|
| I-59 | 0.058| 384-well|
| I-60 | 0.29 | 384-well|
| I-61 | 1.3  | 384-well|
| I-62 | 0.25 | 384-well|
| I-63 | 5.4  | 384-well|
| I-64 | 0.22 | 384-well|
| I-65 | 1.1  | 384-well|
| I-66 | 0.13 | 384-well|
| I-67 | 0.56 | 384-well|
| I-68 | 0.41 | 384-well|
| I-69 | 0.42 | 384-well|
| I-70 | 2    | 384-well|
| I-71 | 0.54 | 384-well|
| I-75 | 8.3  | 384-well|
| I-76 | 1.6  | 384-well|
| I-77 | 79   | 384-well|
| I-78 | 6.7  | 384-well|
| I-79 | 4.5  | 384-well|
| I-80 | 18   | 384-well|
| I-81 | 21   | 384-well|
| I-82 | 17   | 384-well|
| I-83 | 14   | 384-well|
| I-84 | 2.3  | 384-well|
| I-85 | 4.8  | 384-well|
| I-86 | 2.21 | 384-well|
| I-87 | 0.66 | 384-well|
| I-88 | 0.13 | 384-well|
| I-89 | 1.5  | 384-well|
| I-90 | 0.51 | 384-well|
| I-91 | 0.25 | 384-well|
| I-92 | 1    | 384-well|
| I-93 | 28   | 384-well|
| I-94 | 3.5  | 384-well|
Example 17

(Test Example 3-1: Lowering effect on the brain β amyloid in rats)

Compound of the present invention is suspended in 0.5% methylcellulose, the final concentration is adjusted to 2 mg/mL, and this is orally administered to male Crl:SD rat (7 to 9 weeks old) at 10 mg/kg. In a vehicle control group, only 0.5% methylcellulose is administered, and an administration test is performed at 3 to 8 animals per group. A brain is isolated 3 hours after administration, a cerebral hemisphere is isolated, a weight thereof is measured, the hemisphere is rapidly frozen in liquid nitrogen, and stored at -80 °C until extraction date. The frozen cerebral hemisphere is transferred to a homogenizer manufactured by Teflon (Registered trademark) under ice cooling, a 4-fold volume of a weight of an extraction buffer (containing 1% CHAPS ([3-[(3-chloroamidopropyl)dimethylammonio]-l-propanesulfonate]), 20 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, Complete (Roche) protease inhibitor) is added, up and down movement is repeated, and this is homogenized to solubilize for 2 minutes. The suspension is transferred to a centrifugation tube, allowed to stand on an ice for 3 hours or more and, thereafter centrifuged at 100,000 x g, 4 °C for 20 minutes. After centrifugation, the supernatant is transferred to an ELISA plate (product No. 294-62501, Wako Junyaku Kogyo) for measuring β amyloid 40. ELISA measurement is performed according to the attached instruction. The lowering effect is calculated as a ratio compared to the brain β amyloid 40 level of vehicle control group of each test.

(Test Example 3-2: Lowering effect on the brain β amyloid in mice)
Compound of the present invention is dissolved in 20% hydroxyl-beta-cyclodextrin, the final concentration is adjusted to 2 mg/mL, and this is orally administered to male Crl:CD1 (ICR) mouse (6 to 8 weeks old) at 1 to 10 mg/kg. In a vehicle control group, only 20% hydroxyl-beta-cyclodextrin is administered, and an administration test is performed at 3 to 6 animals per group. A brain is isolated 1 to 6 hours after administration, a cerebral hemisphere is isolated, a weight thereof is measured, the hemisphere is rapidly frozen in liquid nitrogen, and stored at -80 °C until extraction date.

The frozen cerebral hemisphere is transferred to a homogenize tube containing ceramic beads in a 8-fold volume of a weight of an extraction buffer (containing 0.4% DEA (diethylamine), 50 mmol/L NaCl, Complete protease inhibitor (Roche)) and incubated on an ice for 20 minutes. Thereafter, the homogenization is done using MP BIO FastPrep(Registered trademark)-24 with Lysing matrix D 1.4 mm ceramic beads (20 seconds at 6 m/s). Then, the tube spins down for 1 minute, the supernatant is transferred to a centrifugation tube, and centrifuged at 221,000 x g, 4 °C for 50 minutes. After centrifugation, the supernatant is transferred to Nunc Maxisorp (Registered trademark) plate (Thermo Fisher Scientific) coating with antibody against N-terminal of β amyloid for measuring total β amyloid, and the plate is incubated overnight at 4 °C. The plate is washed with TBS-T (Tris buffered saline containing 0.05% Triton X-100), and HRP-conjugated 4G8 dissolved in PBS (pH 7.4) containing 0.1% casein is added in the plate and incubated at 4 °C for 1 hour. After it is washed with TBS-T, SuperSignal ELISA Pico Chemiluminescent Substrate (Thermo Scientific) is added in the plate. Then, the chemi-luminescence counting is measured by ARVO (Registered trademark) MX 1420 Multilabel Counter (Perkin Elmer) as soon as possible. The lowering effect is calculated as a ratio compared to the brain total β amyloid level of vehicle control group of each test.

**Example 18**

[0341] (Test Example 4-1: CYP3A4 fluorescent MBI test)

The CYP3A4 fluorescent MBI test is a test of investigating enhancement of CYP3A4 inhibition of a compound by a metabolism reaction. 7-benzyloxytrifluoromethylcoumarin (7-BFC) is debenzylated by the CYP3A4 enzyme (enzyme expressed in Escherichia coli) and 7-hydroxytrifluoromethylcoumarin (7-HFC) is produced as a fluorescing metabolite. The test is performed using 7-HFC production reaction as an index.

The reaction conditions were as follows: substrate, 5.6 µmol/L 7-BFC; pre-reaction time, 0 or 30 minutes; substrate reaction time, 15 minutes; reaction temperature, 25 °C (room temperature); CYP3A4 content (expressed in Escherichia coli), at pre-reaction
time 62.5 pmol/mL, at reaction time 6.25 pmol/mL (at 10-fold dilution); concentrations of the compound of the present invention, 0.625, 1.25, 2.5, 5, 10, 20 μmol/L (six points).

An enzyme in a K-Pi buffer (pH 7.4) and a compound of the present invention solution as a pre-reaction solution were added to a 96-well plate at the composition of the pre-reaction. A part of pre-reaction solution was transferred to another 96-well plate, and 1/10 diluted by a substrate in a K-Pi buffer. NADPH as a co-factor was added to initiate a reaction as an index (without preincubation). After a predetermined time of a reaction, acetonitrile/0.5 mol/L Tris (trishydroxymethyl methane) = 4/1 (v/v) solution was added to stop the reaction. On the other hand, NADPH was also added to a remaining pre-reaction solution in order to initiate a preincubation (with preincubation). After a predetermined time of a preincubation, a part was transferred to another 96-well plate, and 1/10 diluted by a substrate in a K-Pi buffer in order to initiate a reaction as an index. After a predetermined time of a reaction, acetonitrile/0.5 mol/L Tris (trishydroxymethyl methane) = 4/1 (v/v) solution was added to stop the reaction. Fluorescent values of 7-HFC as a metabolite were measured in each index reaction plate with a fluorescent plate reader (Ex = 420 nm, Em = 535 nm).

The sample adding DMSO to a reaction system instead of compound of the present invention solution was adopted as a control (100 %) because DMSO was used as a solvent to dissolve a compound of the present invention. Remaining activity (%) was calculated at each concentration of the compound of the present invention added as the solution, and IC\textsubscript{50} value was calculated by reverse-presumption by a logistic model using a concentration and an inhibition rate. When a difference subtracting IC\textsubscript{50} value with preincubation from that without IC\textsubscript{50} value was 5 μM or more, this was defined as positive (+). When the difference was 3 μM or less, this was defined as negative (-).

The following compounds were defined as negative.

1-2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 40, 41, 42, 43, 44, 45, 71 and 86.

(Test Example 4-2: CYP3A4(MDZ) MBI test)

CYP3A4(MDZ) MBI test is a test of investigating mechanism based inhibition (MBI) ability on CYP3A4 inhibition of a compound by enhancement of a metabolism reaction. CYP3A4 inhibition is evaluated using 1-hydroxylation reaction of midazolam (MDZ) by pooled human liver microsomes as an index.

The reaction conditions were as follows: substrate, 10 μmol/L MDZ; pre-reaction time, 0 or 30 minutes; substrate reaction time, 2 minutes; reaction temperature, 37 °C; protein content of pooled human liver microsomes, at pre-reaction time 0.5 mg/mL, at reaction time 0.05 pmol/mL (at 10-fold dilution); concentrations of the compound of the present invention, 1, 5, 10, 20 μmol/L (four points).
Pooled human liver microsomes in a K-Pi buffer (pH 7.4) and a compound of the present invention solution as a pre-reaction solution were added to a 96-well plate at the composition of the pre-reaction. A part of pre-reaction solution was transferred to another 96-well plate, and 1/10 diluted by a substrate in a K-Pi buffer. NADPH as a co-factor was added to initiate a reaction as an index (without preincubation). After a predetermined time of a reaction, methanol/acetoneitrile=1/1 (v/v) solution was added to stop the reaction. On the other hand, NADPH was also added to a remaining pre-reaction solution in order to initiate a preincubation (with preincubation). After a predetermined time of a preincubation, a part was transferred to another 96-well plate, and 1/10 diluted by a substrate in a K-Pi buffer in order to initiate a reaction as an index. After a predetermined time of a reaction, methanol/acetoneitrile=1/1 (v/v) solution was added to stop the reaction. After centrifuged at 3000rpm for 15 minutes, 1-hydroxymidazolam in the supernatant was quantified by LC/MS/MS.

The sample adding DMSO to a reaction system instead of compound of the present invention solution was adopted as a control (100 %) because DMSO was used as a solvent to dissolve a compound of the present invention. Remaining activity (%) was calculated at each concentration of the compound of the present invention added as the solution, and IC₅₀ value was calculated by reverse-preservation by a logistic model using a concentration and an inhibition rate. Shifted IC value was calculated as "IC of preincubation at 0 min/IC of preincubation at 30min". When a shifted IC was 1.5 or more, this was defined as positive. When a shifted IC was 1.0 or less, this was defined as negative.

The following compounds were defined as negative.

**Example 19**

[Test Example 5: CYP inhibition test]

The CYP inhibition test is a test to assess the inhibitory effect of a compound of the present invention towards typical substrate metabolism reactions on CYP enzymes in human liver microsomes. The marker reactions on human main five CYP enzymes (CYP1A2, 2C9, 2C19, 2D6, and 3A4) are used as follows: 7-ethoxyresorufin O-deethylation (CYP1A2), tolbutamide methyl-hydroxylation (CYP2C9), mephenytoin 4'-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), and terfenadine hydroxylation (CYP3A4). The commercially available pooled human liver microsomes are used as an enzyme resource.

The reaction conditions were as follows: substrate, 0.5 µmol/L ethoxyresorufin (CYP1A2), 100 µmol/L tolbutamide (CYP2C9), 50 µmol/L S-mephenytoin
(CYP2C19), 5 \mu\text{mol/L} \text{dextromethorphan (CYP2D6), 1 \mu\text{mol/L} terfenadine (CYP3A4); reaction time, 15 minutes; reaction temperature, 37 °C; enzyme, pooled human liver microsomes 0.2 mg protein/mL; concentrations of the compound of the present invention, 1, 5, 10, 20 \mu\text{mol/L} (four points). Five kinds of substrates, human liver microsomes, and a compound solution of the present invention in 50 mmol/L Hepes buffer were added to a 96-well plate at the composition as described above as a reaction solution. NADPH as a cofactor was added to this 96-well plate in order to initiate metabolism reactions. After the incubation at 37 °C for 15 minutes, a methanol/acetonitrile = 1/1 (v/v) solution was added to stop the reaction. After the centrifugation at 3000 rpm for 15 minutes, resorufin (CYP1A2 metabolite) in the supernatant was quantified by a fluorescent plate reader, and hydroxytylbutamide (CYP2C9 metabolite), 4’-hydroxymephenytoin (CYP2C19 metabolite), dextorphan (CYP2D6 metabolite), and terfenadine alcohol metabolite (CYP3A4 metabolite) in the supernatant were quantified by LC/MS/MS. The sample adding DMSO to a reaction system instead of compound of the present invention solution was adopted as a control (100 %) because DMSO was used as a solvent to dissolve a compound of the present invention. Remaining activity (%) was calculated at each concentration of a compound of the present invention, and IC\text{50} value was calculated by reverse presumption by a logistic model using a concentration and an inhibition rate.

CYP1A2 20 \mu\text{M or more: Compound 1-1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33, 34, 35, 36, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 and 116

CYP1A2 10 \mu\text{M or more: Compound 1-29 and 115

CYP2C9 20 \mu\text{M or more: Compound 1-1, 10, 12, 13, 14, 15, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, 56, 57, 58, 59, 60, 61, 71, 78, 86, 87, 88, 89, 90, 102, 105, 106, 112, 113 and 115

CYP2C9 10 \mu\text{M or more: Compound 1-2, 3, 4, 5, 11, 16, 49, 62, 63, 75, 77, 79, 80, 81, 94, 95, 96, 99, 103, 104, 107, 110, 111 and 114

CYP2C19 20 \mu\text{M or more: Compound 1-1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 75, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115 and 116
CYP2C19 10 µM or more: Compound 1-6 and 76
CYP2D6 20 µM or more: Compound 1-1, 4, 10, 13, 15, 18, 20, 23, 25, 26, 27, 28, 29, 31, 34, 35, 36, 40, 43, 45, 49, 52, 53, 64, 85, 87, 88, 89, 90, 96, 102, 103, 104, 105, 106, 107, 112, 113, 114, 115 and 116
CYP2D6 10 µM or more: Compound 1-11, 12, 22, 24, 32, 44, 46, 48, 70, 78, 99, 108 and 110
CYP3A4 20 µM or more: Compound 1-1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 40, 41, 42, 43, 44, 45, 47, 48, 49, 50, 52, 53, 64, 65, 71, 86, 87, 88, 89, 90, 91, 92, 94, 96, 97, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115 and 116
CYP3A4 10 µM or more: Compound 1-51, 55, 56, 57, 61, 66, 68, 69, 70, 78, 79, 80, 81 and 95

Example 20

(Test Example 6: Fluctuation Ames test)

Each 20 µL of freeze-stored Salmonella typhimurium (TA98 and TA100 strain) is inoculated in 10 mL of liquid nutrient medium (2.5% Oxoid nutrient broth No.2), and the cultures are incubated at 37 °C under shaking for 10 hours. 7.70 mL of TA98 culture is centrifuged (2000 X g, 10 minutes) to remove medium, and the bacteria is suspended in 7.70 mL of Micro F buffer (K_2HPO_4: 3.5 g/L, KH_2PO_4: 1 g/L, (NH_4)_2SO_4: 1 g/L, trisodium citrate dihydrate: 0.25 g/L, MgSO_4·7H_2O : 0.1 g/L), and the suspension is added to 120 mL of Exposure medium (Micro F buffer containing Biotin: 8 µg/mL, histidine: 0.2 µg/mL, glucose: 8 mg/mL). 3.42 mL of TA100 culture is added to 130 mL of Exposure medium to prepare the test bacterial solution. 588 µL of the test bacterial solution (or mixed solution of 498 µL of the test bacterial solution and 90 µL of the S9 mix in the case with metabolic activation system) are mixed with each 12 µL of the following solution: DMSO solution of the compound of the present invention (several stage dilution from maximum dose 50 mg/mL at 2 to 3-fold ratio); DMSO as negative control; 50 µg/mL of 4-nitroquinoline-1-oxide DMSO solution as positive control for TA98 without metabolic activation system; 0.25 µg/mL of 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide DMSO solution as positive control for TA100 without metabolic activation system; 40 µg/mL of 2-aminoanthracene DMSO solution as positive control for TA98 with metabolic activation system; or 20 µg/mL of 2-aminoanthracene DMSO solution as positive control for TA100 with metabolic activation system. A mixed solution is incubated at 37 °C under shaking for 90 minutes. 460 µL of the bacterial solution exposed to the compound of the present invention is mixed with 2300 µL of Indicator medium (Micro F buffer containing biotin: 8 µg/mL, histidine: 0.2 µg/mL, glucose: 8 mg/mL, Bromo Cresol Purple: 37.5 µg/mL), each 50
μL is dispensed into 48 wells/dose in the microwell plates, and is subjected to stationary cultivation at 37 °C for 3 days. A well containing the bacteria, which has obtained the ability of proliferation by mutation in the gene coding amino acid (histidine) synthetase, turns the color from purple to yellow due to pH change. The number of the yellow wells among the 48 total wells per dose is counted, and evaluate the mutagenicity by comparing with the negative control group. (-) means that mutagenicity is negative and (+) means positive.

Example 21

(Test Example 7 : Solubility test)

The solubility of each compound of the present invention was determined under 1% DMSO addition conditions. A 10 mmol/L solution of the compound was prepared with DMSO, and 2 μL of the compound of the present invention solution was added, respectively, to 198 μL of JP 1st fluid (water was added to 2.0 g of sodium chloride and 7.0 mL of hydrochloric acid to reach 1000 mL) and JP 2nd fluid (See Table 4). The mixture was left standing for 16 hours at 25 °C or shaken for 1 hour at room temperature, and the mixture was vacuum-filtered. The filtrate was ten or one hundred-fold diluted with methanol/water = 1/1 (v/v) or MeCN/MeOH/H₂O(=l/l/2), and the compound concentration in the filtrate was measured with LC/MS or solid phase extraction (SPE)/MS by the absolute calibration method.
<table>
<thead>
<tr>
<th>No.</th>
<th>Condition</th>
<th>JP2 fluid</th>
<th>JP1</th>
<th>JP2</th>
<th>μM</th>
<th>μM</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-1</td>
<td>*1</td>
<td>A</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-2</td>
<td>*1</td>
<td>A</td>
<td>23.3</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-3</td>
<td>*1</td>
<td>A</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-4</td>
<td>*1</td>
<td>A</td>
<td>35.8</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-5</td>
<td>*1</td>
<td>A</td>
<td>34.3</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-6</td>
<td>*1</td>
<td>A</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-7</td>
<td>*1</td>
<td>A</td>
<td>46.4</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-8</td>
<td>*1</td>
<td>A</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-9</td>
<td>*2</td>
<td>A</td>
<td>30.1</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-10</td>
<td>*1</td>
<td>A</td>
<td>36.1</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-11</td>
<td>*1</td>
<td>A</td>
<td>39.6</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-12</td>
<td>*1</td>
<td>A</td>
<td>38.3</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-13</td>
<td>*2</td>
<td>A</td>
<td>31.9</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-14</td>
<td>*2</td>
<td>A</td>
<td>33.9</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-15</td>
<td>*1</td>
<td>A</td>
<td>38.9</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-16</td>
<td>*1</td>
<td>A</td>
<td>37.1</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-17</td>
<td>*1</td>
<td>A</td>
<td>28.8</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-18</td>
<td>*1</td>
<td>A</td>
<td>31.2</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-19</td>
<td>*1</td>
<td>A</td>
<td>46.7</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-20</td>
<td>*1</td>
<td>A</td>
<td>38.8</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-21</td>
<td>*1</td>
<td>A</td>
<td>46.7</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-26</td>
<td>*1</td>
<td>A</td>
<td>41.9</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-27</td>
<td>*1</td>
<td>A</td>
<td>39.7</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-28</td>
<td>*1</td>
<td>A</td>
<td>40.4</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-29</td>
<td>*1</td>
<td>A</td>
<td>35</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-30</td>
<td>*1</td>
<td>A</td>
<td>39.2</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-31</td>
<td>*1</td>
<td>A</td>
<td>38.8</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-32</td>
<td>*1</td>
<td>A</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-33</td>
<td>*2</td>
<td>A</td>
<td>39.4</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-34</td>
<td>*1</td>
<td>A</td>
<td>44.4</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-35</td>
<td>n</td>
<td>A</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-36</td>
<td>*2</td>
<td>A</td>
<td>37.6</td>
<td>15.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-40</td>
<td>*2</td>
<td>A</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-41</td>
<td>*2</td>
<td>A</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-42</td>
<td>*2</td>
<td>A</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-43</td>
<td>*1</td>
<td>A</td>
<td>29.9</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-44</td>
<td>*1</td>
<td>A</td>
<td>34</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-45</td>
<td>*1</td>
<td>A</td>
<td>35.8</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-46</td>
<td>*2</td>
<td>A</td>
<td>&gt;50</td>
<td>8.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-47</td>
<td>*2</td>
<td>A</td>
<td>&gt;50</td>
<td>30.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-48</td>
<td>*2</td>
<td>A</td>
<td>&gt;50</td>
<td>39.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-49</td>
<td>*2</td>
<td>A</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-50</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-51</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-52</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>13.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-53</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-54</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>38.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-55</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-56</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-57</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-58</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-59</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-60</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-61</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-62</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-63</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-64</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-65</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-66</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-67</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-68</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>9.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-69</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-70</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-71</td>
<td>*2</td>
<td>A</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-75</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-76</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>8.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-77</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>11.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-78</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-79</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-80</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-81</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>19.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-82</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-83</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>29.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-84</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>49.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-85</td>
<td>*2</td>
<td>B</td>
<td>47.2</td>
<td>0.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-86</td>
<td>*2</td>
<td>A</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-87</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-88</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-89</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-90</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-91</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-92</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-93</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>6.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-94</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-95</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-96</td>
<td>*2</td>
<td>B</td>
<td>45.8</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-97</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-98</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-100</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-101</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-102</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-103</td>
<td>*2</td>
<td>B</td>
<td>49.4</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-104</td>
<td>*2</td>
<td>B</td>
<td>40.6</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-105</td>
<td>*2</td>
<td>B</td>
<td>47.3</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-106</td>
<td>*2</td>
<td>B</td>
<td>42</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-107</td>
<td>*2</td>
<td>B</td>
<td>33.5</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-108</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-109</td>
<td>*2</td>
<td>B</td>
<td>&gt;50</td>
<td>19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-110</td>
<td>*2</td>
<td>B</td>
<td>42.1</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-111</td>
<td>*2</td>
<td>B</td>
<td>48.4</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-112</td>
<td>*2</td>
<td>B</td>
<td>&gt;50.0</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-113</td>
<td>*2</td>
<td>B</td>
<td>&gt;50.0</td>
<td>48.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-114</td>
<td>*2</td>
<td>B</td>
<td>&gt;50.0</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-115</td>
<td>*2</td>
<td>B</td>
<td>&gt;50.0</td>
<td>&gt;50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-116</td>
<td>*1</td>
<td>A</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*1: standing for 16 hours at 25 °C
*2: shaken for 1 hour at room temperature

A: 0.2 mol/L potassium dihydrogen phosphate solution adjusted to pH 6.8 with 0.2 mol/L sodium hydroxide solution / water = 1/1.5

B: Dissolve 3.40 g of potassium dihydrogen phosphate and 3.55 g of anhydrous disodium hydrogen phosphate in water to make 1000 mL

Example 22
(Test Example 8: Metabolic stability test)

Using a commercially available pooled human liver microsomes, a compound of the present invention was reacted for a constant time, a remaining rate was calculated by comparing a reacted sample and an unreacted sample, thereby, a degree of metabolism in liver was assessed.

A reaction was performed (oxidative reaction) at 37 °C for 0 minute or 30 minutes in the presence of 1 mmol/L NADPH in 0.2 mL of a buffer (50 mmol/L Tris-HCl pH 7.4, 150 mmol/L potassium chloride, 10 mmol/L magnesium chloride) containing 0.5 mg protein/mL of human liver microsomes. After the reaction, 50 µL of the reaction solution was added to 100 µL of a methanol/acetonitrile = 1/1 (v/v), mixed and centrifuged at 3000 rpm for 15 minutes. The compound of the present invention in the supernatant was quantified by LC/MS/MS or solid phase extraction (SPE)/MS, and a remaining amount of the compound of the present invention after the reaction was calculated, letting a compound amount at 0 minute reaction time to be 100%.

[Table 5]

<table>
<thead>
<tr>
<th>No.</th>
<th>remaining %</th>
<th>No.</th>
<th>remaining %</th>
<th>No.</th>
<th>remaining %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-1</td>
<td>82.4</td>
<td>1-43</td>
<td>84.5</td>
<td>1-86</td>
<td>67.5</td>
</tr>
<tr>
<td>1-2</td>
<td>88</td>
<td>1-44</td>
<td>86.4</td>
<td>1-87</td>
<td>81</td>
</tr>
<tr>
<td>1-3</td>
<td>81.4</td>
<td>1-45</td>
<td>93.5</td>
<td>1-88</td>
<td>83.5</td>
</tr>
<tr>
<td>1-7</td>
<td>82</td>
<td>1-46</td>
<td>97.8</td>
<td>1-89</td>
<td>86.7</td>
</tr>
<tr>
<td>1-9</td>
<td>95.7</td>
<td>1-47</td>
<td>96.9</td>
<td>1-90</td>
<td>83.1</td>
</tr>
<tr>
<td>1-10</td>
<td>95.6</td>
<td>1-48</td>
<td>92.9</td>
<td>1-91</td>
<td>74.4</td>
</tr>
<tr>
<td>1-11</td>
<td>104</td>
<td>1-49</td>
<td>95.4</td>
<td>1-92</td>
<td>81</td>
</tr>
<tr>
<td>1-12</td>
<td>97.8</td>
<td>1-51</td>
<td>76.5</td>
<td>1-93</td>
<td>82.2</td>
</tr>
<tr>
<td>1-13</td>
<td>101</td>
<td>1-52</td>
<td>60.3</td>
<td>1-94</td>
<td>96.8</td>
</tr>
<tr>
<td>1-14</td>
<td>103</td>
<td>1-53</td>
<td>109</td>
<td>1-95</td>
<td>105</td>
</tr>
<tr>
<td>1-15</td>
<td>104</td>
<td>1-54</td>
<td>91</td>
<td>1-96</td>
<td>101</td>
</tr>
<tr>
<td>1-16</td>
<td>97.6</td>
<td>1-59</td>
<td>66.8</td>
<td>1-99</td>
<td>89.4</td>
</tr>
<tr>
<td>1-18</td>
<td>71.4</td>
<td>1-61</td>
<td>71.5</td>
<td>1-100</td>
<td>60.2</td>
</tr>
<tr>
<td>1-19</td>
<td>69.9</td>
<td>1-63</td>
<td>75.8</td>
<td>1-101</td>
<td>91.8</td>
</tr>
<tr>
<td>1-20</td>
<td>75.4</td>
<td>1-64</td>
<td>80.3</td>
<td>1-102</td>
<td>78.1</td>
</tr>
<tr>
<td>1-23</td>
<td>86.6</td>
<td>1-65</td>
<td>96.5</td>
<td>1-103</td>
<td>78.3</td>
</tr>
<tr>
<td>1-24</td>
<td>95.5</td>
<td>1-66</td>
<td>67</td>
<td>1-104</td>
<td>77.7</td>
</tr>
<tr>
<td>1-25</td>
<td>89.1</td>
<td>1-67</td>
<td>69</td>
<td>1-105</td>
<td>56.8</td>
</tr>
<tr>
<td>1-26</td>
<td>76</td>
<td>1-69</td>
<td>77.6</td>
<td>1-106</td>
<td>84.1</td>
</tr>
<tr>
<td>1-27</td>
<td>84.7</td>
<td>1-70</td>
<td>74.3</td>
<td>1-107</td>
<td>64.2</td>
</tr>
<tr>
<td>1-29</td>
<td>98.2</td>
<td>1-71</td>
<td>63</td>
<td>1-108</td>
<td>92.1</td>
</tr>
<tr>
<td>1-31</td>
<td>85</td>
<td>1-75</td>
<td>85.2</td>
<td>1-109</td>
<td>86.8</td>
</tr>
<tr>
<td>1-32</td>
<td>94.6</td>
<td>1-77</td>
<td>93.1</td>
<td>1-110</td>
<td>81.1</td>
</tr>
<tr>
<td>1-33</td>
<td>87.5</td>
<td>1-81</td>
<td>101</td>
<td>1-111</td>
<td>64.9</td>
</tr>
<tr>
<td>1-40</td>
<td>106</td>
<td>1-82</td>
<td>96.5</td>
<td>1-114</td>
<td>80.5</td>
</tr>
<tr>
<td>1-41</td>
<td>105</td>
<td>1-83</td>
<td>55.3</td>
<td>1-115</td>
<td>78.9</td>
</tr>
<tr>
<td>1-42</td>
<td>68.2</td>
<td>1-85</td>
<td>93.2</td>
<td>1-116</td>
<td>106</td>
</tr>
</tbody>
</table>
Example 23

For the purpose of assessing risk of an electrocardiogram QT interval prolongation, effects on delayed rectifier K+ current (IKr), which plays an important role in the ventricular repolarization process of the compound of the present invention, was studied using CHO cells expressing human ether-a-go-go related gene (hERG) channel.

A cell was retained at a membrane potential of -80 mV by whole cell patch clamp method using an automated patch clamp system (QPatch; Sophion Bioscience A/S). After application of leak potential at -50 mV, IKr induced by depolarization pulse stimulation at +20 mV for 2 seconds and, further, repolarization pulse stimulation at -50 mV for 2 seconds was recorded.

After the generated current was stabilized, extracellular solution (NaCl: 145 mmol/L, KCl: 4 mmol/L, CaCl2:2 mmol/L, MgCl2:1 mmol/L, 1 mmol/L, HEPES(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid: 10 mmol/L, glucose: 10 mmol/L pH=7.4) in which the compound of the present invention have been dissolved at an objective concentration was applied to the cell under the room temperature condition for 10 minutes. From the recording IKr, an absolute value of the tail peak current was measured based on the current value at the resting membrane potential using an analysis software (Falster Patch; Sophion Bioscience A/S). Further, the % inhibition relative to the tail peak current before application of the compound of the present invention was calculated, and compared with the vehicle-applied group (0.1% dimethyl sulfoxide solution) to assess influence of the compound of the present invention on IKr.
### Example 24

(Test Example 10: Powder solubility test)

Appropriate amounts of the compound of the present invention are put into ap-

<table>
<thead>
<tr>
<th>No.</th>
<th>( \text{hERG}_{3\mu\text{M}} ) %</th>
<th>No.</th>
<th>( \text{hERG}_{3\mu\text{M}} ) %</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-2</td>
<td>38.7</td>
<td>I-49</td>
<td>27.2</td>
</tr>
<tr>
<td>I-3</td>
<td>45.5</td>
<td>I-50</td>
<td>34.3</td>
</tr>
<tr>
<td>I-4</td>
<td>47.9</td>
<td>I-51</td>
<td>39.4</td>
</tr>
<tr>
<td>I-5</td>
<td>27.7</td>
<td>I-52</td>
<td>55.7</td>
</tr>
<tr>
<td>I-7</td>
<td>47.4</td>
<td>I-53</td>
<td>47.9</td>
</tr>
<tr>
<td>I-8</td>
<td>16.7</td>
<td>I-54</td>
<td>37.7</td>
</tr>
<tr>
<td>I-9</td>
<td>30.6</td>
<td>I-55</td>
<td>39.6</td>
</tr>
<tr>
<td>I-11</td>
<td>42.5</td>
<td>I-56</td>
<td>37.6</td>
</tr>
<tr>
<td>I-12</td>
<td>35.5</td>
<td>I-58</td>
<td>58.6</td>
</tr>
<tr>
<td>I-13</td>
<td>52.8</td>
<td>I-62</td>
<td>29.6</td>
</tr>
<tr>
<td>I-14</td>
<td>16.1</td>
<td>I-63</td>
<td>53.2</td>
</tr>
<tr>
<td>I-15</td>
<td>57</td>
<td>I-64</td>
<td>41.3</td>
</tr>
<tr>
<td>I-16</td>
<td>31.5</td>
<td>I-65</td>
<td>28</td>
</tr>
<tr>
<td>I-17</td>
<td>19.5</td>
<td>I-66</td>
<td>27.1</td>
</tr>
<tr>
<td>I-18</td>
<td>44.8</td>
<td>I-67</td>
<td>56.5</td>
</tr>
<tr>
<td>I-19</td>
<td>18.8</td>
<td>I-70</td>
<td>58.6</td>
</tr>
<tr>
<td>I-20</td>
<td>30.4</td>
<td>I-71</td>
<td>17</td>
</tr>
<tr>
<td>I-21</td>
<td>51.1</td>
<td>I-75</td>
<td>21.3</td>
</tr>
<tr>
<td>I-22</td>
<td>14.2</td>
<td>I-76</td>
<td>5.8</td>
</tr>
<tr>
<td>I-24</td>
<td>6.7</td>
<td>I-77</td>
<td>44.1</td>
</tr>
<tr>
<td>I-25</td>
<td>41.9</td>
<td>I-78</td>
<td>39.6</td>
</tr>
<tr>
<td>I-26</td>
<td>29.6</td>
<td>I-79</td>
<td>7.8</td>
</tr>
<tr>
<td>I-27</td>
<td>28.8</td>
<td>I-80</td>
<td>8.9</td>
</tr>
<tr>
<td>I-28</td>
<td>36.2</td>
<td>I-81</td>
<td>49.3</td>
</tr>
<tr>
<td>I-29</td>
<td>45.4</td>
<td>I-82</td>
<td>17.5</td>
</tr>
<tr>
<td>I-30</td>
<td>15.1</td>
<td>I-83</td>
<td>18.1</td>
</tr>
<tr>
<td>I-31</td>
<td>27.4</td>
<td>I-84</td>
<td>28.8</td>
</tr>
<tr>
<td>I-32</td>
<td>15.2</td>
<td>I-85</td>
<td>41.4</td>
</tr>
<tr>
<td>I-33</td>
<td>21.9</td>
<td>I-86</td>
<td>23.8</td>
</tr>
<tr>
<td>I-34</td>
<td>15.5</td>
<td>I-87</td>
<td>13.8</td>
</tr>
<tr>
<td>I-35</td>
<td>41.1</td>
<td>I-88</td>
<td>45.6</td>
</tr>
<tr>
<td>I-36</td>
<td>29.9</td>
<td>I-89</td>
<td>42.7</td>
</tr>
<tr>
<td>I-40</td>
<td>48.4</td>
<td>I-90</td>
<td>11.4</td>
</tr>
<tr>
<td>I-41</td>
<td>24.8</td>
<td>I-91</td>
<td>11.3</td>
</tr>
<tr>
<td>I-42</td>
<td>15.5</td>
<td>I-94</td>
<td>25.7</td>
</tr>
<tr>
<td>I-44</td>
<td>28.9</td>
<td>I-108</td>
<td>39.5</td>
</tr>
<tr>
<td>I-45</td>
<td>51.6</td>
<td>I-109</td>
<td>11</td>
</tr>
<tr>
<td>I-46</td>
<td>33.4</td>
<td>I-116</td>
<td>45.5</td>
</tr>
<tr>
<td>I-47</td>
<td>40.4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
propriate containers. 200 µL of JP 1st fluid (water is added to 2.0 g of sodium chloride and 7.0 mL of hydrochloric acid to reach 1000 mL), 200 µL of JP 2nd fluid (1 volume of water is added to 1 volume of the solution which 3.40 g of potassium dihydrogen phosphate and 3.55 g of anhydrous disodium hydrogen phosphate dissolve in water to reach 1000 mL), and 200 µL of JP 2nd fluid containing 20 mmol/L of sodium taurocholate (TCA) (TCA 1.08 g and JP 2nd fluid to make 100 mL) are added to the respective containers. When total amount of the compound of the present invention is dissolved after the addition of the test fluid, the compound is added as appropriate. The containers are sealed, and shaken for 1 hour at 37 °C. The mixtures are filtered, and 100 µL of methanol is added to each of the filtrate (100 µL) so that the filtrates are two-fold diluted. The dilution ratio may be changed if necessary. After confirming that there is no bubbles and precipitates in the diluted solution, the containers are sealed and shaken. Quantification is performed by HPLC with an absolute calibration method.

**Example 25**

[Test Example 11: Pharmacokinetic study]

Materials and methods for studies on oral absorption

1. Animal: mouse or rat
2. Breeding conditions: mouse or rat was allowed free access to the tap water and the solid food.
3. Dose and grouping: orally or intravenously administered at a predetermined dose; grouping was as follows (Dose depends on the compound)
   - Oral administration: 1 to 30 mg/kg (n=2 to 3)
   - Intravenous administration: 0.5 to 10 mg/kg (n=2 to 3)
4. Dosing formulation: for oral administration, in a solution or a suspension state; for intravenous administration, in a solubilized state
5. Dosing method: in oral administration, forcibly administer using a syringe attached a flexible feeding tube; in intravenous administration, administer from caudal vein using a syringe attached with a needle.
6. Evaluation items: blood was collected at the scheduled time, and the plasma concentration of the compound of the present invention was measured by LC/MS/MS
7. Statistical analysis: regarding the transition of the plasma concentration of the compound of the present invention, the area under the plasma concentration-time curve (AUC) was calculated by non-linear least squares program WinNonlin (Registered trademark), and the bioavailability (BA) of the compound of the present invention was calculated from the AUCs of the oral administration group and intravenous administration group

[0353]
[Table 7]

<table>
<thead>
<tr>
<th>No.</th>
<th>BA_%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-1</td>
<td>66.7</td>
</tr>
<tr>
<td>1-2</td>
<td>51.3</td>
</tr>
<tr>
<td>1-3</td>
<td>38.8</td>
</tr>
<tr>
<td>1-4</td>
<td>83.2</td>
</tr>
<tr>
<td>1-7</td>
<td>32.8</td>
</tr>
<tr>
<td>1-8</td>
<td>27.4</td>
</tr>
<tr>
<td>1-9</td>
<td>31.4</td>
</tr>
<tr>
<td>1-10</td>
<td>46.3</td>
</tr>
<tr>
<td>1-12</td>
<td>47.4</td>
</tr>
<tr>
<td>1-13</td>
<td>47.3</td>
</tr>
<tr>
<td>1-14</td>
<td>40.5</td>
</tr>
<tr>
<td>1-15</td>
<td>37.4</td>
</tr>
<tr>
<td>1-19</td>
<td>39.1</td>
</tr>
<tr>
<td>1-24</td>
<td>44</td>
</tr>
<tr>
<td>1-40</td>
<td>36.2</td>
</tr>
<tr>
<td>1-41</td>
<td>35.2</td>
</tr>
<tr>
<td>1-42</td>
<td>28.7</td>
</tr>
<tr>
<td>1-46</td>
<td>22.2</td>
</tr>
<tr>
<td>1-52</td>
<td>39.1</td>
</tr>
<tr>
<td>1-116</td>
<td>78.7</td>
</tr>
</tbody>
</table>

**Example 26**  
(Test Example 12: Brain distribution studies)

Compound of the present invention was intravenously administered to a rat at 0.5 mg/mL/kg dosage. 30 minutes later, all blood was drawn from the abdominal aorta under isoflurane anesthesia for death from exsanguination.

The brain was enucleated and 20 to 25% of homogenate thereof was prepared with distilled water.

The obtained blood was used as plasma after centrifuging. The control plasma was added to the brain sample at 1:1. The control brain homogenate was added to the plasma sample at 1:1. Each sample was measured using LC/MS/MS. The obtained area ratio (a brain/plasma) was used for the brain Kp value.
Example 27

(Test Example 13: Ames test)

Ames test is performed by using Salmonellas (Salmonella typhimurium) TA98, TA100, TA1535 and TA1537 and Escherichia coli WP2uvrA as test strains with or without metabolic activation in the pre-incubation method to check the presence or absence of gene mutagenicity of compounds of the present invention.

Example 28

(Test Example 14: P-gp substrate test)

1. Cell line:
   a. MDR1/LLC-PK1 (Becton Dickinson)
   b. LLC-PK1 (Becton Dickinson)

2. Reference substrates:
   a. Digoxin (2 µM)

Methods and Procedures

1. MDR1 expressing LLC-PK1 cells and its parent cells were routinely cultured in Medium A (Medium 199 (Invitrogen) supplemented with 10% FBS (Invitrogen), gentamycin (0.05 mg/mL, Invitrogen) and hygromycin B (100 µg/mL, Invitrogen)) at
37 °C under 5% CO\(_2\)/95% \(O_2\) gasses. For the transport experiments, these cells were seeded on Transwell (Registered trademark) insert (96-well, pore size: 0.4 μm, Coaster) at a density of 1.4 x 10\(^4\) cells/insert and added Medium B (Medium 199 supplemented with 10% FBS and gentamycin at 0.05 mg/mL) to the feeder tray. These cells were incubated in a CO\(_2\) incubator (5% CO\(_2\)/95% \(O_2\) gasses, 37°C) and replace apical and basolateral culture medium every 48-72 hr after seeding. These cells were used between 4 and 6 days after seeding.

2. The medium in the culture insert seeded with MDR1 expressing cells or parent cells were removed by aspiration and rinsed by HBSS. The apical side (140 μL) or basolateral side (175 μL) was replaced with transport buffer containing reference substrates and the present invention and then an aliquot (50 μL) of transport buffer in the donor side was collected to estimate initial concentration of reference substrate and the present invention. After incubation for designed time at 37°C, an aliquot (50 μL) of transport buffer in the donor and receiver side were collected. Assay was performed by duplicate or triplicate.

3. Reference substrate and the present invention in the aliquot was quantified by LC/MS/MS.

Calculations

Permeated amounts across monolayers of MDR1 expressing and parent cells were determined, and permeation coefficients (Pe) were calculated using Excel 2003 from the following equation:

\[
\text{Pe (cm/sec)} = \frac{\text{Permeated amount (pmol)}}{\text{area of cell membrane (cm}^2\rangle}{/}\text{initial concentration (nM)}{/}\text{incubation time (sec)}
\]

Where, permeated amount was calculated from permeation concentration (nM, concentration of the receiver side) of the substance after incubation for the defined time (sec) multiplied by volume.(mL) and area of cell membrane was used 0.1433 (cm\(^2\)).

The efflux ratio was calculated using the following equation:

\[
\text{Efflux Ratio} = \frac{\text{Basolateral- to-Apical Pe}}{\text{Apical-to-Basolateral Pe}}
\]

The net flux was calculated using the following equation:

\[
\text{Net flux} = \text{Efflux Ratio in MDR1 expressing cells} / \text{Efflux Ratio in parent cells}
\]
Example 29

[Test Example 15: Inhibitory Effects on P-gp Transport]

Materials

1. Cell line:
   a. MDR1/LLC-PK1 (Becton Dickinson)
   b. LLC-PK1 (Becton Dickinson)

2. Reference substrates:
   a. [3H]Digoxin (1 µM)
   b. [14C]Mannitol (5 µM)

3. Reference inhibitor:
   Cyclosporin A (10 µM)

Methods and Procedures

1. MDR1 expressing LLC-PK1 cells and its parent cells are routinely cultured in
Medium A (Medium 199 (Invitrogen) supplemented with 10% FBS (Invitrogen), gentamycin (0.05 mg/mL, Invitrogen) and hygromycin B (100 µg/mL, Invitrogen)) at 37°C under 5% CO₂/95% N₂ gasses. For the transport experiments, these cells are seeded on Transwell (Registered trademark) insert (24-well, pore size: 0.4 µm, Coaster) at a density of 4 x 10⁴ cells/insert and added Medium B (Medium 199 supplemented with 10% FBS and gentamycin at 0.05 mg/mL) to the feeder tray. These cells are incubated in a CO₂ incubator (5% CO₂/95% N₂ gasses, 37°C) and replace apical and basolateral culture medium every 48-72 hr after seeding. These cells are used between 6 and 9 days after seeding.

2. The medium in the culture insert seeded with MDRI expressing cells or parent cells are removed by aspiration and rinsed by HBSS. The apical side (250 µL) or basolateral side (850 µL) is replaced with transport buffer containing reference substrates with or without the compound of the present invention and then an aliquot (50 µL) of transport buffer in the donor side is collected to estimate initial concentration of reference substrate. After incubation for designed time at 37°C, an aliquot (50 µL) of transport buffer in the donor and receiver side are collected. Assay is performed by triplicate.

3. An aliquot (50 µL) of the transport buffer is mixed with 5 mL of a scintillation cocktail, and the radioactivity is measured using a liquid scintillation counter.

Calculations
Permeated amounts across monolayers of MDRI expressing and parent cells are determined, and permeation coefficients (Pe) are calculated using Excel 2003 from the following equitation:

\[ Pe \ (\text{cm/sec}) = \frac{\text{Permeated amount (pmol)}}{\text{area of cell membrane (cm}^2\text{)}} / \text{initial concentration (nM) / incubation time (sec)} \]

Where, permeated amount is calculated from permeation concentration (nM, concentration of the receiver side) of the substance after incubation for the defined time (sec) multiplied by volume.(mL) and area of cell membrane is used 0.33 (cm²).

The efflux ratio will be calculated using the following equation:

\[ \text{Efflux Ratio} = \frac{\text{Basolateral- to- Apical Pe}}{\text{Apical-to-Basolateral Pe}} \]

The net flux is calculated using the following equation:

\[ \text{Net flux} = \text{Efflux Ratio in MDRI expressing cells} / \text{Efflux Ratio in parent cells} \]

The percent of control is calculated as the net efflux ratio of reference compounds in the presence of the compound of the present invention to that in the absence of the compound of the present invention. 

IC₅₀ values are calculated using WinNonlin (Registered trademark) pharmacokinetic software modeling program.

**Example 30**
(Test Example 16: P-gp Substrate Test using mdrla (-/-) B6 mice)

Materials
Animal: mdrla (-/-) B6 mice (KO mouse) or C57BL/6J mice (Wild mouse)

Methods and Procedures
1. Animals may be fed prior to dosing of the compounds of the present invention.
2. The compounds of the present invention were dosed to three animals for each time point and blood and brain samples were removed at selected time points (e.g. 15 min, 30 min, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, or 24 hr) after dosing. Blood (0.3-0.7 mL) was collected via trunk blood collection with syringe containing anticoagulants (EDTA and heparin). Blood and tissue (e.g. brain) samples were immediately placed on melting ice.
3. Blood samples were centrifuged (1780 x g for 10 minutes) for cell removal to obtain plasma. Then, plasma samples were transferred to a clean tube and stored in a -70 °C freezer until analysis.
4. Tissue (e.g. brain) samples were homogenized at a 1:3 ratio of tissue weight to ml of still water and transferred to a clean tube and stored in a -70 °C freezer until analysis.
5. Plasma and tissue (e.g. brain) samples were prepared using protein precipitation and analyzed by LC/MS/MS. The analytical method was calibrated by including a standard curve constructed with blank plasma or brain samples and known quantities of analyte. Quality control samples were included to monitor the accuracy and precision of the methodology.
6. Plasma and brain concentration values (ng/mL and ng/g) were introduced into an appropriate mathematical tool used for calculating the pharmacokinetic parameters. A common platform was the WinNonlin (Registered trademark) pharmacokinetic software modeling program.

Calculations
Kp; Tissue to Plasma concentration ratio
Kp ratio = Kp in KO mouse / Kp in Wild mouse
KO / Wild ratio of AUC Tissue/AUC Plasma
= {AUC Tissue/AUC Plasma (KO mouse)} / {AUC Tissue/AUC Plasma (Wild mouse)}
Example 3

(Test Example 17: Anesthetized guinea pig cardiovascular study)
Animal species: Guinea pig (Slc:Hartley, 4-6 weeks old, male), N = 4
Study design:
Dosage: 3, 10, and 30 mg/kg (in principle)
(The compounds of the present invention are administered cumulatively)
Formulation:
Composition of Vehicle; Dimethylacetamide (DMA): Polyethylene glycol 400
The compounds of the present invention are dissolved with DMA and then added
PEG400 and D.W. Finally, 1.5, 5, and 15 mg/mL solutions are prepared.
Dosing route and schedule:
Intravenous infusion for 10 min (2 mL/kg).
0 to 10 min: 3 mg/kg, 30 to 40 min: 10 mg/kg, 60 to 70 min: 30 mg/kg
Vehicle is administered by the same schedule as the above.
Group composition:
Vehicle group and the compound of the present invention group (4 guinea pigs per
group).
Evaluation method:

<table>
<thead>
<tr>
<th>No.</th>
<th>Kp ratio (2 mg/kg, po. 2 hr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-1</td>
<td>4.12</td>
</tr>
<tr>
<td>1-2</td>
<td>0.959</td>
</tr>
<tr>
<td>1-3</td>
<td>5.16</td>
</tr>
<tr>
<td>1-4</td>
<td>2.92</td>
</tr>
<tr>
<td>1-7</td>
<td>4.21</td>
</tr>
<tr>
<td>1-8</td>
<td>2.22</td>
</tr>
<tr>
<td>1-9</td>
<td>3.13</td>
</tr>
<tr>
<td>1-14</td>
<td>6.32</td>
</tr>
<tr>
<td>1-16</td>
<td>8.13</td>
</tr>
<tr>
<td>1-28</td>
<td>5.41</td>
</tr>
<tr>
<td>1-30</td>
<td>3.63</td>
</tr>
<tr>
<td>1-35</td>
<td>5.15</td>
</tr>
<tr>
<td>1-40</td>
<td>6.97</td>
</tr>
<tr>
<td>1-41</td>
<td>2.66</td>
</tr>
<tr>
<td>1-42</td>
<td>2.07</td>
</tr>
<tr>
<td>1-46</td>
<td>6.13</td>
</tr>
<tr>
<td>1-47</td>
<td>2.12</td>
</tr>
<tr>
<td>1-48</td>
<td>5.57</td>
</tr>
<tr>
<td>1-116</td>
<td>4.34</td>
</tr>
</tbody>
</table>
Evaluation items:
Mean blood pressure [mmHg], Heart rate (derived from blood pressure waveform [beats/min]), QTc (ms), and Toxicokinetics.

Experimental Procedure:
Guinea pigs are anesthetized by urethane (1.4 g/kg, i.p.), and inserted polyethylene tubes into carotid artery (for measuring blood pressure and sampling blood) and jugular vein (for infusion test compounds). Electrodes are attached subcutaneously (Lead 2). Blood pressure, heart rate and electrocardiogram (ECG) are measured using PowerLab (Registered trademark) system (ADInstruments).

Toxicokinetics:
Approximately 0.3 mL of blood (approximately 150 µL as plasma) is drawn from carotid artery with a syringe containing heparin sodium and cooled with ice immediately at each evaluation point. Plasma samples are obtained by centrifugation (4°C, 10000 rpm, 9300 x g, 2 minutes). The procedure for separation of plasma is conducted on ice or at 4°C. The obtained plasma (TK samples) is stored in a deep freezer (set temperature: -80°C).

Analysis methods: Mean blood pressure and heart rate are averaged a 30-second period at each evaluation time point. ECG parameters (QT interval [ms] and QTc) are derived as the average waveform of a 10-second consecutive beats in the evaluation time points. QTc [Fridericia's formula; QTc=QT/(RR)1/3] is calculated using the PowerLab (Registered trademark) system. The incidence of arrhythmia is visually evaluated for all ECG recordings (from 0.5 hours before dosing to end of experiment) for all four animals.

Evaluation time points:
Before (pre dosing), and 10, 25, 40, 55, 70, and 85 min after the first dosing.

Data analysis of QTc:
Percentage changes (%) in QTc from the pre-dose value are calculated (the pre-dose value is regarded as 100%). Relative QTc is compared with vehicle value at the same evaluation point.

[0363] Formulation Examples
The following Formulation Examples are only exemplified and not intended to limit the scope of the present invention.

Formulation Example 1: Tablet
Compound of the present invention 15 mg
Lactose 15 mg
Calcium stearate 3 mg

All of the above ingredients except for calcium stearate are uniformly mixed. Then the mixture is crushed, granulated and dried to obtain a suitable size of granules. Then,
calcium stearate is added to the granules. Finally, tableting is performed under a compression force.

[0364] Formulation Example 2: Capsules
  Compound of the present invention 10 mg
  Magnesium stearate 10 mg
  Lactose 80 mg
  The above ingredients are mixed uniformly to obtain powders or fine granules, and then the obtained mixture is filled in capsules.

[0365] Formulation Example 3: Granules
  Compound of the present invention 30 g
  Lactose 265 g
  Magnesium stearate 5 g
  After the above ingredients are mixed uniformly, the mixture is compressed. The compressed matters are crushed, granulated and sieved to obtain suitable size of granules.

[0366] Formulation Example 4: Orally disintegrated tablets
  The compounds of the present invention and crystalline cellulose are mixed, granulated and tablets are made to give orally disintegrated tablets.

[0367] Formulation Example 5: Dry syrups
  The compounds of the present invention and lactose are mixed, crushed, granulated and sieved to give suitable sizes of dry syrups.

[0368] Formulation Example 6: Injections
  The compounds of the present invention and phosphate buffer are mixed to give injection.

[0369] Formulation Example 7: Infusions
  The compounds of the present invention and phosphate buffer are mixed to give injection.

[0370] Formulation Example 8: Inhalations
  The compound of the present invention and lactose are mixed and crushed finely to give inhalations.

[0371] Formulation Example 9: Ointments
  The compounds of the present invention and petrolatum are mixed to give ointments.

[0372] Formulation Example 10: Patches
  The compounds of the present invention and base such as adhesive plaster or the like are mixed to give patches.

**Industrial Applicability**

[0373] The compounds of the present invention can be a medicament useful as an agent for
treating or preventing a disease induced by production, secretion and/or deposition of amyloid β proteins.
Claims

[Claim 1] A compound of formula (I):

wherein

X is -S- or -O-, (i) when X is -S-, then

R\(\text{a}^\text{i}\) is alkyl, haloalkyl, hydroxyalkyl, or alkyloxyalkyl,
R\(\text{a}^\text{ii}\) is halogen, alkyloxy or haloalkyloxy and
R\(\text{a}^\text{iii}\) may be alkyl when R\(\text{a}^\text{iv}\) is haloalkyl,
R\(\text{b}^\text{ii}\) is H,
R\(\text{a}^\text{ii}\) and R\(\text{b}^\text{ii}\) together with the carbon atom to which they are attached may form substituted cycloalkane,
R\(\text{a}^\text{ii}\) may be H when R\(\text{a}^\text{ii}\) and R\(\text{b}^\text{ii}\) together with the carbon atom to which they are attached may form substituted cycloalkane,

(ii) when X is -O-, then

R\(\text{a}^\text{ii}\) is haloalkyl optionally substituted with one or more selected from alkyloxy and cycloalkyl, or cycloalkyl substituted with one or more selected from halogen,
R\(\text{a}^\text{ii}\) is H, halogen, alkyl, alkyloxy or haloalkyloxy,
R\(\text{b}^\text{ii}\) is H,
R\(\text{a}^\text{ii}\) and R\(\text{b}^\text{ii}\) together with the carbon atom to which they are attached may form substituted cycloalkane,
R\(\text{a}^\text{ii}\) may be H or alkyl when R\(\text{a}^\text{ii}\) and R\(\text{b}^\text{ii}\) together with the carbon atom to which they are attached may form substituted cycloalkane,
and R\(\text{a}^\text{iv}\) is H or alkyl,

[Chem.2]
ring A is a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted non-aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle, ring B is a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted non-aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle, R¹ is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted cycloalkyl, R⁵ is halogen or substituted or unsubstituted alkyl, n is an integer of 0 to 2, provided that the following compounds are excluded: (1) a compound wherein X is -0-, R³a is CH₂F or CF₃, R³b is H, R²a is H or F, and R²b is H, (2) a compound wherein X is -0-, R³a is CHF₂, R³b is H, R²a is OMe and R²b is H, and (3) the following compound: [Chem.3]

or a pharmaceutically acceptable salt thereof.

[Claim 2] The compound according to claim 1 wherein X is -0-, or a pharmaceutically acceptable salt thereof.

[Claim 3] The compound according to claim 2 wherein R³a is CH₂F, CHF₂, CF₃, CH(F)CH₃ or CF₂CH₃, and R³b is H or CH₃, or a pharmaceutically acceptable salt thereof.

[Claim 4] The compound according to claim 2 or 3 wherein R²a is H, F, CH₃, OCH₃ or OCH₂CF₃, or a pharmaceutically acceptable salt thereof.

[Claim 5] The compound according to claim 2 or 3 wherein R²a is H, halogen or alkyl, R²b is H, and R³b is CHF₂, CH(F)CH₃ or CF₂CH₃, or a pharmaceutically acceptable salt thereof.

[Claim 6] The compound according to claim 2 wherein R²a is H or halogen, R²b is H, R³b is CH₂F or CF₃, R³b is alkyl, and R¹ is unsubstituted alkyl, or a
pharmaceutically acceptable salt thereof.

[Claim 7] The compound according to claims 2 or 3 wherein \( R^{2a} \) is alkyl, alkoxy or haloalkoxy, or a pharmaceutically acceptable salt thereof.

[Claim 8] The compound according to claim 2 wherein

[Chem.4] \[\text{is} \]

\( R^5 \) is halogen and \( n \) is 1 or 2, or a pharmaceutically acceptable salt thereof.

[Claim 9] The compound according to claim 2 or 4 wherein \( R^{3a} \) is haloalkyl substituted with alkoxy or cycloalkyl, or a pharmaceutically acceptable salt thereof.

[Claim 10] The compound according to claim 1 wherein \( X = -S- \), \( R^{2a} \) is halogen or alkoxy, \( R^2 \) is \( H \), \( R^{3a} \) is alkyl, haloalkyl, hydroxyalkyl or alkoxyalkyl, and \( R^{3b} \) is \( H \), or a pharmaceutically acceptable salt thereof.

[Claim 11] The compound according to claim 1 wherein \( X = -S- \), \( R^{2a} \) is \( F \), \( R^2 \) is \( H \), \( R^{3a} \) is \( CH_3 \) or \( CH_2F \), and \( R^{3b} \) is \( H \), or a pharmaceutically acceptable salt thereof.

[Claim 12] The compound according to claim 1 wherein \( R^{2a} \) and \( R^{3b} \) together with the carbon atom to which they are attached form cycloalkane substituted with halogen, \( R^{3a} \) is \( H \) or alkyl, or a pharmaceutically acceptable salt thereof.

[Claim 13] The compound according to any one of claims 1 to 12 wherein \( R^1 \) is alkyl, or a pharmaceutically acceptable salt thereof.

[Claim 14] The compound according to any one of claims 1 to 13 wherein ring A is

[Chem.5] \[\text{wherein} \ R^4 \text{is} \ H \text{or halogen, and} \ -Z= \text{is} \ -CH= \text{or} \ -N=, \text{or a pharmaceutically acceptable salt thereof.} \]

[Claim 15] The compound according to claim 14 wherein \( R^4 \) is halogen and \( -Z= \) is
-CH=, or a pharmaceutically acceptable salt thereof.

[Claim 16] The compound according to any one of claims 1 to 15 wherein ring B is substituted or unsubstituted pyridine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrimidine, substituted or unsubstituted pyridazine or substituted or unsubstituted oxazole, or a pharmaceutically acceptable salt thereof.

[Claim 17] A pharmaceutical composition comprising the compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof.

[Claim 18] A pharmaceutical composition having BACE1 inhibitory activity comprising the compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof.

[Claim 19] A method for inhibiting BACE1 activity comprising administering the compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof.

[Claim 20] The compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof for use in a method for inhibiting BACE1 activity.

[Claim 21] The pharmaceutical composition according to claim 17 or 18 for treating or preventing Alzheimer dementia, mild cognitive impairment or prodromal Alzheimer's disease, for preventing the progression of Alzheimer dementia, mild cognitive impairment, or prodromal Alzheimer's disease, or for preventing the progression in a patient asymptomatic at risk for Alzheimer dementia.

[Claim 22] A method for treating or preventing Alzheimer dementia, mild cognitive impairment or prodromal Alzheimer's disease, for preventing the progression of Alzheimer dementia, mild cognitive impairment, or prodromal Alzheimer's disease, or for preventing the progression in a patient asymptomatic at risk for Alzheimer dementia comprising administering the compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof.

[Claim 23] A compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof for use in treating or preventing Alzheimer dementia, mild cognitive impairment or prodromal Alzheimer's disease, for use in preventing the progression of Alzheimer dementia, mild cognitive impairment or prodromal Alzheimer's disease, or for use in preventing the progression in a patient asymptomatic at risk for Alzheimer dementia.
**INTERNATIONAL SEARCH REPORT**

**International application No**

PCT/JP2015/062314

### A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D413/14 C07D413/12 C07D417/12 C07D417/14 A61K31/535

A61K31/54 A61P25/28

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>EP 1 942 105 Al (SHI0N0GI &amp; CO [JP]) 9 July 2008 (2008-07-09) cited in the application on examples claims</td>
<td>1-23</td>
</tr>
<tr>
<td>X</td>
<td>EP 2 147 914 Al (SHI0N0GI &amp; CO [JP]) 27 January 2010 (2010-01-27) cited in the application on examples claims</td>
<td>1-23</td>
</tr>
<tr>
<td>X</td>
<td>EP 2 514 747 Al (SHI0N0GI &amp; CO [JP]) 24 October 2012 (2012-10-24) cited in the application on examples tables 1-8 claims</td>
<td>1-23</td>
</tr>
</tbody>
</table>

-/-

Further documents are listed in the continuation of Box C. See patent family annex.

- Special categories of cited documents:
  - "A" document defining the general state of the art which is not considered to be of particular relevance
  - "B" earlier application or patent but published on or after the international filing date
  - "L" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  - "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  - "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  - "Z" document member of the same patent family

Date of the actual completion of the international search: 30 June 2015

Date of mailing of the international search report: 10/07/2015

Name and mailing address of the ISA:

European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016

Authorized officer: Sint-Malzaun, Elke
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EP 2 511 268 AI (SHIONOGI &amp; CO [JP]) 17 October 2012 (2012-10-17) cited in the application claims</td>
<td>1-23</td>
</tr>
<tr>
<td></td>
<td>WO 2012/168164 AI (HOFFMANN LA ROCHE [CH]; SI ENA BIOTECH SPA [IT]; WOLTERING THOMAS [DE]) 13 December 2012 (2012-12-13) cited in the application claims</td>
<td>1-23</td>
</tr>
<tr>
<td></td>
<td>WO 2013/110622 AI (HOFFMANN LA ROCHE [CH]; SI ENA BIOTECH SPA [IT]; HILPERT HANS [CH]; HUM) 1 August 2013 (2013-08-01) cited in the application claims</td>
<td>1-23</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>E P 1942105</td>
<td>09-07-2008</td>
<td>AU 2006307314 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR PI0617852 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2628074 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 101346357 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 103936690 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1942105 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2597087 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2612854 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2476027 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2537898 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5281794 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 56908250 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2013116902 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20080059330 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RU 2010151410 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TW 201245159 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2009082560 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2012016116 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 20120222249 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2013158260 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2013303755 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2007049532 A1</td>
</tr>
<tr>
<td>E P 2147914</td>
<td>27-01-2010</td>
<td>AU 2008245082 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR PI0811034 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2683887 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 101687827 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2147914 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2689780 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2476605 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5383484 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2013216666 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20100017255 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RU 2009143333 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TW 200902526 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010075957 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2012172355 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2014073815 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2008133274 A1</td>
</tr>
<tr>
<td>E P 2514747</td>
<td>24-10-2012</td>
<td>EP 2514747 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2012245154 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2011070781 A1</td>
</tr>
<tr>
<td>E P 2511268</td>
<td>17-10-2012</td>
<td>AU 2010328975 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2783958 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 102834384 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2511268 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20120104570 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RU 2012129168 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TW 201127833 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2012245157 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2011071135 A1</td>
</tr>
<tr>
<td>WO 2012168164</td>
<td>13-12-2012</td>
<td>AU 2012266544 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2837252 A1</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>CN 103717592 A</td>
<td>09-04-2014</td>
<td></td>
</tr>
<tr>
<td>CO 6811854 A2</td>
<td>16-12-2013</td>
<td></td>
</tr>
<tr>
<td>CR 20130588 A</td>
<td>18-02-2014</td>
<td></td>
</tr>
<tr>
<td>EA 201391786 A1</td>
<td>30-04-2014</td>
<td></td>
</tr>
<tr>
<td>EC SP13013068 A</td>
<td>31-01-2014</td>
<td></td>
</tr>
<tr>
<td>EP 2718286 A1</td>
<td>16-04-2014</td>
<td></td>
</tr>
<tr>
<td>JP 2014516063 A</td>
<td>07-07-2014</td>
<td></td>
</tr>
<tr>
<td>KR 20140041687 A</td>
<td>04-04-2014</td>
<td></td>
</tr>
<tr>
<td>MA 35193 B1</td>
<td>02-06-2014</td>
<td></td>
</tr>
<tr>
<td>PE 06232014 A1</td>
<td>03-05-2014</td>
<td></td>
</tr>
<tr>
<td>US 2014080819 A1</td>
<td>20-03-2014</td>
<td></td>
</tr>
<tr>
<td>WO 2012168164 A1</td>
<td>13-12-2012</td>
<td></td>
</tr>
<tr>
<td>WO 2013110622 A1</td>
<td>01-08-2013</td>
<td>AR 089781 A1</td>
</tr>
<tr>
<td>AU 2013211646 A1</td>
<td>05-06-2014</td>
<td>CA 2856892 A1</td>
</tr>
<tr>
<td>CL 2014001838 A1</td>
<td>07-11-2014</td>
<td>CN 104066727 A</td>
</tr>
<tr>
<td>CO 6960553 A2</td>
<td>30-05-2014</td>
<td>CR 20140306 A</td>
</tr>
<tr>
<td>KR 20140117625 A</td>
<td>07-10-2014</td>
<td>MA 35748 B1</td>
</tr>
<tr>
<td>TW 201335153 A</td>
<td>01-09-2013</td>
<td>US 2015031690 A</td>
</tr>
<tr>
<td>WO 2013110622 A1</td>
<td>01-08-2013</td>
<td>WO 2014065434 A1</td>
</tr>
<tr>
<td>WO 2014114532 A1</td>
<td>31-07-2014</td>
<td>NONE</td>
</tr>
<tr>
<td>WO 2014114532 A1</td>
<td>31-07-2014</td>
<td>NONE</td>
</tr>
</tbody>
</table>